drug_name,targets,mechanism_of_action,research_institution,indication_original,global_highest_phase_indication,global_highest_phase_indication_start_date,global_development_status,drug_category_3,drug_category_2,drug_tag,pharmacological_type,drug_category_1,drug_synonyms,carrier_type,disease_area,formulation_china,npuid,additional_data,originator_country,originator_rightsregion,china_highest_phase,usa_highest_phase,china_highest_phase_start_date,usa_highest_phase_start_date,highest_phase_indication_standard,global_highest_phase_all_indication,global_highest_phase_all_indication_date,global_highest_phase_all_indication_standard,research_institution_count,is_cyclic_peptide,is_rare_disease,is_top20_mnc,top20_mnc_list,originator_company_list,count_originator,research_institution_list,therapeutic_area_norm,indication,therapeutic_area_list,count_therapeutic_area,therapeutic_area_primary,therapeutic_area_secondary,therapeutic_area_tertiary,global_highest_phase_all_indication_sort_val,highest_phase_standard_sort_val,therapeutic_area_norm_en,therapeutic_area_primary_en,therapeutic_area_secondary_en,therapeutic_area_tertiary_en,indication_en,drug_name_en,drug_synonyms_en
杆菌肽,not available,多肽类抗生素,Columbia University(原研),细菌感染,批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,多肽类抗生素,创新药,杆菌肽;bacitracin,,感染领域,,DR004636,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2010-10-18,approved,批准上市,1948-07-29,approved,1,True,False,False,[],['Columbia University'],1,['Columbia University(原研)'],感染领域,细菌感染,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,bacterial infection,bacitracin,杆菌肽;bacitracin
杆菌肽,not available,多肽类抗生素,Columbia University(原研),感染,III期临床,2009-10-28,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,多肽类抗生素,创新药,杆菌肽;bacitracin,,感染领域,,DR004636,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2016-06-22,phase 3,批准上市,1948-07-29,approved,1,True,False,False,[],['Columbia University'],1,['Columbia University(原研)'],感染领域,感染,['感染领域'],1,感染领域,,,5,3,Infectious Diseases,Infectious Diseases,,,Infect,bacitracin,杆菌肽;bacitracin
杆菌肽,not available,多肽类抗生素,Columbia University(原研),接触性皮炎(差异化疾病),II期临床,2005-08-22,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,多肽类抗生素,创新药,杆菌肽;bacitracin,,皮肤领域,,DR004636,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2005-08-22,phase 2,批准上市,1948-07-29,approved,1,True,False,False,[],['Columbia University'],1,['Columbia University(原研)'],皮肤领域,接触性皮炎,['皮肤领域'],1,皮肤领域,,,5,2,Dermatology,Dermatology,,,contact dermatitis,bacitracin,杆菌肽;bacitracin
杆菌肽,not available,多肽类抗生素,Columbia University(原研),葡萄球菌感染,I期临床,2009-10-19,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,多肽类抗生素,创新药,杆菌肽;bacitracin,,感染领域,,DR004636,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2009-10-19,phase 1,批准上市,1948-07-29,approved,1,True,False,False,[],['Columbia University'],1,['Columbia University(原研)'],感染领域,葡萄球菌感染,['感染领域'],1,感染领域,,,5,1,Infectious Diseases,Infectious Diseases,,,Staph infection,bacitracin,杆菌肽;bacitracin
缩宫素,oxytocin,合成的oxytocin,Travere Therapeutics(原研),催产/引产,批准上市,,Active,多肽,化药,环肽;First-in-Class,合成的,创新药,缩宫素;oxytocin;催产素;Syntocinon;TTA-121;OT;Pitocin,,泌尿生殖领域,,DR032561,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1954-06-30,approved,1,True,False,False,[],['Travere Therapeutics'],1,['Travere Therapeutics(原研)'],泌尿生殖领域,催产/引产,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,,Oxygen/induced labor,oxytocin,缩宫素;oxytocin;催产素;Syntocinon;TTA-121;OT;Pitocin
缩宫素,oxytocin,合成的oxytocin,Travere Therapeutics(原研),产后子宫出血,批准上市,,Active,多肽,化药,环肽;First-in-Class,合成的,创新药,缩宫素;oxytocin;催产素;Syntocinon;TTA-121;OT;Pitocin,,泌尿生殖领域,,DR032561,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1954-06-30,approved,1,True,False,False,[],['Travere Therapeutics'],1,['Travere Therapeutics(原研)'],泌尿生殖领域,产后子宫出血,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,,Postpartum uterine bleeding,oxytocin,缩宫素;oxytocin;催产素;Syntocinon;TTA-121;OT;Pitocin
缩宫素,oxytocin,合成的oxytocin,Travere Therapeutics(原研),孤独症谱系障碍,III期临床,,Active,多肽,化药,环肽;First-in-Class,合成的,创新药,缩宫素;oxytocin;催产素;Syntocinon;TTA-121;OT;Pitocin,,精神领域,,DR032561,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,1954-06-30,approved,1,True,False,False,[],['Travere Therapeutics'],1,['Travere Therapeutics(原研)'],精神领域,孤独症谱系障碍,['精神领域'],1,精神领域,,,5,3,Psychiatry,Psychiatry,,,autism spectrum disorder,oxytocin,缩宫素;oxytocin;催产素;Syntocinon;TTA-121;OT;Pitocin
多粘菌素B,not available,多粘菌素类抗生素,--,细菌性肺炎,批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,多粘菌素类抗生素,创新药,多粘菌素B;polymyxin B,,感染领域;呼吸领域,,DR049372,否,,,,,,,approved,批准上市,1956-08-06,approved,0,True,False,False,[],[],0,[],感染领域,细菌性肺炎,"['感染领域', '呼吸领域']",2,感染领域,呼吸领域,,5,5,Infectious Diseases,Infectious Diseases,Respiratory,,bacterial pneumonia,polymyxin B,多粘菌素B;polymyxin B
多粘菌素B,not available,多粘菌素类抗生素,--,菌血症(差异化疾病),批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,多粘菌素类抗生素,创新药,多粘菌素B;polymyxin B,,感染领域,,DR049372,否,,,,,,,approved,批准上市,1956-08-06,approved,0,True,False,False,[],[],0,[],感染领域,菌血症,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,bacteremia,polymyxin B,多粘菌素B;polymyxin B
多粘菌素B,not available,多粘菌素类抗生素,--,细菌性心内膜炎(差异化疾病),批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,多粘菌素类抗生素,创新药,多粘菌素B;polymyxin B,,感染领域;心脑血管领域,,DR049372,否,,,,,,,approved,批准上市,1956-08-06,approved,0,True,False,False,[],[],0,[],感染领域,细菌性心内膜炎,"['感染领域', '心脑血管领域']",2,感染领域,心脑血管领域,,5,5,Infectious Diseases,Infectious Diseases,Cardiovascular & Cerebrovascular,,bacterial endocarditis,polymyxin B,多粘菌素B;polymyxin B
放线菌素D,DNA,放线菌素抗生素,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),肾母细胞瘤,批准上市,,Active,其他,化药,环肽;First-in-Class,放线菌素抗生素,创新药,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,,罕见疾病领域;肿瘤领域,,DR001704,否,欧洲,未知,,,,,approved,批准上市,1964-12-10,approved,3,True,True,False,[],['Recordati Rare Diseases'],1,"['Recordati Rare Diseases(原研)', 'Tiziana Life Sciences', 'Rasna(无权益)']",肿瘤领域,肾母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,nephroblastoma,dactinomycin,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D
放线菌素D,DNA,放线菌素抗生素,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),横纹肌肉瘤,批准上市,,Active,其他,化药,环肽;First-in-Class,放线菌素抗生素,创新药,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,,罕见疾病领域;肿瘤领域,,DR001704,否,欧洲,未知,,,,,approved,批准上市,1964-12-10,approved,3,True,True,False,[],['Recordati Rare Diseases'],1,"['Recordati Rare Diseases(原研)', 'Tiziana Life Sciences', 'Rasna(无权益)']",肿瘤领域,横纹肌肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,rhabdomyosarcoma,dactinomycin,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D
放线菌素D,DNA,放线菌素抗生素,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),睾丸癌,批准上市,,Active,其他,化药,环肽;First-in-Class,放线菌素抗生素,创新药,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,,罕见疾病领域;肿瘤领域,,DR001704,否,欧洲,未知,,,,,approved,批准上市,1964-12-10,approved,3,True,True,False,[],['Recordati Rare Diseases'],1,"['Recordati Rare Diseases(原研)', 'Tiziana Life Sciences', 'Rasna(无权益)']",肿瘤领域,睾丸癌,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,testicular cancer,dactinomycin,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D
放线菌素D,DNA,放线菌素抗生素,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),尤文氏肉瘤,批准上市,,Active,其他,化药,环肽;First-in-Class,放线菌素抗生素,创新药,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,,罕见疾病领域;肿瘤领域,,DR001704,否,欧洲,未知,,,,,approved,批准上市,1964-12-10,approved,3,True,True,False,[],['Recordati Rare Diseases'],1,"['Recordati Rare Diseases(原研)', 'Tiziana Life Sciences', 'Rasna(无权益)']",肿瘤领域,尤文氏肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,Ewing's sarcoma,dactinomycin,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D
放线菌素D,DNA,放线菌素抗生素,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),妊娠滋养细胞肿瘤,批准上市,,Active,其他,化药,环肽;First-in-Class,放线菌素抗生素,创新药,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,,罕见疾病领域;肿瘤领域,,DR001704,否,欧洲,未知,,,,,approved,批准上市,1964-12-10,approved,3,True,True,False,[],['Recordati Rare Diseases'],1,"['Recordati Rare Diseases(原研)', 'Tiziana Life Sciences', 'Rasna(无权益)']",肿瘤领域,妊娠滋养细胞肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,gestational trophoblastic tumor,dactinomycin,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D
卷曲霉素,not available,多肽类抗生素,Eli Lilly(Top20 MNC)(原研),肺结核(差异化疾病),批准上市,,Active,小分子,化药,环肽;差异化疾病,多肽类抗生素,创新药,卷曲霉素;capreomycin;卷须霉素;结核霉素;Capastat,,感染领域,,DR023297,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,,,approved,批准上市,1971-06-02,approved,1,True,False,True,['Eli Lilly'],['Eli Lilly'],1,['Eli Lilly(Top20 MNC)(原研)'],感染领域,肺结核,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,tuberculosis,capreomycin,卷曲霉素;capreomycin;卷须霉素;结核霉素;Capastat
杆菌肽+多粘菌素B,not available,多粘菌素类抗生素;多肽类抗生素,--,细菌感染,批准上市,,Active,复方;多肽,化药,环肽,多粘菌素类抗生素;多肽类抗生素,创新药,杆菌肽+多粘菌素B;bacitracin+polymyxin B,,感染领域,,DR066181,否,,,,,,,approved,批准上市,1974-04-16,approved,0,True,False,False,[],[],0,[],感染领域,细菌感染,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,bacterial infection,bacitracin+polymyxin B,杆菌肽+多粘菌素B;bacitracin+polymyxin B
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,肾盂肾炎(差异化疾病),批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,感染领域;泌尿生殖领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,,,approved,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",感染领域,肾盂肾炎,"['感染领域', '泌尿生殖领域']",2,感染领域,泌尿生殖领域,,5,5,Infectious Diseases,Infectious Diseases,Genitourinary,,Pyelonephritis,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,A型血友病(差异化疾病),批准上市,2023-04-10,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,血液领域;罕见疾病领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,I期临床,2023-04-10,2015-07-22,approved,批准上市,1978-02-21,approved,2,True,True,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",血液领域,A型血友病,['血液领域'],1,血液领域,,,5,5,Hematology,Hematology,,,Hemophilia A,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,血管性血友病(差异化疾病),批准上市,2023-04-10,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,血液领域;罕见疾病领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,2023-04-10,,approved,批准上市,1978-02-21,approved,2,True,True,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",血液领域,血管性血友病,['血液领域'],1,血液领域,,,5,5,Hematology,Hematology,,,von Willebrand disease,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,血小板减少症(差异化疾病),批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,血液领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,,,approved,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",血液领域,血小板减少症,['血液领域'],1,血液领域,,,5,5,Hematology,Hematology,,,Thrombocytopenia,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,中枢性尿崩症,批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,内分泌及代谢领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,I期临床,,1999-10-19,approved,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",内分泌及代谢领域,中枢性尿崩症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,central diabetes insipidus,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,遗尿症(差异化疾病),批准上市,1995-06-01,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,精神领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,I期临床,1995-06-01,2015-12-21,approved,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",精神领域,遗尿症,['精神领域'],1,精神领域,,,5,5,Psychiatry,Psychiatry,,,enuresis,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,肝硬化(差异化疾病),批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,消化领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,,,approved,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",消化领域,肝硬化,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,Cirrhosis,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,膀胱炎(差异化疾病),批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,泌尿生殖领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,,,approved,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",泌尿生殖领域,膀胱炎,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,,Cystitis,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,尿频(差异化疾病),批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,泌尿生殖领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,,,approved,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",泌尿生殖领域,尿频,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,,Frequent urination,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,出血,批准上市,2023-04-10,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,其他领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,II期临床,2023-04-10,2013-11-13,approved,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",其他领域,出血,['其他领域'],1,其他领域,,,5,5,Others,Others,,,Bleeding,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,夜尿症(差异化疾病),批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,泌尿生殖领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,III期临床,,2007-05-23,approved,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",泌尿生殖领域,夜尿症,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,,Nocturia,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,外伤,申请上市,2016-11-17,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,其他领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,申请上市,,2016-11-17,,pre-registration,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",其他领域,外伤,['其他领域'],1,其他领域,,,5,4,Others,Others,,,trauma,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,低钠血症(差异化疾病),III期临床,2023-08-31,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,内分泌及代谢领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",内分泌及代谢领域,低钠血症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Hyponatremia,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,肾绞痛(差异化疾病),III期临床,2012-12-05,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,泌尿生殖领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",泌尿生殖领域,肾绞痛,['泌尿生殖领域'],1,泌尿生殖领域,,,5,3,Genitourinary,Genitourinary,,,renal colic,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,钩端螺旋体病(差异化疾病),II/III期临床,2008-01-14,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,感染领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",感染领域,钩端螺旋体病,['感染领域'],1,感染领域,,,5,3,Infectious Diseases,Infectious Diseases,,,leptospirosis,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,脑出血(差异化疾病),II期临床,2009-08-19,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,心脑血管领域;罕见疾病领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2009-08-19,phase 2,批准上市,1978-02-21,approved,2,True,True,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",心脑血管领域,脑出血,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,cerebral hemorrhage,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,膀胱过度活动症(差异化疾病),II期临床,2012-11-20,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,泌尿生殖领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2012-11-20,phase 2,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",泌尿生殖领域,膀胱过度活动症,['泌尿生殖领域'],1,泌尿生殖领域,,,5,2,Genitourinary,Genitourinary,,,overactive bladder,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,出血性卒中(差异化疾病),II期临床,2018-10-04,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,心脑血管领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",心脑血管领域,出血性卒中,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,hemorrhagic stroke,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,尿崩症,I期临床,1999-10-19,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,内分泌及代谢领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",内分泌及代谢领域,尿崩症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,diabetes insipidus,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,肾源性尿崩症(差异化疾病),I期临床,2022-04-01,Unknown,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,内分泌及代谢领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",内分泌及代谢领域,肾源性尿崩症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,nephrogenic diabetes insipidus,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,维生素D缺乏(差异化疾病),I期临床,2025-12-18,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,内分泌及代谢领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",内分泌及代谢领域,维生素D缺乏,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Vitamin D deficiency,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,双相情感障碍(差异化疾病),I期临床,2022-04-01,Unknown,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,精神领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",精神领域,双相情感障碍,['精神领域'],1,精神领域,,,5,1,Psychiatry,Psychiatry,,,bipolar disorder,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,低血压(差异化疾病),I期临床,2025-10-28,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,心脑血管领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-10-28,,phase 1,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",心脑血管领域,低血压,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,hypotension,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,动脉粥样硬化(差异化疾病),I期临床,2019-09-25,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,心脑血管领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",心脑血管领域,动脉粥样硬化,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,atherosclerosis,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,子宫内膜异位(差异化疾病),I期临床,2017-08-13,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,泌尿生殖领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2017-08-13,,phase 1,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",泌尿生殖领域,子宫内膜异位,['泌尿生殖领域'],1,泌尿生殖领域,,,5,1,Genitourinary,Genitourinary,,,endometriosis,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,前列腺疾病(差异化疾病),I期临床,2009-05-15,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,泌尿生殖领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",泌尿生殖领域,前列腺疾病,['泌尿生殖领域'],1,泌尿生殖领域,,,5,1,Genitourinary,Genitourinary,,,prostate disease,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,月经过多(差异化疾病),I期临床,2005-05-19,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,泌尿生殖领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2005-05-19,phase 1,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",泌尿生殖领域,月经过多,['泌尿生殖领域'],1,泌尿生殖领域,,,5,1,Genitourinary,Genitourinary,,,Menorrhagia,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,术后出血,I期临床,2019-04-21,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,其他领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2019-04-21,,phase 1,批准上市,1978-02-21,approved,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",其他领域,术后出血,['其他领域'],1,其他领域,,,5,1,Others,Others,,,postoperative bleeding,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
去氨加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,获得性血友病(差异化疾病),I期临床,2011-07-27,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,,血液领域;罕见疾病领域,"批准上市:注射剂;片剂_x000D_
I期临床:舌下片",DR032515,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,1978-02-21,approved,2,True,True,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",血液领域,获得性血友病,['血液领域'],1,血液领域,,,5,1,Hematology,Hematology,,,acquired hemophilia,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna
粘菌素,not available,多粘菌素类抗生素,Par Pharmaceutical(Endo International)(原研),志贺杆菌病(差异化疾病),批准上市,,Active,其他,化药,环肽;差异化疾病,多粘菌素类抗生素,创新药,粘菌素;colistin;抗敌素;COL,,感染领域;消化领域,,DR049240,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1982-01-01,approved,1,True,False,False,[],['Par Pharmaceutical(Endo International)'],1,['Par Pharmaceutical(Endo International)(原研)'],感染领域,志贺杆菌病,"['感染领域', '消化领域']",2,感染领域,消化领域,,5,5,Infectious Diseases,Infectious Diseases,Digestive System,,shigellosis,colistin,粘菌素;colistin;抗敌素;COL
紫霉素,not available,多肽类抗生素,Pfizer(Top20 MNC)(原研),结核病,批准上市,,Active,小分子,化药,环肽,多肽类抗生素,创新药,紫霉素;viomycin,,感染领域,,DR051819,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1982-01-01,approved,1,True,False,True,['Pfizer'],['Pfizer'],1,['Pfizer(Top20 MNC)(原研)'],感染领域,结核病,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,tuberculosis,viomycin,紫霉素;viomycin
血管加压素,vasopressin,vasopressin,Par Sterile Products(原研),中枢性尿崩症,批准上市,,Active,多肽,化药,环肽;差异化疾病,原形,创新药,血管加压素;vasopressin;arginine vasopressin;精氨酸加压素;抗利尿激素;Vasostrict;Vasopressins;argipressin,,内分泌及代谢领域,,DR001309,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1982-01-01,approved,1,True,False,False,[],['Par Sterile Products'],1,['Par Sterile Products(原研)'],内分泌及代谢领域,中枢性尿崩症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,central diabetes insipidus,vasopressin,血管加压素;vasopressin;arginine vasopressin;精氨酸加压素;抗利尿激素;Vasostrict;Vasopressins;argipressin
血管加压素,vasopressin,vasopressin,Par Sterile Products(原研),血管扩张性休克(差异化疾病),批准上市,,Active,多肽,化药,环肽;差异化疾病,原形,创新药,血管加压素;vasopressin;arginine vasopressin;精氨酸加压素;抗利尿激素;Vasostrict;Vasopressins;argipressin,,其他领域,,DR001309,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1982-01-01,approved,1,True,False,False,[],['Par Sterile Products'],1,['Par Sterile Products(原研)'],其他领域,血管扩张性休克,['其他领域'],1,其他领域,,,5,5,Others,Others,,,vasodilatory shock,vasopressin,血管加压素;vasopressin;arginine vasopressin;精氨酸加压素;抗利尿激素;Vasostrict;Vasopressins;argipressin
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),再生障碍性贫血(差异化疾病),批准上市,,Active,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,血液领域;罕见疾病领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1983-11-14,approved,1,True,True,False,[],['Sandoz'],1,['Sandoz(原研)'],血液领域,再生障碍性贫血,['血液领域'],1,血液领域,,,5,5,Hematology,Hematology,,,aplastic anemia,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),类风湿性关节炎(差异化疾病),批准上市,,Active,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,骨骼肌肉领域;免疫领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],骨骼肌肉领域,类风湿性关节炎,"['骨骼肌肉领域', '免疫领域']",2,骨骼肌肉领域,免疫领域,,5,5,Musculoskeletal,Musculoskeletal,Immunology,,rheumatoid arthritis,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),银屑病,批准上市,,Active,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,免疫领域;皮肤领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],免疫领域,银屑病,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,5,5,Immunology,Immunology,Dermatology,,psoriasis,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),器官移植排斥,批准上市,,Active,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,罕见疾病领域;免疫领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1983-11-14,approved,1,True,True,False,[],['Sandoz'],1,['Sandoz(原研)'],免疫领域,器官移植排斥,['免疫领域'],1,免疫领域,,,5,5,Immunology,Immunology,,,organ transplant rejection,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),移植物抗宿主病(差异化疾病),批准上市,,Active,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,罕见疾病领域;免疫领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1983-11-14,approved,1,True,True,False,[],['Sandoz'],1,['Sandoz(原研)'],免疫领域,移植物抗宿主病,['免疫领域'],1,免疫领域,,,5,5,Immunology,Immunology,,,graft versus host disease,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),特应性皮炎(差异化疾病),批准上市,,Active,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,免疫领域;皮肤领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],免疫领域,特应性皮炎,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,5,5,Immunology,Immunology,Dermatology,,atopic dermatitis,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),狼疮性肾炎,批准上市,,Active,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,免疫领域;泌尿生殖领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],免疫领域,狼疮性肾炎,"['免疫领域', '泌尿生殖领域']",2,免疫领域,泌尿生殖领域,,5,5,Immunology,Immunology,Genitourinary,,lupus nephritis,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),肾病综合征(差异化疾病),批准上市,,Active,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,泌尿生殖领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],泌尿生殖领域,肾病综合征,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,,nephrotic syndrome,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),干眼病,批准上市,,Active,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,眼科领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],眼科领域,干眼病,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,,dry eye disease,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),角结膜炎,批准上市,,Active,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,眼科领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],眼科领域,角结膜炎,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,,keratoconjunctivitis,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),非感染性葡萄膜炎,批准上市,,Active,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,眼科领域;免疫领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],眼科领域,非感染性葡萄膜炎,"['眼科领域', '免疫领域']",2,眼科领域,免疫领域,,5,5,Ophthalmology,Ophthalmology,Immunology,,noninfectious uveitis,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),心肌梗塞(差异化疾病),III期临床,,Inactive,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,心脑血管领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],心脑血管领域,心肌梗塞,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,myocardial infarction,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),溃疡性结肠炎(差异化疾病),III期临床,,Active,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,消化领域;免疫领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],消化领域,溃疡性结肠炎,"['消化领域', '免疫领域']",2,消化领域,免疫领域,,5,3,Digestive System,Digestive System,Immunology,,ulcerative colitis,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),慢性丙肝(差异化疾病),III期临床,,Inactive,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,感染领域;消化领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],感染领域,慢性丙肝,"['感染领域', '消化领域']",2,感染领域,消化领域,,5,3,Infectious Diseases,Infectious Diseases,Digestive System,,Chronic hepatitis C,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),心脏停搏(差异化疾病),III期临床,,Inactive,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,心脑血管领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],心脑血管领域,心脏停搏,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,cardiac arrest,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),克罗恩病(差异化疾病),II期临床,,Inactive,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,消化领域;免疫领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],消化领域,克罗恩病,"['消化领域', '免疫领域']",2,消化领域,免疫领域,,5,2,Digestive System,Digestive System,Immunology,,Crohn's disease,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),重症肌无力(差异化疾病),II期临床,,Inactive,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,罕见疾病领域;免疫领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1983-11-14,approved,1,True,True,False,[],['Sandoz'],1,['Sandoz(原研)'],免疫领域,重症肌无力,['免疫领域'],1,免疫领域,,,5,2,Immunology,Immunology,,,myasthenia gravis,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),章鱼壶心肌症(差异化疾病),II期临床,,Active,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,罕见疾病领域;心脑血管领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1983-11-14,approved,1,True,True,False,[],['Sandoz'],1,['Sandoz(原研)'],心脑血管领域,章鱼壶心肌症,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Takotsubo cardiomyopathy,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),乙型肝炎(差异化疾病),临床前,,Inactive,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,感染领域;消化领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],感染领域,乙型肝炎,"['感染领域', '消化领域']",2,感染领域,消化领域,,5,-1,Infectious Diseases,Infectious Diseases,Digestive System,,Hepatitis B,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
环孢素,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),丁型肝炎(差异化疾病),临床前,,Inactive,多肽,化药,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,创新药,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,,感染领域;消化领域,批准上市:注射剂;软胶囊,DR032554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,批准上市,1983-11-14,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],感染领域,丁型肝炎,"['感染领域', '消化领域']",2,感染领域,消化领域,,5,-1,Infectious Diseases,Infectious Diseases,Digestive System,,Hepatitis D,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),类癌,批准上市,1988-10-21,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,批准上市,2003-07-08,1988-10-21,approved,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,类癌,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,carcinoid,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),类癌综合征,批准上市,2003-07-08,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,III期临床,2003-07-08,2004-09-27,approved,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,类癌综合征,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,carcinoid syndrome,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),低血糖症,批准上市,2024-06-03,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,内分泌及代谢领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,III期临床,2024-06-03,2008-12-08,approved,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],内分泌及代谢领域,低血糖症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,hypoglycemia,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),肢端肥大症,批准上市,1988-10-21,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,内分泌及代谢领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,批准上市,2003-07-08,1988-10-21,approved,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],内分泌及代谢领域,肢端肥大症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,acromegaly,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),甲状腺肿(差异化疾病),批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,内分泌及代谢领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],内分泌及代谢领域,甲状腺肿,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,goiter,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),消化性溃疡,批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,,,approved,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,消化性溃疡,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,peptic ulcer,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),肝硬化(差异化疾病),批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,,,approved,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,肝硬化,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,Cirrhosis,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),出血(差异化疾病),批准上市,2023-01-29,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,其他领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,2023-01-29,,approved,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],其他领域,出血,['其他领域'],1,其他领域,,,5,5,Others,Others,,,Bleeding,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),胃泌素瘤(差异化疾病),批准上市,2003-07-08,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,2003-07-08,,approved,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,胃泌素瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,gastrinoma,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),食管静脉曲张出血,批准上市,2023-01-05,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,2023-01-05,,approved,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,食管静脉曲张出血,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,Esophageal variceal bleeding,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),消化性溃疡出血,批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,消化性溃疡出血,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,peptic ulcer bleeding,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),十二指肠溃疡出血,批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,十二指肠溃疡出血,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,duodenal ulcer bleeding,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),胰瘘,批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II期临床,,2024-06-03,,approved,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,胰瘘,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,pancreatic fistula,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),胰岛细胞瘤(差异化疾病),批准上市,2003-07-08,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,II期临床,2003-07-08,2007-01-29,approved,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,胰岛细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,islet cell tumor,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),胃肠胰神经内分泌肿瘤,批准上市,1988-10-21,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,批准上市,2003-07-08,1988-10-21,approved,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),食管静脉曲张,批准上市,2023-01-29,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,2023-01-29,,approved,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,食管静脉曲张,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,Esophageal varices,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),急性胰腺炎(差异化疾病),批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,,,approved,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,急性胰腺炎,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,acute pancreatitis,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),血管活性肠肽瘤(差异化疾病),批准上市,2003-07-08,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,2003-07-08,,approved,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,血管活性肠肽瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,vasoactive intestinal peptide tumor,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),肝细胞癌,III期临床,2005-10-18,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2005-11-08,phase 3,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,肝细胞癌,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,hepatocellular carcinoma,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),乳腺癌,III期临床,2004-06-16,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2004-06-16,phase 3,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,breast cancer,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),HR阳性乳腺癌(差异化疾病),III期临床,,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,HR阳性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,HR positive breast cancer,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),胰腺癌,III期临床,2015-05-29,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2012-11-15,,phase 3,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,pancreatic cancer,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),子宫内膜癌(差异化疾病),III期临床,2004-09-03,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2004-09-03,phase 3,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,子宫内膜癌,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,endometrial cancer,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),癌性腹水(差异化疾病),III期临床,2005-09-16,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2005-09-16,phase 3,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,癌性腹水,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,cancerous ascites,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),Prader-Willi综合征(差异化疾病),III期临床,2005-09-15,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,内分泌及代谢领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2006-11-15,phase 3,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],内分泌及代谢领域,Prader-Willi综合征,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Prader-Willi syndrome,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),糖尿病视网膜病变,III期临床,,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,眼科领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],眼科领域,糖尿病视网膜病变,['眼科领域'],1,眼科领域,,,5,3,Ophthalmology,Ophthalmology,,,diabetic retinopathy,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),神经内分泌肿瘤,III期临床,2005-09-15,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,II期临床,2024-03-08,2010-05-12,phase 3,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,neuroendocrine tumors,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),消化道出血,III期临床,2015-03-10,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,I期临床,2019-02-19,2012-10-16,phase 3,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,消化道出血,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,,gastrointestinal bleeding,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),放化疗引起的腹泻(差异化疾病),III期临床,2003-01-27,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域;肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2004-01-13,phase 3,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,放化疗引起的腹泻,"['消化领域', '肿瘤领域']",2,消化领域,肿瘤领域,,5,3,Oncology,Digestive System,Oncology,,Diarrhea caused by radiotherapy and chemotherapy,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),非增殖性糖尿病视网膜病变(差异化疾病),III期临床,2005-08-16,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,眼科领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2005-08-16,phase 3,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],眼科领域,非增殖性糖尿病视网膜病变,['眼科领域'],1,眼科领域,,,5,3,Ophthalmology,Ophthalmology,,,non-proliferative diabetic retinopathy,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),增殖性糖尿病视网膜病变(差异化疾病),III期临床,2005-08-16,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,眼科领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2005-08-16,phase 3,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],眼科领域,增殖性糖尿病视网膜病变,['眼科领域'],1,眼科领域,,,5,3,Ophthalmology,Ophthalmology,,,proliferative diabetic retinopathy,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),肝肾综合征(差异化疾病),II/III期临床,2005-10-17,Unknown,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,泌尿生殖领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],泌尿生殖领域,肝肾综合征,['泌尿生殖领域'],1,泌尿生殖领域,,,5,3,Genitourinary,Genitourinary,,,Hepatorenal syndrome,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),多囊肾病,II/III期临床,2014-04-21,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,泌尿生殖领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],泌尿生殖领域,多囊肾病,['泌尿生殖领域'],1,泌尿生殖领域,,,5,3,Genitourinary,Genitourinary,,,polycystic kidney disease,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),多囊肝病,II/III期临床,2007-01-24,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II/III期临床,,2007-01-24,phase 3,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,多囊肝病,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,,polycystic liver disease,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),肿瘤,II期临床,2023-09-21,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2021-05-24,,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,tumor,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),肺癌,II期临床,2009-10-07,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,肺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,lung cancer,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),前列腺癌,II期临床,2005-09-14,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,前列腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,prostate cancer,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),肥胖,II期临床,2004-10-15,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,内分泌及代谢领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-10-15,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],内分泌及代谢领域,肥胖,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,obesity,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),急性呼吸窘迫综合征(差异化疾病),II期临床,2021-05-27,Unknown,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,呼吸领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2021-05-27,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],呼吸领域,急性呼吸窘迫综合征,['呼吸领域'],1,呼吸领域,,,5,2,Respiratory,Respiratory,,,acute respiratory distress syndrome,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),肠梗阻,II期临床,2003-05-09,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2003-05-09,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,肠梗阻,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,,intestinal obstruction,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),腹水,II期临床,2000-06-12,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,泌尿生殖领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2000-06-12,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],泌尿生殖领域,腹水,['泌尿生殖领域'],1,泌尿生殖领域,,,5,2,Genitourinary,Genitourinary,,,ascites,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),癌症骨转移(差异化疾病),II期临床,2007-08-01,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2007-08-01,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,癌症骨转移,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,cancer bone metastasis,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),去势抵抗前列腺癌,II期临床,2007-08-01,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2007-08-01,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,去势抵抗前列腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Castration-resistant prostate cancer,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),淋巴管肌瘤(差异化疾病),II期临床,2000-06-12,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,罕见疾病领域;肿瘤领域;呼吸领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2000-06-12,phase 2,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,淋巴管肌瘤,"['肿瘤领域', '呼吸领域']",2,肿瘤领域,呼吸领域,,5,2,Oncology,Oncology,Respiratory,,lymphangioleiomyoma,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),肾衰竭(差异化疾病),II期临床,2012-04-30,Unknown,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,泌尿生殖领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],泌尿生殖领域,肾衰竭,['泌尿生殖领域'],1,泌尿生殖领域,,,5,2,Genitourinary,Genitourinary,,,kidney failure,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),垂体瘤,II期临床,1999-11-04,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,1999-11-04,phase 2,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,垂体瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Pituitary tumor,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),胰腺神经内分泌肿瘤,II期临床,2005-06-08,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2005-06-08,phase 2,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,胰腺神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,pancreatic neuroendocrine tumors,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),胃肠道神经内分泌肿瘤,II期临床,2005-09-28,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II期临床,,2011-11-29,,phase 2,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,胃肠道神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,gastrointestinal neuroendocrine tumors,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),消化道癌症,II期临床,2012-03-30,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2018-03-07,,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,消化道癌症,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,digestive tract cancer,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),淋巴水肿(差异化疾病),II期临床,2000-06-12,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,免疫领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2000-06-12,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],免疫领域,淋巴水肿,['免疫领域'],1,免疫领域,,,5,2,Immunology,Immunology,,,Lymphedema,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),终末期肾病(差异化疾病),II期临床,2018-05-30,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,泌尿生殖领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],泌尿生殖领域,终末期肾病,['泌尿生殖领域'],1,泌尿生殖领域,,,5,2,Genitourinary,Genitourinary,,,end stage renal disease,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),脑膜瘤,II期临床,2015-01-07,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,脑膜瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Meningioma,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),惰性非霍奇金淋巴瘤(差异化疾病),II期临床,2004-07-29,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,血液领域;肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-07-29,phase 2,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,惰性非霍奇金淋巴瘤,"['血液领域', '肿瘤领域']",2,血液领域,肿瘤领域,,5,2,Oncology,Hematology,Oncology,,indolent non-Hodgkin lymphoma,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),直肠癌(差异化疾病),II期临床,2006-01-31,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,直肠癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,rectal cancer,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),消化道瘘,II期临床,2015-05-08,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,消化道瘘,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,,gastrointestinal fistula,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),肝病,II期临床,2005-11-22,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2005-11-22,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,肝病,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,,Liver disease,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),十二指肠疾病,II期临床,2023-09-21,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,十二指肠疾病,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,,duodenal disease,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),胸腺癌(差异化疾病),II期临床,2004-04-14,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-04-14,phase 2,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,胸腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,thymic cancer,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),胸腺瘤,II期临床,2004-04-14,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-04-14,phase 2,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,胸腺瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,thymoma,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),遗传性出血性毛细血管扩张症(差异化疾病),II期临床,1999-10-19,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,心脑血管领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],心脑血管领域,遗传性出血性毛细血管扩张症,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,hereditary hemorrhagic telangiectasia,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),多发性内分泌肿瘤(差异化疾病),II期临床,2009-10-07,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,多发性内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,multiple endocrine neoplasms,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),脑膜血管外皮细胞瘤(差异化疾病),II期临床,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,脑膜血管外皮细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Meningeal hemangiopericytoma,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),超重(差异化疾病),II期临床,2004-10-15,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,内分泌及代谢领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-10-15,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],内分泌及代谢领域,超重,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,overweight,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),特发性肺纤维化(差异化疾病),I/II期临床,2007-04-20,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,呼吸领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],呼吸领域,特发性肺纤维化,['呼吸领域'],1,呼吸领域,,,5,2,Respiratory,Respiratory,,,idiopathic pulmonary fibrosis,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),门静脉高压,I/II期临床,2010-08-25,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2014-03-10,,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,门静脉高压,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,,portal hypertension,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),体位性心动过速综合征(差异化疾病),I/II期临床,2005-12-06,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,心脑血管领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2005-12-06,phase 2,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],心脑血管领域,体位性心动过速综合征,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,postural tachycardia syndrome,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),实体瘤,I期临床,2004-05-24,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2004-05-24,phase 1,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,solid tumors,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),2型糖尿病(差异化疾病),I期临床,2024-06-21,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,内分泌及代谢领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-06-21,,phase 1,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],内分泌及代谢领域,2型糖尿病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,type 2 diabetes,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),肠易激综合征(差异化疾病),I期临床,2008-01-02,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2008-01-02,phase 1,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,肠易激综合征,['消化领域'],1,消化领域,,,5,1,Digestive System,Digestive System,,,irritable bowel syndrome,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),代谢相关脂肪性肝病(差异化疾病),I期临床,2023-11-13,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2023-11-13,phase 1,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,代谢相关脂肪性肝病,['消化领域'],1,消化领域,,,5,1,Digestive System,Digestive System,,,metabolic related fatty liver disease,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),急性肾损伤(差异化疾病),I期临床,2020-08-21,Unknown,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,泌尿生殖领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],泌尿生殖领域,急性肾损伤,['泌尿生殖领域'],1,泌尿生殖领域,,,5,1,Genitourinary,Genitourinary,,,acute kidney injury,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),糖尿病黄斑水肿(差异化疾病),I期临床,2025-03-18,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,眼科领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2025-03-18,phase 1,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],眼科领域,糖尿病黄斑水肿,['眼科领域'],1,眼科领域,,,5,1,Ophthalmology,Ophthalmology,,,diabetic macular edema,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),腹泻,I期临床,2001-08-31,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,I期临床,2025-01-03,2001-08-31,phase 1,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,腹泻,['消化领域'],1,消化领域,,,5,1,Digestive System,Digestive System,,,diarrhea,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),高胰岛素血症,I期临床,2021-12-29,Unknown,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,内分泌及代谢领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2021-12-29,,phase 1,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],内分泌及代谢领域,高胰岛素血症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,hyperinsulinemia,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),胃神经内分泌肿瘤(差异化疾病),I期临床,2019-01-23,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2019-01-23,,phase 1,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,胃神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,gastric neuroendocrine tumors,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),胃静脉曲张,I期临床,2017-02-23,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,胃静脉曲张,['消化领域'],1,消化领域,,,5,1,Digestive System,Digestive System,,,gastric varices,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),原发性神经外胚层肿瘤(差异化疾病),I期临床,2023-10-12,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,原发性神经外胚层肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,primary neuroectodermal tumor,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),肠道疾病,I期临床,2018-11-08,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,肠道疾病,['消化领域'],1,消化领域,,,5,1,Digestive System,Digestive System,,,intestinal diseases,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),小肠癌(差异化疾病),I期临床,2017-02-20,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2017-02-20,phase 1,批准上市,1988-10-21,approved,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,小肠癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,small bowel cancer,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),壶腹周围癌(差异化疾病),I期临床,2015-09-29,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2015-09-29,,phase 1,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,壶腹周围癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,periampullary cancer,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),甲状腺腺瘤,I期临床,2009-12-09,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,甲状腺腺瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Thyroid adenoma,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
奥曲肽,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),胰腺切除术(差异化疾病),I期临床,2018-01-16,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,,消化领域,批准上市:注射剂;注射剂(微球),DR066054,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2018-01-16,,phase 1,批准上市,1988-10-21,approved,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,胰腺切除术,['消化领域'],1,消化领域,,,5,1,Digestive System,Digestive System,,,pancreatectomy,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),放射性核素显像,批准上市,2015-09-28,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,诊断试剂领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II/III期临床,,2007-03-02,approved,批准上市,1994-06-02,approved,1,True,False,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],诊断试剂领域,放射性核素显像,['诊断试剂领域'],1,诊断试剂领域,,,5,5,Diagnostic Reagents,Diagnostic Reagents,,,radionuclide imaging,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),神经内分泌肿瘤,批准上市,2015-09-28,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,肿瘤领域;罕见疾病领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II/III期临床,,2007-03-02,approved,批准上市,1994-06-02,approved,1,True,True,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,neuroendocrine tumors,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),癌症肝转移,III期临床,2015-06-08,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,肿瘤领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,1994-06-02,approved,1,True,False,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],肿瘤领域,癌症肝转移,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,cancer liver metastasis,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),PET显像,II期临床,1999-11-04,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,诊断试剂领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,1999-11-04,phase 2,批准上市,1994-06-02,approved,1,True,False,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,5,2,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),胃肠胰神经内分泌肿瘤,I/II期临床,2014-03-05,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,肿瘤领域;罕见疾病领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1994-06-02,approved,1,True,True,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),肺癌,I期临床,2004-03-26,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,肿瘤领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2004-03-26,phase 1,批准上市,1994-06-02,approved,1,True,False,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],肿瘤领域,肺癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,lung cancer,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),头颈癌,I期临床,2004-03-26,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,肿瘤领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2004-03-26,phase 1,批准上市,1994-06-02,approved,1,True,False,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],肿瘤领域,头颈癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Head and neck cancer,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),Merkel细胞瘤,I期临床,2004-03-26,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,肿瘤领域;罕见疾病领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2004-03-26,phase 1,批准上市,1994-06-02,approved,1,True,True,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],肿瘤领域,Merkel细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Merkel cell tumor,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),肾癌,I期临床,2004-03-26,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,肿瘤领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2004-03-26,phase 1,批准上市,1994-06-02,approved,1,True,False,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],肿瘤领域,肾癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,kidney cancer,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),脑癌,I期临床,2004-03-26,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,肿瘤领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2004-03-26,phase 1,批准上市,1994-06-02,approved,1,True,False,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],肿瘤领域,脑癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,brain cancer,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),类癌,I期临床,2004-03-26,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,肿瘤领域;罕见疾病领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2004-03-26,phase 1,批准上市,1994-06-02,approved,1,True,True,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],肿瘤领域,类癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,carcinoid,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),嗜铬细胞瘤,I期临床,2004-03-26,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,肿瘤领域;罕见疾病领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2004-03-26,phase 1,批准上市,1994-06-02,approved,1,True,True,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],肿瘤领域,嗜铬细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Pheochromocytoma,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),胰腺神经内分泌肿瘤,I期临床,2004-03-26,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,肿瘤领域;罕见疾病领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2004-03-26,phase 1,批准上市,1994-06-02,approved,1,True,True,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],肿瘤领域,胰腺神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,pancreatic neuroendocrine tumors,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),眼黑色素瘤,I期临床,2004-03-26,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,肿瘤领域;罕见疾病领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2004-03-26,phase 1,批准上市,1994-06-02,approved,1,True,True,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],肿瘤领域,眼黑色素瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,ocular melanoma,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
铟[111In]喷曲肽,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),朗格汉斯细胞组织细胞增生症,I期临床,2004-03-26,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,创新药,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,,肿瘤领域;血液领域;罕见疾病领域,,DR020836,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2004-03-26,phase 1,批准上市,1994-06-02,approved,1,True,True,False,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],肿瘤领域,朗格汉斯细胞组织细胞增生症,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,,Langerhans cell histiocytosis,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide
卡培立肽,ANP,重组ANP,Astellas Pharma(Top20 MNC);Daiichi Sankyo(原研),急性心力衰竭,批准上市,,Active,多肽,生物,环肽;First-in-Class,重组,创新药,卡培立肽;carperitide;卡哌利汀;recombinant human atrial natriuretic polypeptide,,心脑血管领域,,DR007785,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1995-01-20,approved,2,True,False,True,['Astellas Pharma'],['Daiichi Sankyo'],1,"['Astellas Pharma(Top20 MNC)', 'Daiichi Sankyo(原研)']",心脑血管领域,急性心力衰竭,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,acute heart failure,carperitide,卡培立肽;carperitide;卡哌利汀;recombinant human atrial natriuretic polypeptide
卡培立肽,ANP,重组ANP,Astellas Pharma(Top20 MNC);Daiichi Sankyo(原研),急性呼吸窘迫综合征,II期临床,2002-02-01,Inactive,多肽,生物,环肽;First-in-Class,重组,创新药,卡培立肽;carperitide;卡哌利汀;recombinant human atrial natriuretic polypeptide,,呼吸领域,,DR007785,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1995-01-20,approved,2,True,False,True,['Astellas Pharma'],['Daiichi Sankyo'],1,"['Astellas Pharma(Top20 MNC)', 'Daiichi Sankyo(原研)']",呼吸领域,急性呼吸窘迫综合征,['呼吸领域'],1,呼吸领域,,,5,2,Respiratory,Respiratory,,,acute respiratory distress syndrome,carperitide,卡培立肽;carperitide;卡哌利汀;recombinant human atrial natriuretic polypeptide
卡培立肽,ANP,重组ANP,Astellas Pharma(Top20 MNC);Daiichi Sankyo(原研),充血性心力衰竭,II期临床,2005-11-29,Inactive,多肽,生物,环肽;First-in-Class,重组,创新药,卡培立肽;carperitide;卡哌利汀;recombinant human atrial natriuretic polypeptide,,心脑血管领域,,DR007785,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2005-11-29,phase 2,批准上市,1995-01-20,approved,2,True,False,True,['Astellas Pharma'],['Daiichi Sankyo'],1,"['Astellas Pharma(Top20 MNC)', 'Daiichi Sankyo(原研)']",心脑血管领域,充血性心力衰竭,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,congestive heart failure,carperitide,卡培立肽;carperitide;卡哌利汀;recombinant human atrial natriuretic polypeptide
来匹卢定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,Bayer(Top20 MNC);Hoechst(Sanofi)(Top20 MNC)(原研)(无权益),肝素引起的血小板减少症(差异化疾病),批准上市,,Active,多肽,生物,环肽;First-in-Class;差异化疾病,抑制剂;类似物,创新药,来匹卢定;lepirudin;Refludan;HBW 023;来匹芦定,,血液领域,,DR057151,否,欧洲,,,,,,approved,批准上市,1997-03-12,approved,2,True,False,True,"['Bayer', 'Hoechst(Sanofi)']",['Hoechst(Sanofi)'],1,"['Bayer(Top20 MNC)', 'Hoechst(Sanofi)(Top20 MNC)(原研)(无权益)']",血液领域,肝素引起的血小板减少症,['血液领域'],1,血液领域,,,5,5,Hematology,Hematology,,,Heparin-induced thrombocytopenia,lepirudin,来匹卢定;lepirudin;Refludan;HBW 023;来匹芦定
来匹卢定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,Bayer(Top20 MNC);Hoechst(Sanofi)(Top20 MNC)(原研)(无权益),心肌梗塞(差异化疾病),III期临床,,Inactive,多肽,生物,环肽;First-in-Class;差异化疾病,抑制剂;类似物,创新药,来匹卢定;lepirudin;Refludan;HBW 023;来匹芦定,,心脑血管领域,,DR057151,否,欧洲,,,,,,phase 3,批准上市,1997-03-12,approved,2,True,False,True,"['Bayer', 'Hoechst(Sanofi)']",['Hoechst(Sanofi)'],1,"['Bayer(Top20 MNC)', 'Hoechst(Sanofi)(Top20 MNC)(原研)(无权益)']",心脑血管领域,心肌梗塞,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,myocardial infarction,lepirudin,来匹卢定;lepirudin;Refludan;HBW 023;来匹芦定
来匹卢定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,Bayer(Top20 MNC);Hoechst(Sanofi)(Top20 MNC)(原研)(无权益),不稳定性心绞痛,III期临床,,Inactive,多肽,生物,环肽;First-in-Class;差异化疾病,抑制剂;类似物,创新药,来匹卢定;lepirudin;Refludan;HBW 023;来匹芦定,,心脑血管领域,,DR057151,否,欧洲,,,,,,phase 3,批准上市,1997-03-12,approved,2,True,False,True,"['Bayer', 'Hoechst(Sanofi)']",['Hoechst(Sanofi)'],1,"['Bayer(Top20 MNC)', 'Hoechst(Sanofi)(Top20 MNC)(原研)(无权益)']",心脑血管领域,不稳定性心绞痛,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,unstable angina,lepirudin,来匹卢定;lepirudin;Refludan;HBW 023;来匹芦定
来匹卢定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,Bayer(Top20 MNC);Hoechst(Sanofi)(Top20 MNC)(原研)(无权益),小细胞肺癌(差异化疾病),I/II期临床,2004-05-03,Inactive,多肽,生物,环肽;First-in-Class;差异化疾病,抑制剂;类似物,创新药,来匹卢定;lepirudin;Refludan;HBW 023;来匹芦定,,肿瘤领域;罕见疾病领域,,DR057151,否,欧洲,,,I/II期临床,,2004-05-03,phase 2,批准上市,1997-03-12,approved,2,True,True,True,"['Bayer', 'Hoechst(Sanofi)']",['Hoechst(Sanofi)'],1,"['Bayer(Top20 MNC)', 'Hoechst(Sanofi)(Top20 MNC)(原研)(无权益)']",肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,small cell lung cancer,lepirudin,来匹卢定;lepirudin;Refludan;HBW 023;来匹芦定
地西卢定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,Novartis(Top20 MNC)(原研);Kacefa,深静脉血栓(差异化疾病),批准上市,2003-04-04,Active,多肽,生物,环肽;差异化疾病,抑制剂;类似物,创新药,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定,,心脑血管领域,,DR044002,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,批准上市,,2003-04-04,approved,批准上市,1997-07-08,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'Kacefa']",心脑血管领域,深静脉血栓,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,deep vein thrombosis,desirudin,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定
地西卢定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,Novartis(Top20 MNC)(原研);Kacefa,肺栓塞(差异化疾病),批准上市,,Active,多肽,生物,环肽;差异化疾病,抑制剂;类似物,创新药,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定,,心脑血管领域,,DR044002,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1997-07-08,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'Kacefa']",心脑血管领域,肺栓塞,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,pulmonary embolism,desirudin,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定
地西卢定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,Novartis(Top20 MNC)(原研);Kacefa,髋关节置换术(差异化疾病),批准上市,,Active,多肽,生物,环肽;差异化疾病,抑制剂;类似物,创新药,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定,,骨骼肌肉领域,,DR044002,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1997-07-08,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'Kacefa']",骨骼肌肉领域,髋关节置换术,['骨骼肌肉领域'],1,骨骼肌肉领域,,,5,5,Musculoskeletal,Musculoskeletal,,,hip replacement,desirudin,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定
依替巴肽,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),血栓(抗凝或抗血小板),批准上市,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,,心脑血管领域,,DR028356,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,I/II期临床,,2022-06-10,approved,批准上市,1998-05-18,approved,2,True,False,True,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,血栓(抗凝或抗血小板),['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Thrombosis (anticoagulant or antiplatelet),eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide
依替巴肽,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),经皮冠状动脉介入治疗,批准上市,2020-11-19,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,,心脑血管领域,,DR028356,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,III期临床,2020-11-19,2008-12-22,approved,批准上市,1998-05-18,approved,2,True,False,True,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,经皮冠状动脉介入治疗,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,percutaneous coronary intervention,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide
依替巴肽,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),急性冠脉综合征,批准上市,2020-11-19,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,,心脑血管领域,,DR028356,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,II期临床,2020-11-19,2013-08-09,approved,批准上市,1998-05-18,approved,2,True,False,True,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,急性冠脉综合征,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,acute coronary syndrome,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide
依替巴肽,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),心肌梗塞,批准上市,2021-04-23,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,,心脑血管领域,,DR028356,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,2021-04-23,,approved,批准上市,1998-05-18,approved,2,True,False,True,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,心肌梗塞,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,myocardial infarction,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide
依替巴肽,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),心血管疾病,III期临床,2008-03-19,Inactive,多肽,化药,环肽;差异化疾病,抑制剂,创新药,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,,心脑血管领域,,DR028356,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,1998-05-18,approved,2,True,False,True,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,心血管疾病,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,cardiovascular disease,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide
依替巴肽,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),缺血性卒中,III期临床,2018-11-08,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,,心脑血管领域,,DR028356,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,III期临床,2019-02-18,2018-11-08,phase 3,批准上市,1998-05-18,approved,2,True,False,True,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,缺血性卒中,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,ischemic stroke,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide
依替巴肽,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),不稳定性心绞痛,III期临床,2010-02-26,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,,心脑血管领域,,DR028356,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,III期临床,2025-02-08,2010-02-26,phase 3,批准上市,1998-05-18,approved,2,True,False,True,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,不稳定性心绞痛,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,unstable angina,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide
依替巴肽,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),非ST段抬高型心肌梗死,III期临床,2010-02-26,Inactive,多肽,化药,环肽;差异化疾病,抑制剂,创新药,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,,心脑血管领域,,DR028356,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2010-02-26,phase 3,批准上市,1998-05-18,approved,2,True,False,True,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,非ST段抬高型心肌梗死,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Non-ST segment elevation myocardial infarction,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide
依替巴肽,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),ST段抬高型心肌梗死,III期临床,2007-01-25,Inactive,多肽,化药,环肽;差异化疾病,抑制剂,创新药,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,,心脑血管领域,,DR028356,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2008-07-22,phase 3,批准上市,1998-05-18,approved,2,True,False,True,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,ST段抬高型心肌梗死,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,ST segment elevation myocardial infarction,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide
依替巴肽,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),非ST段抬高型急性冠脉综合征,III期临床,2004-08-19,Inactive,多肽,化药,环肽;差异化疾病,抑制剂,创新药,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,,心脑血管领域,,DR028356,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2006-04-24,phase 3,批准上市,1998-05-18,approved,2,True,False,True,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,非ST段抬高型急性冠脉综合征,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Non-ST segment elevation acute coronary syndrome,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide
依替巴肽,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),感染性休克(差异化疾病),II期临床,2014-07-30,Inactive,多肽,化药,环肽;差异化疾病,抑制剂,创新药,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,,感染领域,,DR028356,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,1998-05-18,approved,2,True,False,True,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",感染领域,感染性休克,['感染领域'],1,感染领域,,,5,2,Infectious Diseases,Infectious Diseases,,,septic shock,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide
依替巴肽,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),镰状细胞病(差异化疾病),I/II期临床,2009-02-03,Inactive,多肽,化药,环肽;差异化疾病,抑制剂,创新药,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,,血液领域;罕见疾病领域,,DR028356,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2009-02-03,phase 2,批准上市,1998-05-18,approved,2,True,True,True,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",血液领域,镰状细胞病,['血液领域'],1,血液领域,,,5,2,Hematology,Hematology,,,sickle cell disease,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide
依替巴肽,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),冠心病,I期临床,2017-12-26,Inactive,多肽,化药,环肽;差异化疾病,抑制剂,创新药,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,,心脑血管领域,,DR028356,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,1998-05-18,approved,2,True,False,True,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,冠心病,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,coronary heart disease,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide
锝[99mTc]地普奥肽,SSTR,anti-SSTR多肽偶联核素;含锝放射性示踪剂,Bayer(Top20 MNC)(原研),癌症,批准上市,,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,创新药,锝[99mTc]地普奥肽;technetium Tc-99m depreotide;NeoSpect;depreotide;地普奥肽,,肿瘤领域,,DR017965,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1999-08-03,approved,1,True,False,True,['Bayer'],['Bayer'],1,['Bayer(Top20 MNC)(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,cancer,technetium Tc-99m depreotide,锝[99mTc]地普奥肽;technetium Tc-99m depreotide;NeoSpect;depreotide;地普奥肽
锝[99mTc]地普奥肽,SSTR,anti-SSTR多肽偶联核素;含锝放射性示踪剂,Bayer(Top20 MNC)(原研),放射性核素显像,批准上市,,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,创新药,锝[99mTc]地普奥肽;technetium Tc-99m depreotide;NeoSpect;depreotide;地普奥肽,,诊断试剂领域,,DR017965,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,1999-08-03,approved,1,True,False,True,['Bayer'],['Bayer'],1,['Bayer(Top20 MNC)(原研)'],诊断试剂领域,放射性核素显像,['诊断试剂领域'],1,诊断试剂领域,,,5,5,Diagnostic Reagents,Diagnostic Reagents,,,radionuclide imaging,technetium Tc-99m depreotide,锝[99mTc]地普奥肽;technetium Tc-99m depreotide;NeoSpect;depreotide;地普奥肽
阿托西班,OXTR;AVPR,AVPR拮抗剂;OXTR拮抗剂,Johnson & Johnson(Top20 MNC);Ferring Pharmaceuticals(原研),推迟早产,批准上市,,Active,多肽,化药,环肽;First-in-Class;G蛋白偶联受体,拮抗剂,创新药,阿托西班;atosiban;Tractocile;依保;dTVT;RWJ-22164,,泌尿生殖领域,批准上市:注射剂,DR042554,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,2000-01-19,approved,2,True,False,True,['Johnson & Johnson'],['Ferring Pharmaceuticals'],1,"['Johnson & Johnson(Top20 MNC)', 'Ferring Pharmaceuticals(原研)']",泌尿生殖领域,推迟早产,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,,postpone premature birth,atosiban,阿托西班;atosiban;Tractocile;依保;dTVT;RWJ-22164
特利加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),肝肾综合征(差异化疾病),批准上市,,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,,泌尿生殖领域,批准上市:注射剂;注射剂(冻干),DR032590,否,美国,中国(内地);中国(港澳台);欧洲;日本;其他,,,,,approved,批准上市,2001-01-22,approved,4,True,False,False,[],['Orphan Therapeutics'],1,"['Ferring Pharmaceuticals', 'Ikaria(Keenova Therapeutics)', 'Orphan Therapeutics(原研)', 'ESP Pharma(PDL BioPharma)(无权益)']",泌尿生殖领域,肝肾综合征,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,,Hepatorenal syndrome,terlipressin,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp
特利加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),产后子宫出血(差异化疾病),批准上市,,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,,泌尿生殖领域,批准上市:注射剂;注射剂(冻干),DR032590,否,美国,中国(内地);中国(港澳台);欧洲;日本;其他,,,,,approved,批准上市,2001-01-22,approved,4,True,False,False,[],['Orphan Therapeutics'],1,"['Ferring Pharmaceuticals', 'Ikaria(Keenova Therapeutics)', 'Orphan Therapeutics(原研)', 'ESP Pharma(PDL BioPharma)(无权益)']",泌尿生殖领域,产后子宫出血,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,,Postpartum uterine bleeding,terlipressin,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp
特利加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),休克,批准上市,,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,,其他领域,批准上市:注射剂;注射剂(冻干),DR032590,否,美国,中国(内地);中国(港澳台);欧洲;日本;其他,,,,,approved,批准上市,2001-01-22,approved,4,True,False,False,[],['Orphan Therapeutics'],1,"['Ferring Pharmaceuticals', 'Ikaria(Keenova Therapeutics)', 'Orphan Therapeutics(原研)', 'ESP Pharma(PDL BioPharma)(无权益)']",其他领域,休克,['其他领域'],1,其他领域,,,5,5,Others,Others,,,shock,terlipressin,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp
特利加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),食管静脉曲张出血(差异化疾病),批准上市,,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,,消化领域,批准上市:注射剂;注射剂(冻干),DR032590,否,美国,中国(内地);中国(港澳台);欧洲;日本;其他,,,,,approved,批准上市,2001-01-22,approved,4,True,False,False,[],['Orphan Therapeutics'],1,"['Ferring Pharmaceuticals', 'Ikaria(Keenova Therapeutics)', 'Orphan Therapeutics(原研)', 'ESP Pharma(PDL BioPharma)(无权益)']",消化领域,食管静脉曲张出血,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,Esophageal variceal bleeding,terlipressin,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp
特利加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),消化性溃疡出血(差异化疾病),批准上市,,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,,消化领域,批准上市:注射剂;注射剂(冻干),DR032590,否,美国,中国(内地);中国(港澳台);欧洲;日本;其他,,,,,approved,批准上市,2001-01-22,approved,4,True,False,False,[],['Orphan Therapeutics'],1,"['Ferring Pharmaceuticals', 'Ikaria(Keenova Therapeutics)', 'Orphan Therapeutics(原研)', 'ESP Pharma(PDL BioPharma)(无权益)']",消化领域,消化性溃疡出血,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,peptic ulcer bleeding,terlipressin,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp
特利加压素,vasopressin,vasopressin类似物,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),术后出血,批准上市,,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,,其他领域,批准上市:注射剂;注射剂(冻干),DR032590,否,美国,中国(内地);中国(港澳台);欧洲;日本;其他,,,,,approved,批准上市,2001-01-22,approved,4,True,False,False,[],['Orphan Therapeutics'],1,"['Ferring Pharmaceuticals', 'Ikaria(Keenova Therapeutics)', 'Orphan Therapeutics(原研)', 'ESP Pharma(PDL BioPharma)(无权益)']",其他领域,术后出血,['其他领域'],1,其他领域,,,5,5,Others,Others,,,postoperative bleeding,terlipressin,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp
卡泊芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Merck & Co.(Top20 MNC)(原研),真菌感染,批准上市,,Active,多肽,化药,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",,感染领域,批准上市:注射剂(冻干),DR014100,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,2001-01-26,approved,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],感染领域,真菌感染,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,fungal infection,caspofungin,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872"
卡泊芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Merck & Co.(Top20 MNC)(原研),曲霉病,批准上市,,Active,多肽,化药,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",,感染领域,批准上市:注射剂(冻干),DR014100,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,2001-01-26,approved,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],感染领域,曲霉病,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,Aspergillosis,caspofungin,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872"
卡泊芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Merck & Co.(Top20 MNC)(原研),念珠菌病,批准上市,,Active,多肽,化药,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",,感染领域,批准上市:注射剂(冻干),DR014100,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,2001-01-26,approved,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],感染领域,念珠菌病,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,candidiasis,caspofungin,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872"
卡泊芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Merck & Co.(Top20 MNC)(原研),念珠菌血症,批准上市,,Active,多肽,化药,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",,感染领域,批准上市:注射剂(冻干),DR014100,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,2001-01-26,approved,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],感染领域,念珠菌血症,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,candidemia,caspofungin,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872"
卡泊芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Merck & Co.(Top20 MNC)(原研),侵袭性念珠菌病,批准上市,,Active,多肽,化药,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",,感染领域,批准上市:注射剂(冻干),DR014100,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,2001-01-26,approved,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],感染领域,侵袭性念珠菌病,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,Invasive candidiasis,caspofungin,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872"
卡泊芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Merck & Co.(Top20 MNC)(原研),侵袭性曲霉病,批准上市,,Active,多肽,化药,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",,感染领域,批准上市:注射剂(冻干),DR014100,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,2001-01-26,approved,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],感染领域,侵袭性曲霉病,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,Invasive aspergillosis,caspofungin,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872"
卡泊芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Merck & Co.(Top20 MNC)(原研),食管念珠菌感染,批准上市,,Active,多肽,化药,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",,感染领域,批准上市:注射剂(冻干),DR014100,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,2001-01-26,approved,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],感染领域,食管念珠菌感染,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,Esophageal Candida Infection,caspofungin,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872"
生长抑素,somatostatin,somatostatin,Merck KGaA(Top20 MNC)(原研);海森生物,食管静脉曲张出血,批准上市,,Active,多肽,化药,环肽;差异化疾病,原形,创新药,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,,消化领域,批准上市:注射剂(冻干),DR011297,否,欧洲,美国;欧洲;日本;其他,,,,,approved,批准上市,2002-03-06,approved,2,True,False,True,['Merck KGaA'],['Merck KGaA'],1,"['Merck KGaA(Top20 MNC)(原研)', '海森生物']",消化领域,食管静脉曲张出血,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,Esophageal variceal bleeding,somatostatin,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁
生长抑素,somatostatin,somatostatin,Merck KGaA(Top20 MNC)(原研);海森生物,消化性溃疡出血,批准上市,,Active,多肽,化药,环肽;差异化疾病,原形,创新药,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,,消化领域,批准上市:注射剂(冻干),DR011297,否,欧洲,美国;欧洲;日本;其他,,,,,approved,批准上市,2002-03-06,approved,2,True,False,True,['Merck KGaA'],['Merck KGaA'],1,"['Merck KGaA(Top20 MNC)(原研)', '海森生物']",消化领域,消化性溃疡出血,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,peptic ulcer bleeding,somatostatin,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁
生长抑素,somatostatin,somatostatin,Merck KGaA(Top20 MNC)(原研);海森生物,十二指肠溃疡出血,批准上市,,Active,多肽,化药,环肽;差异化疾病,原形,创新药,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,,消化领域,批准上市:注射剂(冻干),DR011297,否,欧洲,美国;欧洲;日本;其他,,,,,approved,批准上市,2002-03-06,approved,2,True,False,True,['Merck KGaA'],['Merck KGaA'],1,"['Merck KGaA(Top20 MNC)(原研)', '海森生物']",消化领域,十二指肠溃疡出血,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,duodenal ulcer bleeding,somatostatin,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁
生长抑素,somatostatin,somatostatin,Merck KGaA(Top20 MNC)(原研);海森生物,胰瘘,批准上市,,Active,多肽,化药,环肽;差异化疾病,原形,创新药,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,,消化领域,批准上市:注射剂(冻干),DR011297,否,欧洲,美国;欧洲;日本;其他,,,,,approved,批准上市,2002-03-06,approved,2,True,False,True,['Merck KGaA'],['Merck KGaA'],1,"['Merck KGaA(Top20 MNC)(原研)', '海森生物']",消化领域,胰瘘,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,pancreatic fistula,somatostatin,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁
生长抑素,somatostatin,somatostatin,Merck KGaA(Top20 MNC)(原研);海森生物,胆瘘(差异化疾病),批准上市,,Active,多肽,化药,环肽;差异化疾病,原形,创新药,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,,消化领域,批准上市:注射剂(冻干),DR011297,否,欧洲,美国;欧洲;日本;其他,,,,,approved,批准上市,2002-03-06,approved,2,True,False,True,['Merck KGaA'],['Merck KGaA'],1,"['Merck KGaA(Top20 MNC)(原研)', '海森生物']",消化领域,胆瘘,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,bile fistula,somatostatin,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁
生长抑素,somatostatin,somatostatin,Merck KGaA(Top20 MNC)(原研);海森生物,肠瘘,批准上市,,Active,多肽,化药,环肽;差异化疾病,原形,创新药,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,,消化领域,批准上市:注射剂(冻干),DR011297,否,欧洲,美国;欧洲;日本;其他,,,,,approved,批准上市,2002-03-06,approved,2,True,False,True,['Merck KGaA'],['Merck KGaA'],1,"['Merck KGaA(Top20 MNC)(原研)', '海森生物']",消化领域,肠瘘,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,intestinal fistula,somatostatin,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁
生长抑素,somatostatin,somatostatin,Merck KGaA(Top20 MNC)(原研);海森生物,糖尿病酮症酸中毒(差异化疾病),批准上市,,Active,多肽,化药,环肽;差异化疾病,原形,创新药,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,,内分泌及代谢领域,批准上市:注射剂(冻干),DR011297,否,欧洲,美国;欧洲;日本;其他,,,,,approved,批准上市,2002-03-06,approved,2,True,False,True,['Merck KGaA'],['Merck KGaA'],1,"['Merck KGaA(Top20 MNC)(原研)', '海森生物']",内分泌及代谢领域,糖尿病酮症酸中毒,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,diabetic ketoacidosis,somatostatin,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),类癌,批准上市,,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域;罕见疾病领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,申报临床,,2016-04-12,,approved,批准上市,2002-03-14,approved,4,True,True,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,类癌,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,carcinoid,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),类癌综合征,批准上市,2002-03-14,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域;罕见疾病领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,批准上市,批准上市,2002-03-14,2017-09-15,approved,批准上市,2002-03-14,approved,4,True,True,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,类癌综合征,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,carcinoid syndrome,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),肢端肥大症,批准上市,2002-03-14,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,内分泌及代谢领域;罕见疾病领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,批准上市,批准上市,2002-03-14,2007-08-30,approved,批准上市,2002-03-14,approved,4,True,True,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",内分泌及代谢领域,肢端肥大症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,acromegaly,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),垂体瘤,批准上市,,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域;罕见疾病领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,approved,批准上市,2002-03-14,approved,4,True,True,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,垂体瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,Pituitary tumor,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),胃肠胰神经内分泌肿瘤,批准上市,2014-12-16,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域;罕见疾病领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,批准上市,批准上市,2024-04-03,2014-12-16,approved,批准上市,2002-03-14,approved,4,True,True,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),乳腺癌,III期临床,2008-03-07,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 3,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,breast cancer,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),肠梗阻,III期临床,2005-09-22,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,消化领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 3,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",消化领域,肠梗阻,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,,intestinal obstruction,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),多囊肾病,III期临床,2012-06-12,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,泌尿生殖领域;罕见疾病领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 3,批准上市,2002-03-14,approved,4,True,True,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",泌尿生殖领域,多囊肾病,['泌尿生殖领域'],1,泌尿生殖领域,,,5,3,Genitourinary,Genitourinary,,,polycystic kidney disease,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),神经内分泌肿瘤,III期临床,2016-02-17,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域;罕见疾病领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,III期临床,,2016-02-17,phase 3,批准上市,2002-03-14,approved,4,True,True,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,neuroendocrine tumors,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),去势抵抗前列腺癌,III期临床,2011-03-11,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 3,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,去势抵抗前列腺癌,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,Castration-resistant prostate cancer,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),胰瘘,III期临床,2025-02-04,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,消化领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,III期临床,,2025-02-04,phase 3,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",消化领域,胰瘘,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,,pancreatic fistula,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),胰腺神经内分泌肿瘤,III期临床,2009-02-12,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域;罕见疾病领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,III期临床,,2009-02-12,phase 3,批准上市,2002-03-14,approved,4,True,True,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,胰腺神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,pancreatic neuroendocrine tumors,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),胃肠道神经内分泌肿瘤,III期临床,2025-03-17,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域;罕见疾病领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 3,批准上市,2002-03-14,approved,4,True,True,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,胃肠道神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,gastrointestinal neuroendocrine tumors,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),消化道瘘,III期临床,2008-08-07,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,消化领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 3,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",消化领域,消化道瘘,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,,gastrointestinal fistula,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),肠外瘘(差异化疾病),III期临床,,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,消化领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 3,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",消化领域,肠外瘘,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,,Enteroenteric fistula,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),多囊肝病,III期临床,,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,消化领域;罕见疾病领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 3,批准上市,2002-03-14,approved,4,True,True,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",消化领域,多囊肝病,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,,polycystic liver disease,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),肝细胞癌,II/III期临床,2007-07-03,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,I期临床,,2008-10-20,,phase 3,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,肝细胞癌,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,hepatocellular carcinoma,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),腹泻,II/III期临床,2009-05-01,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,消化领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 3,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",消化领域,腹泻,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,,diarrhea,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),Merkel细胞瘤,II期临床,2015-01-30,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域;罕见疾病领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 2,批准上市,2002-03-14,approved,4,True,True,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,Merkel细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Merkel cell tumor,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),反流性食管炎(差异化疾病),II期临床,2014-02-04,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,消化领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 2,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",消化领域,反流性食管炎,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,,Reflux esophagitis,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),甲状腺相关性眼病(差异化疾病),II期临床,2006-02-08,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,眼科领域;内分泌及代谢领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 2,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",眼科领域,甲状腺相关性眼病,"['眼科领域', '内分泌及代谢领域']",2,眼科领域,内分泌及代谢领域,,5,2,Ophthalmology,Ophthalmology,Endocrinology & Metabolism,,Thyroid-related eye disease,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),嗜铬细胞瘤(差异化疾病),II期临床,2019-05-10,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域;罕见疾病领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,II期临床,,2019-05-10,phase 2,批准上市,2002-03-14,approved,4,True,True,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,嗜铬细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Pheochromocytoma,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),副神经节瘤(差异化疾病),II期临床,2019-05-10,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域;罕见疾病领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,II期临床,,2019-05-10,phase 2,批准上市,2002-03-14,approved,4,True,True,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,副神经节瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,paraganglioma,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),胃肠动力障碍,II期临床,2017-01-06,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,消化领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,II期临床,,2017-01-06,phase 2,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",消化领域,胃肠动力障碍,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,,gastrointestinal motility disorder,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),倾倒综合征,II期临床,2013-08-15,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,消化领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 2,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",消化领域,倾倒综合征,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,,dumping syndrome,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),肺癌,I期临床,2016-07-06,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 1,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,肺癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,lung cancer,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),前列腺癌,I期临床,2016-11-25,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,肿瘤领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 1,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,前列腺癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,prostate cancer,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
兰瑞肽,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),胃肠道疾病,I期临床,2016-07-06,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,,消化领域,批准上市:注射剂(冻干);注射剂(长效),DR015935,否,美国,未知,,,,,phase 1,批准上市,2002-03-14,approved,4,True,False,False,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",消化领域,胃肠道疾病,['消化领域'],1,消化领域,,,5,1,Digestive System,Digestive System,,,Gastrointestinal diseases,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel
米卡芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),曲霉病,批准上市,,Active,多肽,化药,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,,感染领域,批准上市:注射剂(冻干),DR042817,否,日本,,,,,,approved,批准上市,2002-10-08,approved,2,True,False,True,['Astellas Pharma'],['Astellas Pharma'],1,"['Sandoz', 'Astellas Pharma(Top20 MNC)(原研)(无权益)']",感染领域,曲霉病,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,Aspergillosis,micafungin,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard
米卡芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),念珠菌病,批准上市,,Active,多肽,化药,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,,感染领域,批准上市:注射剂(冻干),DR042817,否,日本,,,,,,approved,批准上市,2002-10-08,approved,2,True,False,True,['Astellas Pharma'],['Astellas Pharma'],1,"['Sandoz', 'Astellas Pharma(Top20 MNC)(原研)(无权益)']",感染领域,念珠菌病,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,candidiasis,micafungin,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard
米卡芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),侵袭性念珠菌病,批准上市,,Active,多肽,化药,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,,感染领域,批准上市:注射剂(冻干),DR042817,否,日本,,,,,,approved,批准上市,2002-10-08,approved,2,True,False,True,['Astellas Pharma'],['Astellas Pharma'],1,"['Sandoz', 'Astellas Pharma(Top20 MNC)(原研)(无权益)']",感染领域,侵袭性念珠菌病,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,Invasive candidiasis,micafungin,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard
米卡芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),食管念珠菌感染,批准上市,,Active,多肽,化药,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,,感染领域,批准上市:注射剂(冻干),DR042817,否,日本,,,,,,approved,批准上市,2002-10-08,approved,2,True,False,True,['Astellas Pharma'],['Astellas Pharma'],1,"['Sandoz', 'Astellas Pharma(Top20 MNC)(原研)(无权益)']",感染领域,食管念珠菌感染,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,Esophageal Candida Infection,micafungin,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard
Restasis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Allergan(AbbVie)(Top20 MNC)(原研),干眼病,批准上市,2002-12-23,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,Restasis;Restasis (环孢素);Restasis (cyclosporine A),,眼科领域,申报临床:眼用乳剂,DR031879,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,批准上市,,2002-12-23,approved,批准上市,2002-12-23,approved,1,True,False,True,['Allergan(AbbVie)'],['Allergan(AbbVie)'],1,['Allergan(AbbVie)(Top20 MNC)(原研)'],眼科领域,干眼病,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,,dry eye disease,Restasis (cyclosporine A),Restasis;Restasis (环孢素);Restasis (cyclosporine A)
Restasis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Allergan(AbbVie)(Top20 MNC)(原研),流泪,II/III期临床,2020-11-20,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,Restasis;Restasis (环孢素);Restasis (cyclosporine A),,其他领域,申报临床:眼用乳剂,DR031879,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,2002-12-23,approved,1,True,False,True,['Allergan(AbbVie)'],['Allergan(AbbVie)'],1,['Allergan(AbbVie)(Top20 MNC)(原研)'],其他领域,流泪,['其他领域'],1,其他领域,,,5,3,Others,Others,,,shed tears,Restasis (cyclosporine A),Restasis;Restasis (环孢素);Restasis (cyclosporine A)
Restasis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Allergan(AbbVie)(Top20 MNC)(原研),眼科疾病,I期临床,2024-10-03,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,Restasis;Restasis (环孢素);Restasis (cyclosporine A),,眼科领域,申报临床:眼用乳剂,DR031879,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,2002-12-23,approved,1,True,False,True,['Allergan(AbbVie)'],['Allergan(AbbVie)'],1,['Allergan(AbbVie)(Top20 MNC)(原研)'],眼科领域,眼科疾病,['眼科领域'],1,眼科领域,,,5,1,Ophthalmology,Ophthalmology,,,Eye diseases,Restasis (cyclosporine A),Restasis;Restasis (环孢素);Restasis (cyclosporine A)
Restasis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Allergan(AbbVie)(Top20 MNC)(原研),青光眼或高眼压症,I期临床,2006-11-30,Inactive,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,Restasis;Restasis (环孢素);Restasis (cyclosporine A),,眼科领域,申报临床:眼用乳剂,DR031879,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2006-11-30,phase 1,批准上市,2002-12-23,approved,1,True,False,True,['Allergan(AbbVie)'],['Allergan(AbbVie)'],1,['Allergan(AbbVie)(Top20 MNC)(原研)'],眼科领域,青光眼或高眼压症,['眼科领域'],1,眼科领域,,,5,1,Ophthalmology,Ophthalmology,,,glaucoma or ocular hypertension,Restasis (cyclosporine A),Restasis;Restasis (环孢素);Restasis (cyclosporine A)
达托霉素,not available,脂肽类抗生素,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),皮肤/皮肤结构感染,批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,脂肽类抗生素,创新药,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,,感染领域;皮肤领域,,DR038793,否,美国,未知,,,,,approved,批准上市,2003-09-12,approved,3,True,False,True,"['Gilead Sciences', 'Eli Lilly', 'Cubist Pharmaceuticals(Merck & Co.)']",['Eli Lilly'],1,"['Gilead Sciences(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC)']",感染领域,皮肤/皮肤结构感染,"['感染领域', '皮肤领域']",2,感染领域,皮肤领域,,5,5,Infectious Diseases,Infectious Diseases,Dermatology,,Skin/skin structure infection,daptomycin,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin
达托霉素,not available,脂肽类抗生素,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),菌血症(差异化疾病),批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,脂肽类抗生素,创新药,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,,感染领域,,DR038793,否,美国,未知,,,,,approved,批准上市,2003-09-12,approved,3,True,False,True,"['Gilead Sciences', 'Eli Lilly', 'Cubist Pharmaceuticals(Merck & Co.)']",['Eli Lilly'],1,"['Gilead Sciences(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC)']",感染领域,菌血症,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,bacteremia,daptomycin,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin
达托霉素,not available,脂肽类抗生素,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),细菌性心内膜炎(差异化疾病),批准上市,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,脂肽类抗生素,创新药,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,,感染领域;心脑血管领域,,DR038793,否,美国,未知,,,,,approved,批准上市,2003-09-12,approved,3,True,False,True,"['Gilead Sciences', 'Eli Lilly', 'Cubist Pharmaceuticals(Merck & Co.)']",['Eli Lilly'],1,"['Gilead Sciences(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC)']",感染领域,细菌性心内膜炎,"['感染领域', '心脑血管领域']",2,感染领域,心脑血管领域,,5,5,Infectious Diseases,Infectious Diseases,Cardiovascular & Cerebrovascular,,bacterial endocarditis,daptomycin,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin
达托霉素,not available,脂肽类抗生素,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),社区获得性细菌性肺炎(差异化疾病),III期临床,,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,脂肽类抗生素,创新药,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,,感染领域;呼吸领域,,DR038793,否,美国,未知,,,,,phase 3,批准上市,2003-09-12,approved,3,True,False,True,"['Gilead Sciences', 'Eli Lilly', 'Cubist Pharmaceuticals(Merck & Co.)']",['Eli Lilly'],1,"['Gilead Sciences(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC)']",感染领域,社区获得性细菌性肺炎,"['感染领域', '呼吸领域']",2,感染领域,呼吸领域,,5,3,Infectious Diseases,Infectious Diseases,Respiratory,,community acquired bacterial pneumonia,daptomycin,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin
达托霉素,not available,脂肽类抗生素,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),骨髓炎(差异化疾病),III期临床,,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,脂肽类抗生素,创新药,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,,感染领域,,DR038793,否,美国,未知,,,,,phase 3,批准上市,2003-09-12,approved,3,True,False,True,"['Gilead Sciences', 'Eli Lilly', 'Cubist Pharmaceuticals(Merck & Co.)']",['Eli Lilly'],1,"['Gilead Sciences(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC)']",感染领域,骨髓炎,['感染领域'],1,感染领域,,,5,3,Infectious Diseases,Infectious Diseases,,,osteomyelitis,daptomycin,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin
达托霉素,not available,脂肽类抗生素,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),糖尿病足感染(差异化疾病),III期临床,,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,脂肽类抗生素,创新药,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,,感染领域,,DR038793,否,美国,未知,,,,,phase 3,批准上市,2003-09-12,approved,3,True,False,True,"['Gilead Sciences', 'Eli Lilly', 'Cubist Pharmaceuticals(Merck & Co.)']",['Eli Lilly'],1,"['Gilead Sciences(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC)']",感染领域,糖尿病足感染,['感染领域'],1,感染领域,,,5,3,Infectious Diseases,Infectious Diseases,,,diabetic foot infection,daptomycin,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin
达托霉素,not available,脂肽类抗生素,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),腹膜炎(差异化疾病),II/III期临床,,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,脂肽类抗生素,创新药,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,,感染领域,,DR038793,否,美国,未知,,,,,phase 3,批准上市,2003-09-12,approved,3,True,False,True,"['Gilead Sciences', 'Eli Lilly', 'Cubist Pharmaceuticals(Merck & Co.)']",['Eli Lilly'],1,"['Gilead Sciences(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC)']",感染领域,腹膜炎,['感染领域'],1,感染领域,,,5,3,Infectious Diseases,Infectious Diseases,,,peritonitis,daptomycin,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin
卡贝缩宫素,oxytocin,oxytocin类似物,Ferring Pharmaceuticals(原研),产后子宫收缩乏力(差异化疾病),批准上市,,Active,小分子,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,卡贝缩宫素;carbetocin;卡比托辛;Duratocin;巧特欣,,泌尿生殖领域,批准上市:注射剂,DR016036,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,2004-10-20,approved,1,True,False,False,[],['Ferring Pharmaceuticals'],1,['Ferring Pharmaceuticals(原研)'],泌尿生殖领域,产后子宫收缩乏力,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,,Postpartum uterine atony,carbetocin,卡贝缩宫素;carbetocin;卡比托辛;Duratocin;巧特欣
卡贝缩宫素,oxytocin,oxytocin类似物,Ferring Pharmaceuticals(原研),产后子宫出血(差异化疾病),批准上市,,Active,小分子,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,卡贝缩宫素;carbetocin;卡比托辛;Duratocin;巧特欣,,泌尿生殖领域,批准上市:注射剂,DR016036,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,2004-10-20,approved,1,True,False,False,[],['Ferring Pharmaceuticals'],1,['Ferring Pharmaceuticals(原研)'],泌尿生殖领域,产后子宫出血,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,,Postpartum uterine bleeding,carbetocin,卡贝缩宫素;carbetocin;卡比托辛;Duratocin;巧特欣
齐考诺肽,N-type calcium channel,N-type calcium channel阻断剂,Tersera;Neurex(Perrigo)(原研);Jazz Pharmaceuticals(无权益),慢性疼痛,批准上市,2004-12-28,Active,多肽,化药,环肽;First-in-Class;差异化疾病,阻断剂,创新药,齐考诺肽;ziconotide;Prialt;SNX-111,,麻醉镇痛领域,,DR026760,否,美国,未知,,批准上市,,2004-12-28,approved,批准上市,2004-12-28,approved,3,True,False,False,[],['Neurex(Perrigo)'],1,"['Tersera', 'Neurex(Perrigo)(原研)', 'Jazz Pharmaceuticals(无权益)']",麻醉镇痛领域,慢性疼痛,['麻醉镇痛领域'],1,麻醉镇痛领域,,,5,5,Anesthesia & Analgesia,Anesthesia & Analgesia,,,chronic pain,ziconotide,齐考诺肽;ziconotide;Prialt;SNX-111
齐考诺肽,N-type calcium channel,N-type calcium channel阻断剂,Tersera;Neurex(Perrigo)(原研);Jazz Pharmaceuticals(无权益),神经痛(差异化疾病),II期临床,2009-10-16,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,阻断剂,创新药,齐考诺肽;ziconotide;Prialt;SNX-111,,麻醉镇痛领域,,DR026760,否,美国,未知,,,,,phase 2,批准上市,2004-12-28,approved,3,True,False,False,[],['Neurex(Perrigo)'],1,"['Tersera', 'Neurex(Perrigo)(原研)', 'Jazz Pharmaceuticals(无权益)']",麻醉镇痛领域,神经痛,['麻醉镇痛领域'],1,麻醉镇痛领域,,,5,2,Anesthesia & Analgesia,Anesthesia & Analgesia,,,neuralgia,ziconotide,齐考诺肽;ziconotide;Prialt;SNX-111
普兰林肽,amylin,amylin类似物,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),1型糖尿病(差异化疾病),批准上市,2005-03-16,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,普兰林肽;pramlintide;Symlin;AC137,,内分泌及代谢领域,,DR062469,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,批准上市,2014-04-28,2005-03-16,approved,批准上市,2005-03-16,approved,2,True,False,True,"['Bristol-Myers Squibb', 'Amylin Pharmaceuticals(AstraZeneca)']",['Amylin Pharmaceuticals(AstraZeneca)'],1,"['Bristol-Myers Squibb(Top20 MNC)', 'Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研)']",内分泌及代谢领域,1型糖尿病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,type 1 diabetes,pramlintide,普兰林肽;pramlintide;Symlin;AC137
普兰林肽,amylin,amylin类似物,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),2型糖尿病,批准上市,2005-03-16,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,普兰林肽;pramlintide;Symlin;AC137,,内分泌及代谢领域,,DR062469,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,批准上市,2014-03-25,2005-03-16,approved,批准上市,2005-03-16,approved,2,True,False,True,"['Bristol-Myers Squibb', 'Amylin Pharmaceuticals(AstraZeneca)']",['Amylin Pharmaceuticals(AstraZeneca)'],1,"['Bristol-Myers Squibb(Top20 MNC)', 'Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研)']",内分泌及代谢领域,2型糖尿病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,type 2 diabetes,pramlintide,普兰林肽;pramlintide;Symlin;AC137
普兰林肽,amylin,amylin类似物,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),肥胖,II/III期临床,2024-10-01,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,普兰林肽;pramlintide;Symlin;AC137,,内分泌及代谢领域,,DR062469,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2002-08-01,phase 3,批准上市,2005-03-16,approved,2,True,False,True,"['Bristol-Myers Squibb', 'Amylin Pharmaceuticals(AstraZeneca)']",['Amylin Pharmaceuticals(AstraZeneca)'],1,"['Bristol-Myers Squibb(Top20 MNC)', 'Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研)']",内分泌及代谢领域,肥胖,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,,obesity,pramlintide,普兰林肽;pramlintide;Symlin;AC137
普兰林肽,amylin,amylin类似物,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),糖尿病前期(差异化疾病),II/III期临床,2024-10-01,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,普兰林肽;pramlintide;Symlin;AC137,,内分泌及代谢领域,,DR062469,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,2005-03-16,approved,2,True,False,True,"['Bristol-Myers Squibb', 'Amylin Pharmaceuticals(AstraZeneca)']",['Amylin Pharmaceuticals(AstraZeneca)'],1,"['Bristol-Myers Squibb(Top20 MNC)', 'Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研)']",内分泌及代谢领域,糖尿病前期,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,,prediabetes,pramlintide,普兰林肽;pramlintide;Symlin;AC137
普兰林肽,amylin,amylin类似物,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),超重,II期临床,2002-08-01,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,普兰林肽;pramlintide;Symlin;AC137,,内分泌及代谢领域,,DR062469,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2002-08-01,phase 2,批准上市,2005-03-16,approved,2,True,False,True,"['Bristol-Myers Squibb', 'Amylin Pharmaceuticals(AstraZeneca)']",['Amylin Pharmaceuticals(AstraZeneca)'],1,"['Bristol-Myers Squibb(Top20 MNC)', 'Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研)']",内分泌及代谢领域,超重,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,overweight,pramlintide,普兰林肽;pramlintide;Symlin;AC137
普兰林肽,amylin,amylin类似物,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),糖尿病,I/II期临床,2010-07-20,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,普兰林肽;pramlintide;Symlin;AC137,,内分泌及代谢领域,,DR062469,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2010-07-20,phase 2,批准上市,2005-03-16,approved,2,True,False,True,"['Bristol-Myers Squibb', 'Amylin Pharmaceuticals(AstraZeneca)']",['Amylin Pharmaceuticals(AstraZeneca)'],1,"['Bristol-Myers Squibb(Top20 MNC)', 'Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研)']",内分泌及代谢领域,糖尿病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,diabetes,pramlintide,普兰林肽;pramlintide;Symlin;AC137
普兰林肽,amylin,amylin类似物,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),低血糖症(差异化疾病),I期临床,2018-06-06,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,普兰林肽;pramlintide;Symlin;AC137,,内分泌及代谢领域,,DR062469,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2018-06-06,phase 1,批准上市,2005-03-16,approved,2,True,False,True,"['Bristol-Myers Squibb', 'Amylin Pharmaceuticals(AstraZeneca)']",['Amylin Pharmaceuticals(AstraZeneca)'],1,"['Bristol-Myers Squibb(Top20 MNC)', 'Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研)']",内分泌及代谢领域,低血糖症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,hypoglycemia,pramlintide,普兰林肽;pramlintide;Symlin;AC137
普兰林肽,amylin,amylin类似物,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),代谢性骨病(差异化疾病),I期临床,2023-12-29,Active,多肽,化药,环肽;First-in-Class;差异化疾病,类似物,创新药,普兰林肽;pramlintide;Symlin;AC137,,骨骼肌肉领域;内分泌及代谢领域,,DR062469,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,2005-03-16,approved,2,True,False,True,"['Bristol-Myers Squibb', 'Amylin Pharmaceuticals(AstraZeneca)']",['Amylin Pharmaceuticals(AstraZeneca)'],1,"['Bristol-Myers Squibb(Top20 MNC)', 'Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研)']",骨骼肌肉领域,代谢性骨病,"['骨骼肌肉领域', '内分泌及代谢领域']",2,骨骼肌肉领域,内分泌及代谢领域,,5,1,Musculoskeletal,Musculoskeletal,Endocrinology & Metabolism,,metabolic bone disease,pramlintide,普兰林肽;pramlintide;Symlin;AC137
脑利钠肽,BNP,重组BNP,西藏药业(康哲药业)(原研),心力衰竭(差异化疾病),批准上市,,Active,多肽,生物,环肽;差异化疾病,重组,生物类似药,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,,心脑血管领域,批准上市:注射剂(冻干),DR014028,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,,,approved,批准上市,2005-03-31,approved,1,True,False,False,[],['西藏药业(康哲药业)'],1,['西藏药业(康哲药业)(原研)'],心脑血管领域,心力衰竭,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,heart failure,nesiritide biosimilar,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素
脑利钠肽,BNP,重组BNP,西藏药业(康哲药业)(原研),急性心力衰竭,I期临床,2025-11-16,Active,多肽,生物,环肽;差异化疾病,重组,生物类似药,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,,心脑血管领域,批准上市:注射剂(冻干),DR014028,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-11-16,,phase 1,批准上市,2005-03-31,approved,1,True,False,False,[],['西藏药业(康哲药业)'],1,['西藏药业(康哲药业)(原研)'],心脑血管领域,急性心力衰竭,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,acute heart failure,nesiritide biosimilar,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素
脑利钠肽,BNP,重组BNP,西藏药业(康哲药业)(原研),慢性心力衰竭(差异化疾病),I期临床,2025-12-17,Active,多肽,生物,环肽;差异化疾病,重组,生物类似药,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,,心脑血管领域,批准上市:注射剂(冻干),DR014028,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-12-17,,phase 1,批准上市,2005-03-31,approved,1,True,False,False,[],['西藏药业(康哲药业)'],1,['西藏药业(康哲药业)(原研)'],心脑血管领域,慢性心力衰竭,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,chronic heart failure,nesiritide biosimilar,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素
脑利钠肽,BNP,重组BNP,西藏药业(康哲药业)(原研),急性肾损伤(差异化疾病),I期临床,2020-07-26,Unknown,多肽,生物,环肽;差异化疾病,重组,生物类似药,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,,泌尿生殖领域,批准上市:注射剂(冻干),DR014028,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2020-07-26,,phase 1,批准上市,2005-03-31,approved,1,True,False,False,[],['西藏药业(康哲药业)'],1,['西藏药业(康哲药业)(原研)'],泌尿生殖领域,急性肾损伤,['泌尿生殖领域'],1,泌尿生殖领域,,,5,1,Genitourinary,Genitourinary,,,acute kidney injury,nesiritide biosimilar,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素
脑利钠肽,BNP,重组BNP,西藏药业(康哲药业)(原研),充血性心力衰竭(差异化疾病),I期临床,2008-11-04,Inactive,多肽,生物,环肽;差异化疾病,重组,生物类似药,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,,心脑血管领域,批准上市:注射剂(冻干),DR014028,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2008-11-04,,phase 1,批准上市,2005-03-31,approved,1,True,False,False,[],['西藏药业(康哲药业)'],1,['西藏药业(康哲药业)(原研)'],心脑血管领域,充血性心力衰竭,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,congestive heart failure,nesiritide biosimilar,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素
脑利钠肽,BNP,重组BNP,西藏药业(康哲药业)(原研),心脏病(差异化疾病),I期临床,2023-01-28,Active,多肽,生物,环肽;差异化疾病,重组,生物类似药,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,,心脑血管领域,批准上市:注射剂(冻干),DR014028,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2023-01-28,,phase 1,批准上市,2005-03-31,approved,1,True,False,False,[],['西藏药业(康哲药业)'],1,['西藏药业(康哲药业)(原研)'],心脑血管领域,心脏病,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,heart disease,nesiritide biosimilar,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素
脑利钠肽,BNP,重组BNP,西藏药业(康哲药业)(原研),急性失代偿性心力衰竭,I期临床,2025-06-11,Active,多肽,生物,环肽;差异化疾病,重组,生物类似药,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,,心脑血管领域,批准上市:注射剂(冻干),DR014028,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-06-11,,phase 1,批准上市,2005-03-31,approved,1,True,False,False,[],['西藏药业(康哲药业)'],1,['西藏药业(康哲药业)(原研)'],心脑血管领域,急性失代偿性心力衰竭,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,acute decompensated heart failure,nesiritide biosimilar,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素
脑利钠肽,BNP,重组BNP,苏兰生物(原研),参考原研,批准上市,,Active,多肽,生物,环肽,重组,生物类似药,脑利钠肽;布罗纳泰(重组人脑利钠肽);nesiritide biosimilar;布罗纳泰,,其他领域,批准上市:注射剂(冻干),DR015076,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,2005-05-10,approved,1,True,False,False,[],['苏兰生物'],1,['苏兰生物(原研)'],其他领域,参考原研,['其他领域'],1,其他领域,,,5,5,Others,Others,,,Reference original research,nesiritide biosimilar,脑利钠肽;布罗纳泰(重组人脑利钠肽);nesiritide biosimilar;布罗纳泰
Ikervis/Verkazia,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Novagali Pharma(Santen Pharmaceutical)(原研);Harrow,干眼病,批准上市,,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思,,眼科领域,批准上市:眼用乳剂,DR015576,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,II期临床,III期临床,2023-02-07,2011-03-29,approved,批准上市,2005-10-11,approved,2,True,False,False,[],['Novagali Pharma(Santen Pharmaceutical)'],1,"['Novagali Pharma(Santen Pharmaceutical)(原研)', 'Harrow']",眼科领域,干眼病,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,,dry eye disease,Ikervis/Verkazia (cyclosporine eye drop),Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思
Ikervis/Verkazia,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Novagali Pharma(Santen Pharmaceutical)(原研);Harrow,春季角结膜炎,批准上市,2018-07-06,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思,,眼科领域;罕见疾病领域,批准上市:眼用乳剂,DR015576,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,批准上市,2022-05-07,2021-06-24,approved,批准上市,2005-10-11,approved,2,True,True,False,[],['Novagali Pharma(Santen Pharmaceutical)'],1,"['Novagali Pharma(Santen Pharmaceutical)(原研)', 'Harrow']",眼科领域,春季角结膜炎,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,,Vernal keratoconjunctivitis,Ikervis/Verkazia (cyclosporine eye drop),Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思
Ikervis/Verkazia,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Novagali Pharma(Santen Pharmaceutical)(原研);Harrow,角膜炎,III期临床,2019-02-08,Inactive,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思,,眼科领域,批准上市:眼用乳剂,DR015576,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,2005-10-11,approved,2,True,False,False,[],['Novagali Pharma(Santen Pharmaceutical)'],1,"['Novagali Pharma(Santen Pharmaceutical)(原研)', 'Harrow']",眼科领域,角膜炎,['眼科领域'],1,眼科领域,,,5,3,Ophthalmology,Ophthalmology,,,keratitis,Ikervis/Verkazia (cyclosporine eye drop),Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思
Ikervis/Verkazia,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Novagali Pharma(Santen Pharmaceutical)(原研);Harrow,角结膜炎,II期临床,2023-12-13,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思,,眼科领域,批准上市:眼用乳剂,DR015576,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2005-10-11,approved,2,True,False,False,[],['Novagali Pharma(Santen Pharmaceutical)'],1,"['Novagali Pharma(Santen Pharmaceutical)(原研)', 'Harrow']",眼科领域,角结膜炎,['眼科领域'],1,眼科领域,,,5,2,Ophthalmology,Ophthalmology,,,keratoconjunctivitis,Ikervis/Verkazia (cyclosporine eye drop),Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思
阿尼芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),念珠菌病,批准上市,2006-02-17,Active,多肽,化药,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,,感染领域,申报临床:注射剂(冻干),DR031838,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,申报临床,批准上市,2016-01-28,2006-02-17,approved,批准上市,2006-02-17,approved,3,True,False,True,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",感染领域,念珠菌病,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,candidiasis,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002
阿尼芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),念珠菌血症,批准上市,2006-02-17,Active,多肽,化药,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,,感染领域,申报临床:注射剂(冻干),DR031838,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,批准上市,2010-08-05,2006-02-17,approved,批准上市,2006-02-17,approved,3,True,False,True,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",感染领域,念珠菌血症,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,candidemia,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002
阿尼芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),真菌感染,III期临床,2008-12-10,Inactive,多肽,化药,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,,感染领域,申报临床:注射剂(冻干),DR031838,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,I/II期临床,2019-08-13,2003-09-11,phase 3,批准上市,2006-02-17,approved,3,True,False,True,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",感染领域,真菌感染,['感染领域'],1,感染领域,,,5,3,Infectious Diseases,Infectious Diseases,,,fungal infection,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002
阿尼芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),侵袭性念珠菌病,III期临床,2008-06-03,Inactive,多肽,化药,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,,感染领域,申报临床:注射剂(冻干),DR031838,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2008-09-29,phase 3,批准上市,2006-02-17,approved,3,True,False,True,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",感染领域,侵袭性念珠菌病,['感染领域'],1,感染领域,,,5,3,Infectious Diseases,Infectious Diseases,,,Invasive candidiasis,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002
阿尼芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),侵袭性曲霉病,III期临床,2007-09-18,Active,多肽,化药,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,,感染领域,申报临床:注射剂(冻干),DR031838,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2007-09-18,phase 3,批准上市,2006-02-17,approved,3,True,False,True,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",感染领域,侵袭性曲霉病,['感染领域'],1,感染领域,,,5,3,Infectious Diseases,Infectious Diseases,,,Invasive aspergillosis,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002
阿尼芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),呼吸机相关性细菌性肺炎(差异化疾病),II期临床,2009-07-08,Inactive,多肽,化药,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,,感染领域;呼吸领域,申报临床:注射剂(冻干),DR031838,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2006-02-17,approved,3,True,False,True,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",感染领域,呼吸机相关性细菌性肺炎,"['感染领域', '呼吸领域']",2,感染领域,呼吸领域,,5,2,Infectious Diseases,Infectious Diseases,Respiratory,,ventilator-associated bacterial pneumonia,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002
阿尼芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),血液系统肿瘤(差异化疾病),II期临床,2010-01-22,Inactive,多肽,化药,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,,肿瘤领域;血液领域,申报临床:注射剂(冻干),DR031838,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2006-02-17,approved,3,True,False,True,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",肿瘤领域,血液系统肿瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,hematological tumors,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002
阿尼芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),食管念珠菌感染,II期临床,2002-07-16,Inactive,多肽,化药,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,,感染领域,申报临床:注射剂(冻干),DR031838,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,II期临床,2019-08-08,2002-07-16,phase 2,批准上市,2006-02-17,approved,3,True,False,True,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",感染领域,食管念珠菌感染,['感染领域'],1,感染领域,,,5,2,Infectious Diseases,Infectious Diseases,,,Esophageal Candida Infection,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002
阿尼芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),中性粒细胞减少症(差异化疾病),I/II期临床,2003-03-12,Inactive,多肽,化药,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,,血液领域;罕见疾病领域,申报临床:注射剂(冻干),DR031838,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2003-03-12,phase 2,批准上市,2006-02-17,approved,3,True,True,True,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",血液领域,中性粒细胞减少症,['血液领域'],1,血液领域,,,5,2,Hematology,Hematology,,,neutropenia,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002
阿尼芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),感染,I期临床,2007-06-26,Inactive,多肽,化药,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,,感染领域,申报临床:注射剂(冻干),DR031838,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2007-06-26,phase 1,批准上市,2006-02-17,approved,3,True,False,True,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",感染领域,感染,['感染领域'],1,感染领域,,,5,1,Infectious Diseases,Infectious Diseases,,,Infect,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002
阿尼芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),腹膜炎(差异化疾病),I期临床,2019-08-08,Inactive,多肽,化药,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,,感染领域,申报临床:注射剂(冻干),DR031838,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2019-08-08,,phase 1,批准上市,2006-02-17,approved,3,True,False,True,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",感染领域,腹膜炎,['感染领域'],1,感染领域,,,5,1,Infectious Diseases,Infectious Diseases,,,peritonitis,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002
阿尼芬净,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),腹腔脓肿(差异化疾病),申报临床,2015-06-30,Inactive,多肽,化药,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,创新药,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,,感染领域,申报临床:注射剂(冻干),DR031838,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,申报临床,,2015-06-30,,ind,批准上市,2006-02-17,approved,3,True,False,True,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",感染领域,腹腔脓肿,['感染领域'],1,感染领域,,,5,0,Infectious Diseases,Infectious Diseases,,,abdominal abscess,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),外周T细胞淋巴瘤,批准上市,2011-06-16,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,批准上市,,2011-06-16,approved,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,外周T细胞淋巴瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,peripheral T-cell lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),皮肤T细胞淋巴瘤,批准上市,2009-11-05,Active,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,批准上市,,2009-11-05,approved,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,皮肤T细胞淋巴瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,Cutaneous T-cell lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),血管免疫母细胞性T细胞淋巴瘤,III期临床,2018-07-19,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,血液领域;肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2017-09-12,phase 3,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,血管免疫母细胞性T细胞淋巴瘤,"['血液领域', '肿瘤领域']",2,血液领域,肿瘤领域,,5,3,Oncology,Hematology,Oncology,,angioimmunoblastic T-cell lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),HIV-1感染,II期临床,2015-11-25,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,感染领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2015-11-25,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",感染领域,HIV-1感染,['感染领域'],1,感染领域,,,5,2,Infectious Diseases,Infectious Diseases,,,HIV-1 infection,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),非小细胞肺癌,II期临床,2007-03-05,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2007-03-05,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,non-small cell lung cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),小细胞肺癌,II期临床,2004-07-12,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-07-12,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,small cell lung cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),胃癌,II期临床,2004-12-08,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-12-08,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,胃癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,stomach cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),食管癌,II期临床,2004-12-08,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-12-08,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,食管癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Esophageal cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),乳腺癌,II期临床,2004-12-08,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-12-08,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,breast cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),黑色素瘤,II期临床,2005-03-04,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2012-07-11,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,黑色素瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,melanoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),卵巢癌,II期临床,2004-06-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-06-11,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,卵巢癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,ovarian cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),前列腺癌,II期临床,2005-03-25,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2012-07-11,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,前列腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,prostate cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),肾细胞癌,II期临床,2005-03-23,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2005-03-23,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,肾细胞癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,renal cell carcinoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),尿路上皮癌,II期临床,2004-07-12,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,尿路上皮癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,urothelial carcinoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),急性髓系白血病,II期临床,2003-01-27,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2003-01-27,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,急性髓系白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,acute myeloid leukemia,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),急性早幼粒细胞白血病,II期临床,2003-06-06,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2003-06-06,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,急性早幼粒细胞白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,acute promyelocytic leukemia,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),淋巴瘤,II期临床,2011-05-16,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2011-05-16,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,Lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),非霍奇金淋巴瘤,II期临床,2003-01-27,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2003-01-27,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,非霍奇金淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,non-hodgkin lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),弥漫性大B细胞淋巴瘤,II期临床,2006-10-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2006-10-03,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,弥漫性大B细胞淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,Diffuse large B-cell lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),滤泡性淋巴瘤,II期临床,2004-03-10,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-03-10,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,滤泡性淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,follicular lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),套细胞淋巴瘤,II期临床,2006-10-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2006-10-03,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,套细胞淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,mantle cell lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),间变性大细胞淋巴瘤,II期临床,2018-05-23,Unknown,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2018-05-23,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,间变性大细胞淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,anaplastic large cell lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),多发性骨髓瘤,II期临床,2003-08-07,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2003-08-07,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,多发性骨髓瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,multiple myeloma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),骨髓增生异常综合征,II期临床,2003-01-27,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2003-01-27,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,骨髓增生异常综合征,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,myelodysplastic syndrome,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),结直肠癌,II期临床,2004-02-12,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-02-12,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,结直肠癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,colorectal cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),脂肪肉瘤(差异化疾病),II期临床,2005-06-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2012-02-23,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,脂肪肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,liposarcoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),平滑肌肉瘤,II期临床,2005-06-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,平滑肌肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Leiomyosarcoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),滑膜肉瘤(差异化疾病),II期临床,2005-06-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,滑膜肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,synovial sarcoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),纤维肉瘤(差异化疾病),II期临床,2005-06-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,纤维肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Fibrosarcoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),横纹肌肉瘤,II期临床,2005-06-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,横纹肌肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,rhabdomyosarcoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),胃泌素瘤(差异化疾病),II期临床,2004-06-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-06-11,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,胃泌素瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,gastrinoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),尤文氏肉瘤,II期临床,2005-06-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,尤文氏肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Ewing's sarcoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),胃肠道间质瘤(差异化疾病),II期临床,2005-06-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,胃肠道间质瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,gastrointestinal stromal tumor,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),腹膜癌,II期临床,2004-09-09,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-09-09,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,腹膜癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,peritoneal cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),去势抵抗前列腺癌,II期临床,2005-03-23,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2005-03-23,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,去势抵抗前列腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Castration-resistant prostate cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),胰岛细胞瘤(差异化疾病),II期临床,2004-06-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-06-11,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,胰岛细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,islet cell tumor,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),喉癌,II期临床,2004-06-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-06-11,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,喉癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Throat cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),头颈部鳞状细胞癌,II期临床,2004-06-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-06-11,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,头颈部鳞状细胞癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Head and neck squamous cell carcinoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),小淋巴细胞性淋巴瘤,II期临床,2004-03-10,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-03-10,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,小淋巴细胞性淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,small lymphocytic lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),血管肉瘤(差异化疾病),II期临床,2005-06-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,血管肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,angiosarcoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),口腔癌(差异化疾病),II期临床,2004-06-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-06-11,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,口腔癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,oral cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),恶性外周神经鞘膜瘤,II期临床,2005-06-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,恶性外周神经鞘膜瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,malignant peripheral nerve sheath tumor,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),胃食管交界处癌,II期临床,2004-12-08,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-12-08,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,胃食管交界处癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,gastroesophageal junction cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),上皮样肉瘤(差异化疾病),II期临床,2005-06-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,上皮样肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,epithelioid sarcoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),原发性神经外胚层肿瘤,II期临床,2005-06-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,原发性神经外胚层肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,primary neuroectodermal tumor,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),乳头状甲状腺癌,II期临床,2004-12-09,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-12-09,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,乳头状甲状腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,papillary thyroid cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),软骨肉瘤,II期临床,2005-06-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,软骨肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Chondrosarcoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),下咽癌,II期临床,2004-06-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-06-11,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,下咽癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,hypopharyngeal cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),血管外皮瘤(差异化疾病),II期临床,2005-06-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,血管外皮瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,hemangioperithelioma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),唇癌(差异化疾病),II期临床,2004-06-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-06-11,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,唇癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,lip cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),滤泡状甲状腺癌,II期临床,2004-12-09,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-12-09,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,滤泡状甲状腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,follicular thyroid cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),未分化多形性肉瘤(差异化疾病),II期临床,2005-06-03,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,未分化多形性肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,undifferentiated pleomorphic sarcoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),肺类癌(差异化疾病),II期临床,2004-06-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2004-06-11,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,肺类癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,lung carcinoid,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),三阴性乳腺癌,I/II期临床,2015-03-19,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2015-03-19,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,三阴性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,triple negative breast cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),霍奇金淋巴瘤,I/II期临床,2013-11-28,Unknown,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2013-11-28,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,霍奇金淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,Hodgkin lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),蕈样肉芽肿,I/II期临床,2017-09-12,Unknown,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2017-09-12,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,蕈样肉芽肿,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Mycosis fungoides,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),胰腺导管癌,I/II期临床,2020-02-06,Active,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,pancreatic ductal carcinoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),T细胞淋巴瘤,I/II期临床,2015-01-19,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2015-01-19,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,T细胞淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,T cell lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),高级别胶质瘤,I/II期临床,2004-06-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2004-06-11,phase 2,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,高级别胶质瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,high grade glioma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),肺癌,I期临床,2012-07-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2012-07-11,phase 1,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,肺癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,lung cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),胰腺癌,I期临床,2006-09-22,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2006-09-22,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,pancreatic cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),头颈癌,I期临床,2012-07-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2012-07-11,phase 1,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,头颈癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Head and neck cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),膀胱癌,I期临床,2012-07-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2012-07-11,phase 1,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,膀胱癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,bladder cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),胶质瘤,I期临床,2012-07-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2012-07-11,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,胶质瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,glioma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),胶质母细胞瘤,I期临床,2003-02-06,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2003-02-06,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,胶质母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,glioblastoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),髓母细胞瘤,I期临床,2003-02-06,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2003-02-06,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,髓母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,medulloblastoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),甲状腺癌,I期临床,2002-10-30,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2002-10-30,phase 1,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,甲状腺癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Thyroid cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),白血病,I期临床,2005-06-14,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2005-06-14,phase 1,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,,leukemia,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),急性淋巴细胞白血病,I期临床,2003-01-27,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2003-01-27,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,急性淋巴细胞白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,,acute lymphoblastic leukemia,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),慢性淋巴细胞白血病,I期临床,2003-01-27,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2003-01-27,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,慢性淋巴细胞白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,,chronic lymphocytic leukemia,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),慢性髓系白血病,I期临床,2003-02-06,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2003-02-06,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,慢性髓系白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,,chronic myeloid leukemia,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),成人T细胞白血病/淋巴瘤,I期临床,2020-11-23,Unknown,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2020-11-23,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,成人T细胞白血病/淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,,Adult T-cell leukemia/lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),移植物抗宿主病,I期临床,2014-07-30,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,免疫领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2014-07-30,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",免疫领域,移植物抗宿主病,['免疫领域'],1,免疫领域,,,5,1,Immunology,Immunology,,,graft versus host disease,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),神经内分泌肿瘤,I期临床,2012-07-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2012-07-11,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,neuroendocrine tumors,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),肉瘤,I期临床,2004-10-29,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2004-10-29,phase 1,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,sarcoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),软组织肉瘤,I期临床,2012-07-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2012-07-11,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,软组织肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,soft tissue sarcoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),睾丸癌(差异化疾病),I期临床,2002-05-22,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2002-05-22,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,睾丸癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,testicular cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),间皮瘤,I期临床,2002-05-22,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2002-05-22,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,间皮瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Mesothelioma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),胸膜间皮瘤,I期临床,2004-10-29,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2004-10-29,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,胸膜间皮瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Pleural mesothelioma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),塞泽里综合征,I期临床,2012-11-30,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,罕见疾病领域;肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2012-11-30,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,塞泽里综合征,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Seseli syndrome,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),伯基特淋巴瘤,I期临床,2013-07-11,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2013-07-11,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,伯基特淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,,Burkitt lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),T细胞血癌,I期临床,2015-07-31,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2015-07-31,phase 1,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,T细胞血癌,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,,T cell blood cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),生殖细胞瘤,I期临床,2003-02-06,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2003-02-06,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,生殖细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,germ cell tumor,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),室管膜瘤,I期临床,2003-02-06,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2003-02-06,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,室管膜瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,ependymoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),低级别星形细胞瘤,I期临床,2003-02-06,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2003-02-06,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,低级别星形细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,low grade astrocytoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),脑膜瘤,I期临床,2003-02-06,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2003-02-06,phase 1,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,脑膜瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Meningioma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),肌层浸润性膀胱癌,I期临床,2025-05-09,Active,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2025-05-09,phase 1,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,肌层浸润性膀胱癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,muscle invasive bladder cancer,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),颅咽管瘤,I期临床,2003-02-06,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2003-02-06,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,颅咽管瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,craniopharyngioma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),肠病相关T细胞淋巴瘤,I期临床,2020-11-23,Unknown,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;血液领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2020-11-23,phase 1,批准上市,2009-11-05,approved,2,True,False,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,肠病相关T细胞淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,,Enteropathy-associated T-cell lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),结外NK/T细胞淋巴瘤,I期临床,2013-07-31,Unknown,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,血液领域;肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2020-11-23,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,结外NK/T细胞淋巴瘤,"['血液领域', '肿瘤领域']",2,血液领域,肿瘤领域,,5,1,Oncology,Hematology,Oncology,,Extranodal NK/T cell lymphoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),脉络丛肿瘤,I期临床,2003-02-06,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2003-02-06,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,脉络丛肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,choroid plexus tumors,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
罗米地辛,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),胸腺瘤,I期临床,2004-10-29,Inactive,小分子,化药,环肽;差异化疾病;表观遗传,抑制剂,创新药,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,,肿瘤领域;罕见疾病领域,,DR057058,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2004-10-29,phase 1,批准上市,2009-11-05,approved,2,True,True,True,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,胸腺瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,thymoma,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide
艾卡拉肽,PKK,PKK抑制剂,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),遗传性血管性水肿,批准上市,2009-12-01,Active,多肽,生物,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,,皮肤领域;罕见疾病领域,,DR003372,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,批准上市,,2009-12-01,approved,批准上市,2009-12-01,approved,3,True,True,True,"['Dyax(Takeda Pharmaceuticals)', 'Fovea Pharmaceuticals(Sanofi)']",['Dyax(Takeda Pharmaceuticals)'],1,"['Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'CVie Therapeutics(Windtree Therapeutics)', 'Fovea Pharmaceuticals(Sanofi)(Top20 MNC)']",皮肤领域,遗传性血管性水肿,['皮肤领域'],1,皮肤领域,,,5,5,Dermatology,Dermatology,,,hereditary angioedema,ecallantide,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302
艾卡拉肽,PKK,PKK抑制剂,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),心血管手术,II期临床,2009-04-28,Inactive,多肽,生物,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,,心脑血管领域,,DR003372,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2009-04-28,phase 2,批准上市,2009-12-01,approved,3,True,False,True,"['Dyax(Takeda Pharmaceuticals)', 'Fovea Pharmaceuticals(Sanofi)']",['Dyax(Takeda Pharmaceuticals)'],1,"['Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'CVie Therapeutics(Windtree Therapeutics)', 'Fovea Pharmaceuticals(Sanofi)(Top20 MNC)']",心脑血管领域,心血管手术,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,cardiovascular surgery,ecallantide,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302
艾卡拉肽,PKK,PKK抑制剂,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),冠脉搭桥术(差异化疾病),II期临床,2008-12-31,Inactive,多肽,生物,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,,心脑血管领域,,DR003372,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2008-12-31,phase 2,批准上市,2009-12-01,approved,3,True,False,True,"['Dyax(Takeda Pharmaceuticals)', 'Fovea Pharmaceuticals(Sanofi)']",['Dyax(Takeda Pharmaceuticals)'],1,"['Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'CVie Therapeutics(Windtree Therapeutics)', 'Fovea Pharmaceuticals(Sanofi)(Top20 MNC)']",心脑血管领域,冠脉搭桥术,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,coronary artery bypass grafting,ecallantide,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302
艾卡拉肽,PKK,PKK抑制剂,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),视网膜静脉阻塞(差异化疾病),II期临床,,Inactive,多肽,生物,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,,眼科领域,,DR003372,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2009-12-01,approved,3,True,False,True,"['Dyax(Takeda Pharmaceuticals)', 'Fovea Pharmaceuticals(Sanofi)']",['Dyax(Takeda Pharmaceuticals)'],1,"['Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'CVie Therapeutics(Windtree Therapeutics)', 'Fovea Pharmaceuticals(Sanofi)(Top20 MNC)']",眼科领域,视网膜静脉阻塞,['眼科领域'],1,眼科领域,,,5,2,Ophthalmology,Ophthalmology,,,retinal vein occlusion,ecallantide,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302
艾卡拉肽,PKK,PKK抑制剂,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),出血(差异化疾病),II期临床,2007-03-19,Inactive,多肽,生物,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,,其他领域,,DR003372,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2007-03-19,phase 2,批准上市,2009-12-01,approved,3,True,False,True,"['Dyax(Takeda Pharmaceuticals)', 'Fovea Pharmaceuticals(Sanofi)']",['Dyax(Takeda Pharmaceuticals)'],1,"['Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'CVie Therapeutics(Windtree Therapeutics)', 'Fovea Pharmaceuticals(Sanofi)(Top20 MNC)']",其他领域,出血,['其他领域'],1,其他领域,,,5,2,Others,Others,,,Bleeding,ecallantide,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302
艾卡拉肽,PKK,PKK抑制剂,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),ACE抑制剂引起的血管性水肿(差异化疾病),II期临床,2009-12-21,Active,多肽,生物,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,,心脑血管领域,,DR003372,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2009-12-21,phase 2,批准上市,2009-12-01,approved,3,True,False,True,"['Dyax(Takeda Pharmaceuticals)', 'Fovea Pharmaceuticals(Sanofi)']",['Dyax(Takeda Pharmaceuticals)'],1,"['Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'CVie Therapeutics(Windtree Therapeutics)', 'Fovea Pharmaceuticals(Sanofi)(Top20 MNC)']",心脑血管领域,ACE抑制剂引起的血管性水肿,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Angioedema caused by ACE inhibitors,ecallantide,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302
艾卡拉肽,PKK,PKK抑制剂,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),黄斑水肿,I期临床,2009-09-01,Inactive,多肽,生物,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,,眼科领域,,DR003372,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,2009-12-01,approved,3,True,False,True,"['Dyax(Takeda Pharmaceuticals)', 'Fovea Pharmaceuticals(Sanofi)']",['Dyax(Takeda Pharmaceuticals)'],1,"['Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'CVie Therapeutics(Windtree Therapeutics)', 'Fovea Pharmaceuticals(Sanofi)(Top20 MNC)']",眼科领域,黄斑水肿,['眼科领域'],1,眼科领域,,,5,1,Ophthalmology,Ophthalmology,,,macular edema,ecallantide,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),肢端肥大症,批准上市,2014-11-24,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,内分泌及代谢领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,批准上市,III期临床,2015-05-05,2008-01-25,approved,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",内分泌及代谢领域,肢端肥大症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,acromegaly,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),库欣综合征(差异化疾病),批准上市,2012-04-24,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,内分泌及代谢领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,批准上市,批准上市,2015-05-05,2012-12-14,approved,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",内分泌及代谢领域,库欣综合征,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Cushing's syndrome,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),类癌,III期临床,2008-06-04,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,III期临床,,2008-06-04,phase 3,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,类癌,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,carcinoid,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),胰瘘,III期临床,2009-10-14,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,消化领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,III期临床,,2009-10-14,phase 3,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",消化领域,胰瘘,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,,pancreatic fistula,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),多囊肝病,III期临床,2014-01-29,Unknown,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,消化领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2012-08-21,phase 3,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",消化领域,多囊肝病,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,,polycystic liver disease,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),泌乳素瘤(差异化疾病),II/III期临床,2012-06-15,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2024-03-06,phase 3,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,泌乳素瘤,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,prolactinoma,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),小细胞肺癌(差异化疾病),II期临床,2011-08-16,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2011-08-16,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,small cell lung cancer,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),肝细胞癌,II期临床,2011-12-08,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2011-12-08,phase 2,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,肝细胞癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,hepatocellular carcinoma,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),乳腺癌,II期临床,2011-05-20,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,I期临床,,2011-06-14,phase 2,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,breast cancer,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),胰腺癌,II期临床,2009-08-13,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2009-08-13,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,pancreatic cancer,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),髓样甲状腺癌(差异化疾病),II期临床,2011-01-05,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2011-01-05,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,髓样甲状腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,medullary thyroid cancer,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),多发性骨髓瘤(差异化疾病),II期临床,2010-11-04,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;血液领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2010-11-04,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,多发性骨髓瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,multiple myeloma,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),糖尿病,II期临床,2010-05-21,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,内分泌及代谢领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2010-05-21,phase 2,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",内分泌及代谢领域,糖尿病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,diabetes,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),低血糖症,II期临床,,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,内分泌及代谢领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,,,,phase 2,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",内分泌及代谢领域,低血糖症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,hypoglycemia,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),移植物抗宿主病(差异化疾病),II期临床,2014-08-13,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,免疫领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2014-08-13,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",免疫领域,移植物抗宿主病,['免疫领域'],1,免疫领域,,,5,2,Immunology,Immunology,,,graft versus host disease,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),多囊肾病,II期临床,2012-08-21,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,泌尿生殖领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2012-08-21,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",泌尿生殖领域,多囊肾病,['泌尿生殖领域'],1,泌尿生殖领域,,,5,2,Genitourinary,Genitourinary,,,polycystic kidney disease,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),丛集性头痛(差异化疾病),II期临床,2015-12-02,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,麻醉镇痛领域;神经领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2015-12-02,phase 2,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",麻醉镇痛领域,丛集性头痛,"['麻醉镇痛领域', '神经领域']",2,麻醉镇痛领域,神经领域,,5,2,Anesthesia & Analgesia,Anesthesia & Analgesia,Neurology,,cluster headache,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),神经内分泌肿瘤,II期临床,2010-12-03,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2010-12-03,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,neuroendocrine tumors,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),滑膜肉瘤(差异化疾病),II期临床,2024-06-13,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,,,,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,滑膜肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,synovial sarcoma,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),去势抵抗前列腺癌,II期临床,2011-03-11,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2011-03-11,phase 2,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,去势抵抗前列腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Castration-resistant prostate cancer,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),高胰岛素血症,II期临床,2017-02-15,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,内分泌及代谢领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,I期临床,,2016-07-15,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",内分泌及代谢领域,高胰岛素血症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,hyperinsulinemia,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),垂体瘤,II期临床,2009-06-29,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2009-06-29,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,垂体瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Pituitary tumor,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),胰腺神经内分泌肿瘤,II期临床,2011-06-16,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2011-06-16,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,胰腺神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,pancreatic neuroendocrine tumors,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),促结缔组织增生性小圆细胞瘤(差异化疾病),II期临床,2024-06-13,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,,,,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,促结缔组织增生性小圆细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,desmoplastic small round cell tumor,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),腹膜转移癌(差异化疾病),II期临床,2021-04-01,Unknown,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,,,,phase 2,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,腹膜转移癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,peritoneal metastasis cancer,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),脑膜瘤,II期临床,2008-12-23,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2008-12-23,phase 2,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,脑膜瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Meningioma,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),肺和胸腺类癌(差异化疾病),II期临床,,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,,,,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,肺和胸腺类癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Lung and thymic carcinoid tumors,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),倾倒综合征,II期临床,2012-07-11,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,消化领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2012-07-11,phase 2,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",消化领域,倾倒综合征,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,,dumping syndrome,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),葡萄膜黑色素瘤(差异化疾病),II期临床,2010-12-02,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2010-12-02,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,葡萄膜黑色素瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,uveal melanoma,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),胸腺瘤,II期临床,2013-12-27,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,,,,phase 2,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,胸腺瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,thymoma,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),减肥术后低血糖症(差异化疾病),II期临床,2023-07-03,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,消化领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2023-07-03,phase 2,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",消化领域,减肥术后低血糖症,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,,Hypoglycemia after bariatric surgery,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),甲状腺腺瘤,II期临床,2009-06-29,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,II期临床,,2009-06-29,phase 2,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,甲状腺腺瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Thyroid adenoma,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),巨人症(差异化疾病),II期临床,2012-08-28,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,内分泌及代谢领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,,,,phase 2,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",内分泌及代谢领域,巨人症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,gigantism,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),原位导管癌(差异化疾病),I/II期临床,2011-06-14,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,I/II期临床,,2011-06-14,phase 2,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,原位导管癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Ductal carcinoma in situ,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),黑色素瘤,I期临床,2012-07-30,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,,,,phase 1,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,黑色素瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,melanoma,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),Merkel细胞瘤,I期临床,2012-07-30,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,,,,phase 1,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,Merkel细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Merkel cell tumor,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),胃肠胰神经内分泌肿瘤,I期临床,2010-12-20,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域;罕见疾病领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,,,,phase 1,批准上市,2012-04-24,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),癌症肝转移(差异化疾病),I期临床,2011-11-10,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,I期临床,,2011-11-10,phase 1,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,癌症肝转移,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,cancer liver metastasis,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
帕瑞肽,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),消化道癌症,I期临床,2011-09-14,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,,肿瘤领域,批准上市:注射剂;注射剂(微球),DR015961,否,欧洲,,,I期临床,,2011-09-14,phase 1,批准上市,2012-04-24,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,消化道癌症,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,digestive tract cancer,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C
利那洛肽,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),便秘型肠易激综合征,批准上市,2012-08-30,Active,多肽,化药,环肽;First-in-Class;差异化疾病,激动剂,创新药,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,,消化领域,批准上市:胶囊剂,DR031924,否,美国,中国(港澳台);美国;欧洲;日本;其他,批准上市,批准上市,2018-12-18,2012-08-30,approved,批准上市,2012-08-30,approved,4,True,False,True,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,便秘型肠易激综合征,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,constipation irritable bowel syndrome,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246
利那洛肽,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),便秘,批准上市,2023-06-12,Active,多肽,化药,环肽;First-in-Class;差异化疾病,激动剂,创新药,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,,消化领域,批准上市:胶囊剂,DR031924,否,美国,中国(港澳台);美国;欧洲;日本;其他,I期临床,批准上市,2025-03-31,2023-06-12,approved,批准上市,2012-08-30,approved,4,True,False,True,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,便秘,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,constipate,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246
利那洛肽,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),慢性特发性便秘,批准上市,2012-08-30,Active,多肽,化药,环肽;First-in-Class;差异化疾病,激动剂,创新药,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,,消化领域,批准上市:胶囊剂,DR031924,否,美国,中国(港澳台);美国;欧洲;日本;其他,III期临床,批准上市,2021-03-18,2012-08-30,approved,批准上市,2012-08-30,approved,4,True,False,True,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,慢性特发性便秘,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,chronic idiopathic constipation,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246
利那洛肽,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),腹泻型肠易激综合征(差异化疾病),II期临床,2019-04-30,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,激动剂,创新药,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,,消化领域,批准上市:胶囊剂,DR031924,否,美国,中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2019-04-30,phase 2,批准上市,2012-08-30,approved,4,True,False,True,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,腹泻型肠易激综合征,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,,diarrhea-predominant irritable bowel syndrome,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246
利那洛肽,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),阿片类药物引起的便秘(差异化疾病),II期临床,2014-10-22,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,激动剂,创新药,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,,消化领域,批准上市:胶囊剂,DR031924,否,美国,中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2014-10-22,phase 2,批准上市,2012-08-30,approved,4,True,False,True,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,阿片类药物引起的便秘,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,,Opioid-induced constipation,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246
利那洛肽,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),肝性脑病(差异化疾病),II期临床,2020-10-19,Unknown,多肽,化药,环肽;First-in-Class;差异化疾病,激动剂,创新药,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,,消化领域,批准上市:胶囊剂,DR031924,否,美国,中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2012-08-30,approved,4,True,False,True,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,肝性脑病,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,,hepatic encephalopathy,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246
利那洛肽,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),结直肠癌(差异化疾病),II期临床,2019-01-08,Active,多肽,化药,环肽;First-in-Class;差异化疾病,激动剂,创新药,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,,肿瘤领域,批准上市:胶囊剂,DR031924,否,美国,中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2019-01-08,phase 2,批准上市,2012-08-30,approved,4,True,False,True,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",肿瘤领域,结直肠癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,colorectal cancer,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246
利那洛肽,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),结直肠腺瘤(差异化疾病),II期临床,2019-01-08,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,激动剂,创新药,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,,肿瘤领域,批准上市:胶囊剂,DR031924,否,美国,中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2019-01-08,phase 2,批准上市,2012-08-30,approved,4,True,False,True,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",肿瘤领域,结直肠腺瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,colorectal adenoma,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246
利那洛肽,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),肠易激综合征,I/II期临床,2024-11-18,Active,多肽,化药,环肽;First-in-Class;差异化疾病,激动剂,创新药,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,,消化领域,批准上市:胶囊剂,DR031924,否,美国,中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-18,phase 2,批准上市,2012-08-30,approved,4,True,False,True,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,肠易激综合征,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,,irritable bowel syndrome,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246
利那洛肽,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),肠道清洗(差异化疾病),I期临床,2021-11-30,Active,多肽,化药,环肽;First-in-Class;差异化疾病,激动剂,创新药,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,,消化领域,批准上市:胶囊剂,DR031924,否,美国,中国(港澳台);美国;欧洲;日本;其他,I期临床,,2021-11-30,,phase 1,批准上市,2012-08-30,approved,4,True,False,True,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,肠道清洗,['消化领域'],1,消化领域,,,5,1,Digestive System,Digestive System,,,bowel cleansing,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246
利那洛肽,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),肠道疾病,I期临床,2021-08-15,Unknown,多肽,化药,环肽;First-in-Class;差异化疾病,激动剂,创新药,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,,消化领域,批准上市:胶囊剂,DR031924,否,美国,中国(港澳台);美国;欧洲;日本;其他,I期临床,,2021-08-15,,phase 1,批准上市,2012-08-30,approved,4,True,False,True,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,肠道疾病,['消化领域'],1,消化领域,,,5,1,Digestive System,Digestive System,,,intestinal diseases,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246
利那洛肽,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),急性胰腺炎(差异化疾病),I期临床,2024-01-26,Active,多肽,化药,环肽;First-in-Class;差异化疾病,激动剂,创新药,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,,消化领域,批准上市:胶囊剂,DR031924,否,美国,中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-01-26,,phase 1,批准上市,2012-08-30,approved,4,True,False,True,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,急性胰腺炎,['消化领域'],1,消化领域,,,5,1,Digestive System,Digestive System,,,acute pancreatitis,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246
gallium Ga-68 dotatate,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),PET显像,批准上市,,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,,诊断试剂领域,,DR009499,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,2016-06-01,approved,1,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,5,5,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,gallium Ga-68 dotatate,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate
gallium Ga-68 dotatate,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),神经内分泌肿瘤,批准上市,,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,,罕见疾病领域;肿瘤领域,,DR009499,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,2016-06-01,approved,1,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,neuroendocrine tumors,gallium Ga-68 dotatate,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate
gallium Ga-68 dotatate,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),HR阳性乳腺癌(差异化疾病),II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,,肿瘤领域,,DR009499,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2016-06-01,approved,1,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)'],肿瘤领域,HR阳性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,HR positive breast cancer,gallium Ga-68 dotatate,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate
gallium Ga-68 dotatate,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),鼻咽癌,I/II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,,罕见疾病领域;肿瘤领域,,DR009499,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2016-06-01,approved,1,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)'],肿瘤领域,鼻咽癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Nasopharyngeal cancer,gallium Ga-68 dotatate,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate
gallium Ga-68 dotatate,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),小细胞肺癌,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,,罕见疾病领域;肿瘤领域,,DR009499,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,2016-06-01,approved,1,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)'],肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,small cell lung cancer,gallium Ga-68 dotatate,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),PET显像,批准上市,2019-08-21,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,诊断试剂领域,,DR055026,否,欧洲,未知,III期临床,批准上市,2023-10-16,2019-08-21,approved,批准上市,2016-12-08,approved,4,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,5,5,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),神经内分泌肿瘤,批准上市,2016-12-08,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,III期临床,批准上市,2023-10-16,2019-08-21,approved,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,neuroendocrine tumors,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),乳腺癌,III期临床,2024-09-25,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域,,DR055026,否,欧洲,未知,,,,,phase 3,批准上市,2016-12-08,approved,4,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,breast cancer,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),垂体瘤(差异化疾病),III期临床,2015-04-17,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,,,,,phase 3,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,垂体瘤,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,Pituitary tumor,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),胃肠胰神经内分泌肿瘤,III期临床,2023-10-19,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,III期临床,,2023-10-19,,phase 3,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),高级别胶质瘤(差异化疾病),II/III期临床,2011-10-27,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,,,,,phase 3,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,高级别胶质瘤,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,high grade glioma,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),细菌性心内膜炎(差异化疾病),II期临床,2021-12-23,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,感染领域;心脑血管领域,,DR055026,否,欧洲,未知,,,,,phase 2,批准上市,2016-12-08,approved,4,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",感染领域,细菌性心内膜炎,"['感染领域', '心脑血管领域']",2,感染领域,心脑血管领域,,5,2,Infectious Diseases,Infectious Diseases,Cardiovascular & Cerebrovascular,,bacterial endocarditis,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),HER2阳性乳腺癌(差异化疾病),II期临床,2025-09-17,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域,,DR055026,否,欧洲,未知,,,,,phase 2,批准上市,2016-12-08,approved,4,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,HER2阳性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,HER2-positive breast cancer,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),髓母细胞瘤(差异化疾病),II期临床,2015-05-12,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,,II期临床,,2015-05-12,phase 2,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,髓母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,medulloblastoma,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),神经母细胞瘤,II期临床,2015-05-12,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,I期临床,II期临床,2025-09-26,2015-05-12,phase 2,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,神经母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Neuroblastoma,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),类癌,II期临床,2015-05-12,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,,II期临床,,2015-05-12,phase 2,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,类癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,carcinoid,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),癌症肝转移(差异化疾病),II期临床,2019-08-01,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域,,DR055026,否,欧洲,未知,,,,,phase 2,批准上市,2016-12-08,approved,4,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,癌症肝转移,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,cancer liver metastasis,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),癌症脑转移(差异化疾病),II期临床,2025-09-17,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域,,DR055026,否,欧洲,未知,,,,,phase 2,批准上市,2016-12-08,approved,4,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,癌症脑转移,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,cancer brain metastasis,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),脑膜瘤(差异化疾病),II期临床,2017-01-06,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域,,DR055026,否,欧洲,未知,,II期临床,,2017-09-06,phase 2,批准上市,2016-12-08,approved,4,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,脑膜瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Meningioma,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),实体瘤,I/II期临床,2012-06-14,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域,,DR055026,否,欧洲,未知,,I/II期临床,,2012-06-14,phase 2,批准上市,2016-12-08,approved,4,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,solid tumors,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),鼻咽癌,I/II期临床,2025-05-21,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,,,,,phase 2,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,鼻咽癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Nasopharyngeal cancer,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),副神经节瘤,I/II期临床,2014-06-30,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,I期临床,I/II期临床,2025-09-26,2014-06-30,phase 2,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,副神经节瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,paraganglioma,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),小细胞肺癌,I期临床,2018-07-11,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,,,,,phase 1,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,small cell lung cancer,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),Merkel细胞瘤(差异化疾病),I期临床,2018-07-11,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,,,,,phase 1,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,Merkel细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Merkel cell tumor,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),前列腺癌(差异化疾病),I期临床,2019-07-12,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域,,DR055026,否,欧洲,未知,,,,,phase 1,批准上市,2016-12-08,approved,4,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,前列腺癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,prostate cancer,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),髓样甲状腺癌(差异化疾病),I期临床,2018-07-11,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,,,,,phase 1,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,髓样甲状腺癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,medullary thyroid cancer,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),霍奇金淋巴瘤(差异化疾病),I期临床,2015-03-17,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;血液领域;罕见疾病领域,,DR055026,否,欧洲,未知,,,,,phase 1,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,霍奇金淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,,Hodgkin lymphoma,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),弥漫性大B细胞淋巴瘤(差异化疾病),I期临床,2015-03-17,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;血液领域;罕见疾病领域,,DR055026,否,欧洲,未知,,,,,phase 1,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,弥漫性大B细胞淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,,Diffuse large B-cell lymphoma,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),抑郁症,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,精神领域,,DR055026,否,欧洲,未知,I期临床,,2025-09-26,,phase 1,批准上市,2016-12-08,approved,4,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",精神领域,抑郁症,['精神领域'],1,精神领域,,,5,1,Psychiatry,Psychiatry,,,depression,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),不孕不育,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,泌尿生殖领域,,DR055026,否,欧洲,未知,I期临床,,2025-09-26,,phase 1,批准上市,2016-12-08,approved,4,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",泌尿生殖领域,不孕不育,['泌尿生殖领域'],1,泌尿生殖领域,,,5,1,Genitourinary,Genitourinary,,,Infertility,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),嗜铬细胞瘤,I期临床,2018-07-11,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,I期临床,,2025-09-26,,phase 1,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,嗜铬细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Pheochromocytoma,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),胃泌素瘤(差异化疾病),I期临床,2018-07-11,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,,,,,phase 1,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,胃泌素瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,gastrinoma,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),骨转移疼痛,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域,,DR055026,否,欧洲,未知,I期临床,,2025-09-26,,phase 1,批准上市,2016-12-08,approved,4,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,骨转移疼痛,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,bone metastasis pain,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),心肌炎(差异化疾病),I期临床,2017-11-20,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,心脑血管领域,,DR055026,否,欧洲,未知,,,,,phase 1,批准上市,2016-12-08,approved,4,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",心脑血管领域,心肌炎,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,myocarditis,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),胰岛细胞瘤,I期临床,2018-07-11,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,,,,,phase 1,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,胰岛细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,islet cell tumor,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),胰腺神经内分泌肿瘤,I期临床,2018-11-15,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,,,,,phase 1,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,胰腺神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,pancreatic neuroendocrine tumors,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),胃肠道神经内分泌肿瘤(差异化疾病),I期临床,2025-01-14,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,,,,,phase 1,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,胃肠道神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,gastrointestinal neuroendocrine tumors,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),原发性神经外胚层肿瘤,I期临床,2014-07-18,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,,I期临床,,2014-07-18,phase 1,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,原发性神经外胚层肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,primary neuroectodermal tumor,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),心脏结节病(差异化疾病),I期临床,2019-12-20,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,心脑血管领域;免疫领域,,DR055026,否,欧洲,未知,,,,,phase 1,批准上市,2016-12-08,approved,4,True,False,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",心脑血管领域,心脏结节病,"['心脑血管领域', '免疫领域']",2,心脑血管领域,免疫领域,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,Immunology,,cardiac sarcoidosis,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
镓[68Ga]伊索曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),肺神经内分泌肿瘤(差异化疾病),I期临床,2022-03-07,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,,肿瘤领域;罕见疾病领域,,DR055026,否,欧洲,未知,,,,,phase 1,批准上市,2016-12-08,approved,4,True,True,True,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,肺神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Pulmonary neuroendocrine tumors,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽
普卡那肽,GC-C,GC-C激动剂,Bausch Health;罗欣药业;Synergy Pharmaceuticals(原研)(无权益),便秘型肠易激综合征,批准上市,2018-01-24,Active,多肽,化药,环肽,激动剂,创新药,普卡那肽;plecanatide;SP-304;Trulance;pirnabin,,消化领域,III期临床:片剂,DR041066,否,美国,,,批准上市,,2018-01-24,approved,批准上市,2017-01-19,approved,3,True,False,False,[],['Synergy Pharmaceuticals'],1,"['Bausch Health', '罗欣药业', 'Synergy Pharmaceuticals(原研)(无权益)']",消化领域,便秘型肠易激综合征,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,constipation irritable bowel syndrome,plecanatide,普卡那肽;plecanatide;SP-304;Trulance;pirnabin
普卡那肽,GC-C,GC-C激动剂,Bausch Health;罗欣药业;Synergy Pharmaceuticals(原研)(无权益),慢性特发性便秘,批准上市,2017-01-19,Active,多肽,化药,环肽,激动剂,创新药,普卡那肽;plecanatide;SP-304;Trulance;pirnabin,,消化领域,III期临床:片剂,DR041066,否,美国,,III期临床,批准上市,2021-04-27,2017-01-19,approved,批准上市,2017-01-19,approved,3,True,False,False,[],['Synergy Pharmaceuticals'],1,"['Bausch Health', '罗欣药业', 'Synergy Pharmaceuticals(原研)(无权益)']",消化领域,慢性特发性便秘,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,chronic idiopathic constipation,plecanatide,普卡那肽;plecanatide;SP-304;Trulance;pirnabin
Noctiva,vasopressin,vasopressin类似物,Avadel Pharmaceuticals(原研);Serenity Pharmaceuticals(Acerus Pharmaceuticals),夜尿症,批准上市,2017-03-03,Active,多肽,化药,环肽;中国无申报,类似物,微创新,Noctiva;Noctiva (去氨加压素);Noctiva (desmopressin);AV002;SER120,,泌尿生殖领域,,DR037313,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,批准上市,,2017-03-03,approved,批准上市,2017-03-03,approved,2,True,False,False,[],['Avadel Pharmaceuticals'],1,"['Avadel Pharmaceuticals(原研)', 'Serenity Pharmaceuticals(Acerus Pharmaceuticals)']",泌尿生殖领域,夜尿症,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,,Nocturia,Noctiva (desmopressin),Noctiva;Noctiva (去氨加压素);Noctiva (desmopressin);AV002;SER120
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),胃肠胰神经内分泌肿瘤,批准上市,2017-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,批准上市,2019-06-07,2018-01-26,approved,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),类癌,III期临床,2012-04-16,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2012-04-16,phase 3,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,类癌,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,carcinoid,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),胰腺神经内分泌肿瘤,III期临床,2025-09-22,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2022-02-21,phase 3,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,胰腺神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,pancreatic neuroendocrine tumors,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),胃肠道神经内分泌肿瘤(差异化疾病),III期临床,2013-05-23,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2025-09-02,phase 3,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,胃肠道神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,gastrointestinal neuroendocrine tumors,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),神经内分泌肿瘤,II/III期临床,2024-04-24,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,II/III期临床,II期临床,2024-04-24,2023-01-20,phase 3,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,neuroendocrine tumors,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),实体瘤,II期临床,2024-09-23,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2017-09-26,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,solid tumors,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),小细胞肺癌(差异化疾病),II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,I/II期临床,I/II期临床,2021-12-02,2021-12-02,phase 2,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,small cell lung cancer,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),乳腺癌(差异化疾病),II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2017-09-26,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,breast cancer,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),鼻咽癌,II期临床,2022-01-20,Unknown,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,鼻咽癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Nasopharyngeal cancer,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),Merkel细胞瘤(差异化疾病),II期临床,2022-10-18,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2022-10-18,phase 2,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,Merkel细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Merkel cell tumor,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),前列腺癌,II期临床,2023-01-20,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2023-01-20,phase 2,批准上市,2017-09-26,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,前列腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,prostate cancer,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),胶质母细胞瘤(差异化疾病),II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2021-11-05,phase 2,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,胶质母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,glioblastoma,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),神经母细胞瘤(差异化疾病),II期临床,,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,神经母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Neuroblastoma,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),髓样甲状腺癌(差异化疾病),II期临床,2023-11-07,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,髓样甲状腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,medullary thyroid cancer,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),嗜铬细胞瘤,II期临床,2017-07-02,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,申报临床,II期临床,2023-11-20,2017-07-02,phase 2,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,嗜铬细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Pheochromocytoma,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),副神经节瘤,II期临床,2017-07-02,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,申报临床,II期临床,2023-11-20,2017-07-02,phase 2,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,副神经节瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,paraganglioma,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),癌症肝转移(差异化疾病),II期临床,2019-08-01,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2022-11-09,phase 2,批准上市,2017-09-26,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,癌症肝转移,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,cancer liver metastasis,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),脑膜瘤,II期临床,2019-09-09,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2019-09-09,phase 2,批准上市,2017-09-26,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,脑膜瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Meningioma,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),原发部位不明癌(差异化疾病),II期临床,2019-07-23,Inactive,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2017-09-26,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,原发部位不明癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Cancer of unknown primary site,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),胸腺癌(差异化疾病),II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,胸腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,thymic cancer,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),神经内分泌前列腺癌(差异化疾病),II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2017-09-26,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,神经内分泌前列腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,neuroendocrine prostate cancer,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),肺神经内分泌肿瘤,II期临床,2020-12-14,Unknown,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2020-12-14,phase 2,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,肺神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Pulmonary neuroendocrine tumors,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),弥漫性内因性脑桥神经胶质瘤(差异化疾病),I/II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,弥漫性内因性脑桥神经胶质瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Diffuse intrinsic pontine glioma,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),非霍奇金淋巴瘤(差异化疾病),I期临床,2023-08-16,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;血液领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2023-08-16,phase 1,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,非霍奇金淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,,non-hodgkin lymphoma,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),间皮瘤(差异化疾病),I期临床,2020-05-05,Unknown,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,间皮瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Mesothelioma,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),消化道癌症,I期临床,2020-01-21,Unknown,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2020-01-21,phase 1,批准上市,2017-09-26,approved,2,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,消化道癌症,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,digestive tract cancer,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
镥[177lu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),胸腺瘤(差异化疾病),I期临床,2020-05-05,Unknown,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR030635,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,2017-09-26,approved,2,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,胸腺瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,thymoma,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008
Cequa,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,康哲药业;Ocular Technologies(Sun Pharma);Auven Therapeutics(原研)(无权益),干眼病,批准上市,2018-08-14,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,Cequa;Cequa (环孢素);Cequa (cyclosporine A);Seciera;OTX-101,,眼科领域,III期临床:滴眼剂,DR038984,否,欧洲,,III期临床,批准上市,2020-09-07,2018-08-14,approved,批准上市,2018-08-14,approved,3,True,False,False,[],['Auven Therapeutics'],1,"['康哲药业', 'Ocular Technologies(Sun Pharma)', 'Auven Therapeutics(原研)(无权益)']",眼科领域,干眼病,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,,dry eye disease,Cequa (cyclosporine A),Cequa;Cequa (环孢素);Cequa (cyclosporine A);Seciera;OTX-101
Cequa,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,康哲药业;Ocular Technologies(Sun Pharma);Auven Therapeutics(原研)(无权益),角结膜炎,III期临床,2016-07-27,Inactive,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,Cequa;Cequa (环孢素);Cequa (cyclosporine A);Seciera;OTX-101,,眼科领域,III期临床:滴眼剂,DR038984,否,欧洲,,,,,,phase 3,批准上市,2018-08-14,approved,3,True,False,False,[],['Auven Therapeutics'],1,"['康哲药业', 'Ocular Technologies(Sun Pharma)', 'Auven Therapeutics(原研)(无权益)']",眼科领域,角结膜炎,['眼科领域'],1,眼科领域,,,5,3,Ophthalmology,Ophthalmology,,,keratoconjunctivitis,Cequa (cyclosporine A),Cequa;Cequa (环孢素);Cequa (cyclosporine A);Seciera;OTX-101
Cequa,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,康哲药业;Ocular Technologies(Sun Pharma);Auven Therapeutics(原研)(无权益),炎症(未指明),I期临床,2023-07-24,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,Cequa;Cequa (环孢素);Cequa (cyclosporine A);Seciera;OTX-101,,免疫领域,III期临床:滴眼剂,DR038984,否,欧洲,,,,,,phase 1,批准上市,2018-08-14,approved,3,True,False,False,[],['Auven Therapeutics'],1,"['康哲药业', 'Ocular Technologies(Sun Pharma)', 'Auven Therapeutics(原研)(无权益)']",免疫领域,炎症(未指明),['免疫领域'],1,免疫领域,,,5,1,Immunology,Immunology,,,Inflammation (unspecified),Cequa (cyclosporine A),Cequa;Cequa (环孢素);Cequa (cyclosporine A);Seciera;OTX-101
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,多发性骨髓瘤(差异化疾病),批准上市,2018-12-11,Active,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域;血液领域;罕见疾病领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2010-04-13,approved,批准上市,2018-12-11,approved,4,True,True,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,多发性骨髓瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,5,Oncology,Oncology,Hematology,,multiple myeloma,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,新型冠状病毒感染,III期临床,2021-03-05,Active,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,感染领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,2018-12-11,approved,4,True,False,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",感染领域,新型冠状病毒感染,['感染领域'],1,感染领域,,,5,3,Infectious Diseases,Infectious Diseases,,,novel coronavirus infection,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,非小细胞肺癌(差异化疾病),II期临床,,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2018-12-11,approved,4,True,False,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,non-small cell lung cancer,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,小细胞肺癌(差异化疾病),II期临床,,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域;罕见疾病领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2018-12-11,approved,4,True,True,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,small cell lung cancer,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,黑色素瘤(差异化疾病),II期临床,,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域;罕见疾病领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2018-12-11,approved,4,True,True,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,黑色素瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,melanoma,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,肾细胞癌(差异化疾病),II期临床,,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2018-12-11,approved,4,True,False,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,肾细胞癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,renal cell carcinoma,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,膀胱癌,II期临床,,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2018-12-11,approved,4,True,False,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,膀胱癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,bladder cancer,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,尿路上皮癌(差异化疾病),II期临床,2005-03-31,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2018-12-11,approved,4,True,False,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,尿路上皮癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,urothelial carcinoma,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,髓样甲状腺癌(差异化疾病),II期临床,,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域;罕见疾病领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2018-12-11,approved,4,True,True,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,髓样甲状腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,medullary thyroid cancer,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,非霍奇金淋巴瘤,II期临床,2005-03-30,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域;血液领域;罕见疾病领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2018-12-11,approved,4,True,True,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,非霍奇金淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,non-hodgkin lymphoma,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,骨髓纤维化(差异化疾病),II期临床,2010-06-23,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域;血液领域;罕见疾病领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2010-06-23,phase 2,批准上市,2018-12-11,approved,4,True,True,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,骨髓纤维化,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,myelofibrosis,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,脂肪肉瘤,II期临床,,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域;罕见疾病领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2018-12-11,approved,4,True,True,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,脂肪肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,liposarcoma,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,去势抵抗前列腺癌(差异化疾病),II期临床,2008-10-28,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2008-10-28,phase 2,批准上市,2018-12-11,approved,4,True,False,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,去势抵抗前列腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Castration-resistant prostate cancer,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,血管免疫母细胞性T细胞淋巴瘤(差异化疾病),II期临床,2017-03-06,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,血液领域;肿瘤领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2017-03-06,phase 2,批准上市,2018-12-11,approved,4,True,False,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,血管免疫母细胞性T细胞淋巴瘤,"['血液领域', '肿瘤领域']",2,血液领域,肿瘤领域,,5,2,Oncology,Hematology,Oncology,,angioimmunoblastic T-cell lymphoma,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,侵袭性非霍奇金淋巴瘤,II期临床,2009-04-20,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域;血液领域;罕见疾病领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2018-12-11,approved,4,True,True,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,侵袭性非霍奇金淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,Aggressive non-Hodgkin lymphoma,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,去分化脂肪肉瘤(差异化疾病),II期临床,2009-05-19,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2018-12-11,approved,4,True,False,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,去分化脂肪肉瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,dedifferentiated liposarcoma,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,长新冠(差异化疾病),II期临床,2024-12-05,Active,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,感染领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2018-12-11,approved,4,True,False,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",感染领域,长新冠,['感染领域'],1,感染领域,,,5,2,Infectious Diseases,Infectious Diseases,,,Long new crown,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,急性髓系白血病(差异化疾病),I/II期临床,2008-10-27,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域;血液领域;罕见疾病领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2008-10-27,phase 2,批准上市,2018-12-11,approved,4,True,True,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,急性髓系白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,acute myeloid leukemia,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,实体瘤,I期临床,2008-11-10,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2008-11-10,phase 1,批准上市,2018-12-11,approved,4,True,False,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,solid tumors,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
普利肽新,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,淋巴瘤,I期临床,2008-11-10,Inactive,其他,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,,肿瘤领域;血液领域,,DR011563,否,欧洲,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2008-11-10,phase 1,批准上市,2018-12-11,approved,4,True,False,True,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,,Lymphoma,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine
布美诺肽,MC4R,MC4R激动剂,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),低反应性性欲障碍(差异化疾病),批准上市,2019-06-21,Active,多肽,化药,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,,精神领域;泌尿生殖领域,I期临床:注射剂,DR015256,否,美国,,I期临床,批准上市,2020-07-28,2019-06-21,approved,批准上市,2019-06-21,approved,6,True,False,False,[],['Palatin Technologies'],1,"['KwangDong Pharmaceutical', '复星医药', 'Cosette Pharmaceuticals', 'Gedeon Richter(无权益)', 'AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益)', 'Palatin Technologies(原研)(无权益)']",精神领域,低反应性性欲障碍,"['精神领域', '泌尿生殖领域']",2,精神领域,泌尿生殖领域,,5,5,Psychiatry,Psychiatry,Genitourinary,,hyporesponsive sexual desire disorder,bremelanotide,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi
布美诺肽,MC4R,MC4R激动剂,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),肥胖,II期临床,2024-06-12,Active,多肽,化药,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,,内分泌及代谢领域,I期临床:注射剂,DR015256,否,美国,,,II期临床,,2024-08-22,phase 2,批准上市,2019-06-21,approved,6,True,False,False,[],['Palatin Technologies'],1,"['KwangDong Pharmaceutical', '复星医药', 'Cosette Pharmaceuticals', 'Gedeon Richter(无权益)', 'AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益)', 'Palatin Technologies(原研)(无权益)']",内分泌及代谢领域,肥胖,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,obesity,bremelanotide,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi
布美诺肽,MC4R,MC4R激动剂,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),糖尿病肾病(差异化疾病),II期临床,2023-02-02,Active,多肽,化药,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,,泌尿生殖领域,I期临床:注射剂,DR015256,否,美国,,,II期临床,,2023-02-02,phase 2,批准上市,2019-06-21,approved,6,True,False,False,[],['Palatin Technologies'],1,"['KwangDong Pharmaceutical', '复星医药', 'Cosette Pharmaceuticals', 'Gedeon Richter(无权益)', 'AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益)', 'Palatin Technologies(原研)(无权益)']",泌尿生殖领域,糖尿病肾病,['泌尿生殖领域'],1,泌尿生殖领域,,,5,2,Genitourinary,Genitourinary,,,diabetic nephropathy,bremelanotide,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi
布美诺肽,MC4R,MC4R激动剂,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),勃起功能障碍(差异化疾病),II期临床,2024-06-20,Active,多肽,化药,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,,泌尿生殖领域,I期临床:注射剂,DR015256,否,美国,,,,,,phase 2,批准上市,2019-06-21,approved,6,True,False,False,[],['Palatin Technologies'],1,"['KwangDong Pharmaceutical', '复星医药', 'Cosette Pharmaceuticals', 'Gedeon Richter(无权益)', 'AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益)', 'Palatin Technologies(原研)(无权益)']",泌尿生殖领域,勃起功能障碍,['泌尿生殖领域'],1,泌尿生殖领域,,,5,2,Genitourinary,Genitourinary,,,erectile dysfunction,bremelanotide,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi
布美诺肽,MC4R,MC4R激动剂,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),女性性唤起障碍(差异化疾病),II期临床,2007-01-22,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,,精神领域;泌尿生殖领域,I期临床:注射剂,DR015256,否,美国,,,II期临床,,2007-01-22,phase 2,批准上市,2019-06-21,approved,6,True,False,False,[],['Palatin Technologies'],1,"['KwangDong Pharmaceutical', '复星医药', 'Cosette Pharmaceuticals', 'Gedeon Richter(无权益)', 'AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益)', 'Palatin Technologies(原研)(无权益)']",精神领域,女性性唤起障碍,"['精神领域', '泌尿生殖领域']",2,精神领域,泌尿生殖领域,,5,2,Psychiatry,Psychiatry,Genitourinary,,female sexual arousal disorder,bremelanotide,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi
铜[64Cu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,PET显像,批准上市,2020-09-03,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,,诊断试剂领域,,DR039127,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,申报临床,批准上市,2025-02-12,2020-09-03,approved,批准上市,2020-09-03,approved,3,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,5,5,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide
铜[64Cu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,神经内分泌肿瘤,批准上市,2020-09-03,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,,肿瘤领域;罕见疾病领域,,DR039127,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,申报临床,批准上市,2024-05-07,2020-09-03,approved,批准上市,2020-09-03,approved,3,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,,neuroendocrine tumors,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide
铜[64Cu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,胃肠胰神经内分泌肿瘤,II期临床,2023-02-02,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,,肿瘤领域;罕见疾病领域,,DR039127,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2020-09-03,approved,3,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide
铜[64Cu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,前列腺癌,I期临床,2023-01-11,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,,肿瘤领域,,DR039127,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2023-01-11,phase 1,批准上市,2020-09-03,approved,3,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",肿瘤领域,前列腺癌,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,prostate cancer,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide
铜[64Cu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,神经母细胞瘤,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,,肿瘤领域;罕见疾病领域,,DR039127,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,批准上市,2020-09-03,approved,3,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",肿瘤领域,神经母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Neuroblastoma,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide
铜[64Cu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,抑郁症,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,,精神领域,,DR039127,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,批准上市,2020-09-03,approved,3,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",精神领域,抑郁症,['精神领域'],1,精神领域,,,5,1,Psychiatry,Psychiatry,,,depression,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide
铜[64Cu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,不孕不育,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,,泌尿生殖领域,,DR039127,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,批准上市,2020-09-03,approved,3,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",泌尿生殖领域,不孕不育,['泌尿生殖领域'],1,泌尿生殖领域,,,5,1,Genitourinary,Genitourinary,,,Infertility,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide
铜[64Cu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,嗜铬细胞瘤,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,,肿瘤领域;罕见疾病领域,,DR039127,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,批准上市,2020-09-03,approved,3,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",肿瘤领域,嗜铬细胞瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,Pheochromocytoma,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide
铜[64Cu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,骨转移疼痛,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,,肿瘤领域,,DR039127,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,批准上市,2020-09-03,approved,3,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",肿瘤领域,骨转移疼痛,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,bone metastasis pain,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide
铜[64Cu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,副神经节瘤,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,,肿瘤领域;罕见疾病领域,,DR039127,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,批准上市,2020-09-03,approved,3,True,True,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",肿瘤领域,副神经节瘤,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,,paraganglioma,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide
铜[64Cu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,莱姆病,I期临床,2024-04-30,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,,感染领域,,DR039127,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,2020-09-03,approved,3,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",感染领域,莱姆病,['感染领域'],1,感染领域,,,5,1,Infectious Diseases,Infectious Diseases,,,Lyme disease,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide
铜[64Cu]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,心脏结节病,I期临床,2023-11-14,Active,多肽;放射性药物;偶联药物,化药,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,,心脑血管领域;免疫领域,,DR039127,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,2020-09-03,approved,3,True,False,True,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",心脑血管领域,心脏结节病,"['心脑血管领域', '免疫领域']",2,心脑血管领域,免疫领域,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,Immunology,,cardiac sarcoidosis,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide
setmelanotide,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),肥胖,批准上市,2024-07-31,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,,内分泌及代谢领域,申报临床:注射剂,DR064607,否,欧洲,未知,申报临床,III期临床,2022-06-22,2016-09-12,approved,批准上市,2020-11-25,approved,4,True,False,False,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,肥胖,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,obesity,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072
setmelanotide,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),阿黑皮素原缺乏症,批准上市,2020-11-25,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,,内分泌及代谢领域;罕见疾病领域,申报临床:注射剂,DR064607,否,欧洲,未知,,批准上市,,2020-11-25,approved,批准上市,2020-11-25,approved,4,True,True,False,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,阿黑皮素原缺乏症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,proopiomelanocortin deficiency,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072
setmelanotide,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),瘦素受体缺乏,批准上市,2020-11-25,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,,内分泌及代谢领域;罕见疾病领域,申报临床:注射剂,DR064607,否,欧洲,未知,,批准上市,,2020-11-25,approved,批准上市,2020-11-25,approved,4,True,True,False,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,瘦素受体缺乏,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,leptin receptor deficiency,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072
setmelanotide,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),巴德-毕德氏症候群(差异化疾病),批准上市,2022-06-16,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,,罕见疾病领域,申报临床:注射剂,DR064607,否,欧洲,未知,,批准上市,,2022-06-16,approved,批准上市,2020-11-25,approved,4,True,True,False,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",,巴德-毕德氏症候群,[],0,,,,5,5,,,,,Budd-Bide syndrome,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072
setmelanotide,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),PCSK1缺乏症(差异化疾病),批准上市,2021-07-23,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,,罕见疾病领域;内分泌及代谢领域,申报临床:注射剂,DR064607,否,欧洲,未知,,批准上市,,2024-12-20,approved,批准上市,2020-11-25,approved,4,True,True,False,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,PCSK1缺乏症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,PCSK1 deficiency,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072
setmelanotide,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),下丘脑性肥胖,申请上市,2025-08-20,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,,内分泌及代谢领域,申报临床:注射剂,DR064607,否,欧洲,未知,,申请上市,,2025-08-20,pre-registration,批准上市,2020-11-25,approved,4,True,False,False,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,下丘脑性肥胖,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,4,Endocrinology & Metabolism,Endocrinology & Metabolism,,,hypothalamic obesity,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072
setmelanotide,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),Alström综合征(差异化疾病),申请上市,2021-09-20,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,,罕见疾病领域,申报临床:注射剂,DR064607,否,欧洲,未知,,申请上市,,2021-09-20,pre-registration,批准上市,2020-11-25,approved,4,True,True,False,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",,Alström综合征,[],0,,,,5,4,,,,,Alström syndrome,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072
setmelanotide,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),联合垂体激素缺乏症(差异化疾病),III期临床,2025-01-07,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,,内分泌及代谢领域,申报临床:注射剂,DR064607,否,欧洲,未知,,III期临床,,2025-01-07,phase 3,批准上市,2020-11-25,approved,4,True,False,False,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,联合垂体激素缺乏症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,,combined pituitary hormone deficiency,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072
setmelanotide,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),视-隔发育不良(差异化疾病),III期临床,2025-01-07,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,,罕见疾病领域,申报临床:注射剂,DR064607,否,欧洲,未知,,III期临床,,2025-01-07,phase 3,批准上市,2020-11-25,approved,4,True,True,False,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",,视-隔发育不良,[],0,,,,5,3,,,,,Opto-septal dysplasia,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072
setmelanotide,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),Prader-Willi综合征(差异化疾病),II期临床,2014-12-08,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,,内分泌及代谢领域;罕见疾病领域,申报临床:注射剂,DR064607,否,欧洲,未知,,II期临床,,2014-12-08,phase 2,批准上市,2020-11-25,approved,4,True,True,False,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,Prader-Willi综合征,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Prader-Willi syndrome,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072
setmelanotide,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),瘦素缺乏症(差异化疾病),II期临床,2017-08-25,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,,罕见疾病领域;内分泌及代谢领域,申报临床:注射剂,DR064607,否,欧洲,未知,,II期临床,,2017-08-25,phase 2,批准上市,2020-11-25,approved,4,True,True,False,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,瘦素缺乏症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,leptin deficiency,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072
setmelanotide,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),多食症(差异化疾病),II期临床,2025-01-13,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,,精神领域;内分泌及代谢领域,申报临床:注射剂,DR064607,否,欧洲,未知,,II期临床,,2025-01-13,phase 2,批准上市,2020-11-25,approved,4,True,False,False,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",精神领域,多食症,"['精神领域', '内分泌及代谢领域']",2,精神领域,内分泌及代谢领域,,5,2,Psychiatry,Psychiatry,Endocrinology & Metabolism,,polyphagia,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072
setmelanotide,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),超重,II期临床,2012-12-13,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,,内分泌及代谢领域,申报临床:注射剂,DR064607,否,欧洲,未知,,II期临床,,2012-12-13,phase 2,批准上市,2020-11-25,approved,4,True,False,False,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,超重,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,overweight,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,阵发性睡眠性血红蛋白尿症(差异化疾病),批准上市,2021-05-14,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,罕见疾病领域;血液领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,批准上市,,2021-05-14,approved,批准上市,2021-05-14,approved,2,True,True,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",血液领域,阵发性睡眠性血红蛋白尿症,['血液领域'],1,血液领域,,,5,5,Hematology,Hematology,,,paroxysmal nocturnal hemoglobinuria,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,C3肾小球病(差异化疾病),批准上市,2025-07-28,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,罕见疾病领域;免疫领域;泌尿生殖领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,批准上市,,2025-07-28,approved,批准上市,2021-05-14,approved,2,True,True,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",免疫领域,C3肾小球病,"['免疫领域', '泌尿生殖领域']",2,免疫领域,泌尿生殖领域,,5,5,Immunology,Immunology,Genitourinary,,C3 glomerulopathy,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,地图样萎缩(差异化疾病),批准上市,2023-02-17,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,眼科领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,批准上市,,2023-02-17,approved,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",眼科领域,地图样萎缩,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,,geographical atrophy,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,免疫复合物介导的膜增生性肾小球肾炎(差异化疾病),批准上市,2025-07-28,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,泌尿生殖领域;罕见疾病领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,批准上市,,2025-07-28,approved,批准上市,2021-05-14,approved,2,True,True,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",泌尿生殖领域,免疫复合物介导的膜增生性肾小球肾炎,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,,Immune complex-mediated membranoproliferative glomerulonephritis,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,肾移植后移植物功能延迟恢复(差异化疾病),III期临床,2025-06-13,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,免疫领域;罕见疾病领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,2021-05-14,approved,2,True,True,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",免疫领域,肾移植后移植物功能延迟恢复,['免疫领域'],1,免疫领域,,,5,3,Immunology,Immunology,,,Delayed recovery of graft function after kidney transplantation,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,冷凝集素病(差异化疾病),III期临床,2021-10-27,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,血液领域;罕见疾病领域;免疫领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2021-10-27,phase 3,批准上市,2021-05-14,approved,2,True,True,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",血液领域,冷凝集素病,"['血液领域', '免疫领域']",2,血液领域,免疫领域,,5,3,Hematology,Hematology,Immunology,,cold agglutinin disease,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,局灶性节段性肾小球硬化(差异化疾病),II/III期临床,2025-10-09,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,泌尿生殖领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II/III期临床,,2025-10-09,phase 3,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",泌尿生殖领域,局灶性节段性肾小球硬化,['泌尿生殖领域'],1,泌尿生殖领域,,,5,3,Genitourinary,Genitourinary,,,focal segmental glomerulosclerosis,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,卵巢癌(差异化疾病),II期临床,2021-06-09,Unknown,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,肿瘤领域;罕见疾病领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2021-06-09,phase 2,批准上市,2021-05-14,approved,2,True,True,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",肿瘤领域,卵巢癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,ovarian cancer,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,肌萎缩侧索硬化症(差异化疾病),II期临床,2020-10-08,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,神经领域;罕见疾病领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2020-10-08,phase 2,批准上市,2021-05-14,approved,2,True,True,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",神经领域,肌萎缩侧索硬化症,['神经领域'],1,神经领域,,,5,2,Neurology,Neurology,,,amyotrophic lateral sclerosis,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,狼疮性肾炎(差异化疾病),II期临床,2018-03-05,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,泌尿生殖领域;免疫领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2018-03-05,phase 2,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",泌尿生殖领域,狼疮性肾炎,"['泌尿生殖领域', '免疫领域']",2,泌尿生殖领域,免疫领域,,5,2,Genitourinary,Genitourinary,Immunology,,lupus nephritis,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,IgA肾病(差异化疾病),II期临床,2018-03-05,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,泌尿生殖领域;免疫领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2018-03-05,phase 2,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",泌尿生殖领域,IgA肾病,"['泌尿生殖领域', '免疫领域']",2,泌尿生殖领域,免疫领域,,5,2,Genitourinary,Genitourinary,Immunology,,IgA nephropathy,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,输卵管癌(差异化疾病),II期临床,2021-06-09,Unknown,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,肿瘤领域;罕见疾病领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2021-06-09,phase 2,批准上市,2021-05-14,approved,2,True,True,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",肿瘤领域,输卵管癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,fallopian tube cancer,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,腹膜癌(差异化疾病),II期临床,2021-06-09,Unknown,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,肿瘤领域;罕见疾病领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2021-06-09,phase 2,批准上市,2021-05-14,approved,2,True,True,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",肿瘤领域,腹膜癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,peritoneal cancer,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,膜性肾病(差异化疾病),II期临床,2018-03-05,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,泌尿生殖领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2018-03-05,phase 2,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",泌尿生殖领域,膜性肾病,['泌尿生殖领域'],1,泌尿生殖领域,,,5,2,Genitourinary,Genitourinary,,,membranous nephropathy,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,温抗体型自身免疫溶血性贫血(差异化疾病),II期临床,2017-07-24,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,罕见疾病领域;血液领域;免疫领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2017-07-24,phase 2,批准上市,2021-05-14,approved,2,True,True,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",血液领域,温抗体型自身免疫溶血性贫血,"['血液领域', '免疫领域']",2,血液领域,免疫领域,,5,2,Hematology,Hematology,Immunology,,Warm antibody autoimmune hemolytic anemia,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,造血干细胞移植后血栓性微血管病(差异化疾病),II期临床,2021-12-08,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,血液领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2021-12-08,phase 2,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",血液领域,造血干细胞移植后血栓性微血管病,['血液领域'],1,血液领域,,,5,2,Hematology,Hematology,,,Thrombotic microangiopathy after hematopoietic stem cell transplantation,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,恶性胸水(差异化疾病),I/II期临床,2025-10-09,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,肿瘤领域;罕见疾病领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2025-10-09,phase 2,批准上市,2021-05-14,approved,2,True,True,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",肿瘤领域,恶性胸水,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,malignant pleural effusion,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,血栓(抗凝或抗血小板)(差异化疾病),I/II期临床,2025-10-09,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,心脑血管领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2025-10-09,phase 2,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",心脑血管领域,血栓(抗凝或抗血小板),['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Thrombosis (anticoagulant or antiplatelet),pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,心肌梗塞(差异化疾病),I/II期临床,2025-10-09,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,心脑血管领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2025-10-09,phase 2,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",心脑血管领域,心肌梗塞,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,myocardial infarction,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,卒中,I/II期临床,2025-10-09,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,心脑血管领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2025-10-09,phase 2,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",心脑血管领域,卒中,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Stroke,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,腹水(差异化疾病),I/II期临床,2025-10-09,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,泌尿生殖领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2025-10-09,phase 2,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",泌尿生殖领域,腹水,['泌尿生殖领域'],1,泌尿生殖领域,,,5,2,Genitourinary,Genitourinary,,,ascites,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,年龄相关性黄斑变性,I/II期临床,2018-03-14,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,眼科领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2018-03-14,phase 2,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",眼科领域,年龄相关性黄斑变性,['眼科领域'],1,眼科领域,,,5,2,Ophthalmology,Ophthalmology,,,age-related macular degeneration,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,湿性年龄相关性黄斑变性(差异化疾病),I/II期临床,,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,眼科领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2015-06-03,phase 2,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",眼科领域,湿性年龄相关性黄斑变性,['眼科领域'],1,眼科领域,,,5,2,Ophthalmology,Ophthalmology,,,Wet age-related macular degeneration,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,干性年龄相关性黄斑变性,I/II期临床,2025-09-08,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,眼科领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2025-09-08,phase 2,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",眼科领域,干性年龄相关性黄斑变性,['眼科领域'],1,眼科领域,,,5,2,Ophthalmology,Ophthalmology,,,Dry age-related macular degeneration,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,胰腺导管癌(差异化疾病),I/II期临床,2025-10-09,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,肿瘤领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2025-10-09,phase 2,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,pancreatic ductal carcinoma,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,缺血性卒中(差异化疾病),I期临床,2016-05-27,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,心脑血管领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,批准上市,2021-05-14,approved,2,True,False,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",心脑血管领域,缺血性卒中,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,ischemic stroke,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
pegcetacoplan,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,移植物抗宿主病(差异化疾病),临床前,,Active,多肽,化药,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,创新药,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,,免疫领域;罕见疾病领域,,DR035939,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,批准上市,2021-05-14,approved,2,True,True,False,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",免疫领域,移植物抗宿主病,['免疫领域'],1,免疫领域,,,5,-1,Immunology,Immunology,,,graft versus host disease,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre
伏索利肽,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,软骨发育不全,批准上市,2021-08-27,Active,多肽,生物,环肽;First-in-Class;差异化疾病,类似物,创新药,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,,骨骼肌肉领域;罕见疾病领域,申请上市:注射剂(冻干),DR003025,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,申请上市,批准上市,2025-09-05,2021-11-19,approved,批准上市,2021-08-26,approved,2,True,True,False,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",骨骼肌肉领域,软骨发育不全,['骨骼肌肉领域'],1,骨骼肌肉领域,,,5,5,Musculoskeletal,Musculoskeletal,,,Achondroplasia,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo
伏索利肽,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,矮小,II期临床,2023-05-08,Active,多肽,生物,环肽;First-in-Class;差异化疾病,类似物,创新药,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,,内分泌及代谢领域,申请上市:注射剂(冻干),DR003025,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2023-05-08,phase 2,批准上市,2021-08-26,approved,2,True,False,False,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",内分泌及代谢领域,矮小,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,short,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo
伏索利肽,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,特纳综合征(差异化疾病),II期临床,2023-05-08,Active,多肽,生物,环肽;First-in-Class;差异化疾病,类似物,创新药,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,,罕见疾病领域,申请上市:注射剂(冻干),DR003025,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2023-05-08,phase 2,批准上市,2021-08-26,approved,2,True,True,False,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",,特纳综合征,[],0,,,,5,2,,,,,Turner syndrome,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo
伏索利肽,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,努南综合征(差异化疾病),II期临床,2024-10-31,Active,多肽,生物,环肽;First-in-Class;差异化疾病,类似物,创新药,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,,罕见疾病领域,申请上市:注射剂(冻干),DR003025,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2024-10-31,phase 2,批准上市,2021-08-26,approved,2,True,True,False,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",,努南综合征,[],0,,,,5,2,,,,,Noonan syndrome,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo
伏索利肽,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,特发性矮小(差异化疾病),II期临床,2024-04-24,Active,多肽,生物,环肽;First-in-Class;差异化疾病,类似物,创新药,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,,内分泌及代谢领域,申请上市:注射剂(冻干),DR003025,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2024-04-24,phase 2,批准上市,2021-08-26,approved,2,True,False,False,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",内分泌及代谢领域,特发性矮小,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,idiopathic short stature,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo
伏索利肽,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,SHOX缺陷(差异化疾病),II期临床,2024-10-31,Active,多肽,生物,环肽;First-in-Class;差异化疾病,类似物,创新药,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,,内分泌及代谢领域;罕见疾病领域,申请上市:注射剂(冻干),DR003025,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2024-10-31,phase 2,批准上市,2021-08-26,approved,2,True,True,False,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",内分泌及代谢领域,SHOX缺陷,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,SHOX defects,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo
伏索利肽,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,VI型黏多糖贮积症(差异化疾病),I/II期临床,2023-05-06,Active,多肽,生物,环肽;First-in-Class;差异化疾病,类似物,创新药,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,,内分泌及代谢领域;罕见疾病领域,申请上市:注射剂(冻干),DR003025,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2023-05-06,phase 2,批准上市,2021-08-26,approved,2,True,True,False,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",内分泌及代谢领域,VI型黏多糖贮积症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Mucopolysaccharidosis type VI,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo
伏索利肽,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,IVA型黏多糖贮积症(差异化疾病),I/II期临床,2023-05-06,Active,多肽,生物,环肽;First-in-Class;差异化疾病,类似物,创新药,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,,内分泌及代谢领域;罕见疾病领域,申请上市:注射剂(冻干),DR003025,否,美国,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2023-05-06,phase 2,批准上市,2021-08-26,approved,2,True,True,False,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",内分泌及代谢领域,IVA型黏多糖贮积症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Mucopolysaccharidosis type IVA,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo
CyclASol,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,恒瑞医药;Novaliq(原研);Harrow,干眼病,批准上市,2023-05-30,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,CyclASol;CyclASol (环孢素);CyclASol (cyclosporine A);SHR8028;Vevye;Vevizye,,眼科领域,申请上市:滴眼剂,DR015549,否,欧洲,美国;欧洲;日本;其他,申请上市,批准上市,2023-03-18,2023-05-30,approved,批准上市,2023-05-30,approved,3,True,False,False,[],['Novaliq'],1,"['恒瑞医药', 'Novaliq(原研)', 'Harrow']",眼科领域,干眼病,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,,dry eye disease,CyclASol (cyclosporine A),CyclASol;CyclASol (环孢素);CyclASol (cyclosporine A);SHR8028;Vevye;Vevizye
培莫沙肽,EPO receptor,EPO receptor激动剂,翰森制药(原研),慢性肾病贫血,批准上市,2023-06-30,Active,多肽,化药,环肽;差异化疾病,激动剂,创新药,培莫沙肽;Pegol-sihematide;培化西海马肽;pegol-sihematide;EPO-018B;HS-20039;圣罗莱;pegmolesatide,,血液领域;泌尿生殖领域,批准上市:注射剂,DR032372,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,2023-06-30,,approved,批准上市,2023-06-30,approved,1,True,False,False,[],['翰森制药'],1,['翰森制药(原研)'],血液领域,慢性肾病贫血,"['血液领域', '泌尿生殖领域']",2,血液领域,泌尿生殖领域,,5,5,Hematology,Hematology,Genitourinary,,chronic kidney disease anemia,Pegol-sihematide,培莫沙肽;Pegol-sihematide;培化西海马肽;pegol-sihematide;EPO-018B;HS-20039;圣罗莱;pegmolesatide
培莫沙肽,EPO receptor,EPO receptor激动剂,翰森制药(原研),贫血,申请上市,2021-10-04,Unknown,多肽,化药,环肽;差异化疾病,激动剂,创新药,培莫沙肽;Pegol-sihematide;培化西海马肽;pegol-sihematide;EPO-018B;HS-20039;圣罗莱;pegmolesatide,,血液领域,批准上市:注射剂,DR032372,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,申请上市,,2021-10-04,,pre-registration,批准上市,2023-06-30,approved,1,True,False,False,[],['翰森制药'],1,['翰森制药(原研)'],血液领域,贫血,['血液领域'],1,血液领域,,,5,4,Hematology,Hematology,,,anemia,Pegol-sihematide,培莫沙肽;Pegol-sihematide;培化西海马肽;pegol-sihematide;EPO-018B;HS-20039;圣罗莱;pegmolesatide
培莫沙肽,EPO receptor,EPO receptor激动剂,翰森制药(原研),骨髓增生异常综合征(差异化疾病),I期临床,2015-01-14,Inactive,多肽,化药,环肽;差异化疾病,激动剂,创新药,培莫沙肽;Pegol-sihematide;培化西海马肽;pegol-sihematide;EPO-018B;HS-20039;圣罗莱;pegmolesatide,,肿瘤领域;血液领域;罕见疾病领域,批准上市:注射剂,DR032372,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2015-01-14,,phase 1,批准上市,2023-06-30,approved,1,True,True,False,[],['翰森制药'],1,['翰森制药(原研)'],肿瘤领域,骨髓增生异常综合征,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,,myelodysplastic syndrome,Pegol-sihematide,培莫沙肽;Pegol-sihematide;培化西海马肽;pegol-sihematide;EPO-018B;HS-20039;圣罗莱;pegmolesatide
莫替福肽,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,多发性骨髓瘤,批准上市,2023-09-11,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,,肿瘤领域;血液领域;罕见疾病领域,III期临床:注射剂(冻干),DR041695,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,批准上市,2024-07-17,2023-09-11,approved,批准上市,2023-09-08,approved,5,True,True,False,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,多发性骨髓瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,5,Oncology,Oncology,Hematology,,multiple myeloma,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda
莫替福肽,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,干细胞动员,批准上市,2023-09-11,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,,血液领域;罕见疾病领域,III期临床:注射剂(冻干),DR041695,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,批准上市,2024-07-17,2023-09-11,approved,批准上市,2023-09-08,approved,5,True,True,False,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",血液领域,干细胞动员,['血液领域'],1,血液领域,,,5,5,Hematology,Hematology,,,stem cell mobilization,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda
莫替福肽,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,胰腺癌,II期临床,2016-07-11,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,,肿瘤领域;罕见疾病领域,III期临床:注射剂(冻干),DR041695,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2016-07-11,phase 2,批准上市,2023-09-08,approved,5,True,True,False,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,pancreatic cancer,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda
莫替福肽,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,急性髓系白血病,II期临床,2013-04-24,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,,肿瘤领域;血液领域;罕见疾病领域,III期临床:注射剂(冻干),DR041695,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2013-04-24,phase 2,批准上市,2023-09-08,approved,5,True,True,False,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,急性髓系白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,acute myeloid leukemia,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda
莫替福肽,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,淋巴母细胞淋巴瘤(差异化疾病),II期临床,2016-05-05,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,,肿瘤领域;血液领域;罕见疾病领域,III期临床:注射剂(冻干),DR041695,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2016-05-05,phase 2,批准上市,2023-09-08,approved,5,True,True,False,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,淋巴母细胞淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,lymphoblastic lymphoma,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda
莫替福肽,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,骨髓增生异常综合征,II期临床,2015-06-04,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,,肿瘤领域;血液领域;罕见疾病领域,III期临床:注射剂(冻干),DR041695,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2015-06-04,phase 2,批准上市,2023-09-08,approved,5,True,True,False,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,骨髓增生异常综合征,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,myelodysplastic syndrome,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda
莫替福肽,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,再生障碍性贫血,II期临床,2015-06-04,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,,血液领域;罕见疾病领域,III期临床:注射剂(冻干),DR041695,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2015-06-04,phase 2,批准上市,2023-09-08,approved,5,True,True,False,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",血液领域,再生障碍性贫血,['血液领域'],1,血液领域,,,5,2,Hematology,Hematology,,,aplastic anemia,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda
莫替福肽,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,T细胞急性淋巴细胞白血病(差异化疾病),II期临床,2016-05-05,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,,肿瘤领域;血液领域;罕见疾病领域,III期临床:注射剂(冻干),DR041695,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2016-05-05,phase 2,批准上市,2023-09-08,approved,5,True,True,False,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,T细胞急性淋巴细胞白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,T-cell acute lymphoblastic leukemia,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda
莫替福肽,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,胃癌(差异化疾病),I/II期临床,2017-09-13,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,,肿瘤领域,III期临床:注射剂(冻干),DR041695,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2017-09-13,phase 2,批准上市,2023-09-08,approved,5,True,False,False,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,胃癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,stomach cancer,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda
莫替福肽,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,食管癌(差异化疾病),I/II期临床,2017-09-13,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,,肿瘤领域,III期临床:注射剂(冻干),DR041695,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2017-09-13,phase 2,批准上市,2023-09-08,approved,5,True,False,False,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,食管癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,Esophageal cancer,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda
莫替福肽,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,慢性髓系白血病,I/II期临床,2014-04-16,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,,肿瘤领域;血液领域;罕见疾病领域,III期临床:注射剂(冻干),DR041695,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,批准上市,2023-09-08,approved,5,True,True,False,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,慢性髓系白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,,chronic myeloid leukemia,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda
莫替福肽,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,胰腺导管癌,I/II期临床,2017-06-20,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,,肿瘤领域,III期临床:注射剂(冻干),DR041695,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2017-06-20,phase 2,批准上市,2023-09-08,approved,5,True,False,False,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,pancreatic ductal carcinoma,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda
莫替福肽,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,胃食管交界处癌(差异化疾病),I/II期临床,2017-09-13,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,,肿瘤领域,III期临床:注射剂(冻干),DR041695,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2017-09-13,phase 2,批准上市,2023-09-08,approved,5,True,False,False,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,胃食管交界处癌,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,,gastroesophageal junction cancer,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda
莫替福肽,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,镰状细胞病,I期临床,2022-11-16,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,,血液领域;罕见疾病领域,III期临床:注射剂(冻干),DR041695,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2022-11-16,phase 1,批准上市,2023-09-08,approved,5,True,True,False,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",血液领域,镰状细胞病,['血液领域'],1,血液领域,,,5,1,Hematology,Hematology,,,sickle cell disease,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda
泽卢克布仑钠,C5,C5抑制剂,Ra Pharmaceuticals(UCB)(原研),重症肌无力,批准上市,2023-09-25,Active,多肽,化药,环肽;First-in-Class;差异化疾病,抑制剂,创新药,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,,罕见疾病领域;免疫领域,批准上市:注射剂,DR046869,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,批准上市,2025-09-30,2023-10-17,approved,批准上市,2023-09-25,approved,1,True,True,False,[],['Ra Pharmaceuticals(UCB)'],1,['Ra Pharmaceuticals(UCB)(原研)'],免疫领域,重症肌无力,['免疫领域'],1,免疫领域,,,5,5,Immunology,Immunology,,,myasthenia gravis,zilucoplan,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可
泽卢克布仑钠,C5,C5抑制剂,Ra Pharmaceuticals(UCB)(原研),脑膜炎(差异化疾病),III期临床,2025-10-14,Active,多肽,化药,环肽;First-in-Class;差异化疾病,抑制剂,创新药,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,,神经领域,批准上市:注射剂,DR046869,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2025-10-14,phase 3,批准上市,2023-09-25,approved,1,True,False,False,[],['Ra Pharmaceuticals(UCB)'],1,['Ra Pharmaceuticals(UCB)(原研)'],神经领域,脑膜炎,['神经领域'],1,神经领域,,,5,3,Neurology,Neurology,,,meningitis,zilucoplan,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可
泽卢克布仑钠,C5,C5抑制剂,Ra Pharmaceuticals(UCB)(原研),阵发性睡眠性血红蛋白尿症,III期临床,2019-01-28,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,抑制剂,创新药,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,,罕见疾病领域;血液领域,批准上市:注射剂,DR046869,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2019-01-28,phase 3,批准上市,2023-09-25,approved,1,True,True,False,[],['Ra Pharmaceuticals(UCB)'],1,['Ra Pharmaceuticals(UCB)(原研)'],血液领域,阵发性睡眠性血红蛋白尿症,['血液领域'],1,血液领域,,,5,3,Hematology,Hematology,,,paroxysmal nocturnal hemoglobinuria,zilucoplan,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可
泽卢克布仑钠,C5,C5抑制剂,Ra Pharmaceuticals(UCB)(原研),新型冠状病毒感染(差异化疾病),III期临床,2020-10-19,Active,多肽,化药,环肽;First-in-Class;差异化疾病,抑制剂,创新药,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,,感染领域,批准上市:注射剂,DR046869,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2020-10-19,phase 3,批准上市,2023-09-25,approved,1,True,False,False,[],['Ra Pharmaceuticals(UCB)'],1,['Ra Pharmaceuticals(UCB)(原研)'],感染领域,新型冠状病毒感染,['感染领域'],1,感染领域,,,5,3,Infectious Diseases,Infectious Diseases,,,novel coronavirus infection,zilucoplan,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可
泽卢克布仑钠,C5,C5抑制剂,Ra Pharmaceuticals(UCB)(原研),肌萎缩侧索硬化症(差异化疾病),II/III期临床,2020-03-05,Active,多肽,化药,环肽;First-in-Class;差异化疾病,抑制剂,创新药,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,,神经领域;罕见疾病领域,批准上市:注射剂,DR046869,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II/III期临床,,2020-03-05,phase 3,批准上市,2023-09-25,approved,1,True,True,False,[],['Ra Pharmaceuticals(UCB)'],1,['Ra Pharmaceuticals(UCB)(原研)'],神经领域,肌萎缩侧索硬化症,['神经领域'],1,神经领域,,,5,3,Neurology,Neurology,,,amyotrophic lateral sclerosis,zilucoplan,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可
泽卢克布仑钠,C5,C5抑制剂,Ra Pharmaceuticals(UCB)(原研),免疫介导坏死性肌病(差异化疾病),II期临床,2019-07-19,Inactive,多肽,化药,环肽;First-in-Class;差异化疾病,抑制剂,创新药,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,,骨骼肌肉领域;免疫领域,批准上市:注射剂,DR046869,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2019-07-19,phase 2,批准上市,2023-09-25,approved,1,True,False,False,[],['Ra Pharmaceuticals(UCB)'],1,['Ra Pharmaceuticals(UCB)(原研)'],骨骼肌肉领域,免疫介导坏死性肌病,"['骨骼肌肉领域', '免疫领域']",2,骨骼肌肉领域,免疫领域,,5,2,Musculoskeletal,Musculoskeletal,Immunology,,immune-mediated necrotizing myopathy,zilucoplan,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可
泽卢克布仑钠,C5,C5抑制剂,Ra Pharmaceuticals(UCB)(原研),狼疮性肾炎(差异化疾病),临床前,,Active,多肽,化药,环肽;First-in-Class;差异化疾病,抑制剂,创新药,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,,泌尿生殖领域;免疫领域,批准上市:注射剂,DR046869,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,批准上市,2023-09-25,approved,1,True,False,False,[],['Ra Pharmaceuticals(UCB)'],1,['Ra Pharmaceuticals(UCB)(原研)'],泌尿生殖领域,狼疮性肾炎,"['泌尿生殖领域', '免疫领域']",2,泌尿生殖领域,免疫领域,,5,-1,Genitourinary,Genitourinary,Immunology,,lupus nephritis,zilucoplan,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可
倍维巴肽,GPIIb/IIIa,GPIIb/IIIa拮抗剂,百奥泰(原研),血栓(抗凝或抗血小板),批准上市,2024-06-28,Active,多肽,化药,环肽;差异化疾病,拮抗剂,创新药,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,,心脑血管领域,批准上市:注射剂,DR030700,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,2024-06-28,,approved,批准上市,2024-06-25,approved,1,True,False,False,[],['百奥泰'],1,['百奥泰(原研)'],心脑血管领域,血栓(抗凝或抗血小板),['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Thrombosis (anticoagulant or antiplatelet),bevifibatide,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin
倍维巴肽,GPIIb/IIIa,GPIIb/IIIa拮抗剂,百奥泰(原研),急性冠脉综合征,批准上市,2024-06-28,Active,多肽,化药,环肽;差异化疾病,拮抗剂,创新药,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,,心脑血管领域,批准上市:注射剂,DR030700,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,批准上市,,2024-06-28,,approved,批准上市,2024-06-25,approved,1,True,False,False,[],['百奥泰'],1,['百奥泰(原研)'],心脑血管领域,急性冠脉综合征,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,acute coronary syndrome,bevifibatide,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin
倍维巴肽,GPIIb/IIIa,GPIIb/IIIa拮抗剂,百奥泰(原研),心肌梗塞,III期临床,2024-11-14,Active,多肽,化药,环肽;差异化疾病,拮抗剂,创新药,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,,心脑血管领域,批准上市:注射剂,DR030700,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,,2024-11-14,,phase 3,批准上市,2024-06-25,approved,1,True,False,False,[],['百奥泰'],1,['百奥泰(原研)'],心脑血管领域,心肌梗塞,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,myocardial infarction,bevifibatide,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin
倍维巴肽,GPIIb/IIIa,GPIIb/IIIa拮抗剂,百奥泰(原研),不稳定性心绞痛,III期临床,2018-05-02,Active,多肽,化药,环肽;差异化疾病,拮抗剂,创新药,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,,心脑血管领域,批准上市:注射剂,DR030700,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,,2018-05-02,,phase 3,批准上市,2024-06-25,approved,1,True,False,False,[],['百奥泰'],1,['百奥泰(原研)'],心脑血管领域,不稳定性心绞痛,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,unstable angina,bevifibatide,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin
倍维巴肽,GPIIb/IIIa,GPIIb/IIIa拮抗剂,百奥泰(原研),非ST段抬高型心肌梗死,III期临床,2018-05-02,Active,多肽,化药,环肽;差异化疾病,拮抗剂,创新药,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,,心脑血管领域,批准上市:注射剂,DR030700,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,,2018-05-02,,phase 3,批准上市,2024-06-25,approved,1,True,False,False,[],['百奥泰'],1,['百奥泰(原研)'],心脑血管领域,非ST段抬高型心肌梗死,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Non-ST segment elevation myocardial infarction,bevifibatide,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin
倍维巴肽,GPIIb/IIIa,GPIIb/IIIa拮抗剂,百奥泰(原研),缺血性卒中,II期临床,2024-12-02,Active,多肽,化药,环肽;差异化疾病,拮抗剂,创新药,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,,心脑血管领域,批准上市:注射剂,DR030700,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II期临床,,2024-12-02,,phase 2,批准上市,2024-06-25,approved,1,True,False,False,[],['百奥泰'],1,['百奥泰(原研)'],心脑血管领域,缺血性卒中,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,ischemic stroke,bevifibatide,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin
倍维巴肽,GPIIb/IIIa,GPIIb/IIIa拮抗剂,百奥泰(原研),血栓闭塞性脉管炎(差异化疾病),I期临床,2025-01-22,Active,多肽,化药,环肽;差异化疾病,拮抗剂,创新药,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,,心脑血管领域,批准上市:注射剂,DR030700,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-01-22,,phase 1,批准上市,2024-06-25,approved,1,True,False,False,[],['百奥泰'],1,['百奥泰(原研)'],心脑血管领域,血栓闭塞性脉管炎,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Thromboangitis obliterans,bevifibatide,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin
CAM2029,somatostatin,somatostatin类似物,Novartis(Top20 MNC);Camurus(原研),肢端肥大症,批准上市,2025-06-30,Active,多肽,化药,环肽,类似物,微创新,CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,,内分泌及代谢领域;罕见疾病领域,,DR031328,否,欧洲,未知,,III期临床,,2019-06-04,approved,批准上市,2025-06-30,approved,2,True,True,True,['Novartis'],['Camurus'],1,"['Novartis(Top20 MNC)', 'Camurus(原研)']",内分泌及代谢领域,肢端肥大症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,acromegaly,CAM2029 (octreotide),CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa
CAM2029,somatostatin,somatostatin类似物,Novartis(Top20 MNC);Camurus(原研),胃肠胰神经内分泌肿瘤,III期临床,2021-09-21,Active,多肽,化药,环肽,类似物,微创新,CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,,肿瘤领域;罕见疾病领域,,DR031328,否,欧洲,未知,,III期临床,,2021-09-21,phase 3,批准上市,2025-06-30,approved,2,True,True,True,['Novartis'],['Camurus'],1,"['Novartis(Top20 MNC)', 'Camurus(原研)']",肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,CAM2029 (octreotide),CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa
CAM2029,somatostatin,somatostatin类似物,Novartis(Top20 MNC);Camurus(原研),多囊肝病,II/III期临床,2022-03-16,Active,多肽,化药,环肽,类似物,微创新,CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,,消化领域;罕见疾病领域,,DR031328,否,欧洲,未知,,II/III期临床,,2022-03-16,phase 3,批准上市,2025-06-30,approved,2,True,True,True,['Novartis'],['Camurus'],1,"['Novartis(Top20 MNC)', 'Camurus(原研)']",消化领域,多囊肝病,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,,polycystic liver disease,CAM2029 (octreotide),CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa
CAM2029,somatostatin,somatostatin类似物,Novartis(Top20 MNC);Camurus(原研),多囊肾病,临床前,,Active,多肽,化药,环肽,类似物,微创新,CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,,泌尿生殖领域;罕见疾病领域,,DR031328,否,欧洲,未知,,,,,pre-clinical,批准上市,2025-06-30,approved,2,True,True,True,['Novartis'],['Camurus'],1,"['Novartis(Top20 MNC)', 'Camurus(原研)']",泌尿生殖领域,多囊肾病,['泌尿生殖领域'],1,泌尿生殖领域,,,5,-1,Genitourinary,Genitourinary,,,polycystic kidney disease,CAM2029 (octreotide),CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa
Cyporin N,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Taejoon Pharm(原研),干眼病,批准上市,,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,微创新,Cyporin N;Cyporin N (环孢素纳米乳);Cyporin N (cyclosporine nanoemulsion);TJO-087,,眼科领域,,DR022738,否,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,,approved,1,True,False,False,[],['Taejoon Pharm'],1,['Taejoon Pharm(原研)'],眼科领域,干眼病,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,,dry eye disease,Cyporin N (cyclosporine nanoemulsion),Cyporin N;Cyporin N (环孢素纳米乳);Cyporin N (cyclosporine nanoemulsion);TJO-087
Octreonax,somatostatin,somatostatin类似物,Nanox Release Technology(原研),肢端肥大症,批准上市,,Active,多肽,化药,环肽;中国无申报,类似物,微创新,Octreonax;Octreonax(注射用奥曲肽微球);Octreonax (octreotide injectable microsphere),,内分泌及代谢领域;罕见疾病领域,,DR047438,否,阿根廷,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,,approved,1,True,True,False,[],['Nanox Release Technology'],1,['Nanox Release Technology(原研)'],内分泌及代谢领域,肢端肥大症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,acromegaly,Octreonax (octreotide injectable microsphere),Octreonax;Octreonax(注射用奥曲肽微球);Octreonax (octreotide injectable microsphere)
Octreonax,somatostatin,somatostatin类似物,Nanox Release Technology(原研),巨人症,批准上市,,Active,多肽,化药,环肽;中国无申报,类似物,微创新,Octreonax;Octreonax(注射用奥曲肽微球);Octreonax (octreotide injectable microsphere),,内分泌及代谢领域,,DR047438,否,阿根廷,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,,approved,1,True,False,False,[],['Nanox Release Technology'],1,['Nanox Release Technology(原研)'],内分泌及代谢领域,巨人症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,,gigantism,Octreonax (octreotide injectable microsphere),Octreonax;Octreonax(注射用奥曲肽微球);Octreonax (octreotide injectable microsphere)
伐普肽,somatostatin,somatostatin类似物,Debiopharm(原研),食管静脉曲张出血,批准上市,,Active,多肽,化药,环肽,类似物,创新药,伐普肽;vapreotide;Sanvar;RC-160,,消化领域,,DR010387,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,,approved,1,True,False,False,[],['Debiopharm'],1,['Debiopharm(原研)'],消化领域,食管静脉曲张出血,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,,Esophageal variceal bleeding,vapreotide,伐普肽;vapreotide;Sanvar;RC-160
伐普肽,somatostatin,somatostatin类似物,Debiopharm(原研),门静脉高压,III期临床,2006-05-29,Inactive,多肽,化药,环肽,类似物,创新药,伐普肽;vapreotide;Sanvar;RC-160,,消化领域,,DR010387,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2006-05-29,phase 3,批准上市,,approved,1,True,False,False,[],['Debiopharm'],1,['Debiopharm(原研)'],消化领域,门静脉高压,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,,portal hypertension,vapreotide,伐普肽;vapreotide;Sanvar;RC-160
伐普肽,somatostatin,somatostatin类似物,Debiopharm(原研),胃静脉曲张,III期临床,2006-05-29,Inactive,多肽,化药,环肽,类似物,创新药,伐普肽;vapreotide;Sanvar;RC-160,,消化领域,,DR010387,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2006-05-29,phase 3,批准上市,,approved,1,True,False,False,[],['Debiopharm'],1,['Debiopharm(原研)'],消化领域,胃静脉曲张,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,,gastric varices,vapreotide,伐普肽;vapreotide;Sanvar;RC-160
伐普肽,somatostatin,somatostatin类似物,Debiopharm(原研),食管静脉曲张,III期临床,2006-05-29,Inactive,多肽,化药,环肽,类似物,创新药,伐普肽;vapreotide;Sanvar;RC-160,,消化领域,,DR010387,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2006-05-29,phase 3,批准上市,,approved,1,True,False,False,[],['Debiopharm'],1,['Debiopharm(原研)'],消化领域,食管静脉曲张,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,,Esophageal varices,vapreotide,伐普肽;vapreotide;Sanvar;RC-160
夫沙芬净,not available,,Servier(原研),上呼吸道感染,批准上市,,Active,小分子,化药,环肽,其他,创新药,夫沙芬净;fusafungin;fusafungine;S-314;Bioparox;Locabiotal,,感染领域;呼吸领域,,DR001193,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,,approved,1,True,False,False,[],['Servier'],1,['Servier(原研)'],感染领域,上呼吸道感染,"['感染领域', '呼吸领域']",2,感染领域,呼吸领域,,5,5,Infectious Diseases,Infectious Diseases,Respiratory,,upper respiratory tract infection,fusafungin,夫沙芬净;fusafungin;fusafungine;S-314;Bioparox;Locabiotal
普那霉素,50S subunit,链阳性菌素类抗生素,Rhône-Poulenc(Sanofi)(Top20 MNC)(原研),细菌感染,批准上市,,Active,其他,化药,环肽;First-in-Class;差异化疾病,链阳性菌素类抗生素,创新药,普那霉素;pristinamycin;Pyostacine;pristinamycine;RP 7293;原始霉素,,感染领域,,DR044796,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,,approved,1,True,False,True,['Rhône-Poulenc(Sanofi)'],['Rhône-Poulenc(Sanofi)'],1,['Rhône-Poulenc(Sanofi)(Top20 MNC)(原研)'],感染领域,细菌感染,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,,bacterial infection,pristinamycin,普那霉素;pristinamycin;Pyostacine;pristinamycine;RP 7293;原始霉素
普那霉素,50S subunit,链阳性菌素类抗生素,Rhône-Poulenc(Sanofi)(Top20 MNC)(原研),扁桃体炎(差异化疾病),III期临床,2006-10-29,Inactive,其他,化药,环肽;First-in-Class;差异化疾病,链阳性菌素类抗生素,创新药,普那霉素;pristinamycin;Pyostacine;pristinamycine;RP 7293;原始霉素,,感染领域;耳鼻喉领域;呼吸领域,,DR044796,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,批准上市,,approved,1,True,False,True,['Rhône-Poulenc(Sanofi)'],['Rhône-Poulenc(Sanofi)'],1,['Rhône-Poulenc(Sanofi)(Top20 MNC)(原研)'],感染领域,扁桃体炎,"['感染领域', '耳鼻喉领域', '呼吸领域']",3,感染领域,耳鼻喉领域,呼吸领域,5,3,Infectious Diseases,Infectious Diseases,,Respiratory,tonsillitis,pristinamycin,普那霉素;pristinamycin;Pyostacine;pristinamycine;RP 7293;原始霉素
苯赖加压素,vasopressin,vasopressin类似物,Sandoz(原研),局部麻醉(差异化疾病),批准上市,,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,苯赖加压素;felypressin;Octapressin,,麻醉镇痛领域,,DR051774,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,,approved,1,True,False,False,[],['Sandoz'],1,['Sandoz(原研)'],麻醉镇痛领域,局部麻醉,['麻醉镇痛领域'],1,麻醉镇痛领域,,,5,5,Anesthesia & Analgesia,Anesthesia & Analgesia,,,local anesthesia,felypressin,苯赖加压素;felypressin;Octapressin
重组水蛭素,hirudin,重组hirudin,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),深静脉血栓,批准上市,,Active,多肽,生物,环肽;First-in-Class;差异化疾病,重组,创新药,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,,心脑血管领域,,DR010644,否,欧洲;埃及,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,,approved,2,True,False,True,['Rhein biotech'],"['Minapharm', 'Rhein biotech']",2,"['Minapharm(原研)', 'Rhein biotech(Top20 MNC)(原研)']",心脑血管领域,深静脉血栓,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,deep vein thrombosis,recombinant hirudin,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin
重组水蛭素,hirudin,重组hirudin,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),静脉曲张(差异化疾病),批准上市,,Active,多肽,生物,环肽;First-in-Class;差异化疾病,重组,创新药,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,,心脑血管领域,,DR010644,否,欧洲;埃及,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,,approved,2,True,False,True,['Rhein biotech'],"['Minapharm', 'Rhein biotech']",2,"['Minapharm(原研)', 'Rhein biotech(Top20 MNC)(原研)']",心脑血管领域,静脉曲张,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Varicose veins,recombinant hirudin,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin
重组水蛭素,hirudin,重组hirudin,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),血栓性静脉炎(差异化疾病),批准上市,,Active,多肽,生物,环肽;First-in-Class;差异化疾病,重组,创新药,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,,心脑血管领域,,DR010644,否,欧洲;埃及,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,,approved,2,True,False,True,['Rhein biotech'],"['Minapharm', 'Rhein biotech']",2,"['Minapharm(原研)', 'Rhein biotech(Top20 MNC)(原研)']",心脑血管领域,血栓性静脉炎,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,thrombophlebitis,recombinant hirudin,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin
重组水蛭素,hirudin,重组hirudin,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),血肿(差异化疾病),批准上市,,Active,多肽,生物,环肽;First-in-Class;差异化疾病,重组,创新药,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,,其他领域,,DR010644,否,欧洲;埃及,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,approved,批准上市,,approved,2,True,False,True,['Rhein biotech'],"['Minapharm', 'Rhein biotech']",2,"['Minapharm(原研)', 'Rhein biotech(Top20 MNC)(原研)']",其他领域,血肿,['其他领域'],1,其他领域,,,5,5,Others,Others,,,hematoma,recombinant hirudin,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin
环孢素A眼凝胶,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,兆科眼科(原研),干眼病,申请上市,2022-06-09,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,环孢素A眼凝胶;cyclosporine A ophthalmic gel,,眼科领域,申请上市:凝胶剂(眼用),DR049927,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,申请上市,申报临床,2022-06-09,2025-06-04,pre-registration,申请上市,2022-06-09,pre-registration,1,True,False,False,[],['兆科眼科'],1,['兆科眼科(原研)'],眼科领域,干眼病,['眼科领域'],1,眼科领域,,,4,4,Ophthalmology,Ophthalmology,,,dry eye disease,cyclosporine A ophthalmic gel,环孢素A眼凝胶;cyclosporine A ophthalmic gel
那韦培肽,CNP,CNP类似物,Teijin;Ascendis Pharma(原研);维昇药业,软骨发育不全,申请上市,2025-03-31,Active,多肽,化药,环肽;差异化疾病,类似物,创新药,那韦培肽;navepegritide;TransCon CNP,,骨骼肌肉领域;罕见疾病领域,II期临床:注射剂(冻干),DR011859,否,欧洲,美国;欧洲;日本;其他,II期临床,申请上市,2021-07-09,2025-03-31,pre-registration,申请上市,2025-03-31,pre-registration,3,True,True,False,[],['Ascendis Pharma'],1,"['Teijin', 'Ascendis Pharma(原研)', '维昇药业']",骨骼肌肉领域,软骨发育不全,['骨骼肌肉领域'],1,骨骼肌肉领域,,,4,4,Musculoskeletal,Musculoskeletal,,,Achondroplasia,navepegritide,那韦培肽;navepegritide;TransCon CNP
那韦培肽,CNP,CNP类似物,Teijin;Ascendis Pharma(原研);维昇药业,致死性侏儒症(差异化疾病),I期临床,2018-07-13,Inactive,多肽,化药,环肽;差异化疾病,类似物,创新药,那韦培肽;navepegritide;TransCon CNP,,骨骼肌肉领域;罕见疾病领域,II期临床:注射剂(冻干),DR011859,否,欧洲,美国;欧洲;日本;其他,,,,,phase 1,申请上市,2025-03-31,pre-registration,3,True,True,False,[],['Ascendis Pharma'],1,"['Teijin', 'Ascendis Pharma(原研)', '维昇药业']",骨骼肌肉领域,致死性侏儒症,['骨骼肌肉领域'],1,骨骼肌肉领域,,,4,1,Musculoskeletal,Musculoskeletal,,,fatal dwarfism,navepegritide,那韦培肽;navepegritide;TransCon CNP
ET-600,vasopressin,vasopressin类似物,Eton Pharmaceuticals(原研),中枢性尿崩症,申请上市,2025-04-28,Active,多肽,化药,环肽,类似物,微创新,ET-600;ET-600 (去氨加压素口服溶液);ET-600 (desmopressin oral solution),,内分泌及代谢领域,,DR068510,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,申请上市,,2025-04-28,pre-registration,申请上市,2025-04-28,pre-registration,1,True,False,False,[],['Eton Pharmaceuticals'],1,['Eton Pharmaceuticals(原研)'],内分泌及代谢领域,中枢性尿崩症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,4,4,Endocrinology & Metabolism,Endocrinology & Metabolism,,,central diabetes insipidus,ET-600 (desmopressin oral solution),ET-600;ET-600 (去氨加压素口服溶液);ET-600 (desmopressin oral solution)
镥[177Lu]依多曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,胃肠胰神经内分泌肿瘤,申请上市,2025-11-13,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR064918,否,欧洲,美国;欧洲;日本;其他,III期临床,申请上市,2021-06-09,2025-11-13,pre-registration,申请上市,2025-11-13,pre-registration,3,True,True,False,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,4,4,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽
镥[177Lu]依多曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,神经内分泌肿瘤,III期临床,2022-05-24,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR064918,否,欧洲,美国;欧洲;日本;其他,申报临床,I期临床,2023-02-22,2024-06-04,phase 3,申请上市,2025-11-13,pre-registration,3,True,True,False,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,4,3,Oncology,Oncology,,,neuroendocrine tumors,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽
镥[177Lu]依多曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,嗜铬细胞瘤,II期临床,2019-08-20,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR064918,否,欧洲,美国;欧洲;日本;其他,,II期临床,,2020-02-19,phase 2,申请上市,2025-11-13,pre-registration,3,True,True,False,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,嗜铬细胞瘤,['肿瘤领域'],1,肿瘤领域,,,4,2,Oncology,Oncology,,,Pheochromocytoma,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽
镥[177Lu]依多曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,胃泌素瘤(差异化疾病),II期临床,2021-06-07,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR064918,否,欧洲,美国;欧洲;日本;其他,,,,,phase 2,申请上市,2025-11-13,pre-registration,3,True,True,False,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,胃泌素瘤,['肿瘤领域'],1,肿瘤领域,,,4,2,Oncology,Oncology,,,gastrinoma,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽
镥[177Lu]依多曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,副神经节瘤,II期临床,2020-02-19,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR064918,否,欧洲,美国;欧洲;日本;其他,,II期临床,,2020-02-19,phase 2,申请上市,2025-11-13,pre-registration,3,True,True,False,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,副神经节瘤,['肿瘤领域'],1,肿瘤领域,,,4,2,Oncology,Oncology,,,paraganglioma,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽
镥[177Lu]依多曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,胰岛细胞瘤(差异化疾病),II期临床,2021-06-07,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR064918,否,欧洲,美国;欧洲;日本;其他,,,,,phase 2,申请上市,2025-11-13,pre-registration,3,True,True,False,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,胰岛细胞瘤,['肿瘤领域'],1,肿瘤领域,,,4,2,Oncology,Oncology,,,islet cell tumor,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽
镥[177Lu]依多曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,脑膜瘤,II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,,肿瘤领域,III期临床:注射剂,DR064918,否,欧洲,美国;欧洲;日本;其他,,,,,phase 2,申请上市,2025-11-13,pre-registration,3,True,False,False,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,脑膜瘤,['肿瘤领域'],1,肿瘤领域,,,4,2,Oncology,Oncology,,,Meningioma,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽
镥[177Lu]依多曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,肺类癌(差异化疾病),II期临床,2021-06-07,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR064918,否,欧洲,美国;欧洲;日本;其他,,,,,phase 2,申请上市,2025-11-13,pre-registration,3,True,True,False,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,肺类癌,['肿瘤领域'],1,肿瘤领域,,,4,2,Oncology,Oncology,,,lung carcinoid,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽
镥[177Lu]依多曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,实体瘤,I期临床,2025-03-19,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,,肿瘤领域,III期临床:注射剂,DR064918,否,欧洲,美国;欧洲;日本;其他,,I期临床,,2025-03-19,phase 1,申请上市,2025-11-13,pre-registration,3,True,False,False,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,4,1,Oncology,Oncology,,,solid tumors,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽
镥[177Lu]依多曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,脑癌,I期临床,2024-06-04,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,,肿瘤领域,III期临床:注射剂,DR064918,否,欧洲,美国;欧洲;日本;其他,,I期临床,,2024-06-04,phase 1,申请上市,2025-11-13,pre-registration,3,True,False,False,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,脑癌,['肿瘤领域'],1,肿瘤领域,,,4,1,Oncology,Oncology,,,brain cancer,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽
镥[177Lu]依多曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,淋巴瘤,I期临床,2024-06-04,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,,肿瘤领域;血液领域,III期临床:注射剂,DR064918,否,欧洲,美国;欧洲;日本;其他,,I期临床,,2024-06-04,phase 1,申请上市,2025-11-13,pre-registration,3,True,False,False,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,4,1,Oncology,Oncology,Hematology,,Lymphoma,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽
镥[177Lu]依多曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,胰腺神经内分泌肿瘤,申报临床,2024-09-27,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,,肿瘤领域;罕见疾病领域,III期临床:注射剂,DR064918,否,欧洲,美国;欧洲;日本;其他,申报临床,,2024-09-27,,ind,申请上市,2025-11-13,pre-registration,3,True,True,False,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,胰腺神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,4,0,Oncology,Oncology,,,pancreatic neuroendocrine tumors,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽
LV-101,oxytocin,oxytocin类似物,Ferring Pharmaceuticals(原研);Levo Therapeutics(Acadia Pharmaceuticals),Prader-Willi综合征,申请上市,,Active,多肽,化药,环肽;中国无申报,类似物,微创新,LV-101;LV-101 (卡贝缩宫素);LV-101 (intranasal carbetocin);ACP-101,,内分泌及代谢领域;罕见疾病领域,,DR000577,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2018-08-28,pre-registration,申请上市,,pre-registration,2,True,True,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', 'Levo Therapeutics(Acadia Pharmaceuticals)']",内分泌及代谢领域,Prader-Willi综合征,['内分泌及代谢领域'],1,内分泌及代谢领域,,,4,4,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Prader-Willi syndrome,LV-101 (intranasal carbetocin),LV-101;LV-101 (卡贝缩宫素);LV-101 (intranasal carbetocin);ACP-101
LV-101,oxytocin,oxytocin类似物,Ferring Pharmaceuticals(原研);Levo Therapeutics(Acadia Pharmaceuticals),多食症,III期临床,2024-05-20,Active,多肽,化药,环肽;中国无申报,类似物,微创新,LV-101;LV-101 (卡贝缩宫素);LV-101 (intranasal carbetocin);ACP-101,,精神领域;内分泌及代谢领域,,DR000577,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2024-05-20,phase 3,申请上市,,pre-registration,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', 'Levo Therapeutics(Acadia Pharmaceuticals)']",精神领域,多食症,"['精神领域', '内分泌及代谢领域']",2,精神领域,内分泌及代谢领域,,4,3,Psychiatry,Psychiatry,Endocrinology & Metabolism,,polyphagia,LV-101 (intranasal carbetocin),LV-101;LV-101 (卡贝缩宫素);LV-101 (intranasal carbetocin);ACP-101
CMS I-neb,not available,多粘菌素类抗生素,Zambon(原研),支气管扩张,III期临床,2017-02-10,Active,其他,化药,环肽,多粘菌素类抗生素,微创新,CMS I-neb;CMS I-neb (多粘菌素E甲磺酸钠雾化剂);CMS I-neb (colistimethate sodium powder for nebulization);Promixin,,呼吸领域,,DR055713,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2017-03-20,phase 3,III期临床,2017-02-10,phase 3,1,True,False,False,[],['Zambon'],1,['Zambon(原研)'],呼吸领域,支气管扩张,['呼吸领域'],1,呼吸领域,,,3,3,Respiratory,Respiratory,,,bronchiectasis,CMS I-neb (colistimethate sodium powder for nebulization),CMS I-neb;CMS I-neb (多粘菌素E甲磺酸钠雾化剂);CMS I-neb (colistimethate sodium powder for nebulization);Promixin
CMS I-neb,not available,多粘菌素类抗生素,Zambon(原研),假单胞菌感染,III期临床,2017-02-10,Inactive,其他,化药,环肽,多粘菌素类抗生素,微创新,CMS I-neb;CMS I-neb (多粘菌素E甲磺酸钠雾化剂);CMS I-neb (colistimethate sodium powder for nebulization);Promixin,,感染领域,,DR055713,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2017-03-20,phase 3,III期临床,2017-02-10,phase 3,1,True,False,False,[],['Zambon'],1,['Zambon(原研)'],感染领域,假单胞菌感染,['感染领域'],1,感染领域,,,3,3,Infectious Diseases,Infectious Diseases,,,Pseudomonas infection,CMS I-neb (colistimethate sodium powder for nebulization),CMS I-neb;CMS I-neb (多粘菌素E甲磺酸钠雾化剂);CMS I-neb (colistimethate sodium powder for nebulization);Promixin
莫瑞伐定,LptD,抗生素,Polyphor(Spexis)(原研);Roche(Top20 MNC)(无权益),医院获得性细菌性肺炎,III期临床,2018-07-10,Inactive,多肽,化药,环肽;Potential First-in-Class,抗生素,创新药,莫瑞伐定;murepavadin;POL7080;RG7929;RO7033877,,感染领域;呼吸领域,,DR030039,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2018-07-10,phase 3,III期临床,2018-01-24,phase 3,2,True,False,True,['Roche'],['Polyphor(Spexis)'],1,"['Polyphor(Spexis)(原研)', 'Roche(Top20 MNC)(无权益)']",感染领域,医院获得性细菌性肺炎,"['感染领域', '呼吸领域']",2,感染领域,呼吸领域,,3,3,Infectious Diseases,Infectious Diseases,Respiratory,,hospital acquired bacterial pneumonia,murepavadin,莫瑞伐定;murepavadin;POL7080;RG7929;RO7033877
莫瑞伐定,LptD,抗生素,Polyphor(Spexis)(原研);Roche(Top20 MNC)(无权益),呼吸机相关性细菌性肺炎,III期临床,2018-01-24,Inactive,多肽,化药,环肽;Potential First-in-Class,抗生素,创新药,莫瑞伐定;murepavadin;POL7080;RG7929;RO7033877,,感染领域;呼吸领域,,DR030039,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2018-01-24,phase 3,III期临床,2018-01-24,phase 3,2,True,False,True,['Roche'],['Polyphor(Spexis)'],1,"['Polyphor(Spexis)(原研)', 'Roche(Top20 MNC)(无权益)']",感染领域,呼吸机相关性细菌性肺炎,"['感染领域', '呼吸领域']",2,感染领域,呼吸领域,,3,3,Infectious Diseases,Infectious Diseases,Respiratory,,ventilator-associated bacterial pneumonia,murepavadin,莫瑞伐定;murepavadin;POL7080;RG7929;RO7033877
莫瑞伐定,LptD,抗生素,Polyphor(Spexis)(原研);Roche(Top20 MNC)(无权益),绿脓杆菌感染,II期临床,2014-03-26,Inactive,多肽,化药,环肽;Potential First-in-Class,抗生素,创新药,莫瑞伐定;murepavadin;POL7080;RG7929;RO7033877,,感染领域,,DR030039,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2018-01-24,phase 3,2,True,False,True,['Roche'],['Polyphor(Spexis)'],1,"['Polyphor(Spexis)(原研)', 'Roche(Top20 MNC)(无权益)']",感染领域,绿脓杆菌感染,['感染领域'],1,感染领域,,,3,2,Infectious Diseases,Infectious Diseases,,,Pseudomonas aeruginosa infection,murepavadin,莫瑞伐定;murepavadin;POL7080;RG7929;RO7033877
莫瑞伐定,LptD,抗生素,Polyphor(Spexis)(原研);Roche(Top20 MNC)(无权益),囊性纤维化,申报临床,,Active,多肽,化药,环肽;Potential First-in-Class,抗生素,创新药,莫瑞伐定;murepavadin;POL7080;RG7929;RO7033877,,呼吸领域;罕见疾病领域,,DR030039,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,ind,III期临床,2018-01-24,phase 3,2,True,True,True,['Roche'],['Polyphor(Spexis)'],1,"['Polyphor(Spexis)(原研)', 'Roche(Top20 MNC)(无权益)']",呼吸领域,囊性纤维化,['呼吸领域'],1,呼吸领域,,,3,0,Respiratory,Respiratory,,,cystic fibrosis,murepavadin,莫瑞伐定;murepavadin;POL7080;RG7929;RO7033877
Liposomal cyclosporine A,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Breath Therapeutics(Zambon)(原研),闭塞性细支气管炎,III期临床,2018-09-04,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,Liposomal cyclosporine A;环孢素A脂质体 (Breath Therapeutics);L-CsA-i,,呼吸领域;罕见疾病领域,,DR019246,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2018-09-04,phase 3,III期临床,2018-09-04,phase 3,1,True,True,False,[],['Breath Therapeutics(Zambon)'],1,['Breath Therapeutics(Zambon)(原研)'],呼吸领域,闭塞性细支气管炎,['呼吸领域'],1,呼吸领域,,,3,3,Respiratory,Respiratory,,,bronchiolitis obliterans,Liposomal cyclosporine A,Liposomal cyclosporine A;环孢素A脂质体 (Breath Therapeutics);L-CsA-i
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),乳腺癌,III期临床,2018-12-24,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,肿瘤领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,I期临床,III期临床,2024-12-03,2018-12-24,phase 3,III期临床,2018-12-24,phase 3,3,True,False,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,,breast cancer,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),多发性骨髓瘤,II期临床,2008-10-29,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,肿瘤领域;血液领域;罕见疾病领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,I/II期临床,,2011-08-10,phase 2,III期临床,2018-12-24,phase 3,3,True,True,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,多发性骨髓瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,2,Oncology,Oncology,Hematology,,multiple myeloma,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),心肌梗塞,II期临床,,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,心脑血管领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,,,,phase 2,III期临床,2018-12-24,phase 3,3,True,False,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",心脑血管领域,心肌梗塞,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,myocardial infarction,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),ST段抬高型心肌梗死(差异化疾病),II期临床,2013-07-23,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,心脑血管领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,,,,phase 2,III期临床,2018-12-24,phase 3,3,True,False,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",心脑血管领域,ST段抬高型心肌梗死,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,ST segment elevation myocardial infarction,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),急性淋巴细胞白血病,I/II期临床,2011-08-10,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,肿瘤领域;血液领域;罕见疾病领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,I/II期临床,,2011-08-10,phase 2,III期临床,2018-12-24,phase 3,3,True,True,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,急性淋巴细胞白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,2,Oncology,Oncology,Hematology,,acute lymphoblastic leukemia,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),慢性淋巴细胞白血病,I/II期临床,2011-08-10,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,肿瘤领域;血液领域;罕见疾病领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,I/II期临床,,2011-08-10,phase 2,III期临床,2018-12-24,phase 3,3,True,True,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,慢性淋巴细胞白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,2,Oncology,Oncology,Hematology,,chronic lymphocytic leukemia,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),急性髓系白血病,I/II期临床,2011-08-10,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,肿瘤领域;血液领域;罕见疾病领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,I/II期临床,,2011-08-10,phase 2,III期临床,2018-12-24,phase 3,3,True,True,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,急性髓系白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,2,Oncology,Oncology,Hematology,,acute myeloid leukemia,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),慢性髓系白血病,I/II期临床,2011-08-10,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,肿瘤领域;血液领域;罕见疾病领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,I/II期临床,,2011-08-10,phase 2,III期临床,2018-12-24,phase 3,3,True,True,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,慢性髓系白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,2,Oncology,Oncology,Hematology,,chronic myeloid leukemia,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),霍奇金淋巴瘤,I/II期临床,2011-08-10,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,肿瘤领域;血液领域;罕见疾病领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,I/II期临床,,2011-08-10,phase 2,III期临床,2018-12-24,phase 3,3,True,True,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,霍奇金淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,2,Oncology,Oncology,Hematology,,Hodgkin lymphoma,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),非霍奇金淋巴瘤,I/II期临床,2011-08-10,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,肿瘤领域;血液领域;罕见疾病领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,I/II期临床,,2011-08-10,phase 2,III期临床,2018-12-24,phase 3,3,True,True,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,非霍奇金淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,2,Oncology,Oncology,Hematology,,non-hodgkin lymphoma,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),骨髓增生异常综合征,I/II期临床,2011-08-10,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,肿瘤领域;血液领域;罕见疾病领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,I/II期临床,,2011-08-10,phase 2,III期临床,2018-12-24,phase 3,3,True,True,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,骨髓增生异常综合征,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,2,Oncology,Oncology,Hematology,,myelodysplastic syndrome,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),HR阳性乳腺癌(差异化疾病),I期临床,2013-04-22,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,肿瘤领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,I期临床,,2013-04-22,phase 1,III期临床,2018-12-24,phase 3,3,True,False,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,HR阳性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,HR positive breast cancer,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),三阴性乳腺癌,I期临床,2013-04-22,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,肿瘤领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,I期临床,,2013-04-22,phase 1,III期临床,2018-12-24,phase 3,3,True,False,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,三阴性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,triple negative breast cancer,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),胰腺导管癌,I期临床,2025-05-21,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,肿瘤领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,I期临床,,2025-05-21,phase 1,III期临床,2018-12-24,phase 3,3,True,False,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,pancreatic ductal carcinoma,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),B细胞淋巴瘤,临床前,,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,肿瘤领域;血液领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,,,,pre-clinical,III期临床,2018-12-24,phase 3,3,True,False,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,B细胞淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,-1,Oncology,Oncology,Hematology,,B cell lymphoma,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
巴利福肽,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),新型冠状病毒感染,临床前,,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,创新药,巴利福肽;balixafortide;POL6326;SPX6326,,感染领域,申报临床:未知,DR042535,否,欧洲,美国;欧洲;日本;其他,,,,,pre-clinical,III期临床,2018-12-24,phase 3,3,True,False,False,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",感染领域,新型冠状病毒感染,['感染领域'],1,感染领域,,,3,-1,Infectious Diseases,Infectious Diseases,,,novel coronavirus infection,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326
TNX-2900,oxytocin,合成的oxytocin,Tonix Pharmaceuticals(原研);Institut National de la Sante et de la Recherche Medicale (INSERM),Prader-Willi综合征,III期临床,2020-02-25,Active,多肽,化药,环肽;中国无申报,合成的,微创新,TNX-2900;TNX-2900 (缩宫素鼻喷雾);TNX-2900 (intranasal potentiated oxytocin),,内分泌及代谢领域;罕见疾病领域,,DR003204,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2015-12-15,phase 3,III期临床,2020-02-25,phase 3,2,True,True,False,[],['Tonix Pharmaceuticals'],1,"['Tonix Pharmaceuticals(原研)', 'Institut National de la Sante et de la Recherche Medicale (INSERM)']",内分泌及代谢领域,Prader-Willi综合征,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Prader-Willi syndrome,TNX-2900 (intranasal potentiated oxytocin),TNX-2900;TNX-2900 (缩宫素鼻喷雾);TNX-2900 (intranasal potentiated oxytocin)
TNX-2900,oxytocin,合成的oxytocin,Tonix Pharmaceuticals(原研);Institut National de la Sante et de la Recherche Medicale (INSERM),口咽性吞咽困难,II/III期临床,2022-03-28,Unknown,多肽,化药,环肽;中国无申报,合成的,微创新,TNX-2900;TNX-2900 (缩宫素鼻喷雾);TNX-2900 (intranasal potentiated oxytocin),,骨骼肌肉领域,,DR003204,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,III期临床,2020-02-25,phase 3,2,True,False,False,[],['Tonix Pharmaceuticals'],1,"['Tonix Pharmaceuticals(原研)', 'Institut National de la Sante et de la Recherche Medicale (INSERM)']",骨骼肌肉领域,口咽性吞咽困难,['骨骼肌肉领域'],1,骨骼肌肉领域,,,3,3,Musculoskeletal,Musculoskeletal,,,Oropharyngeal dysphagia,TNX-2900 (intranasal potentiated oxytocin),TNX-2900;TNX-2900 (缩宫素鼻喷雾);TNX-2900 (intranasal potentiated oxytocin)
TNX-2900,oxytocin,合成的oxytocin,Tonix Pharmaceuticals(原研);Institut National de la Sante et de la Recherche Medicale (INSERM),多食症,II期临床,2015-12-15,Inactive,多肽,化药,环肽;中国无申报,合成的,微创新,TNX-2900;TNX-2900 (缩宫素鼻喷雾);TNX-2900 (intranasal potentiated oxytocin),,精神领域;内分泌及代谢领域,,DR003204,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2015-12-15,phase 2,III期临床,2020-02-25,phase 3,2,True,False,False,[],['Tonix Pharmaceuticals'],1,"['Tonix Pharmaceuticals(原研)', 'Institut National de la Sante et de la Recherche Medicale (INSERM)']",精神领域,多食症,"['精神领域', '内分泌及代谢领域']",2,精神领域,内分泌及代谢领域,,3,2,Psychiatry,Psychiatry,Endocrinology & Metabolism,,polyphagia,TNX-2900 (intranasal potentiated oxytocin),TNX-2900;TNX-2900 (缩宫素鼻喷雾);TNX-2900 (intranasal potentiated oxytocin)
氟[18F]阿法肽,αvβ3,anti-αvβ3多肽偶联核素;18F标记的PET药物,东诚药业;National Institute of Biomedical Imaging and Bioengineering;施美康(无权益);厦门大学(原研)(无权益),非小细胞肺癌,III期临床,2021-12-10,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,创新药,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016,,肿瘤领域,III期临床:注射剂,DR043061,否,中国(内地),,III期临床,,2021-12-10,,phase 3,III期临床,2020-08-06,phase 3,4,True,False,False,[],['厦门大学'],1,"['东诚药业', 'National Institute of Biomedical Imaging and Bioengineering', '施美康(无权益)', '厦门大学(原研)(无权益)']",肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,,non-small cell lung cancer,alfatide F-18,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016
氟[18F]阿法肽,αvβ3,anti-αvβ3多肽偶联核素;18F标记的PET药物,东诚药业;National Institute of Biomedical Imaging and Bioengineering;施美康(无权益);厦门大学(原研)(无权益),PET显像,III期临床,2021-12-10,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,创新药,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016,,诊断试剂领域,III期临床:注射剂,DR043061,否,中国(内地),,III期临床,,2021-12-10,,phase 3,III期临床,2020-08-06,phase 3,4,True,False,False,[],['厦门大学'],1,"['东诚药业', 'National Institute of Biomedical Imaging and Bioengineering', '施美康(无权益)', '厦门大学(原研)(无权益)']",诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,3,3,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,alfatide F-18,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016
氟[18F]阿法肽,αvβ3,anti-αvβ3多肽偶联核素;18F标记的PET药物,东诚药业;National Institute of Biomedical Imaging and Bioengineering;施美康(无权益);厦门大学(原研)(无权益),实体瘤,I期临床,2019-12-23,Inactive,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,创新药,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016,,肿瘤领域,III期临床:注射剂,DR043061,否,中国(内地),,I期临床,,2019-12-23,,phase 1,III期临床,2020-08-06,phase 3,4,True,False,False,[],['厦门大学'],1,"['东诚药业', 'National Institute of Biomedical Imaging and Bioengineering', '施美康(无权益)', '厦门大学(原研)(无权益)']",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,solid tumors,alfatide F-18,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016
氟[18F]阿法肽,αvβ3,anti-αvβ3多肽偶联核素;18F标记的PET药物,东诚药业;National Institute of Biomedical Imaging and Bioengineering;施美康(无权益);厦门大学(原研)(无权益),肿瘤,申报临床,2016-07-14,Inactive,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,创新药,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016,,肿瘤领域,III期临床:注射剂,DR043061,否,中国(内地),,申报临床,,2016-07-14,,ind,III期临床,2020-08-06,phase 3,4,True,False,False,[],['厦门大学'],1,"['东诚药业', 'National Institute of Biomedical Imaging and Bioengineering', '施美康(无权益)', '厦门大学(原研)(无权益)']",肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,3,0,Oncology,Oncology,,,tumor,alfatide F-18,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016
PL-8331,MC1R;MC5R,MC5R激动剂;MC1R激动剂,Palatin Technologies(原研),干眼病(差异化疾病),III期临床,2022-01-21,Active,多肽,其他,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;Melanogenesis,激动剂,创新药,PL-8331;PL-9643;PL9643;PL8331,,眼科领域,,DR054606,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2022-01-21,phase 3,III期临床,2022-01-21,phase 3,1,True,False,False,[],['Palatin Technologies'],1,['Palatin Technologies(原研)'],眼科领域,干眼病,['眼科领域'],1,眼科领域,,,3,3,Ophthalmology,Ophthalmology,,,dry eye disease,PL-8331,PL-8331;PL-9643;PL9643;PL8331
PL-8331,MC1R;MC5R,MC5R激动剂;MC1R激动剂,Palatin Technologies(原研),葡萄膜炎(差异化疾病),临床前,,Active,多肽,其他,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;Melanogenesis,激动剂,创新药,PL-8331;PL-9643;PL9643;PL8331,,眼科领域,,DR054606,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,III期临床,2022-01-21,phase 3,1,True,False,False,[],['Palatin Technologies'],1,['Palatin Technologies(原研)'],眼科领域,葡萄膜炎,['眼科领域'],1,眼科领域,,,3,-1,Ophthalmology,Ophthalmology,,,uveitis,PL-8331,PL-8331;PL-9643;PL9643;PL8331
PL-8331,MC1R;MC5R,MC5R激动剂;MC1R激动剂,Palatin Technologies(原研),糖尿病视网膜病变(差异化疾病),临床前,,Active,多肽,其他,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;Melanogenesis,激动剂,创新药,PL-8331;PL-9643;PL9643;PL8331,,眼科领域,,DR054606,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,III期临床,2022-01-21,phase 3,1,True,False,False,[],['Palatin Technologies'],1,['Palatin Technologies(原研)'],眼科领域,糖尿病视网膜病变,['眼科领域'],1,眼科领域,,,3,-1,Ophthalmology,Ophthalmology,,,diabetic retinopathy,PL-8331,PL-8331;PL-9643;PL9643;PL8331
rusfertide,Hepc,合成的Hepc,Takeda Pharmaceuticals(Top20 MNC);Protagonist Therapeutics(原研),真性红细胞增多症(差异化疾病),III期临床,2022-01-27,Active,多肽,化药,环肽;差异化疾病;铁代谢;中国无申报;Potential First-in-Class,合成的,创新药,rusfertide;PTG-300;鲁斯费尔肽;TAK-121,,肿瘤领域;血液领域;罕见疾病领域,,DR043844,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2022-01-27,phase 3,III期临床,2022-01-27,phase 3,2,True,True,True,['Takeda Pharmaceuticals'],['Protagonist Therapeutics'],1,"['Takeda Pharmaceuticals(Top20 MNC)', 'Protagonist Therapeutics(原研)']",肿瘤领域,真性红细胞增多症,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,3,Oncology,Oncology,Hematology,,polycythemia vera,rusfertide,rusfertide;PTG-300;鲁斯费尔肽;TAK-121
rusfertide,Hepc,合成的Hepc,Takeda Pharmaceuticals(Top20 MNC);Protagonist Therapeutics(原研),铁负荷过载,II期临床,,Active,多肽,化药,环肽;差异化疾病;铁代谢;中国无申报;Potential First-in-Class,合成的,创新药,rusfertide;PTG-300;鲁斯费尔肽;TAK-121,,内分泌及代谢领域;罕见疾病领域,,DR043844,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2022-01-27,phase 3,2,True,True,True,['Takeda Pharmaceuticals'],['Protagonist Therapeutics'],1,"['Takeda Pharmaceuticals(Top20 MNC)', 'Protagonist Therapeutics(原研)']",内分泌及代谢领域,铁负荷过载,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,iron load overload,rusfertide,rusfertide;PTG-300;鲁斯费尔肽;TAK-121
rusfertide,Hepc,合成的Hepc,Takeda Pharmaceuticals(Top20 MNC);Protagonist Therapeutics(原研),遗传性血色素沉着病,II期临床,2019-12-18,Active,多肽,化药,环肽;差异化疾病;铁代谢;中国无申报;Potential First-in-Class,合成的,创新药,rusfertide;PTG-300;鲁斯费尔肽;TAK-121,,罕见疾病领域;内分泌及代谢领域,,DR043844,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2019-12-18,phase 2,III期临床,2022-01-27,phase 3,2,True,True,True,['Takeda Pharmaceuticals'],['Protagonist Therapeutics'],1,"['Takeda Pharmaceuticals(Top20 MNC)', 'Protagonist Therapeutics(原研)']",内分泌及代谢领域,遗传性血色素沉着病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,hereditary hemochromatosis,rusfertide,rusfertide;PTG-300;鲁斯费尔肽;TAK-121
rusfertide,Hepc,合成的Hepc,Takeda Pharmaceuticals(Top20 MNC);Protagonist Therapeutics(原研),β-地中海贫血(差异化疾病),II期临床,2019-01-14,Unknown,多肽,化药,环肽;差异化疾病;铁代谢;中国无申报;Potential First-in-Class,合成的,创新药,rusfertide;PTG-300;鲁斯费尔肽;TAK-121,,血液领域;罕见疾病领域,,DR043844,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2019-01-14,phase 2,III期临床,2022-01-27,phase 3,2,True,True,True,['Takeda Pharmaceuticals'],['Protagonist Therapeutics'],1,"['Takeda Pharmaceuticals(Top20 MNC)', 'Protagonist Therapeutics(原研)']",血液领域,β-地中海贫血,['血液领域'],1,血液领域,,,3,2,Hematology,Hematology,,,beta-thalassemia,rusfertide,rusfertide;PTG-300;鲁斯费尔肽;TAK-121
RYZ101,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),胃肠胰神经内分泌肿瘤,III期临床,2022-07-28,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,,肿瘤领域;罕见疾病领域,,DR055976,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,III期临床,2024-12-13,2022-07-28,phase 3,III期临床,2022-07-28,phase 3,1,True,True,True,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,RYZ101,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽
RYZ101,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),HR阳性乳腺癌(差异化疾病),I/II期临床,2024-09-19,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,,肿瘤领域,,DR055976,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-09-19,phase 2,III期临床,2022-07-28,phase 3,1,True,False,True,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,HR阳性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,HR positive breast cancer,RYZ101,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽
RYZ101,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),脑膜瘤(差异化疾病),I/II期临床,2025-09-02,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,,肿瘤领域,,DR055976,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2025-09-02,phase 2,III期临床,2022-07-28,phase 3,1,True,False,True,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,脑膜瘤,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,Meningioma,RYZ101,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽
RYZ101,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),小细胞肺癌,I期临床,2022-10-27,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,,肿瘤领域;罕见疾病领域,,DR055976,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2022-10-27,phase 1,III期临床,2022-07-28,phase 3,1,True,True,True,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,small cell lung cancer,RYZ101,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽
RYZ101,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),多发性骨髓瘤(差异化疾病),I期临床,2024-05-13,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,,肿瘤领域;血液领域;罕见疾病领域,,DR055976,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,III期临床,2022-07-28,phase 3,1,True,True,True,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,多发性骨髓瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,1,Oncology,Oncology,Hematology,,multiple myeloma,RYZ101,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽
[68Ga]CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),PET显像,III期临床,2022-11-16,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]CBP8;68Ga-CBP8,,诊断试剂领域,,DR022856,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2022-11-16,phase 3,III期临床,2022-11-16,phase 3,1,True,False,False,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,3,3,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8
[68Ga]CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),心脏淀粉样变性,III期临床,2022-11-16,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]CBP8;68Ga-CBP8,,罕见疾病领域;心脑血管领域,,DR022856,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2022-11-16,phase 3,III期临床,2022-11-16,phase 3,1,True,True,False,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],心脑血管领域,心脏淀粉样变性,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,cardiac amyloidosis,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8
[68Ga]CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),肺癌,II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]CBP8;68Ga-CBP8,,肿瘤领域,,DR022856,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2018-05-24,phase 2,III期临床,2022-11-16,phase 3,1,True,False,False,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],肿瘤领域,肺癌,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,lung cancer,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8
[68Ga]CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),特发性肺纤维化,II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]CBP8;68Ga-CBP8,,呼吸领域;罕见疾病领域,,DR022856,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2018-05-24,phase 2,III期临床,2022-11-16,phase 3,1,True,True,False,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],呼吸领域,特发性肺纤维化,['呼吸领域'],1,呼吸领域,,,3,2,Respiratory,Respiratory,,,idiopathic pulmonary fibrosis,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8
[68Ga]CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),间质性肺病,II期临床,2022-06-14,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]CBP8;68Ga-CBP8,,呼吸领域,,DR022856,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2022-06-14,phase 2,III期临床,2022-11-16,phase 3,1,True,False,False,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],呼吸领域,间质性肺病,['呼吸领域'],1,呼吸领域,,,3,2,Respiratory,Respiratory,,,interstitial lung disease,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8
[68Ga]CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),进展性肺纤维化,II期临床,2024-08-01,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]CBP8;68Ga-CBP8,,呼吸领域;罕见疾病领域,,DR022856,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2024-08-01,phase 2,III期临床,2022-11-16,phase 3,1,True,True,False,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],呼吸领域,进展性肺纤维化,['呼吸领域'],1,呼吸领域,,,3,2,Respiratory,Respiratory,,,progressive pulmonary fibrosis,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8
[68Ga]CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),原发性硬化性胆管炎,I期临床,2024-02-09,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]CBP8;68Ga-CBP8,,消化领域;罕见疾病领域,,DR022856,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2024-02-09,phase 1,III期临床,2022-11-16,phase 3,1,True,True,False,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],消化领域,原发性硬化性胆管炎,['消化领域'],1,消化领域,,,3,1,Digestive System,Digestive System,,,primary sclerosing cholangitis,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8
[68Ga]CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),克罗恩病,I期临床,2024-02-09,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]CBP8;68Ga-CBP8,,消化领域;免疫领域,,DR022856,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2024-02-09,phase 1,III期临床,2022-11-16,phase 3,1,True,False,False,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],消化领域,克罗恩病,"['消化领域', '免疫领域']",2,消化领域,免疫领域,,3,1,Digestive System,Digestive System,Immunology,,Crohn's disease,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8
[68Ga]CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),子宫内膜异位,I期临床,2024-04-22,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]CBP8;68Ga-CBP8,,泌尿生殖领域,,DR022856,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2024-04-22,phase 1,III期临床,2022-11-16,phase 3,1,True,False,False,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],泌尿生殖领域,子宫内膜异位,['泌尿生殖领域'],1,泌尿生殖领域,,,3,1,Genitourinary,Genitourinary,,,endometriosis,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8
solnatide,ENaC,ENaC激活剂,Apeptico(原研),慢性肾病高磷血症,III期临床,2023-06-30,Active,多肽,化药,环肽;Potential First-in-Class,激活剂,创新药,solnatide;AP301;AP-301;TIP-peptide,,泌尿生殖领域,,DR019331,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,,2023-06-30,,phase 3,III期临床,2023-06-30,phase 3,1,True,False,False,[],['Apeptico'],1,['Apeptico(原研)'],泌尿生殖领域,慢性肾病高磷血症,['泌尿生殖领域'],1,泌尿生殖领域,,,3,3,Genitourinary,Genitourinary,,,Chronic kidney disease hyperphosphatemia,solnatide,solnatide;AP301;AP-301;TIP-peptide
solnatide,ENaC,ENaC激活剂,Apeptico(原研),急性呼吸窘迫综合征,II期临床,,Unknown,多肽,化药,环肽;Potential First-in-Class,激活剂,创新药,solnatide;AP301;AP-301;TIP-peptide,,呼吸领域,,DR019331,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2023-06-30,phase 3,1,True,False,False,[],['Apeptico'],1,['Apeptico(原研)'],呼吸领域,急性呼吸窘迫综合征,['呼吸领域'],1,呼吸领域,,,3,2,Respiratory,Respiratory,,,acute respiratory distress syndrome,solnatide,solnatide;AP301;AP-301;TIP-peptide
solnatide,ENaC,ENaC激活剂,Apeptico(原研),肾移植后移植物功能延迟恢复,II期临床,2014-03-26,Unknown,多肽,化药,环肽;Potential First-in-Class,激活剂,创新药,solnatide;AP301;AP-301;TIP-peptide,,免疫领域;罕见疾病领域,,DR019331,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2023-06-30,phase 3,1,True,True,False,[],['Apeptico'],1,['Apeptico(原研)'],免疫领域,肾移植后移植物功能延迟恢复,['免疫领域'],1,免疫领域,,,3,2,Immunology,Immunology,,,Delayed recovery of graft function after kidney transplantation,solnatide,solnatide;AP301;AP-301;TIP-peptide
solnatide,ENaC,ENaC激活剂,Apeptico(原研),肺水肿,II期临床,2018-06-26,Unknown,多肽,化药,环肽;Potential First-in-Class,激活剂,创新药,solnatide;AP301;AP-301;TIP-peptide,,呼吸领域,,DR019331,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2023-06-30,phase 3,1,True,False,False,[],['Apeptico'],1,['Apeptico(原研)'],呼吸领域,肺水肿,['呼吸领域'],1,呼吸领域,,,3,2,Respiratory,Respiratory,,,Pulmonary edema,solnatide,solnatide;AP301;AP-301;TIP-peptide
enlicitide,PCSK9,PCSK9抑制剂,Merck & Co.(Top20 MNC)(原研),血脂异常,III期临床,2025-11-19,Active,多肽,化药,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,创新药,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,,心脑血管领域,"III期临床:片剂_x000D_
I期临床:胶囊剂",DR041755,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2025-11-19,phase 3,III期临床,2023-07-19,phase 3,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],心脑血管领域,血脂异常,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,dyslipidemia,enlicitide,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate
enlicitide,PCSK9,PCSK9抑制剂,Merck & Co.(Top20 MNC)(原研),高胆固醇血症,III期临床,2023-08-25,Active,多肽,化药,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,创新药,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,,心脑血管领域,"III期临床:片剂_x000D_
I期临床:胶囊剂",DR041755,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,III期临床,2023-09-04,2023-09-04,phase 3,III期临床,2023-07-19,phase 3,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],心脑血管领域,高胆固醇血症,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,hypercholesterolemia,enlicitide,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate
enlicitide,PCSK9,PCSK9抑制剂,Merck & Co.(Top20 MNC)(原研),家族性高胆固醇血症,III期临床,2023-07-19,Active,多肽,化药,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,创新药,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,,心脑血管领域,"III期临床:片剂_x000D_
I期临床:胶囊剂",DR041755,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,III期临床,2023-07-19,2023-07-19,phase 3,III期临床,2023-07-19,phase 3,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],心脑血管领域,家族性高胆固醇血症,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,familial hypercholesterolemia,enlicitide,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate
enlicitide,PCSK9,PCSK9抑制剂,Merck & Co.(Top20 MNC)(原研),心血管风险,III期临床,2023-08-24,Active,多肽,化药,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,创新药,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,,心脑血管领域,"III期临床:片剂_x000D_
I期临床:胶囊剂",DR041755,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,III期临床,2023-08-24,2023-08-24,phase 3,III期临床,2023-07-19,phase 3,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],心脑血管领域,心血管风险,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,cardiovascular risk,enlicitide,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate
enlicitide,PCSK9,PCSK9抑制剂,Merck & Co.(Top20 MNC)(原研),杂合子型家族性高胆固醇血症,III期临床,2023-07-19,Active,多肽,化药,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,创新药,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,,心脑血管领域,"III期临床:片剂_x000D_
I期临床:胶囊剂",DR041755,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II/III期临床,III期临床,2025-12-15,2023-07-19,phase 3,III期临床,2023-07-19,phase 3,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],心脑血管领域,杂合子型家族性高胆固醇血症,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Heterozygous familial hypercholesterolemia,enlicitide,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate
enlicitide,PCSK9,PCSK9抑制剂,Merck & Co.(Top20 MNC)(原研),动脉粥样硬化性心血管疾病,III期临床,2023-11-06,Active,多肽,化药,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,创新药,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,,心脑血管领域,"III期临床:片剂_x000D_
I期临床:胶囊剂",DR041755,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,III期临床,2023-11-06,2023-11-06,phase 3,III期临床,2023-07-19,phase 3,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],心脑血管领域,动脉粥样硬化性心血管疾病,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,atherosclerotic cardiovascular disease,enlicitide,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),PET显像,III期临床,2023-11-09,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,诊断试剂领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II/III期临床,II期临床,2021-04-26,2024-02-07,phase 3,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,3,3,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),边缘区淋巴瘤,III期临床,2023-11-09,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域;血液领域;罕见疾病领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,III期临床,2023-11-09,phase 3,2,True,True,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,边缘区淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,3,Oncology,Oncology,Hematology,,marginal zone lymphoma,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),肾上腺疾病,II/III期临床,2021-04-26,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,内分泌及代谢领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II/III期临床,,2021-04-26,,phase 3,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",内分泌及代谢领域,肾上腺疾病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Adrenal gland disease,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),醛固酮过多症,II/III期临床,2024-03-18,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,内分泌及代谢领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,II期临床,2021-11-23,2024-02-07,phase 3,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",内分泌及代谢领域,醛固酮过多症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Hyperaldosteronism,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),脑癌,II期临床,2021-09-22,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,脑癌,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,brain cancer,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),多发性骨髓瘤,II期临床,2020-09-23,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域;血液领域;罕见疾病领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,I期临床,2018-02-19,2021-10-26,phase 2,III期临床,2023-11-09,phase 3,2,True,True,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,多发性骨髓瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,2,Oncology,Oncology,Hematology,,multiple myeloma,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),库欣综合征,II期临床,2024-02-07,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,内分泌及代谢领域;罕见疾病领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,II期临床,2025-09-19,2024-02-07,phase 2,III期临床,2023-11-09,phase 3,2,True,True,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",内分泌及代谢领域,库欣综合征,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Cushing's syndrome,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),心肌炎,II期临床,2022-08-12,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,心脑血管领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",心脑血管领域,心肌炎,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,myocarditis,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),B细胞淋巴瘤,II期临床,2024-06-14,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域;血液领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,B细胞淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,2,Oncology,Oncology,Hematology,,B cell lymphoma,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),心脏移植排斥,II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,免疫领域;罕见疾病领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2023-11-09,phase 3,2,True,True,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",免疫领域,心脏移植排斥,['免疫领域'],1,免疫领域,,,3,2,Immunology,Immunology,,,heart transplant rejection,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),惰性非霍奇金淋巴瘤,II期临床,2024-06-14,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,血液领域;肿瘤领域;罕见疾病领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2023-11-09,phase 3,2,True,True,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,惰性非霍奇金淋巴瘤,"['血液领域', '肿瘤领域']",2,血液领域,肿瘤领域,,3,2,Oncology,Hematology,Oncology,,indolent non-Hodgkin lymphoma,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),中枢神经系统淋巴瘤,II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,血液领域;肿瘤领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,中枢神经系统淋巴瘤,"['血液领域', '肿瘤领域']",2,血液领域,肿瘤领域,,3,2,Oncology,Hematology,Oncology,,central nervous system lymphoma,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),继发性中枢神经系统淋巴瘤,II期临床,2022-02-03,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域;血液领域;罕见疾病领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2023-11-09,phase 3,2,True,True,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,继发性中枢神经系统淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,2,Oncology,Oncology,Hematology,,secondary central nervous system lymphoma,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),心脏结节病,II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,心脑血管领域;免疫领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",心脑血管领域,心脏结节病,"['心脑血管领域', '免疫领域']",2,心脑血管领域,免疫领域,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,Immunology,,cardiac sarcoidosis,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),免疫检查点抑制剂引起的心肌炎,II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,免疫检查点抑制剂引起的心肌炎,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,Myocarditis caused by immune checkpoint inhibitors,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),非小细胞肺癌,I期临床,2015-11-19,Inactive,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,non-small cell lung cancer,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),小细胞肺癌,I期临床,2025-06-05,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域;罕见疾病领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,III期临床,2023-11-09,phase 3,2,True,True,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,small cell lung cancer,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),三阴性乳腺癌,I期临床,2025-05-08,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,三阴性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,triple negative breast cancer,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),分化型甲状腺癌,I期临床,2024-05-14,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-05-14,,phase 1,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,分化型甲状腺癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,differentiated thyroid cancer,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),血液系统肿瘤,I期临床,2022-02-25,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域;血液领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2022-02-25,,phase 1,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,血液系统肿瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,1,Oncology,Oncology,Hematology,,hematological tumors,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),白血病,I期临床,2020-08-07,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域;血液领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2020-08-07,,phase 1,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,1,Oncology,Oncology,Hematology,,leukemia,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),淋巴瘤,I期临床,2018-02-19,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域;血液领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2018-02-19,,phase 1,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,1,Oncology,Oncology,Hematology,,Lymphoma,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),非霍奇金淋巴瘤,I期临床,2021-10-26,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域;血液领域;罕见疾病领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,I期临床,2025-02-19,2021-10-26,phase 1,III期临床,2023-11-09,phase 3,2,True,True,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,非霍奇金淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,1,Oncology,Oncology,Hematology,,non-hodgkin lymphoma,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),高血压,I期临床,2025-06-18,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,心脑血管领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",心脑血管领域,高血压,['心脑血管领域'],1,心脑血管领域,,,3,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,hypertension,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),神经内分泌肿瘤,I期临床,2017-11-08,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域;罕见疾病领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2017-11-08,phase 1,III期临床,2023-11-09,phase 3,2,True,True,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,neuroendocrine tumors,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),肾上腺皮质癌,I期临床,2025-09-19,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域;罕见疾病领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-19,,phase 1,III期临床,2023-11-09,phase 3,2,True,True,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,肾上腺皮质癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,adrenocortical carcinoma,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),小淋巴细胞性淋巴瘤,I期临床,2024-03-01,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域;血液领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-03-01,,phase 1,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,小淋巴细胞性淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,1,Oncology,Oncology,Hematology,,small lymphocytic lymphoma,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),Erdheim-Chester病,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域;罕见疾病领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,III期临床,2023-11-09,phase 3,2,True,True,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,Erdheim-Chester病,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,Erdheim-Chester disease,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),胸腺瘤,I期临床,2023-10-17,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,肿瘤领域;罕见疾病领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2023-10-17,,phase 1,III期临床,2023-11-09,phase 3,2,True,True,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,胸腺瘤,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,thymoma,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),假性醛固酮减少症,I期临床,2025-01-03,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,内分泌及代谢领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",内分泌及代谢领域,假性醛固酮减少症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,pseudohypoaldosteronism,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),意义未明单克隆免疫球蛋白血症,I期临床,2021-10-26,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,血液领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2021-10-26,phase 1,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",血液领域,意义未明单克隆免疫球蛋白血症,['血液领域'],1,血液领域,,,3,1,Hematology,Hematology,,,Monoclonal immunoglobulinemia of undetermined significance,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),罗道病,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,罕见疾病领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,III期临床,2023-11-09,phase 3,2,True,True,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",,罗道病,[],0,,,,3,1,,,,,Rhododendron,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
68Ga-pentixafor,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),自主皮质醇分泌,I期临床,2024-10-10,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,,内分泌及代谢领域,,DR016804,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-10-10,,phase 1,III期临床,2023-11-09,phase 3,2,True,False,False,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",内分泌及代谢领域,自主皮质醇分泌,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Autonomous cortisol secretion,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF
emodepside,not available,,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,蛔虫病,III期临床,2024-12-17,Active,小分子,化药,环肽;中国无申报,其他,创新药,emodepside;BAY 44-4400,,感染领域,,DR066507,否,日本,未知,,,,,phase 3,III期临床,2024-12-17,phase 3,3,True,False,True,"['Bayer', 'Astellas Pharma']",['Astellas Pharma'],1,"['Bayer(Top20 MNC)', 'Astellas Pharma(Top20 MNC)(原研)', 'DNDi']",感染领域,蛔虫病,['感染领域'],1,感染领域,,,3,3,Infectious Diseases,Infectious Diseases,,,Ascariasis,emodepside,emodepside;BAY 44-4400
emodepside,not available,,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,钩虫病,III期临床,2024-12-17,Active,小分子,化药,环肽;中国无申报,其他,创新药,emodepside;BAY 44-4400,,感染领域,,DR066507,否,日本,未知,,,,,phase 3,III期临床,2024-12-17,phase 3,3,True,False,True,"['Bayer', 'Astellas Pharma']",['Astellas Pharma'],1,"['Bayer(Top20 MNC)', 'Astellas Pharma(Top20 MNC)(原研)', 'DNDi']",感染领域,钩虫病,['感染领域'],1,感染领域,,,3,3,Infectious Diseases,Infectious Diseases,,,hookworm disease,emodepside,emodepside;BAY 44-4400
emodepside,not available,,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,鞭虫病,III期临床,2024-12-17,Active,小分子,化药,环肽;中国无申报,其他,创新药,emodepside;BAY 44-4400,,感染领域,,DR066507,否,日本,未知,,,,,phase 3,III期临床,2024-12-17,phase 3,3,True,False,True,"['Bayer', 'Astellas Pharma']",['Astellas Pharma'],1,"['Bayer(Top20 MNC)', 'Astellas Pharma(Top20 MNC)(原研)', 'DNDi']",感染领域,鞭虫病,['感染领域'],1,感染领域,,,3,3,Infectious Diseases,Infectious Diseases,,,Trichuris,emodepside,emodepside;BAY 44-4400
emodepside,not available,,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,类圆线虫病,II期临床,2024-04-18,Active,小分子,化药,环肽;中国无申报,其他,创新药,emodepside;BAY 44-4400,,感染领域,,DR066507,否,日本,未知,,,,,phase 2,III期临床,2024-12-17,phase 3,3,True,False,True,"['Bayer', 'Astellas Pharma']",['Astellas Pharma'],1,"['Bayer(Top20 MNC)', 'Astellas Pharma(Top20 MNC)(原研)', 'DNDi']",感染领域,类圆线虫病,['感染领域'],1,感染领域,,,3,2,Infectious Diseases,Infectious Diseases,,,strongyloidiasis,emodepside,emodepside;BAY 44-4400
emodepside,not available,,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,盘尾丝虫病,II期临床,2022-01-06,Active,小分子,化药,环肽;中国无申报,其他,创新药,emodepside;BAY 44-4400,,感染领域,,DR066507,否,日本,未知,,,,,phase 2,III期临床,2024-12-17,phase 3,3,True,False,True,"['Bayer', 'Astellas Pharma']",['Astellas Pharma'],1,"['Bayer(Top20 MNC)', 'Astellas Pharma(Top20 MNC)(原研)', 'DNDi']",感染领域,盘尾丝虫病,['感染领域'],1,感染领域,,,3,2,Infectious Diseases,Infectious Diseases,,,onchocerciasis,emodepside,emodepside;BAY 44-4400
emodepside,not available,,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,丝虫病,I期临床,2017-12-26,Inactive,小分子,化药,环肽;中国无申报,其他,创新药,emodepside;BAY 44-4400,,感染领域,,DR066507,否,日本,未知,,,,,phase 1,III期临床,2024-12-17,phase 3,3,True,False,True,"['Bayer', 'Astellas Pharma']",['Astellas Pharma'],1,"['Bayer(Top20 MNC)', 'Astellas Pharma(Top20 MNC)(原研)', 'DNDi']",感染领域,丝虫病,['感染领域'],1,感染领域,,,3,1,Infectious Diseases,Infectious Diseases,,,Filariasis,emodepside,emodepside;BAY 44-4400
脑利钠肽,BNP,重组BNP,沃泰生物(原研),急性心力衰竭,III期临床,2025-04-03,Active,多肽,生物,环肽,重组,生物类似药,脑利钠肽;重组人脑利钠肽(沃泰生物);nesiritide biosimilar,,心脑血管领域,III期临床:注射剂(冻干),DR077616,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,,2025-04-03,,phase 3,III期临床,2025-04-03,phase 3,1,True,False,False,[],['沃泰生物'],1,['沃泰生物(原研)'],心脑血管领域,急性心力衰竭,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,acute heart failure,nesiritide biosimilar,脑利钠肽;重组人脑利钠肽(沃泰生物);nesiritide biosimilar
脑利钠肽,BNP,重组BNP,沃泰生物(原研),急性失代偿性心力衰竭,I期临床,2022-07-29,Unknown,多肽,生物,环肽,重组,生物类似药,脑利钠肽;重组人脑利钠肽(沃泰生物);nesiritide biosimilar,,心脑血管领域,III期临床:注射剂(冻干),DR077616,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2022-07-29,,phase 1,III期临床,2025-04-03,phase 3,1,True,False,False,[],['沃泰生物'],1,['沃泰生物(原研)'],心脑血管领域,急性失代偿性心力衰竭,['心脑血管领域'],1,心脑血管领域,,,3,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,acute decompensated heart failure,nesiritide biosimilar,脑利钠肽;重组人脑利钠肽(沃泰生物);nesiritide biosimilar
Debio 4126,somatostatin,somatostatin类似物,Debiopharm(原研),肢端肥大症,III期临床,2025-04-16,Active,多肽,化药,环肽,类似物,微创新,Debio 4126;Debio 4126 (12周缓释奥曲肽);Debio 4126 (12-week prolonged-release octreotide),,内分泌及代谢领域;罕见疾病领域,,DR003491,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,III期临床,,2025-04-16,phase 3,III期临床,2025-04-16,phase 3,1,True,True,False,[],['Debiopharm'],1,['Debiopharm(原研)'],内分泌及代谢领域,肢端肥大症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,,acromegaly,Debio 4126 (12-week prolonged-release octreotide),Debio 4126;Debio 4126 (12周缓释奥曲肽);Debio 4126 (12-week prolonged-release octreotide)
Debio 4126,somatostatin,somatostatin类似物,Debiopharm(原研),胃肠胰神经内分泌肿瘤,II期临床,,Active,多肽,化药,环肽,类似物,微创新,Debio 4126;Debio 4126 (12周缓释奥曲肽);Debio 4126 (12-week prolonged-release octreotide),,肿瘤领域;罕见疾病领域,,DR003491,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,III期临床,2025-04-16,phase 3,1,True,True,False,[],['Debiopharm'],1,['Debiopharm(原研)'],肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,Debio 4126 (12-week prolonged-release octreotide),Debio 4126;Debio 4126 (12周缓释奥曲肽);Debio 4126 (12-week prolonged-release octreotide)
SYHX2008,somatostatin,somatostatin类似物,石药集团(原研),神经内分泌肿瘤,III期临床,2025-11-12,Active,多肽,化药,环肽,类似物,微创新,SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide),,肿瘤领域;罕见疾病领域,III期临床:注射剂(长效),DR064549,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,III期临床,,2025-11-12,,phase 3,III期临床,2025-10-10,phase 3,1,True,True,False,[],['石药集团'],1,['石药集团(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,,neuroendocrine tumors,SYHX2008 (long-acting octreotide),SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide)
SYHX2008,somatostatin,somatostatin类似物,石药集团(原研),胃肠胰神经内分泌肿瘤,II/III期临床,2025-09-10,Active,多肽,化药,环肽,类似物,微创新,SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide),,肿瘤领域;罕见疾病领域,III期临床:注射剂(长效),DR064549,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II/III期临床,,2025-09-10,,phase 3,III期临床,2025-10-10,phase 3,1,True,True,False,[],['石药集团'],1,['石药集团(原研)'],肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,SYHX2008 (long-acting octreotide),SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide)
SYHX2008,somatostatin,somatostatin类似物,石药集团(原研),肢端肥大症,II期临床,2024-01-30,Active,多肽,化药,环肽,类似物,微创新,SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide),,内分泌及代谢领域;罕见疾病领域,III期临床:注射剂(长效),DR064549,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II期临床,,2024-01-30,,phase 2,III期临床,2025-10-10,phase 3,1,True,True,False,[],['石药集团'],1,['石药集团(原研)'],内分泌及代谢领域,肢端肥大症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,acromegaly,SYHX2008 (long-acting octreotide),SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide)
SYHX2008,somatostatin,somatostatin类似物,石药集团(原研),胃肠道神经内分泌肿瘤,II期临床,2024-07-17,Active,多肽,化药,环肽,类似物,微创新,SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide),,肿瘤领域;罕见疾病领域,III期临床:注射剂(长效),DR064549,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II期临床,,2024-07-17,,phase 2,III期临床,2025-10-10,phase 3,1,True,True,False,[],['石药集团'],1,['石药集团(原研)'],肿瘤领域,胃肠道神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,gastrointestinal neuroendocrine tumors,SYHX2008 (long-acting octreotide),SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide)
PNT2003,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Lantheus;POINT Biopharma(Eli Lilly)(Top20 MNC)(原研),神经内分泌肿瘤,III期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,创新药,PNT2003;177Lu-PNT2003,,肿瘤领域;罕见疾病领域,,DR053445,否,加拿大,中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 3,III期临床,,phase 3,2,True,True,True,['POINT Biopharma(Eli Lilly)'],['POINT Biopharma(Eli Lilly)'],1,"['Lantheus', 'POINT Biopharma(Eli Lilly)(Top20 MNC)(原研)']",肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,,neuroendocrine tumors,PNT2003,PNT2003;177Lu-PNT2003
68Ga-DOTA-NOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,PET显像,II/III期临床,2016-07-06,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,,诊断试剂领域,,DR002623,否,,,,,,,phase 3,II/III期临床,2016-07-06,phase 3,0,True,False,False,[],[],0,[],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,3,3,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC
68Ga-DOTA-NOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,神经母细胞瘤,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,,肿瘤领域;罕见疾病领域,,DR002623,否,,,I期临床,,2025-09-26,,phase 1,II/III期临床,2016-07-06,phase 3,0,True,True,False,[],[],0,[],肿瘤领域,神经母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,Neuroblastoma,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC
68Ga-DOTA-NOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,类癌,I期临床,2007-12-07,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,,肿瘤领域;罕见疾病领域,,DR002623,否,,,,,,,phase 1,II/III期临床,2016-07-06,phase 3,0,True,True,False,[],[],0,[],肿瘤领域,类癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,carcinoid,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC
68Ga-DOTA-NOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,抑郁症,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,,精神领域,,DR002623,否,,,I期临床,,2025-09-26,,phase 1,II/III期临床,2016-07-06,phase 3,0,True,False,False,[],[],0,[],精神领域,抑郁症,['精神领域'],1,精神领域,,,3,1,Psychiatry,Psychiatry,,,depression,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC
68Ga-DOTA-NOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,不孕不育,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,,泌尿生殖领域,,DR002623,否,,,I期临床,,2025-09-26,,phase 1,II/III期临床,2016-07-06,phase 3,0,True,False,False,[],[],0,[],泌尿生殖领域,不孕不育,['泌尿生殖领域'],1,泌尿生殖领域,,,3,1,Genitourinary,Genitourinary,,,Infertility,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC
68Ga-DOTA-NOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,慢性肉芽肿病(差异化疾病),I期临床,2016-11-18,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,,罕见疾病领域;免疫领域,,DR002623,否,,,,,,,phase 1,II/III期临床,2016-07-06,phase 3,0,True,True,False,[],[],0,[],免疫领域,慢性肉芽肿病,['免疫领域'],1,免疫领域,,,3,1,Immunology,Immunology,,,chronic granulomatous disease,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC
68Ga-DOTA-NOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,神经内分泌肿瘤,I期临床,2017-09-20,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,,肿瘤领域;罕见疾病领域,,DR002623,否,,,I期临床,,2017-09-20,,phase 1,II/III期临床,2016-07-06,phase 3,0,True,True,False,[],[],0,[],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,neuroendocrine tumors,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC
68Ga-DOTA-NOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,嗜铬细胞瘤,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,,肿瘤领域;罕见疾病领域,,DR002623,否,,,I期临床,,2025-09-26,,phase 1,II/III期临床,2016-07-06,phase 3,0,True,True,False,[],[],0,[],肿瘤领域,嗜铬细胞瘤,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,Pheochromocytoma,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC
68Ga-DOTA-NOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,骨转移疼痛,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,,肿瘤领域,,DR002623,否,,,I期临床,,2025-09-26,,phase 1,II/III期临床,2016-07-06,phase 3,0,True,False,False,[],[],0,[],肿瘤领域,骨转移疼痛,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,bone metastasis pain,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC
68Ga-DOTA-NOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,副神经节瘤,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,,肿瘤领域;罕见疾病领域,,DR002623,否,,,I期临床,,2025-09-26,,phase 1,II/III期临床,2016-07-06,phase 3,0,True,True,False,[],[],0,[],肿瘤领域,副神经节瘤,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,paraganglioma,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC
68Ga-DOTA-NOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,胰岛细胞瘤,I期临床,2007-12-07,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,,肿瘤领域;罕见疾病领域,,DR002623,否,,,,,,,phase 1,II/III期临床,2016-07-06,phase 3,0,True,True,False,[],[],0,[],肿瘤领域,胰岛细胞瘤,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,islet cell tumor,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC
68Ga-DOTA-NOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,胃肠胰神经内分泌肿瘤,I期临床,2012-12-11,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,,肿瘤领域;罕见疾病领域,,DR002623,否,,,,,,,phase 1,II/III期临床,2016-07-06,phase 3,0,True,True,False,[],[],0,[],肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC
68Ga-DOTA-NOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,颅内动脉瘤(差异化疾病),I期临床,2021-01-20,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,,心脑血管领域,,DR002623,否,,,,,,,phase 1,II/III期临床,2016-07-06,phase 3,0,True,False,False,[],[],0,[],心脑血管领域,颅内动脉瘤,['心脑血管领域'],1,心脑血管领域,,,3,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,intracranial aneurysm,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC
VT1021,THBS1,THBS1诱导剂,Vigeo Therapeutics(原研),胶质母细胞瘤,II/III期临床,2019-05-31,Inactive,多肽,化药,环肽;Potential First-in-Class,诱导剂,创新药,VT1021,,肿瘤领域;罕见疾病领域,,DR023742,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II/III期临床,,2019-05-31,phase 3,II/III期临床,2019-05-31,phase 3,1,True,True,False,[],['Vigeo Therapeutics'],1,['Vigeo Therapeutics(原研)'],肿瘤领域,胶质母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,,glioblastoma,VT1021,VT1021
VT1021,THBS1,THBS1诱导剂,Vigeo Therapeutics(原研),实体瘤,I/II期临床,,Active,多肽,化药,环肽;Potential First-in-Class,诱导剂,创新药,VT1021,,肿瘤领域,,DR023742,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II/III期临床,2019-05-31,phase 3,1,True,False,False,[],['Vigeo Therapeutics'],1,['Vigeo Therapeutics(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,solid tumors,VT1021,VT1021
VT1021,THBS1,THBS1诱导剂,Vigeo Therapeutics(原研),三阴性乳腺癌,I期临床,2017-12-06,Inactive,多肽,化药,环肽;Potential First-in-Class,诱导剂,创新药,VT1021,,肿瘤领域,,DR023742,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2017-12-06,phase 1,II/III期临床,2019-05-31,phase 3,1,True,False,False,[],['Vigeo Therapeutics'],1,['Vigeo Therapeutics(原研)'],肿瘤领域,三阴性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,triple negative breast cancer,VT1021,VT1021
VT1021,THBS1,THBS1诱导剂,Vigeo Therapeutics(原研),胰腺癌,I期临床,2017-12-06,Inactive,多肽,化药,环肽;Potential First-in-Class,诱导剂,创新药,VT1021,,肿瘤领域;罕见疾病领域,,DR023742,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2017-12-06,phase 1,II/III期临床,2019-05-31,phase 3,1,True,True,False,[],['Vigeo Therapeutics'],1,['Vigeo Therapeutics(原研)'],肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,pancreatic cancer,VT1021,VT1021
VT1021,THBS1,THBS1诱导剂,Vigeo Therapeutics(原研),卵巢癌,I期临床,2017-12-06,Inactive,多肽,化药,环肽;Potential First-in-Class,诱导剂,创新药,VT1021,,肿瘤领域;罕见疾病领域,,DR023742,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2017-12-06,phase 1,II/III期临床,2019-05-31,phase 3,1,True,True,False,[],['Vigeo Therapeutics'],1,['Vigeo Therapeutics(原研)'],肿瘤领域,卵巢癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,ovarian cancer,VT1021,VT1021
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),PET显像,II/III期临床,2020-09-17,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,诊断试剂领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II/III期临床,,2023-03-01,,phase 3,II/III期临床,2020-09-17,phase 3,1,True,False,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,3,3,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),神经内分泌肿瘤,II/III期临床,2020-09-17,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,肿瘤领域;罕见疾病领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II/III期临床,,2023-03-01,,phase 3,II/III期临床,2020-09-17,phase 3,1,True,True,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,,neuroendocrine tumors,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),心肌梗塞(差异化疾病),II期临床,2025-08-05,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,心脑血管领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II/III期临床,2020-09-17,phase 3,1,True,False,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],心脑血管领域,心肌梗塞,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,myocardial infarction,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),动脉粥样硬化(差异化疾病),II期临床,2024-11-18,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,心脑血管领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II/III期临床,2020-09-17,phase 3,1,True,False,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],心脑血管领域,动脉粥样硬化,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,atherosclerosis,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),卒中(差异化疾病),II期临床,2025-08-05,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,心脑血管领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II/III期临床,2020-09-17,phase 3,1,True,False,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],心脑血管领域,卒中,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Stroke,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),心脏停搏(差异化疾病),II期临床,2025-08-05,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,心脑血管领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II/III期临床,2020-09-17,phase 3,1,True,False,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],心脑血管领域,心脏停搏,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,cardiac arrest,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),不稳定性心绞痛(差异化疾病),II期临床,2025-08-05,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,心脑血管领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II/III期临床,2020-09-17,phase 3,1,True,False,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],心脑血管领域,不稳定性心绞痛,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,unstable angina,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),颈动脉疾病,II期临床,2024-11-18,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,心脑血管领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II/III期临床,2020-09-17,phase 3,1,True,False,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],心脑血管领域,颈动脉疾病,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,carotid artery disease,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),颈动脉狭窄(差异化疾病),II期临床,2025-08-05,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,心脑血管领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II/III期临床,2020-09-17,phase 3,1,True,False,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],心脑血管领域,颈动脉狭窄,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Carotid artery stenosis,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),神经母细胞瘤,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,肿瘤领域;罕见疾病领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,II/III期临床,2020-09-17,phase 3,1,True,True,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],肿瘤领域,神经母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,Neuroblastoma,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),抑郁症,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,精神领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,II/III期临床,2020-09-17,phase 3,1,True,False,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],精神领域,抑郁症,['精神领域'],1,精神领域,,,3,1,Psychiatry,Psychiatry,,,depression,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),不孕不育,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,泌尿生殖领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,II/III期临床,2020-09-17,phase 3,1,True,False,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],泌尿生殖领域,不孕不育,['泌尿生殖领域'],1,泌尿生殖领域,,,3,1,Genitourinary,Genitourinary,,,Infertility,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),嗜铬细胞瘤,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,肿瘤领域;罕见疾病领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,II/III期临床,2020-09-17,phase 3,1,True,True,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],肿瘤领域,嗜铬细胞瘤,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,Pheochromocytoma,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),骨转移疼痛,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,肿瘤领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,II/III期临床,2020-09-17,phase 3,1,True,False,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],肿瘤领域,骨转移疼痛,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,bone metastasis pain,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-octreotide,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),副神经节瘤,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,,肿瘤领域;罕见疾病领域,,DR002664,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,II/III期临床,2020-09-17,phase 3,1,True,True,False,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],肿瘤领域,副神经节瘤,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,paraganglioma,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE
18F-AlF-NOTA-FAPI,FAP,18F标记的PET药物,北京大学(原研),癌症,II/III期临床,2023-03-01,Active,放射性药物;其他,化药,环肽;诊断用放射性药物,18F标记的PET药物,创新药,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI,,肿瘤领域,,DR057490,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II/III期临床,,2023-03-01,,phase 3,II/III期临床,2023-03-01,phase 3,1,True,False,False,[],['北京大学'],1,['北京大学(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,,cancer,18F-AlF-NOTA-FAPI,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI
18F-AlF-NOTA-FAPI,FAP,18F标记的PET药物,北京大学(原研),PET显像,II/III期临床,2023-03-01,Active,放射性药物;其他,化药,环肽;诊断用放射性药物,18F标记的PET药物,创新药,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI,,诊断试剂领域,,DR057490,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II/III期临床,,2023-03-01,,phase 3,II/III期临床,2023-03-01,phase 3,1,True,False,False,[],['北京大学'],1,['北京大学(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,3,3,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,18F-AlF-NOTA-FAPI,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI
18F-AlF-NOTA-FAPI,FAP,18F标记的PET药物,北京大学(原研),肝癌,I期临床,2022-06-24,Unknown,放射性药物;其他,化药,环肽;诊断用放射性药物,18F标记的PET药物,创新药,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI,,肿瘤领域,,DR057490,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2022-06-24,,phase 1,II/III期临床,2023-03-01,phase 3,1,True,False,False,[],['北京大学'],1,['北京大学(原研)'],肿瘤领域,肝癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,liver cancer,18F-AlF-NOTA-FAPI,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI
18F-AlF-NOTA-FAPI,FAP,18F标记的PET药物,北京大学(原研),胃癌,I期临床,2022-06-24,Active,放射性药物;其他,化药,环肽;诊断用放射性药物,18F标记的PET药物,创新药,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI,,肿瘤领域,,DR057490,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2022-06-24,,phase 1,II/III期临床,2023-03-01,phase 3,1,True,False,False,[],['北京大学'],1,['北京大学(原研)'],肿瘤领域,胃癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,stomach cancer,18F-AlF-NOTA-FAPI,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI
18F-AlF-NOTA-FAPI,FAP,18F标记的PET药物,北京大学(原研),胰腺癌,I期临床,2022-06-24,Unknown,放射性药物;其他,化药,环肽;诊断用放射性药物,18F标记的PET药物,创新药,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI,,肿瘤领域;罕见疾病领域,,DR057490,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2022-06-24,,phase 1,II/III期临床,2023-03-01,phase 3,1,True,True,False,[],['北京大学'],1,['北京大学(原研)'],肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,pancreatic cancer,18F-AlF-NOTA-FAPI,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI
zelenectide pevedotin,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),尿路上皮癌(差异化疾病),II/III期临床,2024-01-26,Active,多肽;偶联药物,化药,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,zelenectide pevedotin;BT8009,,肿瘤领域,申报临床:注射剂,DR052156,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,申报临床,II/III期临床,2024-07-23,2024-01-26,phase 3,II/III期临床,2024-01-26,phase 3,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,尿路上皮癌,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,,urothelial carcinoma,zelenectide pevedotin,zelenectide pevedotin;BT8009
zelenectide pevedotin,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),HR阳性乳腺癌(差异化疾病),II期临床,2025-02-21,Active,多肽;偶联药物,化药,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,zelenectide pevedotin;BT8009,,肿瘤领域,申报临床:注射剂,DR052156,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2025-02-21,phase 2,II/III期临床,2024-01-26,phase 3,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,HR阳性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,HR positive breast cancer,zelenectide pevedotin,zelenectide pevedotin;BT8009
zelenectide pevedotin,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),三阴性乳腺癌,II期临床,2025-02-21,Active,多肽;偶联药物,化药,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,zelenectide pevedotin;BT8009,,肿瘤领域,申报临床:注射剂,DR052156,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2025-02-21,phase 2,II/III期临床,2024-01-26,phase 3,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,三阴性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,triple negative breast cancer,zelenectide pevedotin,zelenectide pevedotin;BT8009
zelenectide pevedotin,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),鳞状非小细胞肺癌(差异化疾病),II期临床,2025-04-18,Active,多肽;偶联药物,化药,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,zelenectide pevedotin;BT8009,,肿瘤领域,申报临床:注射剂,DR052156,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2025-04-18,phase 2,II/III期临床,2024-01-26,phase 3,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,鳞状非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,Squamous non-small cell lung cancer,zelenectide pevedotin,zelenectide pevedotin;BT8009
zelenectide pevedotin,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),非鳞状非小细胞肺癌(差异化疾病),II期临床,2025-04-18,Active,多肽;偶联药物,化药,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,zelenectide pevedotin;BT8009,,肿瘤领域,申报临床:注射剂,DR052156,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2025-04-18,phase 2,II/III期临床,2024-01-26,phase 3,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,非鳞状非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,non-squamous non-small cell lung cancer,zelenectide pevedotin,zelenectide pevedotin;BT8009
zelenectide pevedotin,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),癌症,I/II期临床,2024-05-28,Active,多肽;偶联药物,化药,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,zelenectide pevedotin;BT8009,,肿瘤领域,申报临床:注射剂,DR052156,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-05-28,phase 2,II/III期临床,2024-01-26,phase 3,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,cancer,zelenectide pevedotin,zelenectide pevedotin;BT8009
zelenectide pevedotin,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),非小细胞肺癌,I/II期临床,2020-09-23,Active,多肽;偶联药物,化药,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,zelenectide pevedotin;BT8009,,肿瘤领域,申报临床:注射剂,DR052156,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2020-09-23,phase 2,II/III期临床,2024-01-26,phase 3,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,non-small cell lung cancer,zelenectide pevedotin,zelenectide pevedotin;BT8009
zelenectide pevedotin,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),胃癌(差异化疾病),I/II期临床,,Active,多肽;偶联药物,化药,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,zelenectide pevedotin;BT8009,,肿瘤领域,申报临床:注射剂,DR052156,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II/III期临床,2024-01-26,phase 3,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,胃癌,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,stomach cancer,zelenectide pevedotin,zelenectide pevedotin;BT8009
zelenectide pevedotin,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),食管癌,I/II期临床,,Active,多肽;偶联药物,化药,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,zelenectide pevedotin;BT8009,,肿瘤领域,申报临床:注射剂,DR052156,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II/III期临床,2024-01-26,phase 3,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,食管癌,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,Esophageal cancer,zelenectide pevedotin,zelenectide pevedotin;BT8009
zelenectide pevedotin,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),胰腺癌(差异化疾病),I/II期临床,,Active,多肽;偶联药物,化药,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,zelenectide pevedotin;BT8009,,肿瘤领域;罕见疾病领域,申报临床:注射剂,DR052156,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II/III期临床,2024-01-26,phase 3,1,True,True,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,pancreatic cancer,zelenectide pevedotin,zelenectide pevedotin;BT8009
zelenectide pevedotin,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),卵巢癌(差异化疾病),I/II期临床,2020-09-23,Active,多肽;偶联药物,化药,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,zelenectide pevedotin;BT8009,,肿瘤领域;罕见疾病领域,申报临床:注射剂,DR052156,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2020-09-23,phase 2,II/III期临床,2024-01-26,phase 3,1,True,True,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,卵巢癌,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,ovarian cancer,zelenectide pevedotin,zelenectide pevedotin;BT8009
zelenectide pevedotin,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),膀胱癌,I/II期临床,2020-09-23,Active,多肽;偶联药物,化药,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,zelenectide pevedotin;BT8009,,肿瘤领域,申报临床:注射剂,DR052156,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2020-09-23,phase 2,II/III期临床,2024-01-26,phase 3,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,膀胱癌,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,,bladder cancer,zelenectide pevedotin,zelenectide pevedotin;BT8009
zelenectide pevedotin,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),实体瘤,I期临床,2024-07-26,Active,多肽;偶联药物,化药,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,zelenectide pevedotin;BT8009,,肿瘤领域,申报临床:注射剂,DR052156,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,II/III期临床,2024-01-26,phase 3,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,,solid tumors,zelenectide pevedotin,zelenectide pevedotin;BT8009
脑利钠肽,BNP,重组BNP,步长制药(原研),急性失代偿性心力衰竭,II/III期临床,2025-03-04,Active,多肽,生物,环肽,重组,生物类似药,脑利钠肽;BC003 (重组人脑利钠肽);nesiritide biosimilar,,心脑血管领域,,DR075838,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II/III期临床,,2025-03-04,,phase 3,II/III期临床,2025-03-04,phase 3,1,True,False,False,[],['步长制药'],1,['步长制药(原研)'],心脑血管领域,急性失代偿性心力衰竭,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,acute decompensated heart failure,nesiritide biosimilar,脑利钠肽;BC003 (重组人脑利钠肽);nesiritide biosimilar
Tc99m-maraciclatide,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,GE Healthcare(原研),黑色素瘤(差异化疾病),II期临床,2004-11-10,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,创新药,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,,肿瘤领域;罕见疾病领域,,DR016896,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2004-11-10,phase 2,1,True,True,False,[],['GE Healthcare'],1,['GE Healthcare(原研)'],肿瘤领域,黑色素瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,melanoma,Tc99m-maraciclatide,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide
Tc99m-maraciclatide,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,GE Healthcare(原研),卵巢癌(差异化疾病),II期临床,2004-11-10,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,创新药,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,,肿瘤领域;罕见疾病领域,,DR016896,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2004-11-10,phase 2,1,True,True,False,[],['GE Healthcare'],1,['GE Healthcare(原研)'],肿瘤领域,卵巢癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,ovarian cancer,Tc99m-maraciclatide,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide
Tc99m-maraciclatide,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,GE Healthcare(原研),前列腺癌(差异化疾病),II期临床,2004-11-10,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,创新药,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,,肿瘤领域,,DR016896,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2004-11-10,phase 2,1,True,False,False,[],['GE Healthcare'],1,['GE Healthcare(原研)'],肿瘤领域,前列腺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,prostate cancer,Tc99m-maraciclatide,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide
Tc99m-maraciclatide,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,GE Healthcare(原研),糖尿病(差异化疾病),II期临床,2011-09-26,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,创新药,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,,内分泌及代谢领域,,DR016896,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2011-09-26,phase 2,II期临床,2004-11-10,phase 2,1,True,False,False,[],['GE Healthcare'],1,['GE Healthcare(原研)'],内分泌及代谢领域,糖尿病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,diabetes,Tc99m-maraciclatide,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide
Tc99m-maraciclatide,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,GE Healthcare(原研),急性冠脉综合征(差异化疾病),II期临床,2010-10-29,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,创新药,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,,心脑血管领域,,DR016896,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2004-11-10,phase 2,1,True,False,False,[],['GE Healthcare'],1,['GE Healthcare(原研)'],心脑血管领域,急性冠脉综合征,['心脑血管领域'],1,心脑血管领域,,,2,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,acute coronary syndrome,Tc99m-maraciclatide,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide
Tc99m-maraciclatide,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,GE Healthcare(原研),肥厚型心肌病(差异化疾病),II期临床,2010-10-29,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,创新药,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,,心脑血管领域,,DR016896,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2004-11-10,phase 2,1,True,False,False,[],['GE Healthcare'],1,['GE Healthcare(原研)'],心脑血管领域,肥厚型心肌病,['心脑血管领域'],1,心脑血管领域,,,2,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,hypertrophic cardiomyopathy,Tc99m-maraciclatide,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide
Tc99m-maraciclatide,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,GE Healthcare(原研),放射性核素显像,II期临床,2004-11-10,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,创新药,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,,诊断试剂领域,,DR016896,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2011-09-26,phase 2,II期临床,2004-11-10,phase 2,1,True,False,False,[],['GE Healthcare'],1,['GE Healthcare(原研)'],诊断试剂领域,放射性核素显像,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,radionuclide imaging,Tc99m-maraciclatide,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide
Tc99m-maraciclatide,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,GE Healthcare(原研),间质性肺病(差异化疾病),II期临床,2024-09-10,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,创新药,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,,呼吸领域,,DR016896,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2004-11-10,phase 2,1,True,False,False,[],['GE Healthcare'],1,['GE Healthcare(原研)'],呼吸领域,间质性肺病,['呼吸领域'],1,呼吸领域,,,2,2,Respiratory,Respiratory,,,interstitial lung disease,Tc99m-maraciclatide,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide
Tc99m-maraciclatide,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,GE Healthcare(原研),射血分数保留的心力衰竭(差异化疾病),II期临床,2011-09-26,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,创新药,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,,心脑血管领域,,DR016896,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2011-09-26,phase 2,II期临床,2004-11-10,phase 2,1,True,False,False,[],['GE Healthcare'],1,['GE Healthcare(原研)'],心脑血管领域,射血分数保留的心力衰竭,['心脑血管领域'],1,心脑血管领域,,,2,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,heart failure with preserved ejection fraction,Tc99m-maraciclatide,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide
Tc99m-maraciclatide,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,GE Healthcare(原研),类风湿性关节炎,I期临床,2023-08-09,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,创新药,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,,免疫领域;骨骼肌肉领域,,DR016896,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,II期临床,2004-11-10,phase 2,1,True,False,False,[],['GE Healthcare'],1,['GE Healthcare(原研)'],免疫领域,类风湿性关节炎,"['免疫领域', '骨骼肌肉领域']",2,免疫领域,骨骼肌肉领域,,2,1,Immunology,Immunology,Musculoskeletal,,rheumatoid arthritis,Tc99m-maraciclatide,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide
Tc99m-maraciclatide,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,GE Healthcare(原研),子宫内膜异位(差异化疾病),临床前,2024-07-02,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,创新药,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,,泌尿生殖领域,,DR016896,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,II期临床,2004-11-10,phase 2,1,True,False,False,[],['GE Healthcare'],1,['GE Healthcare(原研)'],泌尿生殖领域,子宫内膜异位,['泌尿生殖领域'],1,泌尿生殖领域,,,2,-1,Genitourinary,Genitourinary,,,endometriosis,Tc99m-maraciclatide,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide
TI-001,oxytocin,合成的oxytocin,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),肥胖,II期临床,2022-12-23,Active,多肽,化药,环肽;中国无申报,合成的,微创新,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,,内分泌及代谢领域,,DR057077,否,美国,,,II期临床,,2022-12-23,phase 2,II期临床,2013-04-24,phase 2,3,True,False,False,[],['Trigemina'],1,"['Tonix Pharmaceuticals', 'University of Geneva', 'Trigemina(原研)(无权益)']",内分泌及代谢领域,肥胖,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,obesity,TI-001,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900
TI-001,oxytocin,合成的oxytocin,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),社交恐惧症,II期临床,,Active,多肽,化药,环肽;中国无申报,合成的,微创新,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,,精神领域,,DR057077,否,美国,,,,,,phase 2,II期临床,2013-04-24,phase 2,3,True,False,False,[],['Trigemina'],1,"['Tonix Pharmaceuticals', 'University of Geneva', 'Trigemina(原研)(无权益)']",精神领域,社交恐惧症,['精神领域'],1,精神领域,,,2,2,Psychiatry,Psychiatry,,,social phobia,TI-001,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900
TI-001,oxytocin,合成的oxytocin,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),自闭症,II期临床,2024-03-21,Active,多肽,化药,环肽;中国无申报,合成的,微创新,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,,精神领域,,DR057077,否,美国,,,,,,phase 2,II期临床,2013-04-24,phase 2,3,True,False,False,[],['Trigemina'],1,"['Tonix Pharmaceuticals', 'University of Geneva', 'Trigemina(原研)(无权益)']",精神领域,自闭症,['精神领域'],1,精神领域,,,2,2,Psychiatry,Psychiatry,,,autism,TI-001,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900
TI-001,oxytocin,合成的oxytocin,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),暴食症,II期临床,2022-12-23,Active,多肽,化药,环肽;中国无申报,合成的,微创新,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,,精神领域,,DR057077,否,美国,,,II期临床,,2022-12-23,phase 2,II期临床,2013-04-24,phase 2,3,True,False,False,[],['Trigemina'],1,"['Tonix Pharmaceuticals', 'University of Geneva', 'Trigemina(原研)(无权益)']",精神领域,暴食症,['精神领域'],1,精神领域,,,2,2,Psychiatry,Psychiatry,,,Bulimia,TI-001,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900
TI-001,oxytocin,合成的oxytocin,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),偏头痛,II期临床,2013-04-24,Active,多肽,化药,环肽;中国无申报,合成的,微创新,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,,麻醉镇痛领域;神经领域,,DR057077,否,美国,,,II期临床,,2023-01-11,phase 2,II期临床,2013-04-24,phase 2,3,True,False,False,[],['Trigemina'],1,"['Tonix Pharmaceuticals', 'University of Geneva', 'Trigemina(原研)(无权益)']",麻醉镇痛领域,偏头痛,"['麻醉镇痛领域', '神经领域']",2,麻醉镇痛领域,神经领域,,2,2,Anesthesia & Analgesia,Anesthesia & Analgesia,Neurology,,Migraine,TI-001,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900
TI-001,oxytocin,合成的oxytocin,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),骨密度低,II期临床,2023-11-13,Active,多肽,化药,环肽;中国无申报,合成的,微创新,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,,骨骼肌肉领域;内分泌及代谢领域,,DR057077,否,美国,,,,,,phase 2,II期临床,2013-04-24,phase 2,3,True,False,False,[],['Trigemina'],1,"['Tonix Pharmaceuticals', 'University of Geneva', 'Trigemina(原研)(无权益)']",骨骼肌肉领域,骨密度低,"['骨骼肌肉领域', '内分泌及代谢领域']",2,骨骼肌肉领域,内分泌及代谢领域,,2,2,Musculoskeletal,Musculoskeletal,Endocrinology & Metabolism,,low bone density,TI-001,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900
TI-001,oxytocin,合成的oxytocin,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),面部神经痛,临床前,,Active,多肽,化药,环肽;中国无申报,合成的,微创新,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,,神经领域;麻醉镇痛领域,,DR057077,否,美国,,,,,,pre-clinical,II期临床,2013-04-24,phase 2,3,True,False,False,[],['Trigemina'],1,"['Tonix Pharmaceuticals', 'University of Geneva', 'Trigemina(原研)(无权益)']",神经领域,面部神经痛,"['神经领域', '麻醉镇痛领域']",2,神经领域,麻醉镇痛领域,,2,-1,Neurology,Neurology,Anesthesia & Analgesia,,Facial neuralgia,TI-001,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900
68Ga-satoreotide trizoxetan,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,Ariceum Therapeutics;Ipsen(原研)(无权益),小细胞肺癌,II期临床,2023-05-10,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,,肿瘤领域;罕见疾病领域,,DR002657,否,欧洲,,,I/II期临床,,2018-12-12,phase 2,II期临床,2017-07-18,phase 2,2,True,True,False,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,small cell lung cancer,68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120
68Ga-satoreotide trizoxetan,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,Ariceum Therapeutics;Ipsen(原研)(无权益),乳腺癌,II期临床,2018-10-05,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,,肿瘤领域,,DR002657,否,欧洲,,,I/II期临床,,2018-12-12,phase 2,II期临床,2017-07-18,phase 2,2,True,False,False,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,breast cancer,68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120
68Ga-satoreotide trizoxetan,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,Ariceum Therapeutics;Ipsen(原研)(无权益),PET显像,II期临床,2017-07-18,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,,诊断试剂领域,,DR002657,否,欧洲,,II期临床,II期临床,2020-07-29,2017-07-18,phase 2,II期临床,2017-07-18,phase 2,2,True,False,False,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120
68Ga-satoreotide trizoxetan,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,Ariceum Therapeutics;Ipsen(原研)(无权益),神经内分泌肿瘤,II期临床,2020-07-29,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,,肿瘤领域;罕见疾病领域,,DR002657,否,欧洲,,II期临床,,2020-07-29,,phase 2,II期临床,2017-07-18,phase 2,2,True,True,False,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,neuroendocrine tumors,68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120
68Ga-satoreotide trizoxetan,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,Ariceum Therapeutics;Ipsen(原研)(无权益),胃肠胰神经内分泌肿瘤(差异化疾病),II期临床,2017-07-18,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,,肿瘤领域;罕见疾病领域,,DR002657,否,欧洲,,,II期临床,,2017-07-18,phase 2,II期临床,2017-07-18,phase 2,2,True,True,False,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120
68Ga-satoreotide trizoxetan,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,Ariceum Therapeutics;Ipsen(原研)(无权益),肺神经内分泌肿瘤(差异化疾病),II期临床,2023-05-10,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,,肿瘤领域;罕见疾病领域,,DR002657,否,欧洲,,,,,,phase 2,II期临床,2017-07-18,phase 2,2,True,True,False,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",肿瘤领域,肺神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Pulmonary neuroendocrine tumors,68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120
68Ga-NODAGA-E[c(RGDyK)]2,αvβ3,anti-αvβ3多肽偶联核素;68Ga标记的PET药物,Rigshospitalet(原研),心肌梗塞(差异化疾病),II期临床,2018-02-26,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NODAGA-E[c(RGDyK)]2,,心脑血管领域,,DR062251,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2017-09-05,phase 2,1,True,False,False,[],['Rigshospitalet'],1,['Rigshospitalet(原研)'],心脑血管领域,心肌梗塞,['心脑血管领域'],1,心脑血管领域,,,2,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,myocardial infarction,68Ga-NODAGA-E[c(RGDyK)]2,68Ga-NODAGA-E[c(RGDyK)]2
68Ga-NODAGA-E[c(RGDyK)]2,αvβ3,anti-αvβ3多肽偶联核素;68Ga标记的PET药物,Rigshospitalet(原研),PET显像,II期临床,2017-09-05,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NODAGA-E[c(RGDyK)]2,,诊断试剂领域,,DR062251,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2017-09-05,phase 2,1,True,False,False,[],['Rigshospitalet'],1,['Rigshospitalet(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-NODAGA-E[c(RGDyK)]2,68Ga-NODAGA-E[c(RGDyK)]2
68Ga-NODAGA-E[c(RGDyK)]2,αvβ3,anti-αvβ3多肽偶联核素;68Ga标记的PET药物,Rigshospitalet(原研),神经内分泌肿瘤(差异化疾病),II期临床,2017-09-05,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NODAGA-E[c(RGDyK)]2,,肿瘤领域;罕见疾病领域,,DR062251,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2017-09-05,phase 2,1,True,True,False,[],['Rigshospitalet'],1,['Rigshospitalet(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,neuroendocrine tumors,68Ga-NODAGA-E[c(RGDyK)]2,68Ga-NODAGA-E[c(RGDyK)]2
68Ga-NODAGA-E[c(RGDyK)]2,αvβ3,anti-αvβ3多肽偶联核素;68Ga标记的PET药物,Rigshospitalet(原研),乳腺癌,I期临床,2016-11-22,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NODAGA-E[c(RGDyK)]2,,肿瘤领域,,DR062251,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,II期临床,2017-09-05,phase 2,1,True,False,False,[],['Rigshospitalet'],1,['Rigshospitalet(原研)'],肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,breast cancer,68Ga-NODAGA-E[c(RGDyK)]2,68Ga-NODAGA-E[c(RGDyK)]2
68Ga-NODAGA-E[c(RGDyK)]2,αvβ3,anti-αvβ3多肽偶联核素;68Ga标记的PET药物,Rigshospitalet(原研),宫颈癌(差异化疾病),I期临床,2018-09-04,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NODAGA-E[c(RGDyK)]2,,肿瘤领域;罕见疾病领域,,DR062251,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,II期临床,2017-09-05,phase 2,1,True,True,False,[],['Rigshospitalet'],1,['Rigshospitalet(原研)'],肿瘤领域,宫颈癌,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,cervical cancer,68Ga-NODAGA-E[c(RGDyK)]2,68Ga-NODAGA-E[c(RGDyK)]2
68Ga-NODAGA-E[c(RGDyK)]2,αvβ3,anti-αvβ3多肽偶联核素;68Ga标记的PET药物,Rigshospitalet(原研),卵巢癌(差异化疾病),I期临床,2016-11-22,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NODAGA-E[c(RGDyK)]2,,肿瘤领域;罕见疾病领域,,DR062251,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,II期临床,2017-09-05,phase 2,1,True,True,False,[],['Rigshospitalet'],1,['Rigshospitalet(原研)'],肿瘤领域,卵巢癌,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,ovarian cancer,68Ga-NODAGA-E[c(RGDyK)]2,68Ga-NODAGA-E[c(RGDyK)]2
68Ga-NODAGA-E[c(RGDyK)]2,αvβ3,anti-αvβ3多肽偶联核素;68Ga标记的PET药物,Rigshospitalet(原研),肺病或缺氧相关肺高压(差异化疾病),I期临床,2018-09-04,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NODAGA-E[c(RGDyK)]2,,心脑血管领域;呼吸领域,,DR062251,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,II期临床,2017-09-05,phase 2,1,True,False,False,[],['Rigshospitalet'],1,['Rigshospitalet(原研)'],心脑血管领域,肺病或缺氧相关肺高压,"['心脑血管领域', '呼吸领域']",2,心脑血管领域,呼吸领域,,2,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,Respiratory,,Lung disease or hypoxia-related pulmonary hypertension,68Ga-NODAGA-E[c(RGDyK)]2,68Ga-NODAGA-E[c(RGDyK)]2
[68]Ga-HA-DOTATATE,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,University of Alberta(原研),PET显像,II期临床,2019-01-23,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;中国无申报,68Ga标记的PET药物;多肽偶联核素,创新药,[68]Ga-HA-DOTATATE;gallium-68 high affinity-DOTATATE;gallium-68 DOTA-3-iodo-Tyr(3)-octreotate;68Ga-HA-DOTATATE,,诊断试剂领域,,DR062261,否,加拿大,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2019-01-23,phase 2,1,True,False,False,[],['University of Alberta'],1,['University of Alberta(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[68]Ga-HA-DOTATATE,[68]Ga-HA-DOTATATE;gallium-68 high affinity-DOTATATE;gallium-68 DOTA-3-iodo-Tyr(3)-octreotate;68Ga-HA-DOTATATE
[68]Ga-HA-DOTATATE,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,University of Alberta(原研),神经内分泌肿瘤,II期临床,2021-05-17,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;中国无申报,68Ga标记的PET药物;多肽偶联核素,创新药,[68]Ga-HA-DOTATATE;gallium-68 high affinity-DOTATATE;gallium-68 DOTA-3-iodo-Tyr(3)-octreotate;68Ga-HA-DOTATATE,,肿瘤领域;罕见疾病领域,,DR062261,否,加拿大,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2019-01-23,phase 2,1,True,True,False,[],['University of Alberta'],1,['University of Alberta(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,neuroendocrine tumors,[68]Ga-HA-DOTATATE,[68]Ga-HA-DOTATATE;gallium-68 high affinity-DOTATATE;gallium-68 DOTA-3-iodo-Tyr(3)-octreotate;68Ga-HA-DOTATATE
[68]Ga-HA-DOTATATE,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,University of Alberta(原研),巨细胞动脉炎(差异化疾病),II期临床,2019-01-23,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;中国无申报,68Ga标记的PET药物;多肽偶联核素,创新药,[68]Ga-HA-DOTATATE;gallium-68 high affinity-DOTATATE;gallium-68 DOTA-3-iodo-Tyr(3)-octreotate;68Ga-HA-DOTATATE,,免疫领域;罕见疾病领域,,DR062261,否,加拿大,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2019-01-23,phase 2,1,True,True,False,[],['University of Alberta'],1,['University of Alberta(原研)'],免疫领域,巨细胞动脉炎,['免疫领域'],1,免疫领域,,,2,2,Immunology,Immunology,,,giant cell arteritis,[68]Ga-HA-DOTATATE,[68]Ga-HA-DOTATATE;gallium-68 high affinity-DOTATATE;gallium-68 DOTA-3-iodo-Tyr(3)-octreotate;68Ga-HA-DOTATATE
cRGD-ZW800-1 ,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),胰腺癌,II期临床,2022-08-26,Active,多肽,化药,环肽;中国无申报;Potential First-in-Class,荧光显像剂,创新药,cRGD-ZW800-1 ;cRGD-ZW800-1,,肿瘤领域;罕见疾病领域,,DR058158,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2019-12-09,phase 2,2,True,True,False,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,pancreatic cancer,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1
cRGD-ZW800-1 ,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),光学成像剂,II期临床,2022-08-26,Active,多肽,化药,环肽;中国无申报;Potential First-in-Class,荧光显像剂,创新药,cRGD-ZW800-1 ;cRGD-ZW800-1,,诊断试剂领域,,DR058158,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2019-12-09,phase 2,2,True,False,False,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",诊断试剂领域,光学成像剂,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,optical imaging agent,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1
cRGD-ZW800-1 ,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),喉癌,II期临床,2023-03-02,Active,多肽,化药,环肽;中国无申报;Potential First-in-Class,荧光显像剂,创新药,cRGD-ZW800-1 ;cRGD-ZW800-1,,肿瘤领域,,DR058158,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2019-12-09,phase 2,2,True,False,False,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,喉癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Throat cancer,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1
cRGD-ZW800-1 ,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),头颈部鳞状细胞癌,II期临床,2019-12-09,Inactive,多肽,化药,环肽;中国无申报;Potential First-in-Class,荧光显像剂,创新药,cRGD-ZW800-1 ;cRGD-ZW800-1,,肿瘤领域,,DR058158,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2019-12-09,phase 2,2,True,False,False,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,头颈部鳞状细胞癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Head and neck squamous cell carcinoma,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1
cRGD-ZW800-1 ,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),口腔癌,II期临床,2019-12-09,Active,多肽,化药,环肽;中国无申报;Potential First-in-Class,荧光显像剂,创新药,cRGD-ZW800-1 ;cRGD-ZW800-1,,肿瘤领域;罕见疾病领域,,DR058158,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2019-12-09,phase 2,2,True,True,False,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,口腔癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,oral cancer,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1
cRGD-ZW800-1 ,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),胆管癌,II期临床,,Active,多肽,化药,环肽;中国无申报;Potential First-in-Class,荧光显像剂,创新药,cRGD-ZW800-1 ;cRGD-ZW800-1,,肿瘤领域;罕见疾病领域,,DR058158,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2019-12-09,phase 2,2,True,True,False,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,胆管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,cholangiocarcinoma,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1
cRGD-ZW800-1 ,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),肝外胆管癌,II期临床,2022-08-26,Unknown,多肽,化药,环肽;中国无申报;Potential First-in-Class,荧光显像剂,创新药,cRGD-ZW800-1 ;cRGD-ZW800-1,,肿瘤领域;罕见疾病领域,,DR058158,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2019-12-09,phase 2,2,True,True,False,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,肝外胆管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,extrahepatic cholangiocarcinoma,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1
cRGD-ZW800-1 ,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),下咽癌,II期临床,2023-03-02,Active,多肽,化药,环肽;中国无申报;Potential First-in-Class,荧光显像剂,创新药,cRGD-ZW800-1 ;cRGD-ZW800-1,,肿瘤领域,,DR058158,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2019-12-09,phase 2,2,True,False,False,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,下咽癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,hypopharyngeal cancer,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1
cRGD-ZW800-1 ,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),口腔鳞状细胞癌,II期临床,2020-12-17,Unknown,多肽,化药,环肽;中国无申报;Potential First-in-Class,荧光显像剂,创新药,cRGD-ZW800-1 ;cRGD-ZW800-1,,肿瘤领域,,DR058158,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2019-12-09,phase 2,2,True,False,False,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,口腔鳞状细胞癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,oral squamous cell carcinoma,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1
cRGD-ZW800-1 ,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),结肠癌,I期临床,,Active,多肽,化药,环肽;中国无申报;Potential First-in-Class,荧光显像剂,创新药,cRGD-ZW800-1 ;cRGD-ZW800-1,,肿瘤领域,,DR058158,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,II期临床,2019-12-09,phase 2,2,True,False,False,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,结肠癌,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,colon cancer,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1
PL-8177,MC1R,MC1R激动剂,Palatin Technologies(原研),溃疡性结肠炎(差异化疾病),II期临床,2022-07-20,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;Melanogenesis,激动剂,创新药,PL-8177;PL8177,,免疫领域;消化领域,,DR054605,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2022-07-20,phase 2,II期临床,2020-01-20,phase 2,1,True,False,False,[],['Palatin Technologies'],1,['Palatin Technologies(原研)'],免疫领域,溃疡性结肠炎,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,2,2,Immunology,Immunology,Digestive System,,ulcerative colitis,PL-8177,PL-8177;PL8177
PL-8177,MC1R,MC1R激动剂,Palatin Technologies(原研),炎症(未指明),II期临床,2020-01-20,Unknown,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;Melanogenesis,激动剂,创新药,PL-8177;PL8177,,免疫领域,,DR054605,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2020-01-20,phase 2,1,True,False,False,[],['Palatin Technologies'],1,['Palatin Technologies(原研)'],免疫领域,炎症(未指明),['免疫领域'],1,免疫领域,,,2,2,Immunology,Immunology,,,Inflammation (unspecified),PL-8177,PL-8177;PL8177
PL-8177,MC1R,MC1R激动剂,Palatin Technologies(原研),非感染性葡萄膜炎(差异化疾病),II期临床,,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;Melanogenesis,激动剂,创新药,PL-8177;PL8177,,免疫领域;眼科领域,,DR054605,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2020-01-20,phase 2,1,True,False,False,[],['Palatin Technologies'],1,['Palatin Technologies(原研)'],免疫领域,非感染性葡萄膜炎,"['免疫领域', '眼科领域']",2,免疫领域,眼科领域,,2,2,Immunology,Immunology,Ophthalmology,,noninfectious uveitis,PL-8177,PL-8177;PL8177
PL-8177,MC1R,MC1R激动剂,Palatin Technologies(原研),糖尿病肾病(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;Melanogenesis,激动剂,创新药,PL-8177;PL8177,,泌尿生殖领域,,DR054605,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,II期临床,2020-01-20,phase 2,1,True,False,False,[],['Palatin Technologies'],1,['Palatin Technologies(原研)'],泌尿生殖领域,糖尿病肾病,['泌尿生殖领域'],1,泌尿生殖领域,,,2,-1,Genitourinary,Genitourinary,,,diabetic nephropathy,PL-8177,PL-8177;PL8177
68Ga-NODAGA-LM3,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital of Basel(原研),PET显像,II期临床,2020-07-29,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NODAGA-LM3;(68)Ga-NODAGA-LM3;Gallium-68 NODAGA-LM3,,诊断试剂领域,,DR014961,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II期临床,,2020-07-29,,phase 2,II期临床,2020-07-29,phase 2,1,True,False,False,[],['University Hospital of Basel'],1,['University Hospital of Basel(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-NODAGA-LM3,68Ga-NODAGA-LM3;(68)Ga-NODAGA-LM3;Gallium-68 NODAGA-LM3
68Ga-NODAGA-LM3,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital of Basel(原研),神经内分泌肿瘤,II期临床,2020-07-29,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NODAGA-LM3;(68)Ga-NODAGA-LM3;Gallium-68 NODAGA-LM3,,肿瘤领域;罕见疾病领域,,DR014961,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II期临床,,2020-07-29,,phase 2,II期临床,2020-07-29,phase 2,1,True,True,False,[],['University Hospital of Basel'],1,['University Hospital of Basel(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,neuroendocrine tumors,68Ga-NODAGA-LM3,68Ga-NODAGA-LM3;(68)Ga-NODAGA-LM3;Gallium-68 NODAGA-LM3
68Ga-NODAGA-LM3,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital of Basel(原研),希佩尔-林道综合征(差异化疾病),II期临床,2023-04-12,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NODAGA-LM3;(68)Ga-NODAGA-LM3;Gallium-68 NODAGA-LM3,,罕见疾病领域;肿瘤领域,,DR014961,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II期临床,,2023-04-12,,phase 2,II期临床,2020-07-29,phase 2,1,True,True,False,[],['University Hospital of Basel'],1,['University Hospital of Basel(原研)'],肿瘤领域,希佩尔-林道综合征,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Hippel-Lindau syndrome,68Ga-NODAGA-LM3,68Ga-NODAGA-LM3;(68)Ga-NODAGA-LM3;Gallium-68 NODAGA-LM3
THR-149,PKK,PKK抑制剂,Oxurion;Bicycle Therapeutics(原研),糖尿病黄斑水肿,II期临床,2020-08-26,Active,多肽,化药,环肽,抑制剂,创新药,THR-149,,眼科领域,,DR044097,否,欧洲,未知,,II期临床,,2020-08-26,phase 2,II期临床,2020-08-26,phase 2,2,True,False,False,[],['Bicycle Therapeutics'],1,"['Oxurion', 'Bicycle Therapeutics(原研)']",眼科领域,糖尿病黄斑水肿,['眼科领域'],1,眼科领域,,,2,2,Ophthalmology,Ophthalmology,,,diabetic macular edema,THR-149,THR-149
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,胰腺癌,II期临床,,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域;罕见疾病领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,申报临床,I/II期临床,2021-05-27,2021-11-16,phase 2,II期临床,2021-09-13,phase 2,4,True,True,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,pancreatic cancer,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,胶质瘤,II期临床,,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域;罕见疾病领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2021-09-13,phase 2,4,True,True,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,胶质瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,glioma,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,胶质母细胞瘤,II期临床,2023-10-17,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域;罕见疾病领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2021-09-13,phase 2,4,True,True,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,胶质母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,glioblastoma,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,胰腺导管癌,II期临床,2021-09-13,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II期临床,,2024-02-15,,phase 2,II期临床,2021-09-13,phase 2,4,True,False,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,pancreatic ductal carcinoma,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,头颈部鳞状细胞癌,II期临床,2023-02-03,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2023-02-03,phase 2,II期临床,2021-09-13,phase 2,4,True,False,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,头颈部鳞状细胞癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Head and neck squamous cell carcinoma,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,肝内胆管癌,II期临床,,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2021-09-13,phase 2,4,True,False,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,肝内胆管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,intrahepatic cholangiocarcinoma,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,胆囊癌,II期临床,,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域;罕见疾病领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2021-09-13,phase 2,4,True,True,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,胆囊癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,gallbladder cancer,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,胆管癌,II期临床,2023-02-03,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域;罕见疾病领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2023-02-03,phase 2,II期临床,2021-09-13,phase 2,4,True,True,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,胆管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,cholangiocarcinoma,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,肝外胆管癌,II期临床,,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域;罕见疾病领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2021-09-13,phase 2,4,True,True,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,肝外胆管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,extrahepatic cholangiocarcinoma,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,食管鳞状细胞癌,II期临床,2023-02-03,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2023-02-03,phase 2,II期临床,2021-09-13,phase 2,4,True,False,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,食管鳞状细胞癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Esophageal squamous cell carcinoma,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,结肠癌,I/II期临床,2021-11-16,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2021-11-16,phase 2,II期临床,2021-09-13,phase 2,4,True,False,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,结肠癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,colon cancer,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,阑尾癌,I/II期临床,2021-11-16,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域;罕见疾病领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2021-11-16,phase 2,II期临床,2021-09-13,phase 2,4,True,True,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,阑尾癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,appendix cancer,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,腹膜转移癌,I期临床,2024-01-22,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2024-01-22,phase 1,II期临床,2021-09-13,phase 2,4,True,False,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,腹膜转移癌,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,peritoneal metastasis cancer,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,骨肉瘤,临床前,2024-03-21,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域;罕见疾病领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,II期临床,2021-09-13,phase 2,4,True,True,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,骨肉瘤,['肿瘤领域'],1,肿瘤领域,,,2,-1,Oncology,Oncology,,,Osteosarcoma,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
certepetide,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,腹膜癌,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,结合剂,创新药,certepetide;CEND-1;iRGD;QLC12102;LSTA1,,肿瘤领域;罕见疾病领域,II期临床:注射剂(冻干),DR051234,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,II期临床,2021-09-13,phase 2,4,True,True,False,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,腹膜癌,['肿瘤领域'],1,肿瘤领域,,,2,-1,Oncology,Oncology,,,peritoneal cancer,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1
212Pb-dotamtate,SSTR,212Pb标记的放射性药物;anti-SSTR多肽偶联核素,Sanofi(Top20 MNC);Orano Med(原研)(无权益);RadioMedix(原研)(无权益),神经内分泌肿瘤,II期临床,2021-12-10,Active,多肽;放射性药物;偶联药物,化药,环肽;2024年转化医学TOP25;中国无申报;Potential First-in-Class;2024 ASCO新机会,多肽偶联核素;212Pb标记的放射性药物,创新药,212Pb-dotamtate;AlphaMedix;212Pb-DOTAMTATE;212Pb-AR-RMX;ORM2110;SAR447873,,肿瘤领域;罕见疾病领域,,DR056969,否,美国,,,II期临床,,2021-12-10,phase 2,II期临床,2021-12-10,phase 2,3,True,True,True,['Sanofi'],"['Orano Med', 'RadioMedix']",2,"['Sanofi(Top20 MNC)', 'Orano Med(原研)(无权益)', 'RadioMedix(原研)(无权益)']",肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,neuroendocrine tumors,212Pb-dotamtate,212Pb-dotamtate;AlphaMedix;212Pb-DOTAMTATE;212Pb-AR-RMX;ORM2110;SAR447873
212Pb-dotamtate,SSTR,212Pb标记的放射性药物;anti-SSTR多肽偶联核素,Sanofi(Top20 MNC);Orano Med(原研)(无权益);RadioMedix(原研)(无权益),胃肠胰神经内分泌肿瘤,II期临床,2024-02-12,Active,多肽;放射性药物;偶联药物,化药,环肽;2024年转化医学TOP25;中国无申报;Potential First-in-Class;2024 ASCO新机会,多肽偶联核素;212Pb标记的放射性药物,创新药,212Pb-dotamtate;AlphaMedix;212Pb-DOTAMTATE;212Pb-AR-RMX;ORM2110;SAR447873,,肿瘤领域;罕见疾病领域,,DR056969,否,美国,,,II期临床,,2024-02-12,phase 2,II期临床,2021-12-10,phase 2,3,True,True,True,['Sanofi'],"['Orano Med', 'RadioMedix']",2,"['Sanofi(Top20 MNC)', 'Orano Med(原研)(无权益)', 'RadioMedix(原研)(无权益)']",肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,212Pb-dotamtate,212Pb-dotamtate;AlphaMedix;212Pb-DOTAMTATE;212Pb-AR-RMX;ORM2110;SAR447873
GT-02037,somatostatin;SSTR1;SSTR2;SSTR4;SSTR5;SSTR3,SSTR1激动剂;SSTR4激动剂;SSTR2激动剂;SSTR3激动剂;SSTR5激动剂;somatostatin类似物,永信药品;GlyTech(原研),肢端肥大症,II期临床,2022-06-22,Active,多肽,化药,环肽;中国无申报;Potential First-in-Class,类似物;激动剂,创新药,GT-02037,,内分泌及代谢领域;罕见疾病领域,,DR024863,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2022-06-22,phase 2,2,True,True,False,[],['GlyTech'],1,"['永信药品', 'GlyTech(原研)']",内分泌及代谢领域,肢端肥大症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,acromegaly,GT-02037,GT-02037
SCAI-001,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,SCAI Therapeutics(原研),干眼病,II期临床,2023-02-17,Active,小分子,化药,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,微创新,SCAI-001;SCAI-001 (环孢素);SCAI-001 (cyclosporine),,眼科领域,,DR013209,否,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2023-02-17,phase 2,1,True,False,False,[],['SCAI Therapeutics'],1,['SCAI Therapeutics(原研)'],眼科领域,干眼病,['眼科领域'],1,眼科领域,,,2,2,Ophthalmology,Ophthalmology,,,dry eye disease,SCAI-001 (cyclosporine),SCAI-001;SCAI-001 (环孢素);SCAI-001 (cyclosporine)
thiostrepton,FOXM1;PRDX3,FOXM1抑制剂;PRDX3抑制剂;多肽类抗生素,RS Oncology(原研),恶性胸水,II期临床,2024-02-01,Active,多肽,化药,环肽;Potential First-in-Class,多肽类抗生素;抑制剂,创新药,thiostrepton;RSO-021,,肿瘤领域;罕见疾病领域,,DR054387,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2024-02-01,phase 2,1,True,True,False,[],['RS Oncology'],1,['RS Oncology(原研)'],肿瘤领域,恶性胸水,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,malignant pleural effusion,thiostrepton,thiostrepton;RSO-021
thiostrepton,FOXM1;PRDX3,FOXM1抑制剂;PRDX3抑制剂;多肽类抗生素,RS Oncology(原研),胸膜间皮瘤,II期临床,2024-02-01,Active,多肽,化药,环肽;Potential First-in-Class,多肽类抗生素;抑制剂,创新药,thiostrepton;RSO-021,,肿瘤领域;罕见疾病领域,,DR054387,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2024-02-01,phase 2,1,True,True,False,[],['RS Oncology'],1,['RS Oncology(原研)'],肿瘤领域,胸膜间皮瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Pleural mesothelioma,thiostrepton,thiostrepton;RSO-021
M-ANP,NPR1,NPR1激活剂,Mayo Clinic(原研);E-Star BioTech,高血压,II期临床,2024-04-02,Active,多肽,化药,环肽;差异化疾病;Potential First-in-Class,激活剂,创新药,M-ANP;MANP;M-Atrial Natriuretic Peptide,,心脑血管领域,,DR005045,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2024-04-02,phase 2,II期临床,2024-04-02,phase 2,2,True,False,False,[],['Mayo Clinic'],1,"['Mayo Clinic(原研)', 'E-Star BioTech']",心脑血管领域,高血压,['心脑血管领域'],1,心脑血管领域,,,2,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,hypertension,M-ANP,M-ANP;MANP;M-Atrial Natriuretic Peptide
M-ANP,NPR1,NPR1激活剂,Mayo Clinic(原研);E-Star BioTech,射血分数保留的心力衰竭(差异化疾病),I/II期临床,,Active,多肽,化药,环肽;差异化疾病;Potential First-in-Class,激活剂,创新药,M-ANP;MANP;M-Atrial Natriuretic Peptide,,心脑血管领域,,DR005045,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2024-04-02,phase 2,2,True,False,False,[],['Mayo Clinic'],1,"['Mayo Clinic(原研)', 'E-Star BioTech']",心脑血管领域,射血分数保留的心力衰竭,['心脑血管领域'],1,心脑血管领域,,,2,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,heart failure with preserved ejection fraction,M-ANP,M-ANP;MANP;M-Atrial Natriuretic Peptide
DD01,GLP-1R;GCGR,GLP-1R×GCGR激动剂,信立泰;D&D Pharmatech(原研),肥胖,II期临床,2024-05-13,Active,多肽,化药,环肽;肠促胰岛素通路,激动剂,创新药,DD01;SAL0125,,内分泌及代谢领域,申报临床:注射剂,DR016577,否,韩国,中国(港澳台);美国;欧洲;日本;其他,申报临床,II期临床,2024-09-30,2024-05-13,phase 2,II期临床,2024-05-13,phase 2,2,True,False,False,[],['D&D Pharmatech'],1,"['信立泰', 'D&D Pharmatech(原研)']",内分泌及代谢领域,肥胖,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,obesity,DD01,DD01;SAL0125
DD01,GLP-1R;GCGR,GLP-1R×GCGR激动剂,信立泰;D&D Pharmatech(原研),代谢相关脂肪性肝炎,II期临床,2024-05-13,Active,多肽,化药,环肽;肠促胰岛素通路,激动剂,创新药,DD01;SAL0125,,消化领域,申报临床:注射剂,DR016577,否,韩国,中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2024-05-13,phase 2,II期临床,2024-05-13,phase 2,2,True,False,False,[],['D&D Pharmatech'],1,"['信立泰', 'D&D Pharmatech(原研)']",消化领域,代谢相关脂肪性肝炎,['消化领域'],1,消化领域,,,2,2,Digestive System,Digestive System,,,Metabolic related steatohepatitis,DD01,DD01;SAL0125
DD01,GLP-1R;GCGR,GLP-1R×GCGR激动剂,信立泰;D&D Pharmatech(原研),超重,II期临床,2024-05-13,Active,多肽,化药,环肽;肠促胰岛素通路,激动剂,创新药,DD01;SAL0125,,内分泌及代谢领域,申报临床:注射剂,DR016577,否,韩国,中国(港澳台);美国;欧洲;日本;其他,申报临床,II期临床,2024-09-30,2024-05-13,phase 2,II期临床,2024-05-13,phase 2,2,True,False,False,[],['D&D Pharmatech'],1,"['信立泰', 'D&D Pharmatech(原研)']",内分泌及代谢领域,超重,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,overweight,DD01,DD01;SAL0125
DD01,GLP-1R;GCGR,GLP-1R×GCGR激动剂,信立泰;D&D Pharmatech(原研),2型糖尿病,I期临床,2021-03-23,Active,多肽,化药,环肽;肠促胰岛素通路,激动剂,创新药,DD01;SAL0125,,内分泌及代谢领域,申报临床:注射剂,DR016577,否,韩国,中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2021-03-23,phase 1,II期临床,2024-05-13,phase 2,2,True,False,False,[],['D&D Pharmatech'],1,"['信立泰', 'D&D Pharmatech(原研)']",内分泌及代谢领域,2型糖尿病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,type 2 diabetes,DD01,DD01;SAL0125
DD01,GLP-1R;GCGR,GLP-1R×GCGR激动剂,信立泰;D&D Pharmatech(原研),代谢相关脂肪性肝病,I期临床,2021-03-23,Active,多肽,化药,环肽;肠促胰岛素通路,激动剂,创新药,DD01;SAL0125,,消化领域,申报临床:注射剂,DR016577,否,韩国,中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2021-03-23,phase 1,II期临床,2024-05-13,phase 2,2,True,False,False,[],['D&D Pharmatech'],1,"['信立泰', 'D&D Pharmatech(原研)']",消化领域,代谢相关脂肪性肝病,['消化领域'],1,消化领域,,,2,1,Digestive System,Digestive System,,,metabolic related fatty liver disease,DD01,DD01;SAL0125
咔喏霉素,not available,脂肽类抗生素,友搏药业(九芝堂);香港大学(原研),急性细菌性皮肤和皮肤结构感染(差异化疾病),II期临床,2025-03-07,Active,多肽,化药,环肽;差异化疾病,脂肽类抗生素,创新药,咔喏霉素;kynomycin;YB211;YBD211,,感染领域;皮肤领域,II期临床:注射剂(冻干),DR049191,否,中国(港澳台),未知,II期临床,,2025-03-07,,phase 2,II期临床,2025-03-07,phase 2,2,True,False,False,[],['香港大学'],1,"['友搏药业(九芝堂)', '香港大学(原研)']",感染领域,急性细菌性皮肤和皮肤结构感染,"['感染领域', '皮肤领域']",2,感染领域,皮肤领域,,2,2,Infectious Diseases,Infectious Diseases,Dermatology,,Acute bacterial skin and skin structure infections,kynomycin,咔喏霉素;kynomycin;YB211;YBD211
咔喏霉素,not available,脂肽类抗生素,友搏药业(九芝堂);香港大学(原研),皮肤/皮肤结构感染,I期临床,2023-11-20,Active,多肽,化药,环肽;差异化疾病,脂肽类抗生素,创新药,咔喏霉素;kynomycin;YB211;YBD211,,感染领域;皮肤领域,II期临床:注射剂(冻干),DR049191,否,中国(港澳台),未知,I期临床,,2023-11-20,,phase 1,II期临床,2025-03-07,phase 2,2,True,False,False,[],['香港大学'],1,"['友搏药业(九芝堂)', '香港大学(原研)']",感染领域,皮肤/皮肤结构感染,"['感染领域', '皮肤领域']",2,感染领域,皮肤领域,,2,1,Infectious Diseases,Infectious Diseases,Dermatology,,Skin/skin structure infection,kynomycin,咔喏霉素;kynomycin;YB211;YBD211
咔喏霉素,not available,脂肽类抗生素,友搏药业(九芝堂);香港大学(原研),复杂性皮肤和皮肤结构感染(差异化疾病),I期临床,2023-12-14,Active,多肽,化药,环肽;差异化疾病,脂肽类抗生素,创新药,咔喏霉素;kynomycin;YB211;YBD211,,感染领域;皮肤领域,II期临床:注射剂(冻干),DR049191,否,中国(港澳台),未知,I期临床,,2023-12-14,,phase 1,II期临床,2025-03-07,phase 2,2,True,False,False,[],['香港大学'],1,"['友搏药业(九芝堂)', '香港大学(原研)']",感染领域,复杂性皮肤和皮肤结构感染,"['感染领域', '皮肤领域']",2,感染领域,皮肤领域,,2,1,Infectious Diseases,Infectious Diseases,Dermatology,,Complicated skin and skin structure infections,kynomycin,咔喏霉素;kynomycin;YB211;YBD211
咔喏霉素,not available,脂肽类抗生素,友搏药业(九芝堂);香港大学(原研),感染,申报临床,2023-07-07,Active,多肽,化药,环肽;差异化疾病,脂肽类抗生素,创新药,咔喏霉素;kynomycin;YB211;YBD211,,感染领域,II期临床:注射剂(冻干),DR049191,否,中国(港澳台),未知,申报临床,,2023-07-07,,ind,II期临床,2025-03-07,phase 2,2,True,False,False,[],['香港大学'],1,"['友搏药业(九芝堂)', '香港大学(原研)']",感染领域,感染,['感染领域'],1,感染领域,,,2,0,Infectious Diseases,Infectious Diseases,,,Infect,kynomycin,咔喏霉素;kynomycin;YB211;YBD211
177Lu-FAP-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),非小细胞肺癌,II期临床,2025-08-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,,肿瘤领域,,DR056891,否,欧洲,,,II期临床,,2025-08-26,phase 2,II期临床,2025-03-18,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', 'Clovis Oncology(无权益)', '3B Pharmaceuticals(原研)(无权益)']",肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,non-small cell lung cancer,177Lu-FAP-2286,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286
177Lu-FAP-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),乳腺癌,II期临床,2025-08-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,,肿瘤领域,,DR056891,否,欧洲,,,II期临床,,2025-08-26,phase 2,II期临床,2025-03-18,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', 'Clovis Oncology(无权益)', '3B Pharmaceuticals(原研)(无权益)']",肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,breast cancer,177Lu-FAP-2286,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286
177Lu-FAP-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),尿路上皮癌(差异化疾病),II期临床,2025-03-18,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,,肿瘤领域,,DR056891,否,欧洲,,,,,,phase 2,II期临床,2025-03-18,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', 'Clovis Oncology(无权益)', '3B Pharmaceuticals(原研)(无权益)']",肿瘤领域,尿路上皮癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,urothelial carcinoma,177Lu-FAP-2286,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286
177Lu-FAP-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),胰腺导管癌,II期临床,2025-08-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,,肿瘤领域,,DR056891,否,欧洲,,,II期临床,,2025-08-26,phase 2,II期临床,2025-03-18,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', 'Clovis Oncology(无权益)', '3B Pharmaceuticals(原研)(无权益)']",肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,pancreatic ductal carcinoma,177Lu-FAP-2286,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286
177Lu-FAP-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),实体瘤,I/II期临床,2021-06-25,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,,肿瘤领域,,DR056891,否,欧洲,,,I/II期临床,,2021-06-25,phase 2,II期临床,2025-03-18,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', 'Clovis Oncology(无权益)', '3B Pharmaceuticals(原研)(无权益)']",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,solid tumors,177Lu-FAP-2286,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286
177Lu-FAP-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),骨转移疼痛(差异化疾病),I期临床,2025-05-12,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,,肿瘤领域,,DR056891,否,欧洲,,I期临床,,2025-05-12,,phase 1,II期临床,2025-03-18,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', 'Clovis Oncology(无权益)', '3B Pharmaceuticals(原研)(无权益)']",肿瘤领域,骨转移疼痛,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,bone metastasis pain,177Lu-FAP-2286,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286
TCMCB07,MC4R,MC4R拮抗剂,Endevica(原研),恶病质(差异化疾病),II期临床,2025-04-17,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;瘦素-黑皮素通路,拮抗剂,创新药,TCMCB07,,内分泌及代谢领域,,DR034281,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2025-04-17,phase 2,1,True,False,False,[],['Endevica'],1,['Endevica(原研)'],内分泌及代谢领域,恶病质,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Cachexia,TCMCB07,TCMCB07
TCMCB07,MC4R,MC4R拮抗剂,Endevica(原研),癌性恶病质,II期临床,2025-04-22,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;瘦素-黑皮素通路,拮抗剂,创新药,TCMCB07,,肿瘤领域,,DR034281,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2025-04-22,phase 2,II期临床,2025-04-17,phase 2,1,True,False,False,[],['Endevica'],1,['Endevica(原研)'],肿瘤领域,癌性恶病质,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,cancer cachexia,TCMCB07,TCMCB07
ALXN2420,GHR,GHR拮抗剂,Alexion Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),肢端肥大症,II期临床,2025-06-25,Active,多肽,化药,环肽,拮抗剂,创新药,ALXN2420,,内分泌及代谢领域;罕见疾病领域,申报临床:注射剂,DR081373,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,II期临床,II期临床,2025-06-25,2025-06-25,phase 2,II期临床,2025-06-25,phase 2,1,True,True,True,['Alexion Pharmaceuticals(AstraZeneca)'],['Alexion Pharmaceuticals(AstraZeneca)'],1,['Alexion Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研)'],内分泌及代谢领域,肢端肥大症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,,acromegaly,ALXN2420,ALXN2420
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),非小细胞肺癌(差异化疾病),II期临床,2025-08-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,肿瘤领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2025-08-26,phase 2,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,non-small cell lung cancer,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),乳腺癌(差异化疾病),II期临床,2025-08-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,肿瘤领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2025-08-26,phase 2,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,breast cancer,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),胰腺导管癌(差异化疾病),II期临床,2025-08-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,肿瘤领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2025-08-26,phase 2,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,pancreatic ductal carcinoma,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),实体瘤,I/II期临床,2021-06-25,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,肿瘤领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2021-06-25,phase 2,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,solid tumors,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),肿瘤,I期临床,2025-08-27,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,肿瘤领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-08-27,,phase 1,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,tumor,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),癌症,I期临床,2022-05-26,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,肿瘤领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2022-05-26,,phase 1,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,cancer,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),头颈癌(差异化疾病),I期临床,2020-11-09,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,肿瘤领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2020-11-09,phase 1,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,头颈癌,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,Head and neck cancer,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),前列腺癌(差异化疾病),I期临床,2020-11-09,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,肿瘤领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2020-11-09,phase 1,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,前列腺癌,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,prostate cancer,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),膀胱癌(差异化疾病),I期临床,2020-11-09,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,肿瘤领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2020-11-09,phase 1,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,膀胱癌,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,bladder cancer,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),肺纤维化,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,呼吸领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",呼吸领域,肺纤维化,['呼吸领域'],1,呼吸领域,,,2,1,Respiratory,Respiratory,,,pulmonary fibrosis,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),特发性肺纤维化(差异化疾病),I期临床,2022-01-06,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,呼吸领域;罕见疾病领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2022-01-06,phase 1,II期临床,2025-08-26,phase 2,3,True,True,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",呼吸领域,特发性肺纤维化,['呼吸领域'],1,呼吸领域,,,2,1,Respiratory,Respiratory,,,idiopathic pulmonary fibrosis,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),肝纤维化(差异化疾病),I期临床,2022-01-06,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,消化领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2022-01-06,phase 1,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",消化领域,肝纤维化,['消化领域'],1,消化领域,,,2,1,Digestive System,Digestive System,,,liver fibrosis,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),PET显像,I期临床,2020-11-09,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,诊断试剂领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,I期临床,2022-05-26,2020-11-09,phase 1,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,2,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),肉瘤(差异化疾病),I期临床,2020-11-09,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,肿瘤领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2020-11-09,phase 1,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,肉瘤,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,sarcoma,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),结肠癌(差异化疾病),I期临床,2020-11-09,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,肿瘤领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2020-11-09,phase 1,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,结肠癌,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,colon cancer,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
68Ga-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),心脏纤维化(差异化疾病),I期临床,2022-01-06,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-FAP-2286;3B-202,,心脑血管领域,,DR033759,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2022-01-06,phase 1,II期临床,2025-08-26,phase 2,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",心脑血管领域,心脏纤维化,['心脑血管领域'],1,心脑血管领域,,,2,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,cardiac fibrosis,68Ga-FAP-2286,68Ga-FAP-2286;3B-202
LS301,ANXA2,荧光显像剂,Washington University in St. Louis;Integro Theranostics(原研),非小细胞肺癌,II期临床,2025-12-11,Active,多肽,化药,环肽;Potential First-in-Class,荧光显像剂,创新药,LS301;LS301-IT,,肿瘤领域,,DR050488,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2025-12-11,phase 2,II期临床,2025-12-11,phase 2,2,True,False,False,[],['Integro Theranostics'],1,"['Washington University in St. Louis', 'Integro Theranostics(原研)']",肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,non-small cell lung cancer,LS301,LS301;LS301-IT
LS301,ANXA2,荧光显像剂,Washington University in St. Louis;Integro Theranostics(原研),光学成像剂,II期临床,2025-12-11,Active,多肽,化药,环肽;Potential First-in-Class,荧光显像剂,创新药,LS301;LS301-IT,,诊断试剂领域,,DR050488,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,II期临床,,2025-12-11,phase 2,II期临床,2025-12-11,phase 2,2,True,False,False,[],['Integro Theranostics'],1,"['Washington University in St. Louis', 'Integro Theranostics(原研)']",诊断试剂领域,光学成像剂,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,optical imaging agent,LS301,LS301;LS301-IT
LS301,ANXA2,荧光显像剂,Washington University in St. Louis;Integro Theranostics(原研),肝癌,I/II期临床,2019-09-26,Inactive,多肽,化药,环肽;Potential First-in-Class,荧光显像剂,创新药,LS301;LS301-IT,,肿瘤领域,,DR050488,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2025-12-11,phase 2,2,True,False,False,[],['Integro Theranostics'],1,"['Washington University in St. Louis', 'Integro Theranostics(原研)']",肿瘤领域,肝癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,liver cancer,LS301,LS301;LS301-IT
LS301,ANXA2,荧光显像剂,Washington University in St. Louis;Integro Theranostics(原研),胃癌,I/II期临床,2019-09-26,Inactive,多肽,化药,环肽;Potential First-in-Class,荧光显像剂,创新药,LS301;LS301-IT,,肿瘤领域,,DR050488,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2025-12-11,phase 2,2,True,False,False,[],['Integro Theranostics'],1,"['Washington University in St. Louis', 'Integro Theranostics(原研)']",肿瘤领域,胃癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,stomach cancer,LS301,LS301;LS301-IT
LS301,ANXA2,荧光显像剂,Washington University in St. Louis;Integro Theranostics(原研),乳腺癌,I/II期临床,2016-06-21,Inactive,多肽,化药,环肽;Potential First-in-Class,荧光显像剂,创新药,LS301;LS301-IT,,肿瘤领域,,DR050488,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2016-06-21,phase 2,II期临床,2025-12-11,phase 2,2,True,False,False,[],['Integro Theranostics'],1,"['Washington University in St. Louis', 'Integro Theranostics(原研)']",肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,breast cancer,LS301,LS301;LS301-IT
LS301,ANXA2,荧光显像剂,Washington University in St. Louis;Integro Theranostics(原研),胰腺癌,I/II期临床,2019-09-26,Inactive,多肽,化药,环肽;Potential First-in-Class,荧光显像剂,创新药,LS301;LS301-IT,,肿瘤领域;罕见疾病领域,,DR050488,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2025-12-11,phase 2,2,True,True,False,[],['Integro Theranostics'],1,"['Washington University in St. Louis', 'Integro Theranostics(原研)']",肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,pancreatic cancer,LS301,LS301;LS301-IT
LS301,ANXA2,荧光显像剂,Washington University in St. Louis;Integro Theranostics(原研),胃肠道间质瘤,I/II期临床,2019-09-26,Inactive,多肽,化药,环肽;Potential First-in-Class,荧光显像剂,创新药,LS301;LS301-IT,,肿瘤领域;罕见疾病领域,,DR050488,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,2025-12-11,phase 2,2,True,True,False,[],['Integro Theranostics'],1,"['Washington University in St. Louis', 'Integro Theranostics(原研)']",肿瘤领域,胃肠道间质瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,gastrointestinal stromal tumor,LS301,LS301;LS301-IT
LS301,ANXA2,荧光显像剂,Washington University in St. Louis;Integro Theranostics(原研),原位导管癌,I/II期临床,2023-06-13,Active,多肽,化药,环肽;Potential First-in-Class,荧光显像剂,创新药,LS301;LS301-IT,,肿瘤领域,,DR050488,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2023-06-13,phase 2,II期临床,2025-12-11,phase 2,2,True,False,False,[],['Integro Theranostics'],1,"['Washington University in St. Louis', 'Integro Theranostics(原研)']",肿瘤领域,原位导管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Ductal carcinoma in situ,LS301,LS301;LS301-IT
LS301,ANXA2,荧光显像剂,Washington University in St. Louis;Integro Theranostics(原研),肺癌,I期临床,2024-12-03,Active,多肽,化药,环肽;Potential First-in-Class,荧光显像剂,创新药,LS301;LS301-IT,,肿瘤领域,,DR050488,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2024-12-03,phase 1,II期临床,2025-12-11,phase 2,2,True,False,False,[],['Integro Theranostics'],1,"['Washington University in St. Louis', 'Integro Theranostics(原研)']",肿瘤领域,肺癌,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,lung cancer,LS301,LS301;LS301-IT
68Ga-BOT5035,PDGFRβ,anti-PDGFRβ多肽偶联核素;68Ga标记的PET药物,BiOrion(原研);Cortalix,射血分数保留的心力衰竭,II期临床,,Active,多肽;放射性药物;偶联药物,其他,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-BOT5035,,心脑血管领域,,DR047985,否,欧洲,未知,,,,,phase 2,II期临床,,phase 2,2,True,False,False,[],['BiOrion'],1,"['BiOrion(原研)', 'Cortalix']",心脑血管领域,射血分数保留的心力衰竭,['心脑血管领域'],1,心脑血管领域,,,2,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,heart failure with preserved ejection fraction,68Ga-BOT5035,68Ga-BOT5035
68Ga-BOT5035,PDGFRβ,anti-PDGFRβ多肽偶联核素;68Ga标记的PET药物,BiOrion(原研);Cortalix,特发性肺纤维化,临床前,,Active,多肽;放射性药物;偶联药物,其他,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-BOT5035,,呼吸领域;罕见疾病领域,,DR047985,否,欧洲,未知,,,,,pre-clinical,II期临床,,phase 2,2,True,True,False,[],['BiOrion'],1,"['BiOrion(原研)', 'Cortalix']",呼吸领域,特发性肺纤维化,['呼吸领域'],1,呼吸领域,,,2,-1,Respiratory,Respiratory,,,idiopathic pulmonary fibrosis,68Ga-BOT5035,68Ga-BOT5035
OTX-CSI,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Ocular Therapeutix(原研),干眼病,II期临床,,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,OTX-CSI;OTX-CSI (环孢素);OTX-CSI (cyclosporine A intracanalicular insert),,眼科领域,,DR028223,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2020-04-27,phase 2,II期临床,,phase 2,1,True,False,False,[],['Ocular Therapeutix'],1,['Ocular Therapeutix(原研)'],眼科领域,干眼病,['眼科领域'],1,眼科领域,,,2,2,Ophthalmology,Ophthalmology,,,dry eye disease,OTX-CSI (cyclosporine A intracanalicular insert),OTX-CSI;OTX-CSI (环孢素);OTX-CSI (cyclosporine A intracanalicular insert)
SomaDex,somatostatin,somatostatin类似物,DexTech(原研),去势抵抗前列腺癌,II期临床,,Active,其他,化药,环肽,类似物,创新药,SomaDex,,肿瘤领域,,DR024975,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,II期临床,,phase 2,1,True,False,False,[],['DexTech'],1,['DexTech(原研)'],肿瘤领域,去势抵抗前列腺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Castration-resistant prostate cancer,SomaDex,SomaDex
SomaDex,somatostatin,somatostatin类似物,DexTech(原研),肢端肥大症,临床前,,Active,其他,化药,环肽,类似物,创新药,SomaDex,,内分泌及代谢领域;罕见疾病领域,,DR024975,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,II期临床,,phase 2,1,True,True,False,[],['DexTech'],1,['DexTech(原研)'],内分泌及代谢领域,肢端肥大症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,acromegaly,SomaDex,SomaDex
SomaDex,somatostatin,somatostatin类似物,DexTech(原研),神经内分泌肿瘤,临床前,,Active,其他,化药,环肽,类似物,创新药,SomaDex,,肿瘤领域;罕见疾病领域,,DR024975,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,II期临床,,phase 2,1,True,True,False,[],['DexTech'],1,['DexTech(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,-1,Oncology,Oncology,,,neuroendocrine tumors,SomaDex,SomaDex
177Lu-satoreotide tetraxetan,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,Ariceum Therapeutics;Ipsen(原研)(无权益),神经内分泌肿瘤,I/II期临床,2015-10-29,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110,,肿瘤领域;罕见疾病领域,,DR016814,否,欧洲,,,I/II期临床,,2015-10-30,phase 2,I/II期临床,2015-10-29,phase 2,2,True,True,False,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,neuroendocrine tumors,177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110
177Lu-satoreotide tetraxetan,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,Ariceum Therapeutics;Ipsen(原研)(无权益),脑膜瘤(差异化疾病),I/II期临床,2021-08-09,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110,,肿瘤领域,,DR016814,否,欧洲,,,,,,phase 2,I/II期临床,2015-10-29,phase 2,2,True,False,False,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",肿瘤领域,脑膜瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Meningioma,177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110
177Lu-satoreotide tetraxetan,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,Ariceum Therapeutics;Ipsen(原研)(无权益),小细胞肺癌(差异化疾病),I期临床,2023-02-22,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110,,肿瘤领域;罕见疾病领域,,DR016814,否,欧洲,,,,,,phase 1,I/II期临床,2015-10-29,phase 2,2,True,True,False,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,small cell lung cancer,177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110
lonodelestat,ELA2,ELA2抑制剂,Polyphor(Spexis)(原研);Santhera Pharmaceuticals(无权益),囊性纤维化,I/II期临床,2017-06-23,Unknown,多肽,化药,环肽;差异化疾病,抑制剂,创新药,lonodelestat;POL6014,,呼吸领域;罕见疾病领域,,DR043769,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2017-06-23,phase 2,2,True,True,False,[],['Polyphor(Spexis)'],1,"['Polyphor(Spexis)(原研)', 'Santhera Pharmaceuticals(无权益)']",呼吸领域,囊性纤维化,['呼吸领域'],1,呼吸领域,,,2,2,Respiratory,Respiratory,,,cystic fibrosis,lonodelestat,lonodelestat;POL6014
lonodelestat,ELA2,ELA2抑制剂,Polyphor(Spexis)(原研);Santhera Pharmaceuticals(无权益),慢性阻塞性肺病,I期临床,,Unknown,多肽,化药,环肽;差异化疾病,抑制剂,创新药,lonodelestat;POL6014,,呼吸领域,,DR043769,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I/II期临床,2017-06-23,phase 2,2,True,False,False,[],['Polyphor(Spexis)'],1,"['Polyphor(Spexis)(原研)', 'Santhera Pharmaceuticals(无权益)']",呼吸领域,慢性阻塞性肺病,['呼吸领域'],1,呼吸领域,,,2,1,Respiratory,Respiratory,,,chronic obstructive pulmonary disease,lonodelestat,lonodelestat;POL6014
lonodelestat,ELA2,ELA2抑制剂,Polyphor(Spexis)(原研);Santhera Pharmaceuticals(无权益),α1-抗胰蛋白酶缺乏症,I期临床,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,lonodelestat;POL6014,,罕见疾病领域;呼吸领域,,DR043769,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I/II期临床,2017-06-23,phase 2,2,True,True,False,[],['Polyphor(Spexis)'],1,"['Polyphor(Spexis)(原研)', 'Santhera Pharmaceuticals(无权益)']",呼吸领域,α1-抗胰蛋白酶缺乏症,['呼吸领域'],1,呼吸领域,,,2,1,Respiratory,Respiratory,,,α1-antitrypsin deficiency,lonodelestat,lonodelestat;POL6014
lonodelestat,ELA2,ELA2抑制剂,Polyphor(Spexis)(原研);Santhera Pharmaceuticals(无权益),原发性纤毛运动障碍(差异化疾病),I期临床,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,lonodelestat;POL6014,,呼吸领域;罕见疾病领域,,DR043769,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I/II期临床,2017-06-23,phase 2,2,True,True,False,[],['Polyphor(Spexis)'],1,"['Polyphor(Spexis)(原研)', 'Santhera Pharmaceuticals(无权益)']",呼吸领域,原发性纤毛运动障碍,['呼吸领域'],1,呼吸领域,,,2,1,Respiratory,Respiratory,,,primary ciliary dyskinesia,lonodelestat,lonodelestat;POL6014
67Cu-SARTATE,SSTR,anti-SSTR多肽偶联核素;67Cu标记的放射性药物,Clarity Pharmaceuticals(原研),神经母细胞瘤,I/II期临床,2019-07-17,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,67Cu标记的放射性药物;多肽偶联核素,创新药,67Cu-SARTATE;67Cu-MeCOSar-Tyr3-octreotate;67Cu-CuSarTATE,,肿瘤领域;罕见疾病领域,,DR062471,否,澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2019-07-17,phase 2,I/II期临床,2018-03-01,phase 2,1,True,True,False,[],['Clarity Pharmaceuticals'],1,['Clarity Pharmaceuticals(原研)'],肿瘤领域,神经母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Neuroblastoma,67Cu-SARTATE,67Cu-SARTATE;67Cu-MeCOSar-Tyr3-octreotate;67Cu-CuSarTATE
67Cu-SARTATE,SSTR,anti-SSTR多肽偶联核素;67Cu标记的放射性药物,Clarity Pharmaceuticals(原研),神经内分泌肿瘤,I/II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,67Cu标记的放射性药物;多肽偶联核素,创新药,67Cu-SARTATE;67Cu-MeCOSar-Tyr3-octreotate;67Cu-CuSarTATE,,肿瘤领域;罕见疾病领域,,DR062471,否,澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2018-03-01,phase 2,1,True,True,False,[],['Clarity Pharmaceuticals'],1,['Clarity Pharmaceuticals(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,neuroendocrine tumors,67Cu-SARTATE,67Cu-SARTATE;67Cu-MeCOSar-Tyr3-octreotate;67Cu-CuSarTATE
67Cu-SARTATE,SSTR,anti-SSTR多肽偶联核素;67Cu标记的放射性药物,Clarity Pharmaceuticals(原研),脑膜瘤,I/II期临床,2018-03-01,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,67Cu标记的放射性药物;多肽偶联核素,创新药,67Cu-SARTATE;67Cu-MeCOSar-Tyr3-octreotate;67Cu-CuSarTATE,,肿瘤领域,,DR062471,否,澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2018-03-01,phase 2,1,True,False,False,[],['Clarity Pharmaceuticals'],1,['Clarity Pharmaceuticals(原研)'],肿瘤领域,脑膜瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Meningioma,67Cu-SARTATE,67Cu-SARTATE;67Cu-MeCOSar-Tyr3-octreotate;67Cu-CuSarTATE
BT5528,EphA2,多肽偶联药物,Bicycle Therapeutics(原研),实体瘤,I/II期临床,2019-11-27,Active,多肽;偶联药物,化药,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];受体酪氨酸激酶;Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,BT5528,,肿瘤领域,,DR052083,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2019-11-27,phase 2,I/II期临床,2019-11-27,phase 2,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,solid tumors,BT5528,BT5528
BT5528,EphA2,多肽偶联药物,Bicycle Therapeutics(原研),非小细胞肺癌(差异化疾病),I/II期临床,2019-11-27,Unknown,多肽;偶联药物,化药,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];受体酪氨酸激酶;Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,BT5528,,肿瘤领域,,DR052083,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2019-11-27,phase 2,I/II期临床,2019-11-27,phase 2,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,non-small cell lung cancer,BT5528,BT5528
BT5528,EphA2,多肽偶联药物,Bicycle Therapeutics(原研),胃癌(差异化疾病),I/II期临床,2019-11-27,Unknown,多肽;偶联药物,化药,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];受体酪氨酸激酶;Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,BT5528,,肿瘤领域,,DR052083,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2019-11-27,phase 2,I/II期临床,2019-11-27,phase 2,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,胃癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,stomach cancer,BT5528,BT5528
BT5528,EphA2,多肽偶联药物,Bicycle Therapeutics(原研),三阴性乳腺癌(差异化疾病),I/II期临床,2019-11-27,Unknown,多肽;偶联药物,化药,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];受体酪氨酸激酶;Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,BT5528,,肿瘤领域,,DR052083,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2019-11-27,phase 2,I/II期临床,2019-11-27,phase 2,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,三阴性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,triple negative breast cancer,BT5528,BT5528
BT5528,EphA2,多肽偶联药物,Bicycle Therapeutics(原研),头颈癌(差异化疾病),I/II期临床,2019-11-27,Unknown,多肽;偶联药物,化药,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];受体酪氨酸激酶;Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,BT5528,,肿瘤领域,,DR052083,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2019-11-27,phase 2,I/II期临床,2019-11-27,phase 2,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,头颈癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Head and neck cancer,BT5528,BT5528
BT5528,EphA2,多肽偶联药物,Bicycle Therapeutics(原研),卵巢癌(差异化疾病),I/II期临床,2019-11-27,Unknown,多肽;偶联药物,化药,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];受体酪氨酸激酶;Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,BT5528,,肿瘤领域;罕见疾病领域,,DR052083,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2019-11-27,phase 2,I/II期临床,2019-11-27,phase 2,1,True,True,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,卵巢癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,ovarian cancer,BT5528,BT5528
BT5528,EphA2,多肽偶联药物,Bicycle Therapeutics(原研),尿路上皮癌(差异化疾病),I/II期临床,2019-11-27,Unknown,多肽;偶联药物,化药,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];受体酪氨酸激酶;Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,BT5528,,肿瘤领域,,DR052083,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2019-11-27,phase 2,I/II期临床,2019-11-27,phase 2,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,尿路上皮癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,urothelial carcinoma,BT5528,BT5528
BT5528,EphA2,多肽偶联药物,Bicycle Therapeutics(原研),消化道癌症,I/II期临床,2019-11-27,Unknown,多肽;偶联药物,化药,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];受体酪氨酸激酶;Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,BT5528,,肿瘤领域,,DR052083,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2019-11-27,phase 2,I/II期临床,2019-11-27,phase 2,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,消化道癌症,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,digestive tract cancer,BT5528,BT5528
IDP-121,c-Myc,c-Myc抑制剂,IDP Pharma(原研),小细胞肺癌(差异化疾病),I/II期临床,2025-12-18,Active,多肽,化药,环肽;差异化疾病;难成药靶点,抑制剂,创新药,IDP-121,,肿瘤领域;罕见疾病领域,,DR053886,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2021-10-19,phase 2,1,True,True,False,[],['IDP Pharma'],1,['IDP Pharma(原研)'],肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,small cell lung cancer,IDP-121,IDP-121
IDP-121,c-Myc,c-Myc抑制剂,IDP Pharma(原研),血液系统肿瘤,I/II期临床,2023-10-26,Active,多肽,化药,环肽;差异化疾病;难成药靶点,抑制剂,创新药,IDP-121,,肿瘤领域;血液领域,,DR053886,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2021-10-19,phase 2,1,True,False,False,[],['IDP Pharma'],1,['IDP Pharma(原研)'],肿瘤领域,血液系统肿瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,,hematological tumors,IDP-121,IDP-121
IDP-121,c-Myc,c-Myc抑制剂,IDP Pharma(原研),慢性淋巴细胞白血病(差异化疾病),I/II期临床,2021-10-19,Active,多肽,化药,环肽;差异化疾病;难成药靶点,抑制剂,创新药,IDP-121,,肿瘤领域;血液领域;罕见疾病领域,,DR053886,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2021-10-19,phase 2,1,True,True,False,[],['IDP Pharma'],1,['IDP Pharma(原研)'],肿瘤领域,慢性淋巴细胞白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,,chronic lymphocytic leukemia,IDP-121,IDP-121
IDP-121,c-Myc,c-Myc抑制剂,IDP Pharma(原研),弥漫性大B细胞淋巴瘤,I/II期临床,2021-10-19,Active,多肽,化药,环肽;差异化疾病;难成药靶点,抑制剂,创新药,IDP-121,,肿瘤领域;血液领域;罕见疾病领域,,DR053886,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2021-10-19,phase 2,1,True,True,False,[],['IDP Pharma'],1,['IDP Pharma(原研)'],肿瘤领域,弥漫性大B细胞淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,,Diffuse large B-cell lymphoma,IDP-121,IDP-121
IDP-121,c-Myc,c-Myc抑制剂,IDP Pharma(原研),多发性骨髓瘤(差异化疾病),I/II期临床,2021-10-19,Active,多肽,化药,环肽;差异化疾病;难成药靶点,抑制剂,创新药,IDP-121,,肿瘤领域;血液领域;罕见疾病领域,,DR053886,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2021-10-19,phase 2,1,True,True,False,[],['IDP Pharma'],1,['IDP Pharma(原研)'],肿瘤领域,多发性骨髓瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,,multiple myeloma,IDP-121,IDP-121
IDP-121,c-Myc,c-Myc抑制剂,IDP Pharma(原研),B细胞淋巴瘤,I/II期临床,2024-12-30,Active,多肽,化药,环肽;差异化疾病;难成药靶点,抑制剂,创新药,IDP-121,,肿瘤领域;血液领域,,DR053886,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2021-10-19,phase 2,1,True,False,False,[],['IDP Pharma'],1,['IDP Pharma(原研)'],肿瘤领域,B细胞淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,,B cell lymphoma,IDP-121,IDP-121
IDP-121,c-Myc,c-Myc抑制剂,IDP Pharma(原研),双重打击淋巴瘤(差异化疾病),I/II期临床,,Active,多肽,化药,环肽;差异化疾病;难成药靶点,抑制剂,创新药,IDP-121,,血液领域;肿瘤领域,,DR053886,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2021-10-19,phase 2,1,True,False,False,[],['IDP Pharma'],1,['IDP Pharma(原研)'],肿瘤领域,双重打击淋巴瘤,"['血液领域', '肿瘤领域']",2,血液领域,肿瘤领域,,2,2,Oncology,Hematology,Oncology,,double hit lymphoma,IDP-121,IDP-121
BT7480,nectin-4;4-1BB,4-1BB激动剂;nectin-4配体,Bicycle Therapeutics(原研),实体瘤,I/II期临床,2021-12-20,Active,多肽,化药,环肽;Potential First-in-Class;肿瘤免疫,激动剂;配体,创新药,BT7480,,肿瘤领域,,DR000382,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2021-12-20,phase 2,I/II期临床,2021-12-20,phase 2,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,solid tumors,BT7480,BT7480
64Cu-FBP8,fibrin,64Cu标记的放射性示踪剂;anti-fibrin多肽偶联核素,Massachusetts General Hospital(原研),PET显像,I/II期临床,2022-04-20,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,创新药,64Cu-FBP8;[64Cu]FBP8,,诊断试剂领域,,DR054395,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2022-04-20,phase 2,I/II期临床,2022-04-20,phase 2,1,True,False,False,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,64Cu-FBP8,64Cu-FBP8;[64Cu]FBP8
64Cu-FBP8,fibrin,64Cu标记的放射性示踪剂;anti-fibrin多肽偶联核素,Massachusetts General Hospital(原研),阿尔茨海默病性痴呆,I/II期临床,2022-04-20,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,创新药,64Cu-FBP8;[64Cu]FBP8,,神经领域,,DR054395,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2022-04-20,phase 2,I/II期临床,2022-04-20,phase 2,1,True,False,False,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],神经领域,阿尔茨海默病性痴呆,['神经领域'],1,神经领域,,,2,2,Neurology,Neurology,,,Alzheimer's disease dementia,64Cu-FBP8,64Cu-FBP8;[64Cu]FBP8
64Cu-FBP8,fibrin,64Cu标记的放射性示踪剂;anti-fibrin多肽偶联核素,Massachusetts General Hospital(原研),血栓(抗凝或抗血小板),I期临床,2019-02-05,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,创新药,64Cu-FBP8;[64Cu]FBP8,,心脑血管领域,,DR054395,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2019-02-05,phase 1,I/II期临床,2022-04-20,phase 2,1,True,False,False,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],心脑血管领域,血栓(抗凝或抗血小板),['心脑血管领域'],1,心脑血管领域,,,2,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Thrombosis (anticoagulant or antiplatelet),64Cu-FBP8,64Cu-FBP8;[64Cu]FBP8
177Lu-LNC1010,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,蓝纳成生物(原研),肿瘤,I/II期临床,2022-06-08,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,177Lu-LNC1010;177Lu-EB-TATE-01,,肿瘤领域,I期临床:注射剂,DR015637,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I/II期临床,,2022-06-08,,phase 2,I/II期临床,2022-06-08,phase 2,1,True,False,False,[],['蓝纳成生物'],1,['蓝纳成生物(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,tumor,177Lu-LNC1010,177Lu-LNC1010;177Lu-EB-TATE-01
177Lu-LNC1010,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,蓝纳成生物(原研),实体瘤,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,177Lu-LNC1010;177Lu-EB-TATE-01,,肿瘤领域,I期临床:注射剂,DR015637,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I/II期临床,2022-06-08,phase 2,1,True,False,False,[],['蓝纳成生物'],1,['蓝纳成生物(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,solid tumors,177Lu-LNC1010,177Lu-LNC1010;177Lu-EB-TATE-01
177Lu-LNC1010,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,蓝纳成生物(原研),胃肠胰神经内分泌肿瘤(差异化疾病),I期临床,2024-08-28,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,177Lu-LNC1010;177Lu-EB-TATE-01,,肿瘤领域;罕见疾病领域,I期临床:注射剂,DR015637,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-08-28,,phase 1,I/II期临床,2022-06-08,phase 2,1,True,True,False,[],['蓝纳成生物'],1,['蓝纳成生物(原研)'],肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,177Lu-LNC1010,177Lu-LNC1010;177Lu-EB-TATE-01
68Ga-FAPI-RGD,αvβ3;FAP,anti-αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,--,癌症,I/II期临床,2022-08-25,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-FAPI-RGD;68Ga-FAP-RGD,,肿瘤领域,,DR036681,否,,,I/II期临床,,2022-08-25,,phase 2,I/II期临床,2022-08-25,phase 2,0,True,False,False,[],[],0,[],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,cancer,68Ga-FAPI-RGD,68Ga-FAPI-RGD;68Ga-FAP-RGD
68Ga-FAPI-RGD,αvβ3;FAP,anti-αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,--,PET显像,I/II期临床,2022-08-25,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-FAPI-RGD;68Ga-FAP-RGD,,诊断试剂领域,,DR036681,否,,,I/II期临床,,2022-08-25,,phase 2,I/II期临床,2022-08-25,phase 2,0,True,False,False,[],[],0,[],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-FAPI-RGD,68Ga-FAPI-RGD;68Ga-FAP-RGD
68Ga-FAPI-RGD,αvβ3;FAP,anti-αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,--,肿瘤,I期临床,2024-10-15,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-FAPI-RGD;68Ga-FAP-RGD,,肿瘤领域,,DR036681,否,,,I期临床,,2024-10-15,,phase 1,I/II期临床,2022-08-25,phase 2,0,True,False,False,[],[],0,[],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,tumor,68Ga-FAPI-RGD,68Ga-FAPI-RGD;68Ga-FAP-RGD
68Ga-FAPI-RGD,αvβ3;FAP,anti-αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,--,肺癌,I期临床,2022-09-16,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-FAPI-RGD;68Ga-FAP-RGD,,肿瘤领域,,DR036681,否,,,I期临床,,2022-09-16,,phase 1,I/II期临床,2022-08-25,phase 2,0,True,False,False,[],[],0,[],肿瘤领域,肺癌,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,lung cancer,68Ga-FAPI-RGD,68Ga-FAPI-RGD;68Ga-FAP-RGD
90Y-pentixather,CXCR4,90Y标记的放射性药物,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,多发性骨髓瘤,I/II期临床,2023-01-26,Active,小分子;放射性药物,化药,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,创新药,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,,肿瘤领域;血液领域;罕见疾病领域,,DR024649,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2023-01-26,phase 2,3,True,True,False,[],['PentixaPharm'],1,"['Eckert & Ziegler', 'PentixaPharm(原研)', 'Technische Universität München']",肿瘤领域,多发性骨髓瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,,multiple myeloma,90Y-pentixather,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101
90Y-pentixather,CXCR4,90Y标记的放射性药物,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,原发性中枢神经系统淋巴瘤,I/II期临床,2023-11-15,Active,小分子;放射性药物,化药,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,创新药,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,,肿瘤领域;血液领域,,DR024649,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2023-01-26,phase 2,3,True,False,False,[],['PentixaPharm'],1,"['Eckert & Ziegler', 'PentixaPharm(原研)', 'Technische Universität München']",肿瘤领域,原发性中枢神经系统淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,,primary central nervous system lymphoma,90Y-pentixather,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101
90Y-pentixather,CXCR4,90Y标记的放射性药物,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,继发性中枢神经系统淋巴瘤,I/II期临床,2023-11-15,Active,小分子;放射性药物,化药,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,创新药,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,,肿瘤领域;血液领域;罕见疾病领域,,DR024649,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2023-01-26,phase 2,3,True,True,False,[],['PentixaPharm'],1,"['Eckert & Ziegler', 'PentixaPharm(原研)', 'Technische Universität München']",肿瘤领域,继发性中枢神经系统淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,,secondary central nervous system lymphoma,90Y-pentixather,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101
90Y-pentixather,CXCR4,90Y标记的放射性药物,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,T细胞非霍奇金淋巴瘤,I/II期临床,2023-01-26,Active,小分子;放射性药物,化药,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,创新药,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,,肿瘤领域;血液领域,,DR024649,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2023-01-26,phase 2,3,True,False,False,[],['PentixaPharm'],1,"['Eckert & Ziegler', 'PentixaPharm(原研)', 'Technische Universität München']",肿瘤领域,T细胞非霍奇金淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,,T-cell non-Hodgkin lymphoma,90Y-pentixather,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101
177Lu-DPI-4452,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),非小细胞肺癌(差异化疾病),I/II期临床,2024-03-25,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,,肿瘤领域,,DR056890,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,non-small cell lung cancer,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91
177Lu-DPI-4452,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),三阴性乳腺癌(差异化疾病),I/II期临床,2024-03-25,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,,肿瘤领域,,DR056890,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,三阴性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,triple negative breast cancer,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91
177Lu-DPI-4452,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),头颈癌(差异化疾病),I/II期临床,2024-03-25,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,,肿瘤领域,,DR056890,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,头颈癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Head and neck cancer,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91
177Lu-DPI-4452,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),尿路上皮癌(差异化疾病),I/II期临床,2024-03-25,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,,肿瘤领域,,DR056890,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,尿路上皮癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,urothelial carcinoma,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91
177Lu-DPI-4452,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),肾病(差异化疾病),I/II期临床,2024-03-25,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,,泌尿生殖领域,,DR056890,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",泌尿生殖领域,肾病,['泌尿生殖领域'],1,泌尿生殖领域,,,2,2,Genitourinary,Genitourinary,,,kidney disease,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91
177Lu-DPI-4452,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),结直肠癌(差异化疾病),I/II期临床,2023-01-31,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,,肿瘤领域,,DR056890,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,结直肠癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,colorectal cancer,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91
177Lu-DPI-4452,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),胰腺导管癌(差异化疾病),I/II期临床,2023-01-31,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,,肿瘤领域,,DR056890,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,pancreatic ductal carcinoma,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91
177Lu-DPI-4452,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),肾透明细胞癌,I/II期临床,2023-01-31,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,,肿瘤领域,,DR056890,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,肾透明细胞癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,clear cell renal cell carcinoma,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91
68Ga-DPI-4452,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),非小细胞肺癌(差异化疾病),I/II期临床,2024-03-25,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,,肿瘤领域,,DR014717,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,non-small cell lung cancer,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94
68Ga-DPI-4452,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),三阴性乳腺癌(差异化疾病),I/II期临床,2024-03-25,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,,肿瘤领域,,DR014717,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,三阴性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,triple negative breast cancer,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94
68Ga-DPI-4452,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),头颈癌(差异化疾病),I/II期临床,2024-03-25,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,,肿瘤领域,,DR014717,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,头颈癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Head and neck cancer,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94
68Ga-DPI-4452,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),尿路上皮癌(差异化疾病),I/II期临床,2024-03-25,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,,肿瘤领域,,DR014717,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,尿路上皮癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,urothelial carcinoma,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94
68Ga-DPI-4452,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),肾病(差异化疾病),I/II期临床,2024-03-25,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,,泌尿生殖领域,,DR014717,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",泌尿生殖领域,肾病,['泌尿生殖领域'],1,泌尿生殖领域,,,2,2,Genitourinary,Genitourinary,,,kidney disease,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94
68Ga-DPI-4452,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),PET显像,I/II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,,诊断试剂领域,,DR014717,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94
68Ga-DPI-4452,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),结直肠癌(差异化疾病),I/II期临床,2023-01-31,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,,肿瘤领域,,DR014717,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,结直肠癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,colorectal cancer,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94
68Ga-DPI-4452,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),胰腺导管癌(差异化疾病),I/II期临床,2023-01-31,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,,肿瘤领域,,DR014717,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,pancreatic ductal carcinoma,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94
68Ga-DPI-4452,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),肾透明细胞癌,I/II期临床,2023-01-31,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,,肿瘤领域,,DR014717,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-03-25,phase 2,I/II期临床,2023-01-31,phase 2,3,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,肾透明细胞癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,clear cell renal cell carcinoma,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94
FOG-001,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,Parabilis Medicines(原研),实体瘤,I/II期临床,2023-06-26,Active,多肽,化药,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,创新药,FOG-001,,肿瘤领域,,DR033337,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2023-06-26,phase 2,I/II期临床,2023-06-26,phase 2,1,True,False,False,[],['Parabilis Medicines'],1,['Parabilis Medicines(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,solid tumors,FOG-001,FOG-001
FOG-001,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,Parabilis Medicines(原研),非小细胞肺癌,I/II期临床,,Active,多肽,化药,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,创新药,FOG-001,,肿瘤领域,,DR033337,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2023-06-26,phase 2,1,True,False,False,[],['Parabilis Medicines'],1,['Parabilis Medicines(原研)'],肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,non-small cell lung cancer,FOG-001,FOG-001
FOG-001,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,Parabilis Medicines(原研),胃癌,I/II期临床,,Active,多肽,化药,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,创新药,FOG-001,,肿瘤领域,,DR033337,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2023-06-26,phase 2,1,True,False,False,[],['Parabilis Medicines'],1,['Parabilis Medicines(原研)'],肿瘤领域,胃癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,stomach cancer,FOG-001,FOG-001
FOG-001,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,Parabilis Medicines(原研),结直肠癌,I/II期临床,,Active,多肽,化药,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,创新药,FOG-001,,肿瘤领域,,DR033337,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2023-06-26,phase 2,1,True,False,False,[],['Parabilis Medicines'],1,['Parabilis Medicines(原研)'],肿瘤领域,结直肠癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,colorectal cancer,FOG-001,FOG-001
FOG-001,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,Parabilis Medicines(原研),胃食管交界处癌,I/II期临床,,Active,多肽,化药,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,创新药,FOG-001,,肿瘤领域,,DR033337,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2023-06-26,phase 2,1,True,False,False,[],['Parabilis Medicines'],1,['Parabilis Medicines(原研)'],肿瘤领域,胃食管交界处癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,gastroesophageal junction cancer,FOG-001,FOG-001
FOG-001,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,Parabilis Medicines(原研),硬纤维瘤,I/II期临床,,Active,多肽,化药,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,创新药,FOG-001,,肿瘤领域;罕见疾病领域,,DR033337,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2023-06-26,phase 2,1,True,True,False,[],['Parabilis Medicines'],1,['Parabilis Medicines(原研)'],肿瘤领域,硬纤维瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,desmoid tumor,FOG-001,FOG-001
177Lu-pentixather,CXCR4,177Lu标记的放射性药物,Scintomics(原研),急性淋巴细胞白血病(差异化疾病),I/II期临床,2024-11-21,Active,小分子;放射性药物,化药,环肽;差异化疾病;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,177Lu标记的放射性药物,创新药,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather,,肿瘤领域;血液领域;罕见疾病领域,,DR007291,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2024-04-10,phase 2,1,True,True,False,[],['Scintomics'],1,['Scintomics(原研)'],肿瘤领域,急性淋巴细胞白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,,acute lymphoblastic leukemia,177Lu-pentixather,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather
177Lu-pentixather,CXCR4,177Lu标记的放射性药物,Scintomics(原研),急性髓系白血病(差异化疾病),I/II期临床,2024-11-21,Active,小分子;放射性药物,化药,环肽;差异化疾病;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,177Lu标记的放射性药物,创新药,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather,,肿瘤领域;血液领域;罕见疾病领域,,DR007291,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2024-04-10,phase 2,1,True,True,False,[],['Scintomics'],1,['Scintomics(原研)'],肿瘤领域,急性髓系白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,,acute myeloid leukemia,177Lu-pentixather,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather
177Lu-pentixather,CXCR4,177Lu标记的放射性药物,Scintomics(原研),急性白血病,I/II期临床,2024-04-10,Active,小分子;放射性药物,化药,环肽;差异化疾病;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,177Lu标记的放射性药物,创新药,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather,,肿瘤领域;血液领域,,DR007291,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2024-04-10,phase 2,1,True,False,False,[],['Scintomics'],1,['Scintomics(原研)'],肿瘤领域,急性白血病,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,,acute leukemia,177Lu-pentixather,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather
177Lu-pentixather,CXCR4,177Lu标记的放射性药物,Scintomics(原研),多发性骨髓瘤(差异化疾病),I期临床,,Active,小分子;放射性药物,化药,环肽;差异化疾病;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,177Lu标记的放射性药物,创新药,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather,,肿瘤领域;血液领域;罕见疾病领域,,DR007291,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I/II期临床,2024-04-10,phase 2,1,True,True,False,[],['Scintomics'],1,['Scintomics(原研)'],肿瘤领域,多发性骨髓瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,1,Oncology,Oncology,Hematology,,multiple myeloma,177Lu-pentixather,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather
61Cu-NODAGA-LM3,SSTR2,61Cu标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital of Basel(原研),PET显像,I/II期临床,2024-06-12,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,61Cu标记的PET药物;多肽偶联核素,创新药,61Cu-NODAGA-LM3,,诊断试剂领域,,DR067671,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2024-06-12,phase 2,1,True,False,False,[],['University Hospital of Basel'],1,['University Hospital of Basel(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,61Cu-NODAGA-LM3,61Cu-NODAGA-LM3
61Cu-NODAGA-LM3,SSTR2,61Cu标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital of Basel(原研),胃肠胰神经内分泌肿瘤,I/II期临床,2024-06-12,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,61Cu标记的PET药物;多肽偶联核素,创新药,61Cu-NODAGA-LM3,,肿瘤领域;罕见疾病领域,,DR067671,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2024-06-12,phase 2,1,True,True,False,[],['University Hospital of Basel'],1,['University Hospital of Basel(原研)'],肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,61Cu-NODAGA-LM3,61Cu-NODAGA-LM3
[18F]-FET-βAG-TOCA,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Imperial College London(原研),PET显像,I/II期临床,2024-06-13,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,创新药,[18F]-FET-βAG-TOCA,,诊断试剂领域,,DR067736,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2024-06-13,phase 2,1,True,False,False,[],['Imperial College London'],1,['Imperial College London(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[18F]-FET-βAG-TOCA,[18F]-FET-βAG-TOCA
[18F]-FET-βAG-TOCA,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Imperial College London(原研),神经内分泌肿瘤,I/II期临床,2024-06-13,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,创新药,[18F]-FET-βAG-TOCA,,肿瘤领域;罕见疾病领域,,DR067736,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2024-06-13,phase 2,1,True,True,False,[],['Imperial College London'],1,['Imperial College London(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,neuroendocrine tumors,[18F]-FET-βAG-TOCA,[18F]-FET-βAG-TOCA
[18F]AlF-NOTA-PCP2,PDL1,18F标记的PET药物,山东省肿瘤医院(原研),肿瘤,I/II期临床,,Active,放射性药物;其他,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,创新药,[18F]AlF-NOTA-PCP2,,肿瘤领域,,DR071215,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2024-11-15,phase 2,1,True,False,False,[],['山东省肿瘤医院'],1,['山东省肿瘤医院(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,tumor,[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2
[18F]AlF-NOTA-PCP2,PDL1,18F标记的PET药物,山东省肿瘤医院(原研),非小细胞肺癌(差异化疾病),I/II期临床,2024-11-15,Active,放射性药物;其他,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,创新药,[18F]AlF-NOTA-PCP2,,肿瘤领域,,DR071215,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I/II期临床,,2024-11-15,,phase 2,I/II期临床,2024-11-15,phase 2,1,True,False,False,[],['山东省肿瘤医院'],1,['山东省肿瘤医院(原研)'],肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,non-small cell lung cancer,[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2
[18F]AlF-NOTA-PCP2,PDL1,18F标记的PET药物,山东省肿瘤医院(原研),食管癌(差异化疾病),I/II期临床,2024-11-15,Active,放射性药物;其他,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,创新药,[18F]AlF-NOTA-PCP2,,肿瘤领域,,DR071215,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I/II期临床,,2024-11-15,,phase 2,I/II期临床,2024-11-15,phase 2,1,True,False,False,[],['山东省肿瘤医院'],1,['山东省肿瘤医院(原研)'],肿瘤领域,食管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Esophageal cancer,[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2
[18F]AlF-NOTA-PCP2,PDL1,18F标记的PET药物,山东省肿瘤医院(原研),胶质母细胞瘤(差异化疾病),I/II期临床,2024-11-15,Active,放射性药物;其他,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,创新药,[18F]AlF-NOTA-PCP2,,肿瘤领域;罕见疾病领域,,DR071215,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I/II期临床,,2024-11-15,,phase 2,I/II期临床,2024-11-15,phase 2,1,True,True,False,[],['山东省肿瘤医院'],1,['山东省肿瘤医院(原研)'],肿瘤领域,胶质母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,glioblastoma,[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2
[18F]AlF-NOTA-PCP2,PDL1,18F标记的PET药物,山东省肿瘤医院(原研),PET显像,I/II期临床,2024-11-15,Active,放射性药物;其他,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,创新药,[18F]AlF-NOTA-PCP2,,诊断试剂领域,,DR071215,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I/II期临床,,2024-11-15,,phase 2,I/II期临床,2024-11-15,phase 2,1,True,False,False,[],['山东省肿瘤医院'],1,['山东省肿瘤医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2
[18F]AlF-NOTA-PCP2,PDL1,18F标记的PET药物,山东省肿瘤医院(原研),头颈部鳞状细胞癌(差异化疾病),I/II期临床,2024-11-15,Active,放射性药物;其他,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,创新药,[18F]AlF-NOTA-PCP2,,肿瘤领域,,DR071215,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I/II期临床,,2024-11-15,,phase 2,I/II期临床,2024-11-15,phase 2,1,True,False,False,[],['山东省肿瘤医院'],1,['山东省肿瘤医院(原研)'],肿瘤领域,头颈部鳞状细胞癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Head and neck squamous cell carcinoma,[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2
[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),实体瘤,I/II期临床,2024-11-29,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,创新药,[203Pb]Pb-PSV359,,肿瘤领域,,DR071474,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-29,phase 2,I/II期临床,2024-11-29,phase 2,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,solid tumors,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359
[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),胃癌,I/II期临床,2024-11-29,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,创新药,[203Pb]Pb-PSV359,,肿瘤领域,,DR071474,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-29,phase 2,I/II期临床,2024-11-29,phase 2,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,胃癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,stomach cancer,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359
[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),食管癌,I/II期临床,2024-11-29,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,创新药,[203Pb]Pb-PSV359,,肿瘤领域,,DR071474,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-29,phase 2,I/II期临床,2024-11-29,phase 2,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,食管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Esophageal cancer,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359
[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),头颈癌,I/II期临床,2024-11-29,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,创新药,[203Pb]Pb-PSV359,,肿瘤领域,,DR071474,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-29,phase 2,I/II期临床,2024-11-29,phase 2,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,头颈癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Head and neck cancer,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359
[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),卵巢癌,I/II期临床,2024-11-29,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,创新药,[203Pb]Pb-PSV359,,肿瘤领域;罕见疾病领域,,DR071474,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-29,phase 2,I/II期临床,2024-11-29,phase 2,1,True,True,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,卵巢癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,ovarian cancer,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359
[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),SPECT显像,I/II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,创新药,[203Pb]Pb-PSV359,,诊断试剂领域,,DR071474,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,2024-11-29,phase 2,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],诊断试剂领域,SPECT显像,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,SPECT imaging,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359
[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),结直肠癌,I/II期临床,2024-11-29,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,创新药,[203Pb]Pb-PSV359,,肿瘤领域,,DR071474,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-29,phase 2,I/II期临床,2024-11-29,phase 2,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,结直肠癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,colorectal cancer,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359
[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),胰腺导管癌,I/II期临床,2024-11-29,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,创新药,[203Pb]Pb-PSV359,,肿瘤领域,,DR071474,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-29,phase 2,I/II期临床,2024-11-29,phase 2,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,pancreatic ductal carcinoma,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359
[212Pb]Pb-PSV359,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),实体瘤,I/II期临床,2024-11-29,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,创新药,[212Pb]Pb-PSV359,,肿瘤领域,,DR071475,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-29,phase 2,I/II期临床,2024-11-29,phase 2,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,solid tumors,[212Pb]Pb-PSV359,[212Pb]Pb-PSV359
[212Pb]Pb-PSV359,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),胃癌,I/II期临床,2024-11-29,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,创新药,[212Pb]Pb-PSV359,,肿瘤领域,,DR071475,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-29,phase 2,I/II期临床,2024-11-29,phase 2,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,胃癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,stomach cancer,[212Pb]Pb-PSV359,[212Pb]Pb-PSV359
[212Pb]Pb-PSV359,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),食管癌,I/II期临床,2024-11-29,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,创新药,[212Pb]Pb-PSV359,,肿瘤领域,,DR071475,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-29,phase 2,I/II期临床,2024-11-29,phase 2,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,食管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Esophageal cancer,[212Pb]Pb-PSV359,[212Pb]Pb-PSV359
[212Pb]Pb-PSV359,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),头颈癌,I/II期临床,2024-11-29,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,创新药,[212Pb]Pb-PSV359,,肿瘤领域,,DR071475,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-29,phase 2,I/II期临床,2024-11-29,phase 2,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,头颈癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Head and neck cancer,[212Pb]Pb-PSV359,[212Pb]Pb-PSV359
[212Pb]Pb-PSV359,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),卵巢癌,I/II期临床,2024-11-29,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,创新药,[212Pb]Pb-PSV359,,肿瘤领域;罕见疾病领域,,DR071475,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-29,phase 2,I/II期临床,2024-11-29,phase 2,1,True,True,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,卵巢癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,ovarian cancer,[212Pb]Pb-PSV359,[212Pb]Pb-PSV359
[212Pb]Pb-PSV359,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),结直肠癌,I/II期临床,2024-11-29,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,创新药,[212Pb]Pb-PSV359,,肿瘤领域,,DR071475,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-29,phase 2,I/II期临床,2024-11-29,phase 2,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,结直肠癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,colorectal cancer,[212Pb]Pb-PSV359,[212Pb]Pb-PSV359
[212Pb]Pb-PSV359,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),胰腺导管癌,I/II期临床,2024-11-29,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,创新药,[212Pb]Pb-PSV359,,肿瘤领域,,DR071475,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2024-11-29,phase 2,I/II期临床,2024-11-29,phase 2,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,pancreatic ductal carcinoma,[212Pb]Pb-PSV359,[212Pb]Pb-PSV359
225Ac-SSO110,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,Ariceum Therapeutics(原研),小细胞肺癌,I/II期临床,2025-04-22,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,创新药,225Ac-SSO110;225Ac-satoreotide,,肿瘤领域;罕见疾病领域,,DR068742,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2025-04-22,phase 2,I/II期临床,2025-04-22,phase 2,1,True,True,False,[],['Ariceum Therapeutics'],1,['Ariceum Therapeutics(原研)'],肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,small cell lung cancer,225Ac-SSO110,225Ac-SSO110;225Ac-satoreotide
225Ac-SSO110,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,Ariceum Therapeutics(原研),Merkel细胞瘤(差异化疾病),I/II期临床,2025-04-22,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,创新药,225Ac-SSO110;225Ac-satoreotide,,肿瘤领域;罕见疾病领域,,DR068742,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2025-04-22,phase 2,I/II期临床,2025-04-22,phase 2,1,True,True,False,[],['Ariceum Therapeutics'],1,['Ariceum Therapeutics(原研)'],肿瘤领域,Merkel细胞瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Merkel cell tumor,225Ac-SSO110,225Ac-SSO110;225Ac-satoreotide
225Ac-SSO110,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,Ariceum Therapeutics(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,创新药,225Ac-SSO110;225Ac-satoreotide,,肿瘤领域,,DR068742,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,I/II期临床,2025-04-22,phase 2,1,True,False,False,[],['Ariceum Therapeutics'],1,['Ariceum Therapeutics(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,-1,Oncology,Oncology,,,tumor,225Ac-SSO110,225Ac-SSO110;225Ac-satoreotide
177Lu-DOTA-EB-TATE,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,National Institutes of Health(原研);Molecular Targeting Technologies,许特尔细胞瘤(差异化疾病),I/II期临床,2025-05-28,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,,肿瘤领域,,DR062226,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I/II期临床,,2025-05-28,phase 2,I/II期临床,2025-05-28,phase 2,2,True,False,False,[],['National Institutes of Health'],1,"['National Institutes of Health(原研)', 'Molecular Targeting Technologies']",肿瘤领域,许特尔细胞瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Hütter cell tumor,177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE
177Lu-DOTA-EB-TATE,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,National Institutes of Health(原研);Molecular Targeting Technologies,神经内分泌肿瘤,I期临床,2017-10-12,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,,肿瘤领域;罕见疾病领域,,DR062226,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2017-10-12,,phase 1,I/II期临床,2025-05-28,phase 2,2,True,True,False,[],['National Institutes of Health'],1,"['National Institutes of Health(原研)', 'Molecular Targeting Technologies']",肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,neuroendocrine tumors,177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE
177Lu-DOTA-EB-TATE,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,National Institutes of Health(原研);Molecular Targeting Technologies,胃肠胰神经内分泌肿瘤,I期临床,2022-07-26,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,,肿瘤领域;罕见疾病领域,,DR062226,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2022-07-26,phase 1,I/II期临床,2025-05-28,phase 2,2,True,True,False,[],['National Institutes of Health'],1,"['National Institutes of Health(原研)', 'Molecular Targeting Technologies']",肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE
177Lu-DOTA-EB-TATE,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,National Institutes of Health(原研);Molecular Targeting Technologies,鼻咽癌,申报临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,,肿瘤领域;罕见疾病领域,,DR062226,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,ind,I/II期临床,2025-05-28,phase 2,2,True,True,False,[],['National Institutes of Health'],1,"['National Institutes of Health(原研)', 'Molecular Targeting Technologies']",肿瘤领域,鼻咽癌,['肿瘤领域'],1,肿瘤领域,,,2,0,Oncology,Oncology,,,Nasopharyngeal cancer,177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE
177Lu-DOTA-EB-TATE,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,National Institutes of Health(原研);Molecular Targeting Technologies,甲状腺癌,申报临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,,肿瘤领域,,DR062226,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,ind,I/II期临床,2025-05-28,phase 2,2,True,False,False,[],['National Institutes of Health'],1,"['National Institutes of Health(原研)', 'Molecular Targeting Technologies']",肿瘤领域,甲状腺癌,['肿瘤领域'],1,肿瘤领域,,,2,0,Oncology,Oncology,,,Thyroid cancer,177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE
镓[68Ga]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC)(原研),小细胞肺癌,I/II期临床,2025-06-03,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]氧奥曲肽;gallium [68Ga] oxodotreotide,,肿瘤领域;罕见疾病领域,申报临床:诊断试剂,DR072714,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I/II期临床,I/II期临床,2025-06-03,2025-06-03,phase 2,I/II期临床,2025-06-03,phase 2,1,True,True,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,small cell lung cancer,gallium [68Ga] oxodotreotide,镓[68Ga]氧奥曲肽;gallium [68Ga] oxodotreotide
镓[68Ga]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC)(原研),未知/待定,申报临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]氧奥曲肽;gallium [68Ga] oxodotreotide,,其他领域,申报临床:诊断试剂,DR072714,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,ind,I/II期临床,2025-06-03,phase 2,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,2,0,Others,Others,,,unknown/pending,gallium [68Ga] oxodotreotide,镓[68Ga]氧奥曲肽;gallium [68Ga] oxodotreotide
镓[68Ga]氧奥曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC)(原研),PET显像,申报临床,2025-01-01,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,创新药,镓[68Ga]氧奥曲肽;gallium [68Ga] oxodotreotide,,诊断试剂领域,申报临床:诊断试剂,DR072714,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,申报临床,,2025-01-01,,ind,I/II期临床,2025-06-03,phase 2,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,2,0,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,gallium [68Ga] oxodotreotide,镓[68Ga]氧奥曲肽;gallium [68Ga] oxodotreotide
64Cu-NODAGA-LM3,SSTR2,64Cu标记的放射性示踪剂;anti-SSTR2多肽偶联核素,University Hospital of Basel(原研),PET显像(差异化疾病),I/II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,64Cu-NODAGA-LM3;(64)Cu-NODAGA-LM3,,诊断试剂领域,,DR057503,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,,phase 2,1,True,False,False,[],['University Hospital of Basel'],1,['University Hospital of Basel(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,64Cu-NODAGA-LM3,64Cu-NODAGA-LM3;(64)Cu-NODAGA-LM3
64Cu-NODAGA-LM3,SSTR2,64Cu标记的放射性示踪剂;anti-SSTR2多肽偶联核素,University Hospital of Basel(原研),胃肠胰神经内分泌肿瘤(差异化疾病),I/II期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,64Cu-NODAGA-LM3;(64)Cu-NODAGA-LM3,,肿瘤领域;罕见疾病领域,,DR057503,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 2,I/II期临床,,phase 2,1,True,True,False,[],['University Hospital of Basel'],1,['University Hospital of Basel(原研)'],肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,64Cu-NODAGA-LM3,64Cu-NODAGA-LM3;(64)Cu-NODAGA-LM3
NeuroSTAT,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Abliva(Pharming)(原研);Owl Therapeutics,外伤性脑损伤,I/II期临床,,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,微创新,NeuroSTAT;NeuroSTAT (环孢素);NeuroSTAT (cyclosporine);OWL-1410,,神经领域,,DR062199,否,欧洲,中国(内地);中国(港澳台);其他,,,,,phase 2,I/II期临床,,phase 2,2,True,False,False,[],['Abliva(Pharming)'],1,"['Abliva(Pharming)(原研)', 'Owl Therapeutics']",神经领域,外伤性脑损伤,['神经领域'],1,神经领域,,,2,2,Neurology,Neurology,,,traumatic brain injury,NeuroSTAT (cyclosporine),NeuroSTAT;NeuroSTAT (环孢素);NeuroSTAT (cyclosporine);OWL-1410
68Ga-DOTA-JR11,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital Freiburg(原研),PET显像,I期临床,2020-12-30,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-JR11,,诊断试剂领域,,DR018989,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2020-12-30,,phase 1,I期临床,2015-11-20,phase 1,1,True,False,False,[],['University Hospital Freiburg'],1,['University Hospital Freiburg(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-DOTA-JR11,68Ga-DOTA-JR11
68Ga-DOTA-JR11,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital Freiburg(原研),神经内分泌肿瘤,I期临床,2015-11-20,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-JR11,,肿瘤领域;罕见疾病领域,,DR018989,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,I期临床,2024-11-08,2015-11-20,phase 1,I期临床,2015-11-20,phase 1,1,True,True,False,[],['University Hospital Freiburg'],1,['University Hospital Freiburg(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,neuroendocrine tumors,68Ga-DOTA-JR11,68Ga-DOTA-JR11
68Ga-DOTA-JR11,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital Freiburg(原研),肿瘤性骨软化症(差异化疾病),I期临床,2020-12-30,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-JR11,,骨骼肌肉领域;肿瘤领域;罕见疾病领域,,DR018989,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2020-12-30,,phase 1,I期临床,2015-11-20,phase 1,1,True,True,False,[],['University Hospital Freiburg'],1,['University Hospital Freiburg(原研)'],肿瘤领域,肿瘤性骨软化症,"['骨骼肌肉领域', '肿瘤领域']",2,骨骼肌肉领域,肿瘤领域,,1,1,Oncology,Musculoskeletal,Oncology,,neoplastic osteomalacia,68Ga-DOTA-JR11,68Ga-DOTA-JR11
[18F]FP-R01-MG-F2,αvβ6,anti-αvβ6多肽偶联核素;18F标记的PET药物,Stanford University(原研),胰腺癌,I期临床,2016-02-17,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,创新药,[18F]FP-R01-MG-F2,,肿瘤领域;罕见疾病领域,,DR062395,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2016-02-17,phase 1,I期临床,2016-02-17,phase 1,1,True,True,False,[],['Stanford University'],1,['Stanford University(原研)'],肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,pancreatic cancer,[18F]FP-R01-MG-F2,[18F]FP-R01-MG-F2
[18F]FP-R01-MG-F2,αvβ6,anti-αvβ6多肽偶联核素;18F标记的PET药物,Stanford University(原研),PET显像,I期临床,2016-02-17,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,创新药,[18F]FP-R01-MG-F2,,诊断试剂领域,,DR062395,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2016-02-17,phase 1,I期临床,2016-02-17,phase 1,1,True,False,False,[],['Stanford University'],1,['Stanford University(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[18F]FP-R01-MG-F2,[18F]FP-R01-MG-F2
68Ga-NOTA-3PTATE-RGD,αvβ3;SSTR2,anti-αvβ3×SSTR2多肽偶联核素;68Ga标记的PET药物,天津医科大学(原研),肺癌,I期临床,2016-06-29,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NOTA-3PTATE-RGD,,肿瘤领域,,DR002634,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2016-06-29,,phase 1,I期临床,2016-06-29,phase 1,1,True,False,False,[],['天津医科大学'],1,['天津医科大学(原研)'],肿瘤领域,肺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,lung cancer,68Ga-NOTA-3PTATE-RGD,68Ga-NOTA-3PTATE-RGD
68Ga-NOTA-3PTATE-RGD,αvβ3;SSTR2,anti-αvβ3×SSTR2多肽偶联核素;68Ga标记的PET药物,天津医科大学(原研),甲状腺癌,I期临床,2024-10-09,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NOTA-3PTATE-RGD,,肿瘤领域,,DR002634,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-10-09,,phase 1,I期临床,2016-06-29,phase 1,1,True,False,False,[],['天津医科大学'],1,['天津医科大学(原研)'],肿瘤领域,甲状腺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,Thyroid cancer,68Ga-NOTA-3PTATE-RGD,68Ga-NOTA-3PTATE-RGD
68Ga-NOTA-3PTATE-RGD,αvβ3;SSTR2,anti-αvβ3×SSTR2多肽偶联核素;68Ga标记的PET药物,天津医科大学(原研),PET显像,I期临床,2016-06-29,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NOTA-3PTATE-RGD,,诊断试剂领域,,DR002634,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2016-06-29,,phase 1,I期临床,2016-06-29,phase 1,1,True,False,False,[],['天津医科大学'],1,['天津医科大学(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-NOTA-3PTATE-RGD,68Ga-NOTA-3PTATE-RGD
68Ga-NOTA-3PTATE-RGD,αvβ3;SSTR2,anti-αvβ3×SSTR2多肽偶联核素;68Ga标记的PET药物,天津医科大学(原研),神经内分泌肿瘤,I期临床,2016-06-29,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NOTA-3PTATE-RGD,,肿瘤领域;罕见疾病领域,,DR002634,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2016-06-29,,phase 1,I期临床,2016-06-29,phase 1,1,True,True,False,[],['天津医科大学'],1,['天津医科大学(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,neuroendocrine tumors,68Ga-NOTA-3PTATE-RGD,68Ga-NOTA-3PTATE-RGD
68Ga-NOTA-3PTATE-RGD,αvβ3;SSTR2,anti-αvβ3×SSTR2多肽偶联核素;68Ga标记的PET药物,天津医科大学(原研),脑膜瘤,I期临床,2024-10-09,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NOTA-3PTATE-RGD,,肿瘤领域,,DR002634,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-10-09,,phase 1,I期临床,2016-06-29,phase 1,1,True,False,False,[],['天津医科大学'],1,['天津医科大学(原研)'],肿瘤领域,脑膜瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,Meningioma,68Ga-NOTA-3PTATE-RGD,68Ga-NOTA-3PTATE-RGD
68Ga-DOTA-Siglec-9,VAP-1,anti-VAP-1多肽偶联核素;68Ga标记的PET药物,University of Turku(原研),血管炎,I期临床,2018-11-27,Inactive,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-Siglec-9,,心脑血管领域,,DR057506,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2018-11-27,phase 1,1,True,False,False,[],['University of Turku'],1,['University of Turku(原研)'],心脑血管领域,血管炎,['心脑血管领域'],1,心脑血管领域,,,1,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,Vasculitis,68Ga-DOTA-Siglec-9,68Ga-DOTA-Siglec-9
68Ga-DOTA-Siglec-9,VAP-1,anti-VAP-1多肽偶联核素;68Ga标记的PET药物,University of Turku(原研),类风湿性关节炎,I期临床,2018-11-27,Inactive,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-Siglec-9,,免疫领域;骨骼肌肉领域,,DR057506,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2018-11-27,phase 1,1,True,False,False,[],['University of Turku'],1,['University of Turku(原研)'],免疫领域,类风湿性关节炎,"['免疫领域', '骨骼肌肉领域']",2,免疫领域,骨骼肌肉领域,,1,1,Immunology,Immunology,Musculoskeletal,,rheumatoid arthritis,68Ga-DOTA-Siglec-9,68Ga-DOTA-Siglec-9
68Ga-DOTA-Siglec-9,VAP-1,anti-VAP-1多肽偶联核素;68Ga标记的PET药物,University of Turku(原研),PET显像,I期临床,2018-11-27,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-Siglec-9,,诊断试剂领域,,DR057506,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2018-11-27,phase 1,1,True,False,False,[],['University of Turku'],1,['University of Turku(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-DOTA-Siglec-9,68Ga-DOTA-Siglec-9
68Ga-DOTA-Siglec-9,VAP-1,anti-VAP-1多肽偶联核素;68Ga标记的PET药物,University of Turku(原研),肺结节病,I期临床,2018-11-27,Inactive,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-Siglec-9,,呼吸领域;免疫领域,,DR057506,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2018-11-27,phase 1,1,True,False,False,[],['University of Turku'],1,['University of Turku(原研)'],呼吸领域,肺结节病,"['呼吸领域', '免疫领域']",2,呼吸领域,免疫领域,,1,1,Respiratory,Respiratory,Immunology,,pulmonary sarcoidosis,68Ga-DOTA-Siglec-9,68Ga-DOTA-Siglec-9
68Ga-DOTA-Siglec-9,VAP-1,anti-VAP-1多肽偶联核素;68Ga标记的PET药物,University of Turku(原研),炎症(未指明),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-Siglec-9,,免疫领域,,DR057506,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,I期临床,2018-11-27,phase 1,1,True,False,False,[],['University of Turku'],1,['University of Turku(原研)'],免疫领域,炎症(未指明),['免疫领域'],1,免疫领域,,,1,-1,Immunology,Immunology,,,Inflammation (unspecified),68Ga-DOTA-Siglec-9,68Ga-DOTA-Siglec-9
[18F]BMS-986229,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,胃癌(差异化疾病),I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,创新药,[18F]BMS-986229;18F-BMS-986229,,肿瘤领域,,DR022833,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2019-11-13,phase 1,2,True,False,True,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,"['Bristol-Myers Squibb(Top20 MNC)(原研)', 'PeptiDream']",肿瘤领域,胃癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,stomach cancer,[18F]BMS-986229,[18F]BMS-986229;18F-BMS-986229
[18F]BMS-986229,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,食管癌,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,创新药,[18F]BMS-986229;18F-BMS-986229,,肿瘤领域,,DR022833,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2019-11-13,phase 1,2,True,False,True,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,"['Bristol-Myers Squibb(Top20 MNC)(原研)', 'PeptiDream']",肿瘤领域,食管癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,Esophageal cancer,[18F]BMS-986229,[18F]BMS-986229;18F-BMS-986229
[18F]BMS-986229,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,PET显像,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,创新药,[18F]BMS-986229;18F-BMS-986229,,诊断试剂领域,,DR022833,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2019-11-13,phase 1,2,True,False,True,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,"['Bristol-Myers Squibb(Top20 MNC)(原研)', 'PeptiDream']",诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[18F]BMS-986229,[18F]BMS-986229;18F-BMS-986229
[18F]BMS-986229,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,胃食管交界处癌(差异化疾病),I期临床,2019-11-13,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,创新药,[18F]BMS-986229;18F-BMS-986229,,肿瘤领域,,DR022833,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2019-11-13,phase 1,I期临床,2019-11-13,phase 1,2,True,False,True,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,"['Bristol-Myers Squibb(Top20 MNC)(原研)', 'PeptiDream']",肿瘤领域,胃食管交界处癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,gastroesophageal junction cancer,[18F]BMS-986229,[18F]BMS-986229;18F-BMS-986229
[18F]BMS-986229,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,食管鳞状细胞癌(差异化疾病),I期临床,2019-11-13,Inactive,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,创新药,[18F]BMS-986229;18F-BMS-986229,,肿瘤领域,,DR022833,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2019-11-13,phase 1,I期临床,2019-11-13,phase 1,2,True,False,True,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,"['Bristol-Myers Squibb(Top20 MNC)(原研)', 'PeptiDream']",肿瘤领域,食管鳞状细胞癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,Esophageal squamous cell carcinoma,[18F]BMS-986229,[18F]BMS-986229;18F-BMS-986229
ALS-205,C5aR,C5aR拮抗剂,University of Queensland(原研);Alsonex;Promics(原研),帕金森病(差异化疾病),I期临床,2019-11-25,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,创新药,ALS-205;PMX205,,神经领域,,DR060769,否,澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2019-11-25,phase 1,3,True,False,False,[],"['University of Queensland', 'Promics']",2,"['University of Queensland(原研)', 'Alsonex', 'Promics(原研)']",神经领域,帕金森病,['神经领域'],1,神经领域,,,1,1,Neurology,Neurology,,,Parkinson's disease,ALS-205,ALS-205;PMX205
ALS-205,C5aR,C5aR拮抗剂,University of Queensland(原研);Alsonex;Promics(原研),肌萎缩侧索硬化症(差异化疾病),I期临床,2022-06-29,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,创新药,ALS-205;PMX205,,神经领域;罕见疾病领域,,DR060769,否,澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2019-11-25,phase 1,3,True,True,False,[],"['University of Queensland', 'Promics']",2,"['University of Queensland(原研)', 'Alsonex', 'Promics(原研)']",神经领域,肌萎缩侧索硬化症,['神经领域'],1,神经领域,,,1,1,Neurology,Neurology,,,amyotrophic lateral sclerosis,ALS-205,ALS-205;PMX205
ALS-205,C5aR,C5aR拮抗剂,University of Queensland(原研);Alsonex;Promics(原研),运动神经元病,I期临床,2019-11-25,Inactive,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,创新药,ALS-205;PMX205,,罕见疾病领域;神经领域,,DR060769,否,澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2019-11-25,phase 1,3,True,True,False,[],"['University of Queensland', 'Promics']",2,"['University of Queensland(原研)', 'Alsonex', 'Promics(原研)']",神经领域,运动神经元病,['神经领域'],1,神经领域,,,1,1,Neurology,Neurology,,,motor neurone disease,ALS-205,ALS-205;PMX205
ALS-205,C5aR,C5aR拮抗剂,University of Queensland(原研);Alsonex;Promics(原研),亨廷顿氏病(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,创新药,ALS-205;PMX205,,神经领域;罕见疾病领域,,DR060769,否,澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,I期临床,2019-11-25,phase 1,3,True,True,False,[],"['University of Queensland', 'Promics']",2,"['University of Queensland(原研)', 'Alsonex', 'Promics(原研)']",神经领域,亨廷顿氏病,['神经领域'],1,神经领域,,,1,-1,Neurology,Neurology,,,Huntington's disease,ALS-205,ALS-205;PMX205
18F-WL12,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,北京大学肿瘤医院(原研),实体瘤,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;肿瘤免疫,18F标记的PET药物;多肽偶联核素,创新药,18F-WL12,,肿瘤领域,,DR011153,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2020-03-11,phase 1,1,True,False,False,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,solid tumors,18F-WL12,18F-WL12
18F-WL12,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,北京大学肿瘤医院(原研),肺癌,I期临床,2020-03-11,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;肿瘤免疫,18F标记的PET药物;多肽偶联核素,创新药,18F-WL12,,肿瘤领域,,DR011153,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2020-03-11,,phase 1,I期临床,2020-03-11,phase 1,1,True,False,False,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],肿瘤领域,肺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,lung cancer,18F-WL12,18F-WL12
18F-WL12,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,北京大学肿瘤医院(原研),PET显像,I期临床,2020-03-11,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;肿瘤免疫,18F标记的PET药物;多肽偶联核素,创新药,18F-WL12,,诊断试剂领域,,DR011153,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2020-03-11,,phase 1,I期临床,2020-03-11,phase 1,1,True,False,False,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,18F-WL12,18F-WL12
zosurabalpin,Lpt,抗生素,Roche(Top20 MNC)(原研),细菌感染,I期临床,2022-11-14,Unknown,小分子,化药,环肽;Potential First-in-Class,抗生素,创新药,zosurabalpin;RG6006;Abx MCP;RO7223280,,感染领域,I期临床:注射剂,DR041385,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2022-11-14,phase 1,I期临床,2020-10-28,phase 1,1,True,False,True,['Roche'],['Roche'],1,['Roche(Top20 MNC)(原研)'],感染领域,细菌感染,['感染领域'],1,感染领域,,,1,1,Infectious Diseases,Infectious Diseases,,,bacterial infection,zosurabalpin,zosurabalpin;RG6006;Abx MCP;RO7223280
zosurabalpin,Lpt,抗生素,Roche(Top20 MNC)(原研),鲍曼不动杆菌-醋酸钙不动杆菌复合体感染,I期临床,2023-01-06,Active,小分子,化药,环肽;Potential First-in-Class,抗生素,创新药,zosurabalpin;RG6006;Abx MCP;RO7223280,,感染领域,I期临床:注射剂,DR041385,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2023-01-06,,phase 1,I期临床,2020-10-28,phase 1,1,True,False,True,['Roche'],['Roche'],1,['Roche(Top20 MNC)(原研)'],感染领域,鲍曼不动杆菌-醋酸钙不动杆菌复合体感染,['感染领域'],1,感染领域,,,1,1,Infectious Diseases,Infectious Diseases,,,Acinetobacter baumannii-Acinetobacter calaceticus complex infection,zosurabalpin,zosurabalpin;RG6006;Abx MCP;RO7223280
zosurabalpin,Lpt,抗生素,Roche(Top20 MNC)(原研),鲍曼不动杆菌感染,I期临床,,Active,小分子,化药,环肽;Potential First-in-Class,抗生素,创新药,zosurabalpin;RG6006;Abx MCP;RO7223280,,感染领域,I期临床:注射剂,DR041385,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2020-10-28,phase 1,1,True,False,True,['Roche'],['Roche'],1,['Roche(Top20 MNC)(原研)'],感染领域,鲍曼不动杆菌感染,['感染领域'],1,感染领域,,,1,1,Infectious Diseases,Infectious Diseases,,,Acinetobacter baumannii infection,zosurabalpin,zosurabalpin;RG6006;Abx MCP;RO7223280
zosurabalpin,Lpt,抗生素,Roche(Top20 MNC)(原研),感染,申报临床,2022-07-14,Active,小分子,化药,环肽;Potential First-in-Class,抗生素,创新药,zosurabalpin;RG6006;Abx MCP;RO7223280,,感染领域,I期临床:注射剂,DR041385,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,申报临床,,2022-07-14,,ind,I期临床,2020-10-28,phase 1,1,True,False,True,['Roche'],['Roche'],1,['Roche(Top20 MNC)(原研)'],感染领域,感染,['感染领域'],1,感染领域,,,1,0,Infectious Diseases,Infectious Diseases,,,Infect,zosurabalpin,zosurabalpin;RG6006;Abx MCP;RO7223280
Soralimixin,not available,多粘菌素类抗生素,健康元;腾盛博药;Monash University(原研)(无权益);Qpex Biopharma(Shionogi)(无权益),细菌感染,I期临床,2021-03-22,Active,多肽,化药,环肽,多粘菌素类抗生素,创新药,Soralimixin;QPX9003;BRII-693,,感染领域,申报临床:注射剂(冻干),DR044020,否,澳大利亚,,,I期临床,,2021-03-22,phase 1,I期临床,2021-03-22,phase 1,4,True,False,False,[],['Monash University'],1,"['健康元', '腾盛博药', 'Monash University(原研)(无权益)', 'Qpex Biopharma(Shionogi)(无权益)']",感染领域,细菌感染,['感染领域'],1,感染领域,,,1,1,Infectious Diseases,Infectious Diseases,,,bacterial infection,Soralimixin,Soralimixin;QPX9003;BRII-693
Soralimixin,not available,多粘菌素类抗生素,健康元;腾盛博药;Monash University(原研)(无权益);Qpex Biopharma(Shionogi)(无权益),感染,申报临床,2024-07-20,Active,多肽,化药,环肽,多粘菌素类抗生素,创新药,Soralimixin;QPX9003;BRII-693,,感染领域,申报临床:注射剂(冻干),DR044020,否,澳大利亚,,申报临床,,2024-07-20,,ind,I期临床,2021-03-22,phase 1,4,True,False,False,[],['Monash University'],1,"['健康元', '腾盛博药', 'Monash University(原研)(无权益)', 'Qpex Biopharma(Shionogi)(无权益)']",感染领域,感染,['感染领域'],1,感染领域,,,1,0,Infectious Diseases,Infectious Diseases,,,Infect,Soralimixin,Soralimixin;QPX9003;BRII-693
[68Ga]VMT02,MC1R,anti-MC1R多肽偶联核素;68Ga标记的PET药物,Viewpoint Molecular Targeting(Perspective Therapeutics)(原研),黑色素瘤,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class;Melanogenesis,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]VMT02,,肿瘤领域;罕见疾病领域,,DR053782,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2021-05-27,phase 1,1,True,True,False,[],['Viewpoint Molecular Targeting(Perspective Therapeutics)'],1,['Viewpoint Molecular Targeting(Perspective Therapeutics)(原研)'],肿瘤领域,黑色素瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,melanoma,[68Ga]VMT02,[68Ga]VMT02
[68Ga]VMT02,MC1R,anti-MC1R多肽偶联核素;68Ga标记的PET药物,Viewpoint Molecular Targeting(Perspective Therapeutics)(原研),PET显像,I期临床,2021-05-27,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class;Melanogenesis,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]VMT02,,诊断试剂领域,,DR053782,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2021-05-27,phase 1,I期临床,2021-05-27,phase 1,1,True,False,False,[],['Viewpoint Molecular Targeting(Perspective Therapeutics)'],1,['Viewpoint Molecular Targeting(Perspective Therapeutics)(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[68Ga]VMT02,[68Ga]VMT02
[68Ga]VMT02,MC1R,anti-MC1R多肽偶联核素;68Ga标记的PET药物,Viewpoint Molecular Targeting(Perspective Therapeutics)(原研),葡萄膜黑色素瘤,I期临床,2021-05-27,Unknown,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class;Melanogenesis,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]VMT02,,肿瘤领域;罕见疾病领域,,DR053782,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2021-05-27,phase 1,I期临床,2021-05-27,phase 1,1,True,True,False,[],['Viewpoint Molecular Targeting(Perspective Therapeutics)'],1,['Viewpoint Molecular Targeting(Perspective Therapeutics)(原研)'],肿瘤领域,葡萄膜黑色素瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,uveal melanoma,[68Ga]VMT02,[68Ga]VMT02
177Lu-AB-3PRGD2,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,北京大学(原研),实体瘤,I期临床,2024-04-19,Active,多肽;放射性药物;偶联药物,生物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,创新药,177Lu-AB-3PRGD2,,肿瘤领域,,DR065756,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-04-19,,phase 1,I期临床,2021-08-19,phase 1,1,True,False,False,[],['北京大学'],1,['北京大学(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,solid tumors,177Lu-AB-3PRGD2,177Lu-AB-3PRGD2
177Lu-AB-3PRGD2,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,北京大学(原研),非小细胞肺癌,I期临床,2021-08-19,Active,多肽;放射性药物;偶联药物,生物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,创新药,177Lu-AB-3PRGD2,,肿瘤领域,,DR065756,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2021-08-19,,phase 1,I期临床,2021-08-19,phase 1,1,True,False,False,[],['北京大学'],1,['北京大学(原研)'],肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,non-small cell lung cancer,177Lu-AB-3PRGD2,177Lu-AB-3PRGD2
177Lu-AB-3PRGD2,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,北京大学(原研),神经内分泌肿瘤(差异化疾病),I期临床,2024-10-09,Active,多肽;放射性药物;偶联药物,生物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,创新药,177Lu-AB-3PRGD2,,肿瘤领域;罕见疾病领域,,DR065756,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-10-09,,phase 1,I期临床,2021-08-19,phase 1,1,True,True,False,[],['北京大学'],1,['北京大学(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,neuroendocrine tumors,177Lu-AB-3PRGD2,177Lu-AB-3PRGD2
Tdura,not available,含锝放射性示踪剂;多肽偶联核素,Molecular Targeting Technologies(原研);University of Antwerp(原研),SPECT显像,I期临床,2022-01-04,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;中国无申报,含锝放射性示踪剂;多肽偶联核素,创新药,Tdura;99mTc-Duramycin,,诊断试剂领域,,DR034924,否,美国;欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2022-01-04,phase 1,2,True,False,False,[],"['Molecular Targeting Technologies', 'University of Antwerp']",2,"['Molecular Targeting Technologies(原研)', 'University of Antwerp(原研)']",诊断试剂领域,SPECT显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,SPECT imaging,Tdura,Tdura;99mTc-Duramycin
Tdura,not available,含锝放射性示踪剂;多肽偶联核素,Molecular Targeting Technologies(原研);University of Antwerp(原研),结肠癌,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;中国无申报,含锝放射性示踪剂;多肽偶联核素,创新药,Tdura;99mTc-Duramycin,,肿瘤领域,,DR034924,否,美国;欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2022-01-04,phase 1,2,True,False,False,[],"['Molecular Targeting Technologies', 'University of Antwerp']",2,"['Molecular Targeting Technologies(原研)', 'University of Antwerp(原研)']",肿瘤领域,结肠癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,colon cancer,Tdura,Tdura;99mTc-Duramycin
Oph1,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,OphRx(原研),干眼病,I期临床,2022-01-11,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,微创新,Oph1;Oph1 (0.5%环孢素滴眼液);Oph1 (0.5% Cyclosporine A);OPH-100,,眼科领域,,DR033775,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2022-01-11,phase 1,1,True,False,False,[],['OphRx'],1,['OphRx(原研)'],眼科领域,干眼病,['眼科领域'],1,眼科领域,,,1,1,Ophthalmology,Ophthalmology,,,dry eye disease,Oph1 (0.5% Cyclosporine A),Oph1;Oph1 (0.5%环孢素滴眼液);Oph1 (0.5% Cyclosporine A);OPH-100
PA-001,SARS-CoV-2 S protein,,PeptiDream(原研),新型冠状病毒感染,I期临床,2022-02-07,Active,多肽,化药,环肽,其他,创新药,PA-001,,感染领域,,DR035773,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,申报临床,,2024-06-04,phase 1,I期临床,2022-02-07,phase 1,1,True,False,False,[],['PeptiDream'],1,['PeptiDream(原研)'],感染领域,新型冠状病毒感染,['感染领域'],1,感染领域,,,1,1,Infectious Diseases,Infectious Diseases,,,novel coronavirus infection,PA-001,PA-001
68Ga-N188,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,北京大学肿瘤医院(原研),肺癌(差异化疾病),I期临床,2024-10-18,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-N188;[68Ga]N188,,肿瘤领域,,DR013319,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-10-18,,phase 1,I期临床,2022-04-11,phase 1,1,True,False,False,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],肿瘤领域,肺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,lung cancer,68Ga-N188,68Ga-N188;[68Ga]N188
68Ga-N188,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,北京大学肿瘤医院(原研),膀胱癌,I期临床,2022-10-25,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-N188;[68Ga]N188,,肿瘤领域,,DR013319,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2022-10-25,,phase 1,I期临床,2022-04-11,phase 1,1,True,False,False,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],肿瘤领域,膀胱癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,bladder cancer,68Ga-N188,68Ga-N188;[68Ga]N188
68Ga-N188,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,北京大学肿瘤医院(原研),尿路上皮癌,I期临床,2022-04-11,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-N188;[68Ga]N188,,肿瘤领域,,DR013319,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2022-04-11,,phase 1,I期临床,2022-04-11,phase 1,1,True,False,False,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],肿瘤领域,尿路上皮癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,urothelial carcinoma,68Ga-N188,68Ga-N188;[68Ga]N188
68Ga-N188,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,北京大学肿瘤医院(原研),PET显像,I期临床,2022-04-11,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-N188;[68Ga]N188,,诊断试剂领域,,DR013319,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2022-04-11,,phase 1,I期临床,2022-04-11,phase 1,1,True,False,False,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-N188,68Ga-N188;[68Ga]N188
161Tb-DOTA-LM3,SSTR2,161Tb标记的放射性药物;anti-SSTR2多肽偶联核素,Paul Scherrer Institute(原研),胃肠胰神经内分泌肿瘤,I期临床,2022-05-03,Active,多肽;放射性药物;偶联药物,化药,环肽;Potential First-in-Class,161Tb标记的放射性药物;多肽偶联核素,创新药,161Tb-DOTA-LM3,,肿瘤领域;罕见疾病领域,,DR003476,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2022-05-03,phase 1,1,True,True,False,[],['Paul Scherrer Institute'],1,['Paul Scherrer Institute(原研)'],肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,161Tb-DOTA-LM3,161Tb-DOTA-LM3
68Ga-pentixather,CXCR4,68Ga标记的PET药物,北京协和医院(原研),多发性骨髓瘤(差异化疾病),I期临床,2022-05-06,Active,小分子;放射性药物,化药,环肽;差异化疾病;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物,创新药,68Ga-pentixather,,肿瘤领域;血液领域;罕见疾病领域,,DR055770,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2022-05-06,,phase 1,I期临床,2022-05-06,phase 1,1,True,True,False,[],['北京协和医院'],1,['北京协和医院(原研)'],肿瘤领域,多发性骨髓瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,1,1,Oncology,Oncology,Hematology,,multiple myeloma,68Ga-pentixather,68Ga-pentixather
68Ga-pentixather,CXCR4,68Ga标记的PET药物,北京协和医院(原研),PET显像,I期临床,2022-05-06,Active,小分子;放射性药物,化药,环肽;差异化疾病;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物,创新药,68Ga-pentixather,,诊断试剂领域,,DR055770,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2022-05-06,,phase 1,I期临床,2022-05-06,phase 1,1,True,False,False,[],['北京协和医院'],1,['北京协和医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-pentixather,68Ga-pentixather
PHIN-214,AVPR1A,AVPR1A部分激动剂,PharmaIN(原研),肝硬化,I期临床,2022-08-08,Active,多肽,化药,环肽;Potential First-in-Class,部分激动剂,创新药,PHIN-214,,消化领域,,DR021763,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2022-08-08,phase 1,I期临床,2022-08-08,phase 1,1,True,False,False,[],['PharmaIN'],1,['PharmaIN(原研)'],消化领域,肝硬化,['消化领域'],1,消化领域,,,1,1,Digestive System,Digestive System,,,Cirrhosis,PHIN-214,PHIN-214
PHIN-214,AVPR1A,AVPR1A部分激动剂,PharmaIN(原研),低血压,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,部分激动剂,创新药,PHIN-214,,心脑血管领域,,DR021763,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,I期临床,2022-08-08,phase 1,1,True,False,False,[],['PharmaIN'],1,['PharmaIN(原研)'],心脑血管领域,低血压,['心脑血管领域'],1,心脑血管领域,,,1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,hypotension,PHIN-214,PHIN-214
203Pb-pentixather,CXCR4,203Pb标记的放射性示踪剂,University of Iowa(原研),小细胞肺癌,I期临床,2022-09-28,Active,小分子;放射性药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,203Pb标记的放射性示踪剂,创新药,203Pb-pentixather,,肿瘤领域;罕见疾病领域,,DR013617,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2022-09-28,phase 1,I期临床,2022-09-28,phase 1,1,True,True,False,[],['University of Iowa'],1,['University of Iowa(原研)'],肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,small cell lung cancer,203Pb-pentixather,203Pb-pentixather
203Pb-pentixather,CXCR4,203Pb标记的放射性示踪剂,University of Iowa(原研),SPECT显像,I期临床,,Active,小分子;放射性药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,203Pb标记的放射性示踪剂,创新药,203Pb-pentixather,,诊断试剂领域,,DR013617,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2022-09-28,phase 1,1,True,False,False,[],['University of Iowa'],1,['University of Iowa(原研)'],诊断试剂领域,SPECT显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,SPECT imaging,203Pb-pentixather,203Pb-pentixather
203Pb-pentixather,CXCR4,203Pb标记的放射性示踪剂,University of Iowa(原研),肺类癌,I期临床,2022-09-28,Active,小分子;放射性药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,203Pb标记的放射性示踪剂,创新药,203Pb-pentixather,,肿瘤领域;罕见疾病领域,,DR013617,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2022-09-28,phase 1,I期临床,2022-09-28,phase 1,1,True,True,False,[],['University of Iowa'],1,['University of Iowa(原研)'],肿瘤领域,肺类癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,lung carcinoid,203Pb-pentixather,203Pb-pentixather
212Pb-pentixather,CXCR4,212Pb标记的放射性药物,University of Iowa(原研),小细胞肺癌,I期临床,2022-09-28,Active,小分子;放射性药物,化药,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,212Pb标记的放射性药物,创新药,212Pb-pentixather,,肿瘤领域;罕见疾病领域,,DR028994,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2022-09-28,phase 1,I期临床,2022-09-28,phase 1,1,True,True,False,[],['University of Iowa'],1,['University of Iowa(原研)'],肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,small cell lung cancer,212Pb-pentixather,212Pb-pentixather
212Pb-pentixather,CXCR4,212Pb标记的放射性药物,University of Iowa(原研),肺类癌,I期临床,2022-09-28,Active,小分子;放射性药物,化药,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,212Pb标记的放射性药物,创新药,212Pb-pentixather,,肿瘤领域;罕见疾病领域,,DR028994,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2022-09-28,phase 1,I期临床,2022-09-28,phase 1,1,True,True,False,[],['University of Iowa'],1,['University of Iowa(原研)'],肿瘤领域,肺类癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,lung carcinoid,212Pb-pentixather,212Pb-pentixather
[18F]AlF-NOTA-FAPI-04,FAP,18F标记的PET药物,四川省肿瘤医院(原研),癌症,I期临床,2025-01-26,Active,放射性药物;其他,化药,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物,创新药,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04,,肿瘤领域,,DR057496,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-01-26,,phase 1,I期临床,2022-10-12,phase 1,1,True,False,False,[],['四川省肿瘤医院'],1,['四川省肿瘤医院(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,cancer,[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04
[18F]AlF-NOTA-FAPI-04,FAP,18F标记的PET药物,四川省肿瘤医院(原研),乳腺癌,I期临床,2022-10-12,Unknown,放射性药物;其他,化药,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物,创新药,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04,,肿瘤领域,,DR057496,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2022-10-12,,phase 1,I期临床,2022-10-12,phase 1,1,True,False,False,[],['四川省肿瘤医院'],1,['四川省肿瘤医院(原研)'],肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,breast cancer,[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04
[18F]AlF-NOTA-FAPI-04,FAP,18F标记的PET药物,四川省肿瘤医院(原研),肾炎(差异化疾病),I期临床,2023-03-02,Active,放射性药物;其他,化药,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物,创新药,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04,,泌尿生殖领域,,DR057496,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2023-03-02,,phase 1,I期临床,2022-10-12,phase 1,1,True,False,False,[],['四川省肿瘤医院'],1,['四川省肿瘤医院(原研)'],泌尿生殖领域,肾炎,['泌尿生殖领域'],1,泌尿生殖领域,,,1,1,Genitourinary,Genitourinary,,,Nephritis,[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04
[18F]AlF-NOTA-FAPI-04,FAP,18F标记的PET药物,四川省肿瘤医院(原研),PET显像,I期临床,2022-10-12,Active,放射性药物;其他,化药,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物,创新药,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04,,诊断试剂领域,,DR057496,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2022-10-12,,phase 1,I期临床,2022-10-12,phase 1,1,True,False,False,[],['四川省肿瘤医院'],1,['四川省肿瘤医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04
[18F]AlF-NOTA-FAPI-04,FAP,18F标记的PET药物,四川省肿瘤医院(原研),肾纤维化,I期临床,2023-03-02,Active,放射性药物;其他,化药,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物,创新药,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04,,泌尿生殖领域,,DR057496,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2023-03-02,,phase 1,I期临床,2022-10-12,phase 1,1,True,False,False,[],['四川省肿瘤医院'],1,['四川省肿瘤医院(原研)'],泌尿生殖领域,肾纤维化,['泌尿生殖领域'],1,泌尿生殖领域,,,1,1,Genitourinary,Genitourinary,,,renal fibrosis,[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04
[68Ga]-trivehexin,αvβ6,anti-αvβ6多肽偶联核素;68Ga标记的PET药物,Radiopharm Theranostics(原研),癌症,I期临床,2023-04-28,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]-trivehexin;RAD301;68Ga-trivehexin,,肿瘤领域,,DR027025,否,澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2023-04-28,,phase 1,I期临床,2023-04-05,phase 1,1,True,False,False,[],['Radiopharm Theranostics'],1,['Radiopharm Theranostics(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,cancer,[68Ga]-trivehexin,[68Ga]-trivehexin;RAD301;68Ga-trivehexin
[68Ga]-trivehexin,αvβ6,anti-αvβ6多肽偶联核素;68Ga标记的PET药物,Radiopharm Theranostics(原研),PET显像,I期临床,2023-04-05,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]-trivehexin;RAD301;68Ga-trivehexin,,诊断试剂领域,,DR027025,否,澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,I期临床,2023-04-28,2023-04-05,phase 1,I期临床,2023-04-05,phase 1,1,True,False,False,[],['Radiopharm Theranostics'],1,['Radiopharm Theranostics(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[68Ga]-trivehexin,[68Ga]-trivehexin;RAD301;68Ga-trivehexin
[68Ga]-trivehexin,αvβ6,anti-αvβ6多肽偶联核素;68Ga标记的PET药物,Radiopharm Theranostics(原研),胰腺导管癌,I期临床,2023-04-05,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]-trivehexin;RAD301;68Ga-trivehexin,,肿瘤领域,,DR027025,否,澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2023-04-05,phase 1,I期临床,2023-04-05,phase 1,1,True,False,False,[],['Radiopharm Theranostics'],1,['Radiopharm Theranostics(原研)'],肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,pancreatic ductal carcinoma,[68Ga]-trivehexin,[68Ga]-trivehexin;RAD301;68Ga-trivehexin
[18F]AlF-NOTA-pentixather,CXCR4,18F标记的PET药物,Technische Universität München(原研),醛固酮过多症,I期临床,2023-04-18,Active,小分子;放射性药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体,18F标记的PET药物,创新药,[18F]AlF-NOTA-pentixather,,内分泌及代谢领域,,DR021166,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2023-04-18,,phase 1,I期临床,2023-04-18,phase 1,1,True,False,False,[],['Technische Universität München'],1,['Technische Universität München(原研)'],内分泌及代谢领域,醛固酮过多症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,1,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Hyperaldosteronism,[18F]AlF-NOTA-pentixather,[18F]AlF-NOTA-pentixather
[18F]AlF-NOTA-pentixather,CXCR4,18F标记的PET药物,Technische Universität München(原研),PET显像,I期临床,2023-04-18,Active,小分子;放射性药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体,18F标记的PET药物,创新药,[18F]AlF-NOTA-pentixather,,诊断试剂领域,,DR021166,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2023-04-18,,phase 1,I期临床,2023-04-18,phase 1,1,True,False,False,[],['Technische Universität München'],1,['Technische Universität München(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[18F]AlF-NOTA-pentixather,[18F]AlF-NOTA-pentixather
AZP-3813,GHR,GHR拮抗剂,PeptiDream(原研);Amolyt Pharma(AstraZeneca)(Top20 MNC),肢端肥大症,I期临床,2023-04-24,Active,多肽,化药,环肽;中国无申报,拮抗剂,创新药,AZP-3813,,内分泌及代谢领域;罕见疾病领域,,DR024370,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2023-04-24,phase 1,2,True,True,True,['Amolyt Pharma(AstraZeneca)'],['PeptiDream'],1,"['PeptiDream(原研)', 'Amolyt Pharma(AstraZeneca)(Top20 MNC)']",内分泌及代谢领域,肢端肥大症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,1,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,acromegaly,AZP-3813,AZP-3813
TB-B002,not available,抑制剂,图微安创(原研),特发性肺纤维化,I期临床,2023-05-06,Active,多肽,化药,环肽,抑制剂,创新药,TB-B002;TB-B002D,,呼吸领域;罕见疾病领域,I期临床:注射剂,DR014128,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2023-05-06,,phase 1,I期临床,2023-05-06,phase 1,1,True,True,False,[],['图微安创'],1,['图微安创(原研)'],呼吸领域,特发性肺纤维化,['呼吸领域'],1,呼吸领域,,,1,1,Respiratory,Respiratory,,,idiopathic pulmonary fibrosis,TB-B002,TB-B002;TB-B002D
TB-B002,not available,抑制剂,图微安创(原研),肺损伤,申报临床,2023-08-25,Active,多肽,化药,环肽,抑制剂,创新药,TB-B002;TB-B002D,,呼吸领域,I期临床:注射剂,DR014128,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,申报临床,,2023-08-25,,ind,I期临床,2023-05-06,phase 1,1,True,False,False,[],['图微安创'],1,['图微安创(原研)'],呼吸领域,肺损伤,['呼吸领域'],1,呼吸领域,,,1,0,Respiratory,Respiratory,,,lung damage,TB-B002,TB-B002;TB-B002D
TE-8214,somatostatin,somatostatin类似物,免疫功坊(原研),肢端肥大症,I期临床,2024-04-18,Active,多肽,化药,环肽,类似物,创新药,TE-8214,,内分泌及代谢领域;罕见疾病领域,,DR015375,否,中国(港澳台),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2024-04-18,phase 1,1,True,True,False,[],['免疫功坊'],1,['免疫功坊(原研)'],内分泌及代谢领域,肢端肥大症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,1,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,acromegaly,TE-8214,TE-8214
TE-8214,somatostatin,somatostatin类似物,免疫功坊(原研),神经内分泌肿瘤,临床前,,Active,多肽,化药,环肽,类似物,创新药,TE-8214,,肿瘤领域;罕见疾病领域,,DR015375,否,中国(港澳台),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,I期临床,2024-04-18,phase 1,1,True,True,False,[],['免疫功坊'],1,['免疫功坊(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,1,-1,Oncology,Oncology,,,neuroendocrine tumors,TE-8214,TE-8214
64Cu-PD-32766,CAIX,64Cu标记的放射性示踪剂;anti-CAIX多肽偶联核素,PeptiDream(原研),PET显像,I期临床,2024-04-24,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,64Cu-PD-32766,,诊断试剂领域,,DR068744,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2024-04-24,phase 1,1,True,False,False,[],['PeptiDream'],1,['PeptiDream(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,64Cu-PD-32766,64Cu-PD-32766
64Cu-PD-32766,CAIX,64Cu标记的放射性示踪剂;anti-CAIX多肽偶联核素,PeptiDream(原研),肾透明细胞癌,I期临床,2024-04-24,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,64Cu-PD-32766,,肿瘤领域,,DR068744,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2024-04-24,phase 1,1,True,False,False,[],['PeptiDream'],1,['PeptiDream(原研)'],肿瘤领域,肾透明细胞癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,clear cell renal cell carcinoma,64Cu-PD-32766,64Cu-PD-32766
68Ga-FAPI-JH04,FAP,68Ga标记的PET药物,福建医科大学附属第一医院(原研),癌症,I期临床,2024-05-31,Active,放射性药物;其他,其他,环肽;诊断用放射性药物,68Ga标记的PET药物,创新药,68Ga-FAPI-JH04;68Ga-JH04,,肿瘤领域,,DR067575,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-05-31,,phase 1,I期临床,2024-05-31,phase 1,1,True,False,False,[],['福建医科大学附属第一医院'],1,['福建医科大学附属第一医院(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,cancer,68Ga-FAPI-JH04,68Ga-FAPI-JH04;68Ga-JH04
68Ga-FAPI-JH04,FAP,68Ga标记的PET药物,福建医科大学附属第一医院(原研),PET显像,I期临床,2024-05-31,Active,放射性药物;其他,其他,环肽;诊断用放射性药物,68Ga标记的PET药物,创新药,68Ga-FAPI-JH04;68Ga-JH04,,诊断试剂领域,,DR067575,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-05-31,,phase 1,I期临床,2024-05-31,phase 1,1,True,False,False,[],['福建医科大学附属第一医院'],1,['福建医科大学附属第一医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-FAPI-JH04,68Ga-FAPI-JH04;68Ga-JH04
[177Lu]Lu-NNS309,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);PeptiDream(原研),非小细胞肺癌,I期临床,2024-08-20,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,创新药,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,,肿瘤领域,,DR069256,否,欧洲;日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他;未知,,I期临床,,2024-08-20,phase 1,I期临床,2024-08-20,phase 1,2,True,False,True,['Novartis'],"['Novartis', 'PeptiDream']",2,"['Novartis(Top20 MNC)(原研)', 'PeptiDream(原研)']",肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,non-small cell lung cancer,[177Lu]Lu-NNS309,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489
[177Lu]Lu-NNS309,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);PeptiDream(原研),HR阳性乳腺癌(差异化疾病),I期临床,2024-08-20,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,创新药,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,,肿瘤领域,,DR069256,否,欧洲;日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他;未知,,I期临床,,2024-08-20,phase 1,I期临床,2024-08-20,phase 1,2,True,False,True,['Novartis'],"['Novartis', 'PeptiDream']",2,"['Novartis(Top20 MNC)(原研)', 'PeptiDream(原研)']",肿瘤领域,HR阳性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,HR positive breast cancer,[177Lu]Lu-NNS309,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489
[177Lu]Lu-NNS309,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);PeptiDream(原研),三阴性乳腺癌(差异化疾病),I期临床,2024-08-20,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,创新药,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,,肿瘤领域,,DR069256,否,欧洲;日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他;未知,,I期临床,,2024-08-20,phase 1,I期临床,2024-08-20,phase 1,2,True,False,True,['Novartis'],"['Novartis', 'PeptiDream']",2,"['Novartis(Top20 MNC)(原研)', 'PeptiDream(原研)']",肿瘤领域,三阴性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,triple negative breast cancer,[177Lu]Lu-NNS309,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489
[177Lu]Lu-NNS309,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);PeptiDream(原研),结直肠癌(差异化疾病),I期临床,2024-08-20,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,创新药,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,,肿瘤领域,,DR069256,否,欧洲;日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他;未知,,I期临床,,2024-08-20,phase 1,I期临床,2024-08-20,phase 1,2,True,False,True,['Novartis'],"['Novartis', 'PeptiDream']",2,"['Novartis(Top20 MNC)(原研)', 'PeptiDream(原研)']",肿瘤领域,结直肠癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,colorectal cancer,[177Lu]Lu-NNS309,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489
[177Lu]Lu-NNS309,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);PeptiDream(原研),胰腺导管癌,I期临床,2024-08-20,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,创新药,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,,肿瘤领域,,DR069256,否,欧洲;日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他;未知,,I期临床,,2024-08-20,phase 1,I期临床,2024-08-20,phase 1,2,True,False,True,['Novartis'],"['Novartis', 'PeptiDream']",2,"['Novartis(Top20 MNC)(原研)', 'PeptiDream(原研)']",肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,pancreatic ductal carcinoma,[177Lu]Lu-NNS309,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489
CID-078,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),实体瘤,I期临床,2024-10-15,Active,多肽,化药,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,创新药,CID-078;CID-016;CIR7-7321;CIR-7321,,肿瘤领域,,DR013158,否,美国;欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,申报临床,,2024-07-01,phase 1,I期临床,2024-08-29,phase 1,2,True,False,False,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,solid tumors,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321
CID-078,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),肺癌,I期临床,2024-08-29,Active,多肽,化药,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,创新药,CID-078;CID-016;CIR7-7321;CIR-7321,,肿瘤领域,,DR013158,否,美国;欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2024-08-29,phase 1,I期临床,2024-08-29,phase 1,2,True,False,False,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,肺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,lung cancer,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321
CID-078,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),小细胞肺癌(差异化疾病),I期临床,2025-06-16,Active,多肽,化药,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,创新药,CID-078;CID-016;CIR7-7321;CIR-7321,,肿瘤领域;罕见疾病领域,,DR013158,否,美国;欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2024-08-29,phase 1,2,True,True,False,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,small cell lung cancer,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321
CID-078,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),三阴性乳腺癌(差异化疾病),I期临床,2024-08-29,Active,多肽,化药,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,创新药,CID-078;CID-016;CIR7-7321;CIR-7321,,肿瘤领域,,DR013158,否,美国;欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2024-08-29,phase 1,I期临床,2024-08-29,phase 1,2,True,False,False,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,三阴性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,triple negative breast cancer,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321
CID-078,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),神经内分泌肿瘤(差异化疾病),I期临床,2024-08-29,Active,多肽,化药,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,创新药,CID-078;CID-016;CIR7-7321;CIR-7321,,肿瘤领域;罕见疾病领域,,DR013158,否,美国;欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2024-08-29,phase 1,I期临床,2024-08-29,phase 1,2,True,True,False,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,neuroendocrine tumors,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321
CID-078,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),癌症,临床前,,Active,多肽,化药,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,创新药,CID-078;CID-016;CIR7-7321;CIR-7321,,肿瘤领域,,DR013158,否,美国;欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,I期临床,2024-08-29,phase 1,2,True,False,False,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,1,-1,Oncology,Oncology,,,cancer,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321
CID-078,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),非小细胞肺癌(差异化疾病),临床前,,Active,多肽,化药,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,创新药,CID-078;CID-016;CIR7-7321;CIR-7321,,肿瘤领域,,DR013158,否,美国;欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,I期临床,2024-08-29,phase 1,2,True,False,False,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,1,-1,Oncology,Oncology,,,non-small cell lung cancer,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321
CID-078,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),乳腺癌,临床前,,Active,多肽,化药,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,创新药,CID-078;CID-016;CIR7-7321;CIR-7321,,肿瘤领域,,DR013158,否,美国;欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,I期临床,2024-08-29,phase 1,2,True,False,False,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,1,-1,Oncology,Oncology,,,breast cancer,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321
NN6537-7650,CNP,CNP类似物,Novo Nordisk(Top20 MNC)(原研),心力衰竭,I期临床,2024-10-03,Active,多肽,化药,环肽,类似物,创新药,NN6537-7650;NN6537,,心脑血管领域,,DR070230,否,欧洲,未知,,,,,phase 1,I期临床,2024-10-03,phase 1,1,True,False,True,['Novo Nordisk'],['Novo Nordisk'],1,['Novo Nordisk(Top20 MNC)(原研)'],心脑血管领域,心力衰竭,['心脑血管领域'],1,心脑血管领域,,,1,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,heart failure,NN6537-7650,NN6537-7650;NN6537
177Lu-JH04,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,晶核生物(原研),肿瘤,I期临床,2024-10-10,Active,小分子;多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,177Lu-JH04;JH004;[177Lu]JH040182,,肿瘤领域,申报临床:注射剂,DR069733,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-10-10,,phase 1,I期临床,2024-10-10,phase 1,1,True,False,False,[],['晶核生物'],1,['晶核生物(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,tumor,177Lu-JH04,177Lu-JH04;JH004;[177Lu]JH040182
[18F]AlF-ETN,EphA2,18F标记的PET药物;anti-EphA2多肽偶联核素,北京大学第一医院(原研),实体瘤,I期临床,2024-10-14,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,创新药,[18F]AlF-ETN,,肿瘤领域,,DR070403,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-10-14,,phase 1,I期临床,2024-10-14,phase 1,1,True,False,False,[],['北京大学第一医院'],1,['北京大学第一医院(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,solid tumors,[18F]AlF-ETN,[18F]AlF-ETN
[18F]AlF-ETN,EphA2,18F标记的PET药物;anti-EphA2多肽偶联核素,北京大学第一医院(原研),PET显像,I期临床,2024-10-14,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,创新药,[18F]AlF-ETN,,诊断试剂领域,,DR070403,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-10-14,,phase 1,I期临床,2024-10-14,phase 1,1,True,False,False,[],['北京大学第一医院'],1,['北京大学第一医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[18F]AlF-ETN,[18F]AlF-ETN
ZP9830,Kv1.3,Kv1.3阻断剂,Zealand Pharma(原研),自身免疫性疾病,I期临床,2024-11-12,Active,多肽,化药,环肽,阻断剂,创新药,ZP9830;ZP 9830,,免疫领域,,DR065642,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2024-11-12,phase 1,1,True,False,False,[],['Zealand Pharma'],1,['Zealand Pharma(原研)'],免疫领域,自身免疫性疾病,['免疫领域'],1,免疫领域,,,1,1,Immunology,Immunology,,,autoimmune disease,ZP9830,ZP9830;ZP 9830
ZP9830,Kv1.3,Kv1.3阻断剂,Zealand Pharma(原研),炎症性肠病,临床前,,Active,多肽,化药,环肽,阻断剂,创新药,ZP9830;ZP 9830,,免疫领域;消化领域,,DR065642,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,I期临床,2024-11-12,phase 1,1,True,False,False,[],['Zealand Pharma'],1,['Zealand Pharma(原研)'],免疫领域,炎症性肠病,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,1,-1,Immunology,Immunology,Digestive System,,inflammatory bowel disease,ZP9830,ZP9830;ZP 9830
68Ga-MMP14,MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,北京大学肿瘤医院(原研),实体瘤,I期临床,2024-12-06,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-MMP14,,肿瘤领域,,DR071612,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-12-06,,phase 1,I期临床,2024-12-06,phase 1,1,True,False,False,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,solid tumors,68Ga-MMP14,68Ga-MMP14
68Ga-MMP14,MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,北京大学肿瘤医院(原研),PET显像,I期临床,2024-12-06,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-MMP14,,诊断试剂领域,,DR071612,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2024-12-06,,phase 1,I期临床,2024-12-06,phase 1,1,True,False,False,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-MMP14,68Ga-MMP14
225Ac-RAYZ-8009,GPC3,225Ac标记的放射性药物;anti-GPC3多肽偶联核素,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),肝细胞癌(差异化疾病),I期临床,2024-12-10,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;中国无申报;Potential First-in-Class;Wnt信号通路,多肽偶联核素;225Ac标记的放射性药物,创新药,225Ac-RAYZ-8009;RYZ801,,肿瘤领域,,DR030874,否,美国;日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2024-12-10,phase 1,I期临床,2024-12-10,phase 1,2,True,False,True,['RayzeBio(Bristol-Myers Squibb)'],"['PeptiDream', 'RayzeBio(Bristol-Myers Squibb)']",2,"['PeptiDream(原研)', 'RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)']",肿瘤领域,肝细胞癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,hepatocellular carcinoma,225Ac-RAYZ-8009,225Ac-RAYZ-8009;RYZ801
[68Ga]-RYZ-GPC3,GPC3,anti-GPC3多肽偶联核素;68Ga标记的PET药物,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),肝细胞癌(差异化疾病),I期临床,2024-12-10,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;Wnt信号通路,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]-RYZ-GPC3;RYZ811,,肿瘤领域,,DR036238,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2024-12-10,phase 1,I期临床,2024-12-10,phase 1,1,True,False,True,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,肝细胞癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,hepatocellular carcinoma,[68Ga]-RYZ-GPC3,[68Ga]-RYZ-GPC3;RYZ811
[68Ga]-RYZ-GPC3,GPC3,anti-GPC3多肽偶联核素;68Ga标记的PET药物,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),PET显像,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;Wnt信号通路,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]-RYZ-GPC3;RYZ811,,诊断试剂领域,,DR036238,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2024-12-10,phase 1,1,True,False,True,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[68Ga]-RYZ-GPC3,[68Ga]-RYZ-GPC3;RYZ811
68Ga-3BP-3940,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,3B Pharmaceuticals(原研),实体瘤,I期临床,2025-04-24,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-3BP-3940,,肿瘤领域,,DR078864,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2025-04-24,phase 1,1,True,False,False,[],['3B Pharmaceuticals'],1,['3B Pharmaceuticals(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,solid tumors,68Ga-3BP-3940,68Ga-3BP-3940
68Ga-3BP-3940,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,3B Pharmaceuticals(原研),PET显像,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-3BP-3940,,诊断试剂领域,,DR078864,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2025-04-24,phase 1,1,True,False,False,[],['3B Pharmaceuticals'],1,['3B Pharmaceuticals(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-3BP-3940,68Ga-3BP-3940
13N-oxytocin,OXTR,13N标记的PET药物;anti-OXTR多肽偶联核素,Tonix Pharmaceuticals(原研),PET显像,I期临床,2025-05-02,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,13N标记的PET药物;多肽偶联核素,创新药,13N-oxytocin,,诊断试剂领域,,DR079142,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2025-05-02,phase 1,1,True,False,False,[],['Tonix Pharmaceuticals'],1,['Tonix Pharmaceuticals(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,13N-oxytocin,13N-oxytocin
FAP-2286,FAP,FAP抑制剂,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),实体瘤,I期临床,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,FAP-2286,,肿瘤领域,,DR062105,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2025-05-12,phase 1,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,solid tumors,FAP-2286,FAP-2286
FAP-2286,FAP,FAP抑制剂,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),骨转移疼痛(差异化疾病),I期临床,2025-05-12,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,FAP-2286,,肿瘤领域,,DR062105,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-05-12,,phase 1,I期临床,2025-05-12,phase 1,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,骨转移疼痛,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,bone metastasis pain,FAP-2286,FAP-2286
AUBE00,KRAS,KRAS抑制剂,Chugai Pharmaceutical(Top20 MNC)(原研),实体瘤,I期临床,2025-05-12,Active,其他,化药,环肽;难成药靶点,抑制剂,创新药,AUBE00,,肿瘤领域,,DR080098,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2025-05-12,phase 1,I期临床,2025-05-12,phase 1,1,True,False,True,['Chugai Pharmaceutical'],['Chugai Pharmaceutical'],1,['Chugai Pharmaceutical(Top20 MNC)(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,solid tumors,AUBE00,AUBE00
68Ga-CCZ01048,MSH;MC1R,MSH类似物;anti-MC1R多肽偶联核素;68Ga标记的PET药物,BC Cancer(原研),黑色素瘤,I期临床,2025-05-22,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;中国无申报;Potential First-in-Class;Melanogenesis;瘦素-黑皮素通路,类似物;多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-CCZ01048,,肿瘤领域;罕见疾病领域,,DR080251,否,加拿大,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2025-05-22,phase 1,1,True,True,False,[],['BC Cancer'],1,['BC Cancer(原研)'],肿瘤领域,黑色素瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,melanoma,68Ga-CCZ01048,68Ga-CCZ01048
68Ga-CCZ01048,MSH;MC1R,MSH类似物;anti-MC1R多肽偶联核素;68Ga标记的PET药物,BC Cancer(原研),诊断试剂,I期临床,2025-05-22,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;中国无申报;Potential First-in-Class;Melanogenesis;瘦素-黑皮素通路,类似物;多肽偶联核素;68Ga标记的PET药物,创新药,68Ga-CCZ01048,,诊断试剂领域,,DR080251,否,加拿大,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2025-05-22,phase 1,1,True,False,False,[],['BC Cancer'],1,['BC Cancer(原研)'],诊断试剂领域,诊断试剂,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,diagnostic reagents,68Ga-CCZ01048,68Ga-CCZ01048
MC-339,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),实体瘤,I期临床,2025-06-05,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,,肿瘤领域,,DR007854,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2025-06-05,phase 1,I期临床,2025-06-05,phase 1,1,True,False,True,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,solid tumors,MC-339,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096
MC-339,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),小细胞肺癌,I期临床,2025-06-05,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,,肿瘤领域;罕见疾病领域,,DR007854,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2025-06-05,phase 1,I期临床,2025-06-05,phase 1,1,True,True,True,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,small cell lung cancer,MC-339,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096
MC-339,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),胃肠胰神经内分泌肿瘤,I期临床,2025-06-05,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,,肿瘤领域;罕见疾病领域,,DR007854,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2025-06-05,phase 1,I期临床,2025-06-05,phase 1,1,True,True,True,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,胃肠胰神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,Gastroenteropancreatic neuroendocrine tumors,MC-339,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096
MC-339,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),大细胞神经内分泌癌,I期临床,2025-06-05,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,,肿瘤领域;罕见疾病领域,,DR007854,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2025-06-05,phase 1,I期临床,2025-06-05,phase 1,1,True,True,True,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,大细胞神经内分泌癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,large cell neuroendocrine carcinoma,MC-339,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096
MC-339,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),神经内分泌前列腺癌,I期临床,2025-06-05,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,,肿瘤领域,,DR007854,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2025-06-05,phase 1,I期临床,2025-06-05,phase 1,1,True,False,True,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,神经内分泌前列腺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,neuroendocrine prostate cancer,MC-339,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096
MC-339,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),肺神经内分泌肿瘤,I期临床,2025-06-05,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,,肿瘤领域;罕见疾病领域,,DR007854,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2025-06-05,phase 1,I期临床,2025-06-05,phase 1,1,True,True,True,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,肺神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,Pulmonary neuroendocrine tumors,MC-339,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096
TT-P34,CREB,CREB激活剂,Teitur Trophics(原研),帕金森病,I期临床,2025-06-13,Active,多肽,化药,环肽;Potential First-in-Class,激活剂,创新药,TT-P34,,神经领域,,DR047339,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,2025-06-13,phase 1,1,True,False,False,[],['Teitur Trophics'],1,['Teitur Trophics(原研)'],神经领域,帕金森病,['神经领域'],1,神经领域,,,1,1,Neurology,Neurology,,,Parkinson's disease,TT-P34,TT-P34
TT-P34,CREB,CREB激活剂,Teitur Trophics(原研),亨廷顿氏病,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,激活剂,创新药,TT-P34,,神经领域;罕见疾病领域,,DR047339,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,I期临床,2025-06-13,phase 1,1,True,True,False,[],['Teitur Trophics'],1,['Teitur Trophics(原研)'],神经领域,亨廷顿氏病,['神经领域'],1,神经领域,,,1,-1,Neurology,Neurology,,,Huntington's disease,TT-P34,TT-P34
TT-P34,CREB,CREB激活剂,Teitur Trophics(原研),额颞叶痴呆,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,激活剂,创新药,TT-P34,,神经领域;罕见疾病领域,,DR047339,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,I期临床,2025-06-13,phase 1,1,True,True,False,[],['Teitur Trophics'],1,['Teitur Trophics(原研)'],神经领域,额颞叶痴呆,['神经领域'],1,神经领域,,,1,-1,Neurology,Neurology,,,frontotemporal dementia,TT-P34,TT-P34
68Ga-nectin-4 bicyclic peptide,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,苏州大学附属第一医院(原研),实体瘤,I期临床,2025-07-09,Active,多肽;放射性药物;偶联药物,其他,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-nectin-4 bicyclic peptide,,肿瘤领域,,DR082017,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-07-09,,phase 1,I期临床,2025-07-09,phase 1,1,True,False,False,[],['苏州大学附属第一医院'],1,['苏州大学附属第一医院(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,solid tumors,68Ga-nectin-4 bicyclic peptide,68Ga-nectin-4 bicyclic peptide
68Ga-nectin-4 bicyclic peptide,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,苏州大学附属第一医院(原研),PET显像,I期临床,2025-07-09,Active,多肽;放射性药物;偶联药物,其他,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-nectin-4 bicyclic peptide,,诊断试剂领域,,DR082017,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-07-09,,phase 1,I期临床,2025-07-09,phase 1,1,True,False,False,[],['苏州大学附属第一医院'],1,['苏州大学附属第一医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-nectin-4 bicyclic peptide,68Ga-nectin-4 bicyclic peptide
68Ga-DOTA-WL12,PDL1,anti-PDL1多肽偶联核素;68Ga标记的PET药物,复旦大学附属华山医院(原研),头颈癌(差异化疾病),I期临床,2025-07-30,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-WL12,,肿瘤领域,,DR082669,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-07-30,,phase 1,I期临床,2025-07-30,phase 1,1,True,False,False,[],['复旦大学附属华山医院'],1,['复旦大学附属华山医院(原研)'],肿瘤领域,头颈癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,Head and neck cancer,68Ga-DOTA-WL12,68Ga-DOTA-WL12
68Ga-DOTA-WL12,PDL1,anti-PDL1多肽偶联核素;68Ga标记的PET药物,复旦大学附属华山医院(原研),PET显像,I期临床,2025-07-30,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-WL12,,诊断试剂领域,,DR082669,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-07-30,,phase 1,I期临床,2025-07-30,phase 1,1,True,False,False,[],['复旦大学附属华山医院'],1,['复旦大学附属华山医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-DOTA-WL12,68Ga-DOTA-WL12
68Ga-DOTA-WL12,PDL1,anti-PDL1多肽偶联核素;68Ga标记的PET药物,复旦大学附属华山医院(原研),非小细胞肺癌(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-WL12,,肿瘤领域,,DR082669,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,I期临床,2025-07-30,phase 1,1,True,False,False,[],['复旦大学附属华山医院'],1,['复旦大学附属华山医院(原研)'],肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,1,-1,Oncology,Oncology,,,non-small cell lung cancer,68Ga-DOTA-WL12,68Ga-DOTA-WL12
[18F]DK222,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,Johns Hopkins University;Precision Molecular(原研),非小细胞肺癌(差异化疾病),I期临床,2025-08-24,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,18F标记的PET药物;多肽偶联核素,创新药,[18F]DK222;PMI06,,肿瘤领域,,DR056475,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2025-08-24,phase 1,I期临床,2025-08-24,phase 1,2,True,False,False,[],['Precision Molecular'],1,"['Johns Hopkins University', 'Precision Molecular(原研)']",肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,non-small cell lung cancer,[18F]DK222,[18F]DK222;PMI06
[18F]DK222,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,Johns Hopkins University;Precision Molecular(原研),尿路上皮癌(差异化疾病),I期临床,2025-08-24,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,18F标记的PET药物;多肽偶联核素,创新药,[18F]DK222;PMI06,,肿瘤领域,,DR056475,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2025-08-24,phase 1,I期临床,2025-08-24,phase 1,2,True,False,False,[],['Precision Molecular'],1,"['Johns Hopkins University', 'Precision Molecular(原研)']",肿瘤领域,尿路上皮癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,urothelial carcinoma,[18F]DK222,[18F]DK222;PMI06
[18F]DK222,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,Johns Hopkins University;Precision Molecular(原研),PET显像,I期临床,2025-08-24,Unknown,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,18F标记的PET药物;多肽偶联核素,创新药,[18F]DK222;PMI06,,诊断试剂领域,,DR056475,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,I期临床,,2025-08-24,phase 1,I期临床,2025-08-24,phase 1,2,True,False,False,[],['Precision Molecular'],1,"['Johns Hopkins University', 'Precision Molecular(原研)']",诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[18F]DK222,[18F]DK222;PMI06
18F-SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),神经母细胞瘤,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,创新药,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,,肿瘤领域;罕见疾病领域,,DR081193,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,I期临床,2025-09-26,phase 1,1,True,True,False,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],肿瘤领域,神经母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,Neuroblastoma,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE
18F-SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),抑郁症,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,创新药,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,,精神领域,,DR081193,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,I期临床,2025-09-26,phase 1,1,True,False,False,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],精神领域,抑郁症,['精神领域'],1,精神领域,,,1,1,Psychiatry,Psychiatry,,,depression,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE
18F-SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),不孕不育,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,创新药,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,,泌尿生殖领域,,DR081193,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,I期临床,2025-09-26,phase 1,1,True,False,False,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],泌尿生殖领域,不孕不育,['泌尿生殖领域'],1,泌尿生殖领域,,,1,1,Genitourinary,Genitourinary,,,Infertility,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE
18F-SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),嗜铬细胞瘤,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,创新药,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,,肿瘤领域;罕见疾病领域,,DR081193,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,I期临床,2025-09-26,phase 1,1,True,True,False,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],肿瘤领域,嗜铬细胞瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,Pheochromocytoma,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE
18F-SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),骨转移疼痛,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,创新药,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,,肿瘤领域,,DR081193,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,I期临床,2025-09-26,phase 1,1,True,False,False,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],肿瘤领域,骨转移疼痛,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,bone metastasis pain,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE
18F-SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),副神经节瘤,I期临床,2025-09-26,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,创新药,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,,肿瘤领域;罕见疾病领域,,DR081193,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,I期临床,,2025-09-26,,phase 1,I期临床,2025-09-26,phase 1,1,True,True,False,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],肿瘤领域,副神经节瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,paraganglioma,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE
18F-SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,创新药,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,,诊断试剂领域,,DR081193,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,I期临床,2025-09-26,phase 1,1,True,False,False,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE
18F-SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),脑膜瘤(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,创新药,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,,肿瘤领域,,DR081193,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,I期临床,2025-09-26,phase 1,1,True,False,False,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],肿瘤领域,脑膜瘤,['肿瘤领域'],1,肿瘤领域,,,1,-1,Oncology,Oncology,,,Meningioma,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE
225Ac-DOTA-LM3,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,Università Cattolica del Sacro Cuore(原研),神经内分泌肿瘤,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,创新药,225Ac-DOTA-LM3,,肿瘤领域;罕见疾病领域,,DR089738,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,,phase 1,1,True,True,False,[],['Università Cattolica del Sacro Cuore'],1,['Università Cattolica del Sacro Cuore(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,neuroendocrine tumors,225Ac-DOTA-LM3,225Ac-DOTA-LM3
CAM4071,somatostatin,somatostatin类似物,Camurus(原研),肢端肥大症,I期临床,,Active,多肽,化药,环肽,类似物,微创新,CAM4071;CAM4071 (帕瑞肽FluidCrystal®长效注射剂）;CAM4071 (pasireotide FluidCrystal® long-acting injection),,内分泌及代谢领域;罕见疾病领域,,DR018258,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,,phase 1,1,True,True,False,[],['Camurus'],1,['Camurus(原研)'],内分泌及代谢领域,肢端肥大症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,1,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,acromegaly,CAM4071 (pasireotide FluidCrystal® long-acting injection),CAM4071;CAM4071 (帕瑞肽FluidCrystal®长效注射剂）;CAM4071 (pasireotide FluidCrystal® long-acting injection)
CAM4071,somatostatin,somatostatin类似物,Camurus(原研),库欣综合征,I期临床,,Active,多肽,化药,环肽,类似物,微创新,CAM4071;CAM4071 (帕瑞肽FluidCrystal®长效注射剂）;CAM4071 (pasireotide FluidCrystal® long-acting injection),,内分泌及代谢领域;罕见疾病领域,,DR018258,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,,phase 1,1,True,True,False,[],['Camurus'],1,['Camurus(原研)'],内分泌及代谢领域,库欣综合征,['内分泌及代谢领域'],1,内分泌及代谢领域,,,1,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Cushing's syndrome,CAM4071 (pasireotide FluidCrystal® long-acting injection),CAM4071;CAM4071 (帕瑞肽FluidCrystal®长效注射剂）;CAM4071 (pasireotide FluidCrystal® long-acting injection)
CsA-SNU2001,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,CAMP Therapeutics(原研),干眼病,I期临床,,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,微创新,CsA-SNU2001;SNU2101,,眼科领域,,DR075599,否,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,,phase 1,1,True,False,False,[],['CAMP Therapeutics'],1,['CAMP Therapeutics(原研)'],眼科领域,干眼病,['眼科领域'],1,眼科领域,,,1,1,Ophthalmology,Ophthalmology,,,dry eye disease,CsA-SNU2001,CsA-SNU2001;SNU2101
NVI-100,CGRP receptor,CGRP receptor拮抗剂,Ferring Pharmaceuticals(原研);Nuvie Bio,偏头痛,I期临床,,Active,多肽,化药,环肽;G蛋白偶联受体;中国无申报,拮抗剂,创新药,NVI-100;NVI-100 (AXN-001);FE205030,,麻醉镇痛领域;神经领域,,DR072945,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,,phase 1,2,True,False,False,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', 'Nuvie Bio']",麻醉镇痛领域,偏头痛,"['麻醉镇痛领域', '神经领域']",2,麻醉镇痛领域,神经领域,,1,1,Anesthesia & Analgesia,Anesthesia & Analgesia,Neurology,,Migraine,NVI-100 (AXN-001),NVI-100;NVI-100 (AXN-001);FE205030
ZP BNP,BNP,重组BNP,Zosano Pharma(原研),急性失代偿性心力衰竭,I期临床,,Active,多肽,生物,环肽,重组,微创新,ZP BNP;ZP BNP (奈西立肽贴剂);ZP BNP (nesiritide patch),,心脑血管领域,,DR059743,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,,phase 1,1,True,False,False,[],['Zosano Pharma'],1,['Zosano Pharma(原研)'],心脑血管领域,急性失代偿性心力衰竭,['心脑血管领域'],1,心脑血管领域,,,1,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,acute decompensated heart failure,ZP BNP (nesiritide patch),ZP BNP;ZP BNP (奈西立肽贴剂);ZP BNP (nesiritide patch)
[68Ga]-BCY25286,MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,Bicycle Therapeutics(原研),PET显像,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]-BCY25286,,诊断试剂领域,,DR077676,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,,phase 1,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[68Ga]-BCY25286,[68Ga]-BCY25286
[68Ga]-BCY25286,MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,Bicycle Therapeutics(原研),肺腺癌(差异化疾病),I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]-BCY25286,,肿瘤领域,,DR077676,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,,phase 1,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,肺腺癌,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,lung adenocarcinoma,[68Ga]-BCY25286,[68Ga]-BCY25286
[68Ga]Ga-C1-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,南方医科大学南方医院(原研),肿瘤,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]Ga-C1-FAP-2286,,肿瘤领域,,DR081012,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,,phase 1,1,True,False,False,[],['南方医科大学南方医院'],1,['南方医科大学南方医院(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,tumor,[68Ga]Ga-C1-FAP-2286,[68Ga]Ga-C1-FAP-2286
[68Ga]Ga-C1-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,南方医科大学南方医院(原研),PET显像,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]Ga-C1-FAP-2286,,诊断试剂领域,,DR081012,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,,phase 1,1,True,False,False,[],['南方医科大学南方医院'],1,['南方医科大学南方医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[68Ga]Ga-C1-FAP-2286,[68Ga]Ga-C1-FAP-2286
[68Ga]PSV377,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Perspective Therapeutics(原研),癌症,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]PSV377;[68Ga]Ga-PSV377,,肿瘤领域,,DR089770,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,,phase 1,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,cancer,[68Ga]PSV377,[68Ga]PSV377;[68Ga]Ga-PSV377
[68Ga]PSV377,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Perspective Therapeutics(原研),PET显像,I期临床,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]PSV377;[68Ga]Ga-PSV377,,诊断试剂领域,,DR089770,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,,phase 1,1,True,False,False,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[68Ga]PSV377,[68Ga]PSV377;[68Ga]Ga-PSV377
lanreotide acetate CRF,somatostatin,somatostatin类似物,ASCIL Biopharm(原研),神经内分泌肿瘤,I期临床,,Active,多肽,化药,环肽;中国无申报,类似物,微创新,lanreotide acetate CRF;醋酸兰瑞肽控释注射剂;lanreotide acetate controlled release formulation,,肿瘤领域;罕见疾病领域,,DR009210,否,澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,,phase 1,1,True,True,False,[],['ASCIL Biopharm'],1,['ASCIL Biopharm(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,neuroendocrine tumors,lanreotide acetate controlled release formulation,lanreotide acetate CRF;醋酸兰瑞肽控释注射剂;lanreotide acetate controlled release formulation
octreotide acetate CR,somatostatin,somatostatin类似物,ASCIL Biopharm(原研),神经内分泌肿瘤,I期临床,,Active,多肽,化药,环肽;中国无申报,类似物,微创新,octreotide acetate CR;octreotide acetate CR (奥曲肽控释注射剂）;octreotide acetate CR (octreotide controlled release formulation）;octreotide acetate CRF,,肿瘤领域;罕见疾病领域,,DR059890,否,澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,phase 1,I期临床,,phase 1,1,True,True,False,[],['ASCIL Biopharm'],1,['ASCIL Biopharm(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,,neuroendocrine tumors,octreotide acetate CR (octreotide controlled release formulation）,octreotide acetate CR;octreotide acetate CR (奥曲肽控释注射剂）;octreotide acetate CR (octreotide controlled release formulation）;octreotide acetate CRF
GP-033,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,济群医药(原研),炎症性肠病,申报临床,2024-03-30,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,GP-033,,免疫领域;消化领域,申报临床:软胶囊,DR014293,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,申报临床,,2024-03-30,,ind,申报临床,2024-01-10,ind,1,True,False,False,[],['济群医药'],1,['济群医药(原研)'],免疫领域,炎症性肠病,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,0,0,Immunology,Immunology,Digestive System,,inflammatory bowel disease,GP-033,GP-033
GP-033,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,济群医药(原研),克罗恩病,申报临床,2024-03-30,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,GP-033,,消化领域;免疫领域,申报临床:软胶囊,DR014293,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,申报临床,,2024-03-30,,ind,申报临床,2024-01-10,ind,1,True,False,False,[],['济群医药'],1,['济群医药(原研)'],消化领域,克罗恩病,"['消化领域', '免疫领域']",2,消化领域,免疫领域,,0,0,Digestive System,Digestive System,Immunology,,Crohn's disease,GP-033,GP-033
GP-033,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,济群医药(原研),溃疡性结肠炎,申报临床,2024-01-10,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,GP-033,,免疫领域;消化领域,申报临床:软胶囊,DR014293,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,申报临床,,2024-01-10,,ind,申报临床,2024-01-10,ind,1,True,False,False,[],['济群医药'],1,['济群医药(原研)'],免疫领域,溃疡性结肠炎,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,0,0,Immunology,Immunology,Digestive System,,ulcerative colitis,GP-033,GP-033
[225Ac]Ac-DOTATOC,SSTR,anti-SSTR多肽偶联核素;225Ac标记的放射性药物,Nantes University Hospital(原研);Angers University(原研),胰腺神经内分泌肿瘤(差异化疾病),临床前,2024-09-13,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物;多肽偶联核素,创新药,[225Ac]Ac-DOTATOC,,肿瘤领域;罕见疾病领域,,DR081531,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2024-09-13,pre-clinical,2,True,True,False,[],"['Nantes University Hospital', 'Angers University']",2,"['Nantes University Hospital(原研)', 'Angers University(原研)']",肿瘤领域,胰腺神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,pancreatic neuroendocrine tumors,[225Ac]Ac-DOTATOC,[225Ac]Ac-DOTATOC
[18F]AlF-NOTA-A6P,ITGA6,18F标记的PET药物;anti-ITGA6多肽偶联核素,江南大学附属医院(原研),PET显像,临床前,2024-10-17,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,创新药,[18F]AlF-NOTA-A6P,,诊断试剂领域,,DR081455,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2024-10-17,pre-clinical,1,True,False,False,[],['江南大学附属医院'],1,['江南大学附属医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[18F]AlF-NOTA-A6P,[18F]AlF-NOTA-A6P
[18F]AlF-NOTA-A6P,ITGA6,18F标记的PET药物;anti-ITGA6多肽偶联核素,江南大学附属医院(原研),结直肠癌,临床前,2024-10-17,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,创新药,[18F]AlF-NOTA-A6P,,肿瘤领域,,DR081455,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2024-10-17,pre-clinical,1,True,False,False,[],['江南大学附属医院'],1,['江南大学附属医院(原研)'],肿瘤领域,结直肠癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,colorectal cancer,[18F]AlF-NOTA-A6P,[18F]AlF-NOTA-A6P
[225Ac]Ac-EBTATE,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,University of Saskatchewan(原研),小细胞肺癌,临床前,2024-12-04,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;中国无申报,多肽偶联核素;225Ac标记的放射性药物,创新药,[225Ac]Ac-EBTATE,,肿瘤领域;罕见疾病领域,,DR081419,否,加拿大,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2024-12-04,pre-clinical,1,True,True,False,[],['University of Saskatchewan'],1,['University of Saskatchewan(原研)'],肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,small cell lung cancer,[225Ac]Ac-EBTATE,[225Ac]Ac-EBTATE
[225Ac]Ac-EBTATE,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,University of Saskatchewan(原研),胰腺神经内分泌肿瘤(差异化疾病),临床前,2024-12-04,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;中国无申报,多肽偶联核素;225Ac标记的放射性药物,创新药,[225Ac]Ac-EBTATE,,肿瘤领域;罕见疾病领域,,DR081419,否,加拿大,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2024-12-04,pre-clinical,1,True,True,False,[],['University of Saskatchewan'],1,['University of Saskatchewan(原研)'],肿瘤领域,胰腺神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,pancreatic neuroendocrine tumors,[225Ac]Ac-EBTATE,[225Ac]Ac-EBTATE
myostatin therapeutic peptide,myostatin,myostatin抑制剂,PeptiDream(原研);Kawasaki Medical School(原研),肥胖,临床前,2024-12-12,Active,多肽,化药,环肽;TGF-β信号通路,抑制剂,创新药,myostatin therapeutic peptide;myostatin therapeutic peptide (Kawasaki Medical School),,内分泌及代谢领域,,DR011921,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2024-12-12,pre-clinical,2,True,False,False,[],"['PeptiDream', 'Kawasaki Medical School']",2,"['PeptiDream(原研)', 'Kawasaki Medical School(原研)']",内分泌及代谢领域,肥胖,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,obesity,myostatin therapeutic peptide (Kawasaki Medical School),myostatin therapeutic peptide;myostatin therapeutic peptide (Kawasaki Medical School)
myostatin therapeutic peptide,myostatin,myostatin抑制剂,PeptiDream(原研);Kawasaki Medical School(原研),假肥大性肌营养不良,临床前,,Active,多肽,化药,环肽;TGF-β信号通路,抑制剂,创新药,myostatin therapeutic peptide;myostatin therapeutic peptide (Kawasaki Medical School),,骨骼肌肉领域;罕见疾病领域,,DR011921,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2024-12-12,pre-clinical,2,True,True,False,[],"['PeptiDream', 'Kawasaki Medical School']",2,"['PeptiDream(原研)', 'Kawasaki Medical School(原研)']",骨骼肌肉领域,假肥大性肌营养不良,['骨骼肌肉领域'],1,骨骼肌肉领域,,,-1,-1,Musculoskeletal,Musculoskeletal,,,Duchenne muscular dystrophy,myostatin therapeutic peptide (Kawasaki Medical School),myostatin therapeutic peptide;myostatin therapeutic peptide (Kawasaki Medical School)
MCR环肽,MC4R,MC4R激动剂,万邦德制药(原研),肥胖,临床前,2025-03-29,Active,小分子,化药,环肽;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,MCR环肽;MCR环肽 (wepon);MCR cyclic peptide (wepon),,内分泌及代谢领域,,DR077260,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,临床前,,2025-03-29,,pre-clinical,临床前,2025-03-29,pre-clinical,1,True,False,False,[],['万邦德制药'],1,['万邦德制药(原研)'],内分泌及代谢领域,肥胖,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,obesity,MCR cyclic peptide (wepon),MCR环肽;MCR环肽 (wepon);MCR cyclic peptide (wepon)
[149Tb]Tb-DOTA-LM3,SSTR2,149Tb标记的放射性药物;anti-SSTR2多肽偶联核素,Paul Scherrer Institute(原研),肿瘤,临床前,2025-03-31,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;149Tb标记的放射性药物,创新药,[149Tb]Tb-DOTA-LM3,,肿瘤领域,,DR081317,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2025-03-31,pre-clinical,1,True,False,False,[],['Paul Scherrer Institute'],1,['Paul Scherrer Institute(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,[149Tb]Tb-DOTA-LM3,[149Tb]Tb-DOTA-LM3
[149Tb]Tb-DOTATATE,SSTR,anti-SSTR多肽偶联核素;149Tb标记的放射性药物,Paul Scherrer Institute(原研),肿瘤,临床前,2025-03-31,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;149Tb标记的放射性药物,创新药,[149Tb]Tb-DOTATATE,,肿瘤领域,,DR081316,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2025-03-31,pre-clinical,1,True,False,False,[],['Paul Scherrer Institute'],1,['Paul Scherrer Institute(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,[149Tb]Tb-DOTATATE,[149Tb]Tb-DOTATATE
Al18F-NOTA-FAP-2286,FAP,anti-FAP多肽偶联核素;18F标记的PET药物,贵州医科大学(原研),前列腺癌,临床前,2025-04-23,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,Al18F-NOTA-FAP-2286,,肿瘤领域,,DR081166,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2025-04-23,pre-clinical,1,True,False,False,[],['贵州医科大学'],1,['贵州医科大学(原研)'],肿瘤领域,前列腺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,prostate cancer,Al18F-NOTA-FAP-2286,Al18F-NOTA-FAP-2286
Al18F-NOTA-FAP-2286,FAP,anti-FAP多肽偶联核素;18F标记的PET药物,贵州医科大学(原研),PET显像,临床前,2025-04-23,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,Al18F-NOTA-FAP-2286,,诊断试剂领域,,DR081166,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2025-04-23,pre-clinical,1,True,False,False,[],['贵州医科大学'],1,['贵州医科大学(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,Al18F-NOTA-FAP-2286,Al18F-NOTA-FAP-2286
177Lu-PD-29875,CLDN18.2,177Lu标记的放射性药物;anti-CLDN18.2多肽偶联核素,PeptiDream(原研),胰腺癌,临床前,2025-04-27,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-PD-29875,,肿瘤领域;罕见疾病领域,,DR081156,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2025-04-27,pre-clinical,1,True,True,False,[],['PeptiDream'],1,['PeptiDream(原研)'],肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,pancreatic cancer,177Lu-PD-29875,177Lu-PD-29875
[18F]AlF-NOTA-SC,CXCR4,18F标记的PET药物;anti-CXCR4多肽偶联核素,Katholieke Universiteit Leuven(原研),肿瘤,临床前,2025-04-30,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体,多肽偶联核素;18F标记的PET药物,创新药,[18F]AlF-NOTA-SC,,肿瘤领域,,DR081435,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2025-04-30,pre-clinical,1,True,False,False,[],['Katholieke Universiteit Leuven'],1,['Katholieke Universiteit Leuven(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,[18F]AlF-NOTA-SC,[18F]AlF-NOTA-SC
[18F]AlF-NOTA-SC,CXCR4,18F标记的PET药物;anti-CXCR4多肽偶联核素,Katholieke Universiteit Leuven(原研),PET显像,临床前,2025-04-30,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体,多肽偶联核素;18F标记的PET药物,创新药,[18F]AlF-NOTA-SC,,诊断试剂领域,,DR081435,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2025-04-30,pre-clinical,1,True,False,False,[],['Katholieke Universiteit Leuven'],1,['Katholieke Universiteit Leuven(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[18F]AlF-NOTA-SC,[18F]AlF-NOTA-SC
[64Cu]CARP-2,uPAR,anti-uPAR多肽偶联核素;64Cu标记的放射性示踪剂,中国医学科学院&北京协和医学院(原研),肿瘤,临床前,2025-05-19,Active,多肽;放射性药物;偶联药物,化药,环肽,64Cu标记的放射性示踪剂;多肽偶联核素,创新药,[64Cu]CARP-2,,肿瘤领域,,DR081128,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2025-05-19,pre-clinical,1,True,False,False,[],['中国医学科学院&北京协和医学院'],1,['中国医学科学院&北京协和医学院(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,[64Cu]CARP-2,[64Cu]CARP-2
[64Cu]CARP-2,uPAR,anti-uPAR多肽偶联核素;64Cu标记的放射性示踪剂,中国医学科学院&北京协和医学院(原研),PET显像,临床前,2025-05-19,Active,多肽;放射性药物;偶联药物,化药,环肽,64Cu标记的放射性示踪剂;多肽偶联核素,创新药,[64Cu]CARP-2,,诊断试剂领域,,DR081128,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2025-05-19,pre-clinical,1,True,False,False,[],['中国医学科学院&北京协和医学院'],1,['中国医学科学院&北京协和医学院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[64Cu]CARP-2,[64Cu]CARP-2
[18F]AlF-NOTA-(SDM17)2,αvβ6,anti-αvβ6多肽偶联核素;18F标记的PET药物,南方医科大学(原研),肿瘤,临床前,2025-06-01,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,创新药,[18F]AlF-NOTA-(SDM17)2,,肿瘤领域,,DR081243,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2025-06-01,pre-clinical,1,True,False,False,[],['南方医科大学'],1,['南方医科大学(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,[18F]AlF-NOTA-(SDM17)2,[18F]AlF-NOTA-(SDM17)2
[18F]AlF-NOTA-(SDM17)2,αvβ6,anti-αvβ6多肽偶联核素;18F标记的PET药物,南方医科大学(原研),PET显像,临床前,2025-06-01,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,创新药,[18F]AlF-NOTA-(SDM17)2,,诊断试剂领域,,DR081243,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2025-06-01,pre-clinical,1,True,False,False,[],['南方医科大学'],1,['南方医科大学(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[18F]AlF-NOTA-(SDM17)2,[18F]AlF-NOTA-(SDM17)2
[99mTc]Tc-HYNIC-cycOn,c-Met,anti-c-Met多肽偶联核素;含锝放射性示踪剂,中国药科大学(原研),放射性核素显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;受体酪氨酸激酶;Potential First-in-Class,含锝放射性示踪剂;多肽偶联核素,创新药,[99mTc]Tc-HYNIC-cycOn,,诊断试剂领域,,DR081209,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2025-06-22,pre-clinical,1,True,False,False,[],['中国药科大学'],1,['中国药科大学(原研)'],诊断试剂领域,放射性核素显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,radionuclide imaging,[99mTc]Tc-HYNIC-cycOn,[99mTc]Tc-HYNIC-cycOn
[99mTc]Tc-HYNIC-cycOn,c-Met,anti-c-Met多肽偶联核素;含锝放射性示踪剂,中国药科大学(原研),结直肠癌,临床前,2025-06-22,Active,多肽;放射性药物;偶联药物,化药,环肽;受体酪氨酸激酶;Potential First-in-Class,含锝放射性示踪剂;多肽偶联核素,创新药,[99mTc]Tc-HYNIC-cycOn,,肿瘤领域,,DR081209,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2025-06-22,pre-clinical,1,True,False,False,[],['中国药科大学'],1,['中国药科大学(原研)'],肿瘤领域,结直肠癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,colorectal cancer,[99mTc]Tc-HYNIC-cycOn,[99mTc]Tc-HYNIC-cycOn
IL-17A and IL-17F Dual Inhibitor,IL-17A;IL-17F,IL-17F抑制剂;IL-17A抑制剂,PeptiDream(原研),自身免疫性疾病,临床前,2025-12-17,Active,多肽,化药,环肽;Th17通路,抑制剂,创新药,IL-17A and IL-17F Dual Inhibitor;IL-17A and IL-17F Dual Inhibitor (PeptiDream),,免疫领域,,DR090431,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,2025-12-17,pre-clinical,1,True,False,False,[],['PeptiDream'],1,['PeptiDream(原研)'],免疫领域,自身免疫性疾病,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,autoimmune disease,IL-17A and IL-17F Dual Inhibitor (PeptiDream),IL-17A and IL-17F Dual Inhibitor;IL-17A and IL-17F Dual Inhibitor (PeptiDream)
111In-DPI-4452,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,Debiopharm;3B Pharmaceuticals(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,创新药,111In-DPI-4452,,肿瘤领域,,DR042206,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', '3B Pharmaceuticals(原研)']",肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,111In-DPI-4452,111In-DPI-4452
111In-DPI-4452,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,Debiopharm;3B Pharmaceuticals(原研),SPECT显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,创新药,111In-DPI-4452,,诊断试剂领域,,DR042206,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', '3B Pharmaceuticals(原研)']",诊断试剂领域,SPECT显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,SPECT imaging,111In-DPI-4452,111In-DPI-4452
111In-DPI-4501,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,Debiopharm;3B Pharmaceuticals(原研),肾细胞癌(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,创新药,111In-DPI-4501,,肿瘤领域,,DR014701,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', '3B Pharmaceuticals(原研)']",肿瘤领域,肾细胞癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,renal cell carcinoma,111In-DPI-4501,111In-DPI-4501
111In-DPI-4501,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,Debiopharm;3B Pharmaceuticals(原研),SPECT显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,创新药,111In-DPI-4501,,诊断试剂领域,,DR014701,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', '3B Pharmaceuticals(原研)']",诊断试剂领域,SPECT显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,SPECT imaging,111In-DPI-4501,111In-DPI-4501
111In-DPI-4501,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,Debiopharm;3B Pharmaceuticals(原研),结直肠癌(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,创新药,111In-DPI-4501,,肿瘤领域,,DR014701,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],['3B Pharmaceuticals'],1,"['Debiopharm', '3B Pharmaceuticals(原研)']",肿瘤领域,结直肠癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,colorectal cancer,111In-DPI-4501,111In-DPI-4501
111In-FAP-2286,FAP,含铟放射性示踪剂;anti-FAP多肽偶联核素,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),实体瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,创新药,111In-FAP-2286,,肿瘤领域,,DR042207,否,欧洲,欧洲,,,,,pre-clinical,临床前,,pre-clinical,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,solid tumors,111In-FAP-2286,111In-FAP-2286
111In-FAP-2286,FAP,含铟放射性示踪剂;anti-FAP多肽偶联核素,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),SPECT显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,创新药,111In-FAP-2286,,诊断试剂领域,,DR042207,否,欧洲,欧洲,,,,,pre-clinical,临床前,,pre-clinical,3,True,False,True,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",诊断试剂领域,SPECT显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,SPECT imaging,111In-FAP-2286,111In-FAP-2286
177 Lu-DOTA-EB-RGD,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,Molecular Targeting Technologies(原研),非小细胞肺癌,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,177 Lu-DOTA-EB-RGD,,肿瘤领域,,DR025932,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Molecular Targeting Technologies'],1,['Molecular Targeting Technologies(原研)'],肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,non-small cell lung cancer,177 Lu-DOTA-EB-RGD,177 Lu-DOTA-EB-RGD
177Lu-PD-32766,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,PeptiDream(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-PD-32766,,诊断试剂领域,,DR071097,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PeptiDream'],1,['PeptiDream(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,177Lu-PD-32766,177Lu-PD-32766
177Lu-PD-32766,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,PeptiDream(原研),肾透明细胞癌,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-PD-32766,,肿瘤领域,,DR071097,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PeptiDream'],1,['PeptiDream(原研)'],肿瘤领域,肾透明细胞癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,clear cell renal cell carcinoma,177Lu-PD-32766,177Lu-PD-32766
177Lu-PTR-58,SSTR3,anti-SSTR3多肽偶联核素,Starget Pharma(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,创新药,177Lu-PTR-58,,肿瘤领域,,DR070791,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Starget Pharma'],1,['Starget Pharma(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,177Lu-PTR-58,177Lu-PTR-58
177Lu-PTR-58,SSTR3,anti-SSTR3多肽偶联核素,Starget Pharma(原研),肉瘤(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,创新药,177Lu-PTR-58,,肿瘤领域,,DR070791,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Starget Pharma'],1,['Starget Pharma(原研)'],肿瘤领域,肉瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,sarcoma,177Lu-PTR-58,177Lu-PTR-58
177Lu-RAYZ-6114,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),实体瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,创新药,177Lu-RAYZ-6114,,肿瘤领域,,DR076538,否,美国;日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,True,['RayzeBio(Bristol-Myers Squibb)'],"['PeptiDream', 'RayzeBio(Bristol-Myers Squibb)']",2,"['PeptiDream(原研)', 'RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)']",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,solid tumors,177Lu-RAYZ-6114,177Lu-RAYZ-6114
177Lu-RAYZ-6283,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),实体瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,177Lu-RAYZ-6283,,肿瘤领域,,DR073584,否,美国;日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,True,['RayzeBio(Bristol-Myers Squibb)'],"['PeptiDream', 'RayzeBio(Bristol-Myers Squibb)']",2,"['PeptiDream(原研)', 'RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)']",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,solid tumors,177Lu-RAYZ-6283,177Lu-RAYZ-6283
225Ac-EBTATE,SSTR,anti-SSTR多肽偶联核素;225Ac标记的放射性药物,Molecular Targeting Technologies(原研),小细胞肺癌(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,创新药,225Ac-EBTATE,,肿瘤领域;罕见疾病领域,,DR071624,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Molecular Targeting Technologies'],1,['Molecular Targeting Technologies(原研)'],肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,small cell lung cancer,225Ac-EBTATE,225Ac-EBTATE
225Ac-EBTATE,SSTR,anti-SSTR多肽偶联核素;225Ac标记的放射性药物,Molecular Targeting Technologies(原研),神经内分泌肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,创新药,225Ac-EBTATE,,肿瘤领域;罕见疾病领域,,DR071624,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Molecular Targeting Technologies'],1,['Molecular Targeting Technologies(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,neuroendocrine tumors,225Ac-EBTATE,225Ac-EBTATE
225Ac-PD-29875,CLDN18.2,anti-CLDN18.2多肽偶联核素;225Ac标记的放射性药物,PeptiDream(原研),胃癌,临床前,,Active,多肽;放射性药物;偶联药物,其他,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,225Ac-PD-29875,,肿瘤领域,,DR071926,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PeptiDream'],1,['PeptiDream(原研)'],肿瘤领域,胃癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,stomach cancer,225Ac-PD-29875,225Ac-PD-29875
225Ac-PD-32766,CAIX,anti-CAIX多肽偶联核素;225Ac标记的放射性药物,PeptiDream(原研),肾透明细胞癌(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物;多肽偶联核素,创新药,225Ac-PD-32766,,肿瘤领域,,DR089471,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PeptiDream'],1,['PeptiDream(原研)'],肿瘤领域,肾透明细胞癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,clear cell renal cell carcinoma,225Ac-PD-32766,225Ac-PD-32766
225Ac-PTR-58,SSTR3,anti-SSTR3多肽偶联核素,Starget Pharma(原研),肝细胞癌(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,创新药,225Ac-PTR-58,,肿瘤领域,,DR070792,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Starget Pharma'],1,['Starget Pharma(原研)'],肿瘤领域,肝细胞癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,hepatocellular carcinoma,225Ac-PTR-58,225Ac-PTR-58
225Ac-PTR-58,SSTR3,anti-SSTR3多肽偶联核素,Starget Pharma(原研),黑色素瘤(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,创新药,225Ac-PTR-58,,肿瘤领域;罕见疾病领域,,DR070792,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Starget Pharma'],1,['Starget Pharma(原研)'],肿瘤领域,黑色素瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,melanoma,225Ac-PTR-58,225Ac-PTR-58
225Ac-PTR-58,SSTR3,anti-SSTR3多肽偶联核素,Starget Pharma(原研),神经内分泌肿瘤(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,创新药,225Ac-PTR-58,,肿瘤领域;罕见疾病领域,,DR070792,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Starget Pharma'],1,['Starget Pharma(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,neuroendocrine tumors,225Ac-PTR-58,225Ac-PTR-58
225Ac-RAYZ-6114,EphA2,225Ac标记的放射性药物;anti-EphA2多肽偶联核素,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),实体瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,225Ac-RAYZ-6114,,肿瘤领域,,DR073583,否,美国;日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,True,['RayzeBio(Bristol-Myers Squibb)'],"['PeptiDream', 'RayzeBio(Bristol-Myers Squibb)']",2,"['PeptiDream(原研)', 'RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)']",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,solid tumors,225Ac-RAYZ-6114,225Ac-RAYZ-6114
23-R09 (FAP),FAP,,中晟全肽(原研),胰腺癌,临床前,,Active,多肽,生物,环肽,其他,创新药,23-R09 (FAP),,肿瘤领域;罕见疾病领域,,DR066836,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['中晟全肽'],1,['中晟全肽(原研)'],肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,pancreatic cancer,23-R09 (FAP),23-R09 (FAP)
23-R09 (FAP),FAP,,中晟全肽(原研),消化道癌症,临床前,,Active,多肽,生物,环肽,其他,创新药,23-R09 (FAP),,肿瘤领域,,DR066836,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['中晟全肽'],1,['中晟全肽(原研)'],肿瘤领域,消化道癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,digestive tract cancer,23-R09 (FAP),23-R09 (FAP)
23-R09 (TROP2),TROP2,anti-TROP2多肽偶联核素,中晟全肽(原研),三阴性乳腺癌,临床前,,Active,多肽;放射性药物;偶联药物,生物,环肽;Potential First-in-Class,多肽偶联核素,创新药,23-R09 (TROP2),,肿瘤领域,,DR066827,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['中晟全肽'],1,['中晟全肽(原研)'],肿瘤领域,三阴性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,triple negative breast cancer,23-R09 (TROP2),23-R09 (TROP2)
23-R09 (TROP2/nectin-4),nectin-4;TROP2,anti-nectin-4×TROP2多肽偶联核素,中晟全肽(原研),未知/待定,临床前,,Active,多肽;放射性药物;偶联药物,生物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素,创新药,23-R09 (TROP2/nectin-4),,其他领域,,DR066839,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['中晟全肽'],1,['中晟全肽(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,23-R09 (TROP2/nectin-4),23-R09 (TROP2/nectin-4)
36R-P138,IL-36R,IL-36R抑制剂,Novartis(Top20 MNC)(原研),自身免疫性疾病,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,36R-P138,,免疫领域,,DR076820,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],免疫领域,自身免疫性疾病,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,autoimmune disease,36R-P138,36R-P138
36R-P192,IL-36R,IL-36R抑制剂,Novartis(Top20 MNC)(原研),自身免疫性疾病,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,36R-P192,,免疫领域,,DR076821,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],免疫领域,自身免疫性疾病,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,autoimmune disease,36R-P192,36R-P192
64Cu-NOTA-TP-c(RGDfK),αvβ3,64Cu标记的放射性示踪剂;anti-αvβ3多肽偶联核素,Université de Sherbrooke(原研),胶质母细胞瘤,临床前,,Active,放射性药物;多肽;偶联药物,其他,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,创新药,64Cu-NOTA-TP-c(RGDfK),,肿瘤领域;罕见疾病领域,,DR089672,否,加拿大,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Université de Sherbrooke'],1,['Université de Sherbrooke(原研)'],肿瘤领域,胶质母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,glioblastoma,64Cu-NOTA-TP-c(RGDfK),64Cu-NOTA-TP-c(RGDfK)
64Cu-PD-29875,CLDN18.2,64Cu标记的放射性示踪剂;anti-CLDN18.2多肽偶联核素,PeptiDream(原研),胃癌,临床前,,Active,多肽;放射性药物;偶联药物,其他,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,64Cu-PD-29875,,肿瘤领域,,DR071927,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PeptiDream'],1,['PeptiDream(原研)'],肿瘤领域,胃癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,stomach cancer,64Cu-PD-29875,64Cu-PD-29875
64Cu-PD-29875,CLDN18.2,64Cu标记的放射性示踪剂;anti-CLDN18.2多肽偶联核素,PeptiDream(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,其他,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,64Cu-PD-29875,,诊断试剂领域,,DR071927,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PeptiDream'],1,['PeptiDream(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,64Cu-PD-29875,64Cu-PD-29875
68Ga-DOTA-CEND1,NRP1,anti-NRP1多肽偶联核素;68Ga标记的PET药物,复旦大学附属肿瘤医院(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,其他,环肽;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-CEND1,,肿瘤领域,,DR089668,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['复旦大学附属肿瘤医院'],1,['复旦大学附属肿瘤医院(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,68Ga-DOTA-CEND1,68Ga-DOTA-CEND1
68Ga-DOTA-CEND1,NRP1,anti-NRP1多肽偶联核素;68Ga标记的PET药物,复旦大学附属肿瘤医院(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,其他,环肽;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-DOTA-CEND1,,诊断试剂领域,,DR089668,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['复旦大学附属肿瘤医院'],1,['复旦大学附属肿瘤医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-DOTA-CEND1,68Ga-DOTA-CEND1
68Ga-EMP-100,c-Met,anti-c-Met多肽偶联核素;68Ga标记的PET药物,Edinburgh Molecular Imaging(原研),实体瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-EMP-100;[Ga-68]EMP-100,,肿瘤领域,,DR021187,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Edinburgh Molecular Imaging'],1,['Edinburgh Molecular Imaging(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,solid tumors,68Ga-EMP-100,68Ga-EMP-100;[Ga-68]EMP-100
68Ga-EMP-100,c-Met,anti-c-Met多肽偶联核素;68Ga标记的PET药物,Edinburgh Molecular Imaging(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-EMP-100;[Ga-68]EMP-100,,诊断试剂领域,,DR021187,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Edinburgh Molecular Imaging'],1,['Edinburgh Molecular Imaging(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-EMP-100,68Ga-EMP-100;[Ga-68]EMP-100
68Ga-NOTA-XH05,LAG3,anti-LAG3多肽偶联核素;68Ga标记的PET药物,同济医学院(原研),黑色素瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NOTA-XH05,,肿瘤领域;罕见疾病领域,,DR081119,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,临床前,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['同济医学院'],1,['同济医学院(原研)'],肿瘤领域,黑色素瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,melanoma,68Ga-NOTA-XH05,68Ga-NOTA-XH05
68Ga-NOTA-XH05,LAG3,anti-LAG3多肽偶联核素;68Ga标记的PET药物,同济医学院(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,创新药,68Ga-NOTA-XH05,,诊断试剂领域,,DR081119,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,临床前,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['同济医学院'],1,['同济医学院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,68Ga-NOTA-XH05,68Ga-NOTA-XH05
90Y-CM600,fibrin,90Y标记的放射性药物;anti-fibrin多肽偶联核素,Massachusetts General Hospital(原研);Collagen Medical(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,90Y标记的放射性药物;多肽偶联核素,创新药,90Y-CM600,,肿瘤领域,,DR072127,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['Massachusetts General Hospital', 'Collagen Medical']",2,"['Massachusetts General Hospital(原研)', 'Collagen Medical(原研)']",肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,90Y-CM600,90Y-CM600
99mTc-PentixaTec,CXCR4,含锝放射性示踪剂;anti-CXCR4多肽偶联核素,Technische Universität München(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素;含锝放射性示踪剂,创新药,99mTc-PentixaTec;[99mTc]Tc-PentixaTec,,肿瘤领域,,DR081187,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Technische Universität München'],1,['Technische Universität München(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,99mTc-PentixaTec,99mTc-PentixaTec;[99mTc]Tc-PentixaTec
99mTc-PentixaTec,CXCR4,含锝放射性示踪剂;anti-CXCR4多肽偶联核素,Technische Universität München(原研),SPECT显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素;含锝放射性示踪剂,创新药,99mTc-PentixaTec;[99mTc]Tc-PentixaTec,,诊断试剂领域,,DR081187,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Technische Universität München'],1,['Technische Universität München(原研)'],诊断试剂领域,SPECT显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,SPECT imaging,99mTc-PentixaTec,99mTc-PentixaTec;[99mTc]Tc-PentixaTec
ABZ-706,GPC3,177Lu标记的放射性药物;anti-GPC3多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研);PeptiDream(原研)(无权益);艾博兹医药(无权益),肝细胞癌(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;中国无申报;Potential First-in-Class;Wnt信号通路,多肽偶联核素;177Lu标记的放射性药物,创新药,ABZ-706;177Lu-RAYZ-8009,,肿瘤领域,,DR011510,否,美国;日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,3,True,False,True,['RayzeBio(Bristol-Myers Squibb)'],"['RayzeBio(Bristol-Myers Squibb)', 'PeptiDream']",2,"['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)', 'PeptiDream(原研)(无权益)', '艾博兹医药(无权益)']",肿瘤领域,肝细胞癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,hepatocellular carcinoma,ABZ-706,ABZ-706;177Lu-RAYZ-8009
AP-01,CD47;THBS1,CD47×THBS1蛋白蛋白相互作用抑制剂,Apmonia Therapeutics(原研),实体瘤,临床前,,Active,多肽,其他,环肽;肿瘤相关巨噬细胞;Potential First-in-Class;肿瘤免疫,蛋白蛋白相互作用抑制剂,创新药,AP-01;AP-01 (Apmonia Therapeutics);TAX2 peptide;TAX2,,肿瘤领域,,DR008397,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Apmonia Therapeutics'],1,['Apmonia Therapeutics(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,solid tumors,AP-01 (Apmonia Therapeutics),AP-01;AP-01 (Apmonia Therapeutics);TAX2 peptide;TAX2
ARAspheres,integrin,225Ac标记的放射性药物,Blue Wave Therapeutics(原研),胶质母细胞瘤,临床前,,Active,放射性药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物,创新药,ARAspheres;ARAspheres (225Ac-RGD-Alginate Nanospheres),,肿瘤领域;罕见疾病领域,,DR089758,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Blue Wave Therapeutics'],1,['Blue Wave Therapeutics(原研)'],肿瘤领域,胶质母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,glioblastoma,ARAspheres (225Ac-RGD-Alginate Nanospheres),ARAspheres;ARAspheres (225Ac-RGD-Alginate Nanospheres)
Ano-3/3s,not available,多肽偶联药物,上海中医药大学(原研),黑色素瘤,临床前,,Active,多肽;偶联药物,化药,环肽,多肽偶联药物,创新药,Ano-3/3s,,肿瘤领域;罕见疾病领域,,DR052461,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['上海中医药大学'],1,['上海中医药大学(原研)'],肿瘤领域,黑色素瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,melanoma,Ano-3/3s,Ano-3/3s
BE-43547A2,EEF1A1,EEF1A1抑制剂,--,胰腺癌(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,BE-43547A2,,肿瘤领域;罕见疾病领域,,DR011350,否,,,,,,,pre-clinical,临床前,,pre-clinical,0,True,True,False,[],[],0,[],肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,pancreatic cancer,BE-43547A2,BE-43547A2
BMN 333,,,BioMarin Pharmaceutical(原研),骨骼肌肉疾病,临床前,,Active,多肽,其他,环肽,,微创新,BMN 333,,骨骼肌肉领域,,DR007946,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['BioMarin Pharmaceutical'],1,['BioMarin Pharmaceutical(原研)'],骨骼肌肉领域,骨骼肌肉疾病,['骨骼肌肉领域'],1,骨骼肌肉领域,,,-1,-1,Musculoskeletal,Musculoskeletal,,,musculoskeletal diseases,BMN 333,BMN 333
BT1769,MMP14,多肽偶联药物,Bicycle Therapeutics(原研),骨肉瘤(差异化疾病),临床前,,Active,多肽;偶联药物,化药,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,BT1769,,肿瘤领域;罕见疾病领域,,DR059741,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,骨肉瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,Osteosarcoma,BT1769,BT1769
BT7455,EphA2;4-1BB,EphA2配体;4-1BB激动剂,Bicycle Therapeutics(原研),肿瘤,临床前,,Active,多肽,化药,环肽;受体酪氨酸激酶;Potential First-in-Class;肿瘤免疫,配体;激动剂,创新药,BT7455;BCY12491,,肿瘤领域,,DR004683,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,BT7455,BT7455;BCY12491
Bicycle 46,TSLP,TSLP抑制剂,Bicycle Therapeutics(原研),哮喘,临床前,,Active,多肽,化药,环肽;Th2通路;Potential First-in-Class,抑制剂,创新药,Bicycle 46,,呼吸领域,,DR045043,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],呼吸领域,哮喘,['呼吸领域'],1,呼吸领域,,,-1,-1,Respiratory,Respiratory,,,asthma,Bicycle 46,Bicycle 46
C4m-3127,CTLA4,CTLA4抑制剂,GeneFrontier(原研),未知/待定,临床前,,Active,多肽,化药,环肽;Treg细胞;Potential First-in-Class,抑制剂,创新药,C4m-3127,,其他领域,,DR050438,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['GeneFrontier'],1,['GeneFrontier(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,C4m-3127,C4m-3127
C5 Inhibitor,C5,C5抑制剂,Nimble Therapeutics(AbbVie)(Top20 MNC)(原研),重症肌无力,临床前,,Active,多肽,化药,环肽,抑制剂,创新药,C5 Inhibitor;C5 Inhibitor (Nimble Therapeutics),,罕见疾病领域;免疫领域,,DR071874,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,True,['Nimble Therapeutics(AbbVie)'],['Nimble Therapeutics(AbbVie)'],1,['Nimble Therapeutics(AbbVie)(Top20 MNC)(原研)'],免疫领域,重症肌无力,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,myasthenia gravis,C5 Inhibitor (Nimble Therapeutics),C5 Inhibitor;C5 Inhibitor (Nimble Therapeutics)
CAR Peptide,not available,,Vascular Biosciences(原研),菌血症,临床前,,Active,多肽,化药,环肽,其他,创新药,CAR Peptide;CAR Peptide (Vascular BioSciences);CARSKNKDC,,感染领域,,DR036908,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Vascular Biosciences'],1,['Vascular Biosciences(原研)'],感染领域,菌血症,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,bacteremia,CAR Peptide (Vascular BioSciences),CAR Peptide;CAR Peptide (Vascular BioSciences);CARSKNKDC
CAR Peptide,not available,,Vascular Biosciences(原研),肺动脉高压,临床前,,Active,多肽,化药,环肽,其他,创新药,CAR Peptide;CAR Peptide (Vascular BioSciences);CARSKNKDC,,心脑血管领域;罕见疾病领域,,DR036908,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Vascular Biosciences'],1,['Vascular Biosciences(原研)'],心脑血管领域,肺动脉高压,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,pulmonary hypertension,CAR Peptide (Vascular BioSciences),CAR Peptide;CAR Peptide (Vascular BioSciences);CARSKNKDC
CAR Peptide,not available,,Vascular Biosciences(原研),新型冠状病毒感染,临床前,,Active,多肽,化药,环肽,其他,创新药,CAR Peptide;CAR Peptide (Vascular BioSciences);CARSKNKDC,,感染领域,,DR036908,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Vascular Biosciences'],1,['Vascular Biosciences(原研)'],感染领域,新型冠状病毒感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,novel coronavirus infection,CAR Peptide (Vascular BioSciences),CAR Peptide;CAR Peptide (Vascular BioSciences);CARSKNKDC
CBT-005,NPRB,NPRB激动剂,C-BIOMEX(原研),软骨发育不全,临床前,,Active,多肽,化药,环肽;中国无申报;Potential First-in-Class,激动剂,创新药,CBT-005;CBT-005 (Cbiomex),,骨骼肌肉领域;罕见疾病领域,,DR009364,否,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['C-BIOMEX'],1,['C-BIOMEX(原研)'],骨骼肌肉领域,软骨发育不全,['骨骼肌肉领域'],1,骨骼肌肉领域,,,-1,-1,Musculoskeletal,Musculoskeletal,,,Achondroplasia,CBT-005 (Cbiomex),CBT-005;CBT-005 (Cbiomex)
CN119285702A,EphA2,EphA2抑制剂,禾泰健宇(原研),癌症,临床前,,Active,多肽,化药,环肽;受体酪氨酸激酶;Potential First-in-Class,抑制剂,创新药,CN119285702A,,肿瘤领域,,DR084791,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['禾泰健宇'],1,['禾泰健宇(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,CN119285702A,CN119285702A
CN119303102A,EphA2;nectin-4,多肽偶联药物,博瑞医药(原研),癌症,临床前,,Active,多肽;偶联药物,化药,环肽;受体酪氨酸激酶;Potential First-in-Class,多肽偶联药物,创新药,CN119303102A,,肿瘤领域,,DR084448,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['博瑞医药'],1,['博瑞医药(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,CN119303102A,CN119303102A
CN119390770A,nectin-4,18F标记的PET药物;anti-nectin-4多肽偶联核素,云南白药(原研);北京大学第一医院(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,创新药,CN119390770A,,肿瘤领域,,DR086286,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['云南白药', '北京大学第一医院']",2,"['云南白药(原研)', '北京大学第一医院(原研)']",肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,CN119390770A,CN119390770A
CN119390848A,PSD95,PSD95抑制剂,中晟全肽(原研),神经退行性疾病(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,CN119390848A,,神经领域,,DR084804,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['中晟全肽'],1,['中晟全肽(原研)'],神经领域,神经退行性疾病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,neurodegenerative diseases,CN119390848A,CN119390848A
CN119390848A,PSD95,PSD95抑制剂,中晟全肽(原研),缺血性卒中,临床前,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,CN119390848A,,心脑血管领域,,DR084804,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['中晟全肽'],1,['中晟全肽(原研)'],心脑血管领域,缺血性卒中,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,ischemic stroke,CN119390848A,CN119390848A
CN119552215A,SSTR2,多肽偶联药物,星洲生物(原研),肿瘤,临床前,,Active,多肽;偶联药物,化药,环肽,多肽偶联药物,创新药,CN119552215A,,肿瘤领域,,DR083998,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['星洲生物'],1,['星洲生物(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,CN119552215A,CN119552215A
CN119638783A,APHs,多肽类抗生素,上海交通大学(原研),细菌感染,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,多肽类抗生素,创新药,CN119638783A,,感染领域,,DR085370,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['上海交通大学'],1,['上海交通大学(原研)'],感染领域,细菌感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,bacterial infection,CN119638783A,CN119638783A
CN119701000A,S. aureus,多肽偶联药物,第四军医大学(原研),葡萄球菌感染,临床前,,Active,多肽;偶联药物,化药,环肽;payload [利福霉素类抗生素：dmDNA31];Potential First-in-Class,多肽偶联药物,创新药,CN119701000A,,感染领域,,DR090138,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['第四军医大学'],1,['第四军医大学(原研)'],感染领域,葡萄球菌感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,Staph infection,CN119701000A,CN119701000A
CN119751581A,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,上海交通大学(原研);南京市第一医院(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,生物,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,CN119751581A,,肿瘤领域,,DR086866,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['上海交通大学', '南京市第一医院']",2,"['上海交通大学(原研)', '南京市第一医院(原研)']",肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,CN119751581A,CN119751581A
CN119874812A,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,范恩柯尔(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽,68Ga标记的PET药物;多肽偶联核素,创新药,CN119874812A,,肿瘤领域,,DR083609,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['范恩柯尔'],1,['范恩柯尔(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,CN119874812A,CN119874812A
CN119874812A,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,范恩柯尔(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽,68Ga标记的PET药物;多肽偶联核素,创新药,CN119874812A,,诊断试剂领域,,DR083609,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['范恩柯尔'],1,['范恩柯尔(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,CN119874812A,CN119874812A
CN119874840A,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,晶核生物(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,创新药,CN119874840A,,肿瘤领域,,DR084744,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['晶核生物'],1,['晶核生物(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,CN119874840A,CN119874840A
CN119978071A,NPFFR1,NPFFR1激动剂,中晟全肽(原研),疼痛,临床前,,Active,多肽,化药,环肽;G蛋白偶联受体;Potential First-in-Class,激动剂,创新药,CN119978071A,,麻醉镇痛领域,,DR084841,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['中晟全肽'],1,['中晟全肽(原研)'],麻醉镇痛领域,疼痛,['麻醉镇痛领域'],1,麻醉镇痛领域,,,-1,-1,Anesthesia & Analgesia,Anesthesia & Analgesia,,,pain,CN119978071A,CN119978071A
CN120004985A,uPA,64Cu标记的放射性示踪剂;anti-uPA多肽偶联核素,中国医学科学院药物研究所(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,CN120004985A,,肿瘤领域,,DR090531,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['中国医学科学院药物研究所'],1,['中国医学科学院药物研究所(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,CN120004985A,CN120004985A
CN120004985A,uPA,64Cu标记的放射性示踪剂;anti-uPA多肽偶联核素,中国医学科学院药物研究所(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,CN120004985A,,诊断试剂领域,,DR090531,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['中国医学科学院药物研究所'],1,['中国医学科学院药物研究所(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,CN120004985A,CN120004985A
CN120058842A,uPAR,anti-uPAR多肽偶联核素;64Cu标记的放射性示踪剂,中国医学科学院药物研究所(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,CN120058842A,,肿瘤领域,,DR090536,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['中国医学科学院药物研究所'],1,['中国医学科学院药物研究所(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,CN120058842A,CN120058842A
CN120058842A,uPAR,anti-uPAR多肽偶联核素;64Cu标记的放射性示踪剂,中国医学科学院药物研究所(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,CN120058842A,,诊断试剂领域,,DR090536,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['中国医学科学院药物研究所'],1,['中国医学科学院药物研究所(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,CN120058842A,CN120058842A
CN120136966A,not available,脂肽类抗生素,上海交通大学(原研),细菌感染,临床前,,Active,多肽,化药,环肽,脂肽类抗生素,创新药,CN120136966A,,感染领域,,DR085395,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['上海交通大学'],1,['上海交通大学(原研)'],感染领域,细菌感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,bacterial infection,CN120136966A,CN120136966A
CN120230182A,CAIX,anti-CAIX多肽偶联核素;18F标记的PET药物,北京大学肿瘤医院(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,创新药,CN120230182A,,肿瘤领域,,DR084489,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,CN120230182A,CN120230182A
CN120230182A,CAIX,anti-CAIX多肽偶联核素;18F标记的PET药物,北京大学肿瘤医院(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,创新药,CN120230182A,,诊断试剂领域,,DR084489,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,CN120230182A,CN120230182A
CN120535589A,ACE2;FAP,68Ga标记的PET药物;anti-ACE2×FAP多肽偶联核素,北京大学肿瘤医院(原研),肿瘤,临床前,,Active,放射性药物;多肽;偶联药物,化药,环肽;肾素-血管紧张素-醛固酮系统;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,CN120535589A,,肿瘤领域,,DR084887,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,CN120535589A,CN120535589A
CN120535589A,ACE2;FAP,68Ga标记的PET药物;anti-ACE2×FAP多肽偶联核素,北京大学肿瘤医院(原研),PET显像,临床前,,Active,放射性药物;多肽;偶联药物,化药,环肽;肾素-血管紧张素-醛固酮系统;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,CN120535589A,,诊断试剂领域,,DR084887,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,CN120535589A,CN120535589A
CN120757611A,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,南方医科大学南方医院(原研),肾细胞癌,临床前,,Active,放射性药物;多肽;偶联药物,化药,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,CN120757611A,,肿瘤领域,,DR087164,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['南方医科大学南方医院'],1,['南方医科大学南方医院(原研)'],肿瘤领域,肾细胞癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,renal cell carcinoma,CN120757611A,CN120757611A
CN120757611A,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,南方医科大学南方医院(原研),PET显像,临床前,,Active,放射性药物;多肽;偶联药物,化药,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,CN120757611A,,诊断试剂领域,,DR087164,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['南方医科大学南方医院'],1,['南方医科大学南方医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,CN120757611A,CN120757611A
CN120757611A,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,南方医科大学南方医院(原研),肾透明细胞癌,临床前,,Active,放射性药物;多肽;偶联药物,化药,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,CN120757611A,,肿瘤领域,,DR087164,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['南方医科大学南方医院'],1,['南方医科大学南方医院(原研)'],肿瘤领域,肾透明细胞癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,clear cell renal cell carcinoma,CN120757611A,CN120757611A
CN120818068A,μ opioid receptor;Nav1.8,μ opioid receptor×Nav1.8-白蛋白融合蛋白;μ opioid receptor激动剂;Nav1.8抑制剂,新乡医学院(原研),疼痛,临床前,,Active,多肽;融合蛋白,生物,环肽;G蛋白偶联受体;Potential First-in-Class,激动剂;抑制剂;白蛋白融合蛋白,创新药,CN120818068A,,麻醉镇痛领域,,DR088047,是,中国(内地),未知,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['新乡医学院'],1,['新乡医学院(原研)'],麻醉镇痛领域,疼痛,['麻醉镇痛领域'],1,麻醉镇痛领域,,,-1,-1,Anesthesia & Analgesia,Anesthesia & Analgesia,,,pain,CN120818068A,CN120818068A
CN120837693A,EphA2,anti-EphA2多肽偶联核素;68Ga标记的PET药物,复旦大学附属肿瘤医院(原研),PET显像,临床前,,Active,放射性药物;多肽;偶联药物,化药,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,CN120837693A,,诊断试剂领域,,DR088530,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['复旦大学附属肿瘤医院'],1,['复旦大学附属肿瘤医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,CN120837693A,CN120837693A
CN120865351A,C5,C5抑制剂,普康唯新(原研),阵发性睡眠性血红蛋白尿症,临床前,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,CN120865351A,,罕见疾病领域;血液领域,,DR088535,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['普康唯新'],1,['普康唯新(原研)'],血液领域,阵发性睡眠性血红蛋白尿症,['血液领域'],1,血液领域,,,-1,-1,Hematology,Hematology,,,paroxysmal nocturnal hemoglobinuria,CN120865351A,CN120865351A
CN120865351A,C5,C5抑制剂,普康唯新(原研),非典型溶血尿毒综合征(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,CN120865351A,,罕见疾病领域;泌尿生殖领域,,DR088535,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['普康唯新'],1,['普康唯新(原研)'],泌尿生殖领域,非典型溶血尿毒综合征,['泌尿生殖领域'],1,泌尿生殖领域,,,-1,-1,Genitourinary,Genitourinary,,,atypical hemolytic uremic syndrome,CN120865351A,CN120865351A
CN121005762A,NMDA receptor;PSD95,NMDA receptor×PSD95蛋白蛋白相互作用抑制剂,拜西欧斯(原研),焦虑症,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,CN121005762A,,精神领域,,DR090117,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['拜西欧斯'],1,['拜西欧斯(原研)'],精神领域,焦虑症,['精神领域'],1,精神领域,,,-1,-1,Psychiatry,Psychiatry,,,anxiety disorder,CN121005762A,CN121005762A
CN121005762A,NMDA receptor;PSD95,NMDA receptor×PSD95蛋白蛋白相互作用抑制剂,拜西欧斯(原研),神经退行性疾病,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,CN121005762A,,神经领域,,DR090117,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['拜西欧斯'],1,['拜西欧斯(原研)'],神经领域,神经退行性疾病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,neurodegenerative diseases,CN121005762A,CN121005762A
CN121005762A,NMDA receptor;PSD95,NMDA receptor×PSD95蛋白蛋白相互作用抑制剂,拜西欧斯(原研),癫痫,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,CN121005762A,,神经领域,,DR090117,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['拜西欧斯'],1,['拜西欧斯(原研)'],神经领域,癫痫,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,epilepsy,CN121005762A,CN121005762A
CN121045338A,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,原子高科(原研),肾透明细胞癌,临床前,,Active,放射性药物;多肽;偶联药物,化药,环肽;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,创新药,CN121045338A,,肿瘤领域,,DR090461,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['原子高科'],1,['原子高科(原研)'],肿瘤领域,肾透明细胞癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,clear cell renal cell carcinoma,CN121045338A,CN121045338A
CN121045338A-1,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,原子高科(原研),肾透明细胞癌,临床前,,Active,多肽;放射性药物;偶联药物,生物,环肽,多肽偶联核素;68Ga标记的PET药物,创新药,CN121045338A-1,,肿瘤领域,,DR090564,是,中国(内地),未知,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['原子高科'],1,['原子高科(原研)'],肿瘤领域,肾透明细胞癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,clear cell renal cell carcinoma,CN121045338A-1,CN121045338A-1
CN2097,PSD95,PSD95抑制剂,Aingeal therapeutics(原研),快乐木偶综合症(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,CN2097,,罕见疾病领域,,DR036352,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Aingeal therapeutics'],1,['Aingeal therapeutics(原研)'],,快乐木偶综合症,[],0,,,,-1,-1,,,,,happy puppet syndrome,CN2097,CN2097
CN2097,PSD95,PSD95抑制剂,Aingeal therapeutics(原研),外伤性脑损伤,临床前,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,CN2097,,神经领域,,DR036352,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Aingeal therapeutics'],1,['Aingeal therapeutics(原研)'],神经领域,外伤性脑损伤,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,traumatic brain injury,CN2097,CN2097
CN2097,PSD95,PSD95抑制剂,Aingeal therapeutics(原研),难治性抑郁症(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,CN2097,,精神领域,,DR036352,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Aingeal therapeutics'],1,['Aingeal therapeutics(原研)'],精神领域,难治性抑郁症,['精神领域'],1,精神领域,,,-1,-1,Psychiatry,Psychiatry,,,treatment-resistant depression,CN2097,CN2097
CP7-FP13-2,not available,,南方医科大学(原研),葡萄球菌感染,临床前,,Active,多肽,化药,环肽,其他,创新药,CP7-FP13-2,,感染领域,,DR026410,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['南方医科大学'],1,['南方医科大学(原研)'],感染领域,葡萄球菌感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,Staph infection,CP7-FP13-2,CP7-FP13-2
CPX-101,BMP7,BMP7类似物,Chondropeptix(原研),骨关节炎,临床前,,Active,多肽,其他,环肽;TGF-β信号通路;Potential First-in-Class,类似物,创新药,CPX-101,,骨骼肌肉领域,,DR029351,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Chondropeptix'],1,['Chondropeptix(原研)'],骨骼肌肉领域,骨关节炎,['骨骼肌肉领域'],1,骨骼肌肉领域,,,-1,-1,Musculoskeletal,Musculoskeletal,,,osteoarthritis,CPX-101,CPX-101
CRRL191,NPR1,NPR1激活剂,Mayo Clinic(原研),高血压,临床前,,Active,多肽,化药,环肽,激活剂,创新药,CRRL191,,心脑血管领域,,DR073668,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Mayo Clinic'],1,['Mayo Clinic(原研)'],心脑血管领域,高血压,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,hypertension,CRRL191,CRRL191
CRRL269,NPR1,NPR1激活剂,Mayo Clinic(原研),急性肾损伤(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病,激活剂,创新药,CRRL269,,泌尿生殖领域,,DR052784,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Mayo Clinic'],1,['Mayo Clinic(原研)'],泌尿生殖领域,急性肾损伤,['泌尿生殖领域'],1,泌尿生殖领域,,,-1,-1,Genitourinary,Genitourinary,,,acute kidney injury,CRRL269,CRRL269
CRRL555,ANP,ANP类似物,Mayo Clinic(原研),高血压,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,类似物,创新药,CRRL555,,心脑血管领域,,DR073078,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Mayo Clinic'],1,['Mayo Clinic(原研)'],心脑血管领域,高血压,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,hypertension,CRRL555,CRRL555
CXCR4-targeting radiopharmaceutical,CXCR4,,Alpha-9(原研),肿瘤,临床前,,Active,多肽,其他,环肽;G蛋白偶联受体,其他,创新药,CXCR4-targeting radiopharmaceutical;CXCR4-targeting radiopharmaceutical (Alpha-9),,肿瘤领域,,DR044356,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Alpha-9'],1,['Alpha-9(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,CXCR4-targeting radiopharmaceutical (Alpha-9),CXCR4-targeting radiopharmaceutical;CXCR4-targeting radiopharmaceutical (Alpha-9)
CXJ-2,elastin-binding protein,elastin-binding protein抑制剂,中山大学(原研),肝纤维化,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,CXJ-2,,消化领域,,DR063621,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['中山大学'],1,['中山大学(原研)'],消化领域,肝纤维化,['消化领域'],1,消化领域,,,-1,-1,Digestive System,Digestive System,,,liver fibrosis,CXJ-2,CXJ-2
Colistin Cyclops,not available,多粘菌素类抗生素,PureIMS(原研),肺部感染,临床前,,Active,其他,化药,环肽,多粘菌素类抗生素,微创新,Colistin Cyclops;Colistin Cyclops (粘菌素吸入粉);Colistin Cyclops (inhaled colistin),,感染领域;呼吸领域,,DR075147,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PureIMS'],1,['PureIMS(原研)'],感染领域,肺部感染,"['感染领域', '呼吸领域']",2,感染领域,呼吸领域,,-1,-1,Infectious Diseases,Infectious Diseases,Respiratory,,lung infection,Colistin Cyclops (inhaled colistin),Colistin Cyclops;Colistin Cyclops (粘菌素吸入粉);Colistin Cyclops (inhaled colistin)
Colistin Cyclops,not available,多粘菌素类抗生素,PureIMS(原研),囊性纤维化,临床前,,Active,其他,化药,环肽,多粘菌素类抗生素,微创新,Colistin Cyclops;Colistin Cyclops (粘菌素吸入粉);Colistin Cyclops (inhaled colistin),,呼吸领域;罕见疾病领域,,DR075147,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['PureIMS'],1,['PureIMS(原研)'],呼吸领域,囊性纤维化,['呼吸领域'],1,呼吸领域,,,-1,-1,Respiratory,Respiratory,,,cystic fibrosis,Colistin Cyclops (inhaled colistin),Colistin Cyclops;Colistin Cyclops (粘菌素吸入粉);Colistin Cyclops (inhaled colistin)
Colistin Cyclops,not available,多粘菌素类抗生素,PureIMS(原研),绿脓杆菌感染,临床前,,Active,其他,化药,环肽,多粘菌素类抗生素,微创新,Colistin Cyclops;Colistin Cyclops (粘菌素吸入粉);Colistin Cyclops (inhaled colistin),,感染领域,,DR075147,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PureIMS'],1,['PureIMS(原研)'],感染领域,绿脓杆菌感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,Pseudomonas aeruginosa infection,Colistin Cyclops (inhaled colistin),Colistin Cyclops;Colistin Cyclops (粘菌素吸入粉);Colistin Cyclops (inhaled colistin)
Cp1,C5a,C5a阻断剂,上海长海医院(原研),脓毒症(差异化疾病),临床前,,Active,多肽,其他,环肽;差异化疾病;Potential First-in-Class,阻断剂,创新药,Cp1;Cp1 (长海医院);Cp1 (Changhai Hospital),,感染领域,,DR088698,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['上海长海医院'],1,['上海长海医院(原研)'],感染领域,脓毒症,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,sepsis,Cp1 (Changhai Hospital),Cp1;Cp1 (长海医院);Cp1 (Changhai Hospital)
Cyclin A targeting macrocyclic compound,cyclin A,cyclin A抑制剂,Circle Pharma(原研),小细胞肺癌,临床前,,Active,多肽,化药,环肽;细胞周期;Potential First-in-Class,抑制剂,创新药,Cyclin A targeting macrocyclic compound;Cyclin A targeting macrocyclic compound (Circle Pharma),,肿瘤领域;罕见疾病领域,,DR036896,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Circle Pharma'],1,['Circle Pharma(原研)'],肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,small cell lung cancer,Cyclin A targeting macrocyclic compound (Circle Pharma),Cyclin A targeting macrocyclic compound;Cyclin A targeting macrocyclic compound (Circle Pharma)
Cyclopeptides,TSHR,,advanceCOR(原研),格雷夫斯病,临床前,,Active,多肽,生物,环肽,其他,创新药,Cyclopeptides;Cyclopeptides (advanceCOR),,免疫领域;内分泌及代谢领域,,DR052507,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['advanceCOR'],1,['advanceCOR(原研)'],免疫领域,格雷夫斯病,"['免疫领域', '内分泌及代谢领域']",2,免疫领域,内分泌及代谢领域,,-1,-1,Immunology,Immunology,Endocrinology & Metabolism,,Graves' disease,Cyclopeptides (advanceCOR),Cyclopeptides;Cyclopeptides (advanceCOR)
DYV024,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Dyve Biosciences(原研),银屑病,临床前,,Active,小分子,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,DYV024;DYV024 (环孢素透皮递送);DYV024 (cyclosporine transdermal delivery),,免疫领域;皮肤领域,,DR052450,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Dyve Biosciences'],1,['Dyve Biosciences(原研)'],免疫领域,银屑病,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,-1,-1,Immunology,Immunology,Dermatology,,psoriasis,DYV024 (cyclosporine transdermal delivery),DYV024;DYV024 (环孢素透皮递送);DYV024 (cyclosporine transdermal delivery)
EGFR-targeted cyclic peptides project,EGFR,,GeneFrontier(原研),未知/待定,临床前,,Active,多肽,化药,环肽;受体酪氨酸激酶,其他,创新药,EGFR-targeted cyclic peptides project;EGFR-targeted cyclic peptides project (GeneFrontier),,其他领域,,DR088904,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['GeneFrontier'],1,['GeneFrontier(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,EGFR-targeted cyclic peptides project (GeneFrontier),EGFR-targeted cyclic peptides project;EGFR-targeted cyclic peptides project (GeneFrontier)
Enniatin A ,not available,,University of Notre Dame(原研);Augusta University(原研),三阴性乳腺癌,临床前,,Active,其他,其他,环肽,其他,创新药,Enniatin A ;Enniatin A (Augusta University),,肿瘤领域,,DR084296,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['University of Notre Dame', 'Augusta University']",2,"['University of Notre Dame(原研)', 'Augusta University(原研)']",肿瘤领域,三阴性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,triple negative breast cancer,Enniatin A (Augusta University),Enniatin A ;Enniatin A (Augusta University)
EphA2-68Ga imaging agent,EphA2,anti-EphA2多肽偶联核素;68Ga标记的PET药物,Bicycle Therapeutics(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,EphA2-68Ga imaging agent;EphA2-68Ga imaging agent (Bicycle),,诊断试剂领域,,DR073753,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,EphA2-68Ga imaging agent (Bicycle),EphA2-68Ga imaging agent;EphA2-68Ga imaging agent (Bicycle)
Erk2-targeted cyclic peptides project,ERK2,,GeneFrontier(原研),未知/待定,临床前,,Active,多肽,化药,环肽;MAPK信号通路,其他,创新药,Erk2-targeted cyclic peptides project;Erk2-targeted cyclic peptides project (GeneFrontier),,其他领域,,DR088905,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['GeneFrontier'],1,['GeneFrontier(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,Erk2-targeted cyclic peptides project (GeneFrontier),Erk2-targeted cyclic peptides project;Erk2-targeted cyclic peptides project (GeneFrontier)
FNDR-20364,not available,多肽类抗生素,FNDR(原研);NCPOR(原研),非结核分枝杆菌肺病(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病;中国无申报,多肽类抗生素,创新药,FNDR-20364;NF1001,,罕见疾病领域;感染领域;呼吸领域,,DR073504,否,印度,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,True,False,[],"['FNDR', 'NCPOR']",2,"['FNDR(原研)', 'NCPOR(原研)']",感染领域,非结核分枝杆菌肺病,"['感染领域', '呼吸领域']",2,感染领域,呼吸领域,,-1,-1,Infectious Diseases,Infectious Diseases,Respiratory,,non-tuberculous mycobacterial lung disease,FNDR-20364,FNDR-20364;NF1001
FOXA1 inhibitor,FOXA1,FOXA1抑制剂,Curve Therapeutics(原研),乳腺癌,临床前,,Active,小分子,化药,环肽;Potential First-in-Class,抑制剂,创新药,FOXA1 inhibitor;FOXA1 inhibitor (Curve Therapeutics),,肿瘤领域,,DR015043,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Curve Therapeutics'],1,['Curve Therapeutics(原研)'],肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,breast cancer,FOXA1 inhibitor (Curve Therapeutics),FOXA1 inhibitor;FOXA1 inhibitor (Curve Therapeutics)
FP-002,somatostatin,somatostatin类似物,逸达生物(原研),肢端肥大症,临床前,,Active,多肽,化药,环肽,类似物,微创新,FP-002;FP-002 (奥曲肽);FP-002 (octreotide);FP-008,,内分泌及代谢领域;罕见疾病领域,,DR017674,否,中国(港澳台),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['逸达生物'],1,['逸达生物(原研)'],内分泌及代谢领域,肢端肥大症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,acromegaly,FP-002 (octreotide),FP-002;FP-002 (奥曲肽);FP-002 (octreotide);FP-008
FP-002,somatostatin,somatostatin类似物,逸达生物(原研),糖尿病视网膜病变,临床前,,Active,多肽,化药,环肽,类似物,微创新,FP-002;FP-002 (奥曲肽);FP-002 (octreotide);FP-008,,眼科领域,,DR017674,否,中国(港澳台),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['逸达生物'],1,['逸达生物(原研)'],眼科领域,糖尿病视网膜病变,['眼科领域'],1,眼科领域,,,-1,-1,Ophthalmology,Ophthalmology,,,diabetic retinopathy,FP-002 (octreotide),FP-002;FP-002 (奥曲肽);FP-002 (octreotide);FP-008
FPP29,FOXM1,FOXM1 PROTAC,西南交通大学(原研),肝癌,临床前,,Active,多肽;降解类药物,化药,环肽;E3 ligase [VHL];Potential First-in-Class,PROTAC,创新药,FPP29,,肿瘤领域,,DR083401,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['西南交通大学'],1,['西南交通大学(原研)'],肿瘤领域,肝癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,liver cancer,FPP29,FPP29
HER2-targeted cyclic peptides project,HER2,,GeneFrontier(原研),未知/待定,临床前,,Active,多肽,化药,环肽;受体酪氨酸激酶,其他,创新药,HER2-targeted cyclic peptides project;HER2-targeted cyclic peptides project (GeneFrontier),,其他领域,,DR088903,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['GeneFrontier'],1,['GeneFrontier(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,HER2-targeted cyclic peptides project (GeneFrontier),HER2-targeted cyclic peptides project;HER2-targeted cyclic peptides project (GeneFrontier)
IL-11/IL-11Rα inhibitor,IL-11;IL-11RA,IL-11×IL-11RA蛋白蛋白相互作用抑制剂,Takeda Pharmaceuticals(Top20 MNC)(原研),炎症(未指明),临床前,,Active,多肽,化药,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,IL-11/IL-11Rα inhibitor;IL-11/IL-11Rα inhibitor (Takeda Pharmaceuticals),,免疫领域,,DR072761,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Takeda Pharmaceuticals'],['Takeda Pharmaceuticals'],1,['Takeda Pharmaceuticals(Top20 MNC)(原研)'],免疫领域,炎症(未指明),['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,Inflammation (unspecified),IL-11/IL-11Rα inhibitor (Takeda Pharmaceuticals),IL-11/IL-11Rα inhibitor;IL-11/IL-11Rα inhibitor (Takeda Pharmaceuticals)
IL-11/IL-11Rα inhibitor,IL-11;IL-11RA,IL-11×IL-11RA蛋白蛋白相互作用抑制剂,Takeda Pharmaceuticals(Top20 MNC)(原研),纤维化(未指明),临床前,,Active,多肽,化药,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,IL-11/IL-11Rα inhibitor;IL-11/IL-11Rα inhibitor (Takeda Pharmaceuticals),,其他领域,,DR072761,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Takeda Pharmaceuticals'],['Takeda Pharmaceuticals'],1,['Takeda Pharmaceuticals(Top20 MNC)(原研)'],其他领域,纤维化(未指明),['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,Fibrosis (unspecified),IL-11/IL-11Rα inhibitor (Takeda Pharmaceuticals),IL-11/IL-11Rα inhibitor;IL-11/IL-11Rα inhibitor (Takeda Pharmaceuticals)
IL-23R Inhibitor,IL-23R,IL-23R抑制剂,Nimble Therapeutics(AbbVie)(Top20 MNC)(原研),银屑病,临床前,,Active,多肽,化药,环肽;Th17通路,抑制剂,创新药,IL-23R Inhibitor;IL-23R Inhibitor (Nimble Therapeutics),,免疫领域;皮肤领域,,DR071873,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Nimble Therapeutics(AbbVie)'],['Nimble Therapeutics(AbbVie)'],1,['Nimble Therapeutics(AbbVie)(Top20 MNC)(原研)'],免疫领域,银屑病,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,-1,-1,Immunology,Immunology,Dermatology,,psoriasis,IL-23R Inhibitor (Nimble Therapeutics),IL-23R Inhibitor;IL-23R Inhibitor (Nimble Therapeutics)
IL-6-targeted cyclic peptides project,IL-6,IL-6抑制剂,GeneFrontier(原研),未知/待定,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,IL-6-targeted cyclic peptides project;IL-6-targeted cyclic peptides project (GeneFrontier),,其他领域,,DR088906,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['GeneFrontier'],1,['GeneFrontier(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,IL-6-targeted cyclic peptides project (GeneFrontier),IL-6-targeted cyclic peptides project;IL-6-targeted cyclic peptides project (GeneFrontier)
IL17 therapeutic MPC,IL-17,多肽偶联药物,PeptiDream(原研),自身免疫性疾病,临床前,,Active,多肽;偶联药物,化药,环肽;Th17通路;Potential First-in-Class,多肽偶联药物,创新药,IL17 therapeutic MPC;IL17 therapeutic MPC (PeptiDream),,免疫领域,,DR060945,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PeptiDream'],1,['PeptiDream(原研)'],免疫领域,自身免疫性疾病,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,autoimmune disease,IL17 therapeutic MPC (PeptiDream),IL17 therapeutic MPC;IL17 therapeutic MPC (PeptiDream)
IT-01,TIM3,TIM3抑制剂,Interprotein(原研),肿瘤,临床前,,Active,多肽,化药,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,创新药,IT-01,,肿瘤领域,,DR035071,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Interprotein'],1,['Interprotein(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,IT-01,IT-01
IT-201,TIM3,TIM3抑制剂,Interprotein(原研),肿瘤,临床前,,Active,多肽,化药,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,创新药,IT-201,,肿瘤领域,,DR023651,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Interprotein'],1,['Interprotein(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,IT-201,IT-201
IT-202,TIM3,TIM3抑制剂,Interprotein(原研),肿瘤,临床前,,Active,多肽,化药,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,创新药,IT-202,,肿瘤领域,,DR035073,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Interprotein'],1,['Interprotein(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,IT-202,IT-202
IT-203,TIM3,TIM3抑制剂,Interprotein(原研),肿瘤,临床前,,Active,多肽,化药,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,创新药,IT-203,,肿瘤领域,,DR013523,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Interprotein'],1,['Interprotein(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,IT-203,IT-203
IT-205,TIM3,TIM3抑制剂,Interprotein(原研),肿瘤,临床前,,Active,多肽,化药,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,创新药,IT-205,,肿瘤领域,,DR035072,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Interprotein'],1,['Interprotein(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,IT-205,IT-205
JMKX2301,not available,多肽偶联药物,济煜医药(原研),未知/待定,临床前,,Active,多肽;偶联药物,其他,环肽,多肽偶联药物,创新药,JMKX2301,,其他领域,,DR088411,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['济煜医药'],1,['济煜医药(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,JMKX2301,JMKX2301
JVA-4001,κ opioid receptor,κ opioid receptor拮抗剂,University of Florida(原研),阿片成瘾,临床前,,Active,多肽,化药,环肽;G蛋白偶联受体,拮抗剂,创新药,JVA-4001,,精神领域,,DR025052,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['University of Florida'],1,['University of Florida(原研)'],精神领域,阿片成瘾,['精神领域'],1,精神领域,,,-1,-1,Psychiatry,Psychiatry,,,opiate addiction,JVA-4001,JVA-4001
JWP24,MAGEA4,MAGEA4抑制剂,University of North Carolina at Chapel Hill(原研),癌症,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,JWP24,,肿瘤领域,,DR086918,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['University of North Carolina at Chapel Hill'],1,['University of North Carolina at Chapel Hill(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,JWP24,JWP24
KROS-401,IL-4Rα,IL-4Rα抑制剂,Kairos Pharma(原研),三阴性乳腺癌(差异化疾病),临床前,,Active,多肽,化药,环肽;Th2通路;差异化疾病;Potential First-in-Class,抑制剂,创新药,KROS-401,,肿瘤领域,,DR033240,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Kairos Pharma'],1,['Kairos Pharma(原研)'],肿瘤领域,三阴性乳腺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,triple negative breast cancer,KROS-401,KROS-401
KROS-401,IL-4Rα,IL-4Rα抑制剂,Kairos Pharma(原研),阿尔茨海默病(差异化疾病),临床前,,Active,多肽,化药,环肽;Th2通路;差异化疾病;Potential First-in-Class,抑制剂,创新药,KROS-401,,神经领域,,DR033240,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Kairos Pharma'],1,['Kairos Pharma(原研)'],神经领域,阿尔茨海默病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,Alzheimer's disease,KROS-401,KROS-401
KS-133,VIPR2,VIPR2拮抗剂,Ichimaru Pharcos(原研),精神分裂症,临床前,,Active,多肽,化药,环肽;G蛋白偶联受体;Potential First-in-Class,拮抗剂,创新药,KS-133,,精神领域,,DR005772,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Ichimaru Pharcos'],1,['Ichimaru Pharcos(原研)'],精神领域,精神分裂症,['精神领域'],1,精神领域,,,-1,-1,Psychiatry,Psychiatry,,,Schizophrenia,KS-133,KS-133
LAS200813,Nrf2;Keap1,Nrf2×Keap1蛋白蛋白相互作用抑制剂,AstraZeneca(Top20 MNC);Almirall(原研),呼吸系统疾病,临床前,,Active,多肽,化药,环肽;Keap1-Nrf2通路;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,LAS200813,,呼吸领域,,DR035180,否,欧洲,未知,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,True,['AstraZeneca'],['Almirall'],1,"['AstraZeneca(Top20 MNC)', 'Almirall(原研)']",呼吸领域,呼吸系统疾病,['呼吸领域'],1,呼吸领域,,,-1,-1,Respiratory,Respiratory,,,respiratory diseases,LAS200813,LAS200813
LYTAP-001,EGFR,EGFR降解剂,Filamon(原研),炎症(未指明),临床前,,Active,多肽;降解类药物,化药,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,降解剂,创新药,LYTAP-001,,免疫领域,,DR076530,否,澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Filamon'],1,['Filamon(原研)'],免疫领域,炎症(未指明),['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,Inflammation (unspecified),LYTAP-001,LYTAP-001
MAI-516,activated protein C;ARHGEF4,activated protein C×ARHGEF4蛋白蛋白相互作用抑制剂,上海大学(原研),结直肠癌,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,MAI-516,,肿瘤领域,,DR086913,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['上海大学'],1,['上海大学(原研)'],肿瘤领域,结直肠癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,colorectal cancer,MAI-516,MAI-516
MCB_D2,Mcl-1,Mcl-1结合剂,University of Washington(原研),未知/待定,临床前,,Active,多肽,化药,环肽;细胞凋亡;Potential First-in-Class,结合剂,创新药,MCB_D2;MCB_D2 (University of Washington),,其他领域,,DR087809,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['University of Washington'],1,['University of Washington(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,MCB_D2 (University of Washington),MCB_D2;MCB_D2 (University of Washington)
MT1-MMP targeting BDC,MMP14,多肽偶联药物,Bicycle Therapeutics(原研),非小细胞肺癌(差异化疾病),临床前,,Active,多肽;偶联药物,化药,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,MT1-MMP targeting BDC;MT1-MMP targeting BDC (BicycleTx),,肿瘤领域,,DR087521,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,非小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,non-small cell lung cancer,MT1-MMP targeting BDC (BicycleTx),MT1-MMP targeting BDC;MT1-MMP targeting BDC (BicycleTx)
MT1-MMP-68Ga imaging agent,MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,Bicycle Therapeutics(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,创新药,MT1-MMP-68Ga imaging agent;MT1-MMP-68Ga imaging agent (Bicycle),,诊断试剂领域,,DR073754,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,MT1-MMP-68Ga imaging agent (Bicycle),MT1-MMP-68Ga imaging agent;MT1-MMP-68Ga imaging agent (Bicycle)
NAI-112,not available,,Naicons(原研),疼痛,临床前,,Active,多肽,化药,环肽,其他,创新药,NAI-112,,麻醉镇痛领域,,DR010852,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Naicons'],1,['Naicons(原研)'],麻醉镇痛领域,疼痛,['麻醉镇痛领域'],1,麻醉镇痛领域,,,-1,-1,Anesthesia & Analgesia,Anesthesia & Analgesia,,,pain,NAI-112,NAI-112
NBP14,α7 receptor,α7 receptor抑制剂,Neuro-Bio(原研),阿尔茨海默病(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体,抑制剂,创新药,NBP14,,神经领域,,DR009912,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Neuro-Bio'],1,['Neuro-Bio(原研)'],神经领域,阿尔茨海默病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,Alzheimer's disease,NBP14,NBP14
NK-TICA,EphA2;NKp46,EphA2×NKp46结合剂,Bicycle Therapeutics(原研),肿瘤,临床前,,Active,多肽,化药,环肽;NK cell engager;NK细胞;受体酪氨酸激酶;Potential First-in-Class,结合剂,创新药,NK-TICA;BCY17226,,肿瘤领域,,DR084292,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,NK-TICA,NK-TICA;BCY17226
NL301,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,诺思兰德(原研),干眼病,临床前,,Active,多肽,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,NL301;NL301 (环孢素滴眼液);NL301 (cyclosporine eye drop),,眼科领域,,DR087637,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['诺思兰德'],1,['诺思兰德(原研)'],眼科领域,干眼病,['眼科领域'],1,眼科领域,,,-1,-1,Ophthalmology,Ophthalmology,,,dry eye disease,NL301 (cyclosporine eye drop),NL301;NL301 (环孢素滴眼液);NL301 (cyclosporine eye drop)
NPA7,Mas receptor,Mas receptor激活剂,Mayo Clinic(原研),心血管疾病,临床前,,Active,多肽,化药,环肽;肾素-血管紧张素-醛固酮系统;G蛋白偶联受体,激活剂,创新药,NPA7,,心脑血管领域,,DR047403,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Mayo Clinic'],1,['Mayo Clinic(原研)'],心脑血管领域,心血管疾病,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,cardiovascular disease,NPA7,NPA7
NanoRomi,HDAC,HDAC抑制剂,University of Virginia(原研),T细胞淋巴瘤,临床前,,Active,小分子,化药,环肽;表观遗传,抑制剂,微创新,NanoRomi;NanoRomi (romidepsin nanoparticle),,肿瘤领域;血液领域;罕见疾病领域,,DR086152,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['University of Virginia'],1,['University of Virginia(原研)'],肿瘤领域,T细胞淋巴瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,-1,-1,Oncology,Oncology,Hematology,,T cell lymphoma,NanoRomi (romidepsin nanoparticle),NanoRomi;NanoRomi (romidepsin nanoparticle)
OMN-51,not available,,Omnix Medical(原研),细菌感染,临床前,,Active,多肽,化药,环肽;中国无申报,其他,创新药,OMN-51,,感染领域,,DR047574,否,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Omnix Medical'],1,['Omnix Medical(原研)'],感染领域,细菌感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,bacterial infection,OMN-51,OMN-51
ORYN 1051,not available,,Oryn Therapeutics(原研),克罗恩病,临床前,,Active,多肽,化药,环肽,其他,创新药,ORYN 1051,,消化领域;免疫领域,,DR009768,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Oryn Therapeutics'],1,['Oryn Therapeutics(原研)'],消化领域,克罗恩病,"['消化领域', '免疫领域']",2,消化领域,免疫领域,,-1,-1,Digestive System,Digestive System,Immunology,,Crohn's disease,ORYN 1051,ORYN 1051
ORYN 1051,not available,,Oryn Therapeutics(原研),溃疡性结肠炎,临床前,,Active,多肽,化药,环肽,其他,创新药,ORYN 1051,,免疫领域;消化领域,,DR009768,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Oryn Therapeutics'],1,['Oryn Therapeutics(原研)'],免疫领域,溃疡性结肠炎,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,-1,-1,Immunology,Immunology,Digestive System,,ulcerative colitis,ORYN 1051,ORYN 1051
ORYN 1053,not available,,Oryn Therapeutics(原研),肿瘤,临床前,,Active,多肽,化药,环肽,其他,创新药,ORYN 1053,,肿瘤领域,,DR042056,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Oryn Therapeutics'],1,['Oryn Therapeutics(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,ORYN 1053,ORYN 1053
ORYN 1064,not available,,Oryn Therapeutics(原研),细菌感染,临床前,,Active,多肽,化药,环肽,其他,创新药,ORYN 1064,,感染领域,,DR020136,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Oryn Therapeutics'],1,['Oryn Therapeutics(原研)'],感染领域,细菌感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,bacterial infection,ORYN 1064,ORYN 1064
P1-1,GPR55,GPR55拮抗剂,中山大学(原研);图微安创(原研),肝纤维化(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病;Potential First-in-Class,拮抗剂,创新药,P1-1,,消化领域,,DR068670,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['中山大学', '图微安创']",2,"['中山大学(原研)', '图微安创(原研)']",消化领域,肝纤维化,['消化领域'],1,消化领域,,,-1,-1,Digestive System,Digestive System,,,liver fibrosis,P1-1,P1-1
PBP3s inhibitor,PBP3,PBP3抑制剂,Bicycle Therapeutics(原研),细菌感染,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,PBP3s inhibitor;PBP3s inhibitor (Bicycle Therapeutics),,感染领域,,DR087523,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],感染领域,细菌感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,bacterial infection,PBP3s inhibitor (Bicycle Therapeutics),PBP3s inhibitor;PBP3s inhibitor (Bicycle Therapeutics)
PD-K(111In-DOTA)-RGD,αvβ6;αvβ3,anti-αvβ3×αvβ6多肽偶联核素;含铟放射性示踪剂,National Cancer Center Japan(原研),胰腺导管癌,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,创新药,PD-K(111In-DOTA)-RGD,,肿瘤领域,,DR089733,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['National Cancer Center Japan'],1,['National Cancer Center Japan(原研)'],肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,pancreatic ductal carcinoma,PD-K(111In-DOTA)-RGD,PD-K(111In-DOTA)-RGD
PD-K(177Lu-DOTA)-c(RGDfK),αvβ6;αvβ3,anti-αvβ3×αvβ6多肽偶联核素;177Lu标记的放射性药物,National Cancer Center Japan(原研),胰腺导管癌,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,PD-K(177Lu-DOTA)-c(RGDfK),,肿瘤领域,,DR089726,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['National Cancer Center Japan'],1,['National Cancer Center Japan(原研)'],肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,pancreatic ductal carcinoma,PD-K(177Lu-DOTA)-c(RGDfK),PD-K(177Lu-DOTA)-c(RGDfK)
PD-K(225Ac-DOTA)-c(RGDfK),αvβ6;αvβ3,anti-αvβ3×αvβ6多肽偶联核素;225Ac标记的放射性药物,National Cancer Center Japan(原研),胰腺导管癌,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,PD-K(225Ac-DOTA)-c(RGDfK),,肿瘤领域,,DR089727,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['National Cancer Center Japan'],1,['National Cancer Center Japan(原研)'],肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,pancreatic ductal carcinoma,PD-K(225Ac-DOTA)-c(RGDfK),PD-K(225Ac-DOTA)-c(RGDfK)
PG-004,BMP7;BMP4,BMP4抑制剂;BMP7抑制剂,PeptiGrowth(原研),未知/待定,临床前,,Active,多肽,化药,环肽;TGF-β信号通路;Potential First-in-Class,抑制剂,创新药,PG-004,,其他领域,,DR060120,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PeptiGrowth'],1,['PeptiGrowth(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,PG-004,PG-004
PG-005,BMP7,BMP7抑制剂,PeptiGrowth(原研),未知/待定,临床前,,Active,多肽,化药,环肽;TGF-β信号通路;Potential First-in-Class,抑制剂,创新药,PG-005,,其他领域,,DR013348,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PeptiGrowth'],1,['PeptiGrowth(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,PG-005,PG-005
PG-006,BMP4,BMP4抑制剂,PeptiGrowth(原研),未知/待定,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,PG-006,,其他领域,,DR013349,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PeptiGrowth'],1,['PeptiGrowth(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,PG-006,PG-006
PG-007,VEGFR2,VEGFR2激动剂,PeptiGrowth(原研),未知/待定,临床前,,Active,多肽,化药,环肽;受体酪氨酸激酶;Potential First-in-Class,激动剂,创新药,PG-007,,其他领域,,DR043547,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PeptiGrowth'],1,['PeptiGrowth(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,PG-007,PG-007
PG-008,WNT3A,WNT3A类似物,PeptiGrowth(原研),未知/待定,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,类似物,创新药,PG-008,,其他领域,,DR077632,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PeptiGrowth'],1,['PeptiGrowth(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,PG-008,PG-008
PG-010,TPO receptor,TPO receptor激动剂,PeptiGrowth(原研),未知/待定,临床前,,Active,多肽,化药,环肽,激动剂,创新药,PG-010,,其他领域,,DR077635,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PeptiGrowth'],1,['PeptiGrowth(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,PG-010,PG-010
PG-012,FGFR2,FGFR2激动剂,PeptiGrowth(原研),未知/待定,临床前,,Active,多肽,化药,环肽;受体酪氨酸激酶;Potential First-in-Class,激动剂,创新药,PG-012,,其他领域,,DR077636,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PeptiGrowth'],1,['PeptiGrowth(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,PG-012,PG-012
PHIN-1314,CNP,CNP类似物,PharmaIN(原研),实体瘤,临床前,,Active,多肽,化药,环肽,类似物,创新药,PHIN-1314,,肿瘤领域,,DR036407,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PharmaIN'],1,['PharmaIN(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,solid tumors,PHIN-1314,PHIN-1314
PHIN-1314,CNP,CNP类似物,PharmaIN(原研),纤维化(未指明),临床前,,Active,多肽,化药,环肽,类似物,创新药,PHIN-1314,,其他领域,,DR036407,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PharmaIN'],1,['PharmaIN(原研)'],其他领域,纤维化(未指明),['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,Fibrosis (unspecified),PHIN-1314,PHIN-1314
PLX138,CNP,CNP类似物,ProLynx(原研),软骨发育不全,临床前,,Active,多肽,化药,环肽,类似物,创新药,"PLX138;[Gln6,14]CNP-38",,骨骼肌肉领域;罕见疾病领域,,DR025062,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['ProLynx'],1,['ProLynx(原研)'],骨骼肌肉领域,软骨发育不全,['骨骼肌肉领域'],1,骨骼肌肉领域,,,-1,-1,Musculoskeletal,Musculoskeletal,,,Achondroplasia,PLX138,"PLX138;[Gln6,14]CNP-38"
PN23114,Hepc,Hepc模拟物,Protagonist Therapeutics(原研),遗传性血色素沉着病,临床前,,Active,多肽,化药,环肽;铁代谢,模拟物,创新药,PN23114,,罕见疾病领域;内分泌及代谢领域,,DR073535,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Protagonist Therapeutics'],1,['Protagonist Therapeutics(原研)'],内分泌及代谢领域,遗传性血色素沉着病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,hereditary hemochromatosis,PN23114,PN23114
POL7306,BamA,BamA抑制剂,Polyphor(Spexis)(原研),细菌感染,临床前,,Active,小分子,化药,环肽;Potential First-in-Class,抑制剂,创新药,POL7306,,感染领域,,DR029380,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Polyphor(Spexis)'],1,['Polyphor(Spexis)(原研)'],感染领域,细菌感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,bacterial infection,POL7306,POL7306
PT-2,somatostatin,somatostatin类似物,Imagine Pharma(原研),类癌,临床前,,Active,多肽,化药,环肽,类似物,微创新,PT-2;PT-2 (口服奥曲肽);PT-2 (oral octreotide),,肿瘤领域;罕见疾病领域,,DR074468,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Imagine Pharma'],1,['Imagine Pharma(原研)'],肿瘤领域,类癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,carcinoid,PT-2 (oral octreotide),PT-2;PT-2 (口服奥曲肽);PT-2 (oral octreotide)
PT-2,somatostatin,somatostatin类似物,Imagine Pharma(原研),类癌综合征,临床前,,Active,多肽,化药,环肽,类似物,微创新,PT-2;PT-2 (口服奥曲肽);PT-2 (oral octreotide),,肿瘤领域;罕见疾病领域,,DR074468,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Imagine Pharma'],1,['Imagine Pharma(原研)'],肿瘤领域,类癌综合征,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,carcinoid syndrome,PT-2 (oral octreotide),PT-2;PT-2 (口服奥曲肽);PT-2 (oral octreotide)
Pb-BCY20603,MMP14,212Pb标记的放射性药物;anti-MMP14多肽偶联核素,Bicycle Therapeutics(原研);Orano Med,癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,创新药,Pb-BCY20603,,肿瘤领域,,DR055166,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],['Bicycle Therapeutics'],1,"['Bicycle Therapeutics(原研)', 'Orano Med']",肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,Pb-BCY20603,Pb-BCY20603
RAY0221,GIPR;GLP-1R;GCGR,GIPR激动剂;GLP-1R激动剂;GCGR激动剂,众生睿创(原研),糖尿病,临床前,,Active,多肽,化药,环肽;肠促胰岛素通路,激动剂,创新药,RAY0221,,内分泌及代谢领域,,DR049182,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['众生睿创'],1,['众生睿创(原研)'],内分泌及代谢领域,糖尿病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,diabetes,RAY0221,RAY0221
RAY0221,GIPR;GLP-1R;GCGR,GIPR激动剂;GLP-1R激动剂;GCGR激动剂,众生睿创(原研),肥胖,临床前,,Active,多肽,化药,环肽;肠促胰岛素通路,激动剂,创新药,RAY0221,,内分泌及代谢领域,,DR049182,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['众生睿创'],1,['众生睿创(原研)'],内分泌及代谢领域,肥胖,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,obesity,RAY0221,RAY0221
RAY0221,GIPR;GLP-1R;GCGR,GIPR激动剂;GLP-1R激动剂;GCGR激动剂,众生睿创(原研),代谢相关脂肪性肝炎,临床前,,Active,多肽,化药,环肽;肠促胰岛素通路,激动剂,创新药,RAY0221,,消化领域,,DR049182,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['众生睿创'],1,['众生睿创(原研)'],消化领域,代谢相关脂肪性肝炎,['消化领域'],1,消化领域,,,-1,-1,Digestive System,Digestive System,,,Metabolic related steatohepatitis,RAY0221,RAY0221
RGD-VC-CA,not available,多肽偶联药物,中国科学院深圳先进技术研究院(原研),癌症,临床前,,Active,多肽;偶联药物,化药,环肽,多肽偶联药物,创新药,RGD-VC-CA,,肿瘤领域,,DR052476,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['中国科学院深圳先进技术研究院'],1,['中国科学院深圳先进技术研究院(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,RGD-VC-CA,RGD-VC-CA
SAG602,Muc1,多肽偶联药物,羿肽生物(原研),癌症,临床前,,Active,多肽;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联药物,创新药,SAG602,,肿瘤领域,,DR080142,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['羿肽生物'],1,['羿肽生物(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,SAG602,SAG602
SAG602,Muc1,多肽偶联药物,羿肽生物(原研),光学成像剂,临床前,,Active,多肽;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联药物,创新药,SAG602,,诊断试剂领域,,DR080142,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['羿肽生物'],1,['羿肽生物(原研)'],诊断试剂领域,光学成像剂,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,optical imaging agent,SAG602,SAG602
SBL-PX1-206,PANX1,PANX1抑制剂,Vrije Universiteit Brussel(原研),心血管疾病,临床前,,Active,多肽,化药,环肽,抑制剂,创新药,SBL-PX1-206,,心脑血管领域,,DR060134,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Vrije Universiteit Brussel'],1,['Vrije Universiteit Brussel(原研)'],心脑血管领域,心血管疾病,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,cardiovascular disease,SBL-PX1-206,SBL-PX1-206
SBL-PX1-42,PANX1,PANX1抑制剂,Vrije Universiteit Brussel(原研),心血管疾病,临床前,,Active,多肽,化药,环肽,抑制剂,创新药,SBL-PX1-42,,心脑血管领域,,DR030511,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Vrije Universiteit Brussel'],1,['Vrije Universiteit Brussel(原研)'],心脑血管领域,心血管疾病,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,cardiovascular disease,SBL-PX1-42,SBL-PX1-42
SBL-PX1-44,PANX1,PANX1抑制剂,Vrije Universiteit Brussel(原研),心血管疾病,临床前,,Active,多肽,化药,环肽,抑制剂,创新药,SBL-PX1-44,,心脑血管领域,,DR060133,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Vrije Universiteit Brussel'],1,['Vrije Universiteit Brussel(原研)'],心脑血管领域,心血管疾病,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,cardiovascular disease,SBL-PX1-44,SBL-PX1-44
SG5035,glucan synthase,glucan synthase抑制剂,祥根生物(原研),侵袭性念珠菌病,临床前,,Active,多肽,化药,环肽,抑制剂,创新药,SG5035,,感染领域,,DR076774,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['祥根生物'],1,['祥根生物(原研)'],感染领域,侵袭性念珠菌病,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,Invasive candidiasis,SG5035,SG5035
SP-002,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sentan Pharma(原研),肢体缺血性疾病,临床前,,Active,小分子,化药,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,微创新,SP-002;SP-002 (环孢素纳米粒);SP-002 (cyclosporin nanoparticles),,心脑血管领域,,DR044515,否,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Sentan Pharma'],1,['Sentan Pharma(原研)'],心脑血管领域,肢体缺血性疾病,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,limb ischemic disease,SP-002 (cyclosporin nanoparticles),SP-002;SP-002 (环孢素纳米粒);SP-002 (cyclosporin nanoparticles)
SVC112,not available,,SuviCa(原研),头颈部鳞状细胞癌,临床前,,Active,多肽,化药,环肽,其他,创新药,SVC112,,肿瘤领域,,DR047485,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['SuviCa'],1,['SuviCa(原研)'],肿瘤领域,头颈部鳞状细胞癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,Head and neck squamous cell carcinoma,SVC112,SVC112
SYNB011128,CAIX;EGFR,多肽偶联药物,元思生肽(原研),癌症,临床前,,Active,多肽;偶联药物,化药,环肽;payload [海兔毒素衍生物：MMAE];受体酪氨酸激酶;Potential First-in-Class;可降解连接子,多肽偶联药物,创新药,SYNB011128,,肿瘤领域,,DR078617,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['元思生肽'],1,['元思生肽(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,SYNB011128,SYNB011128
SYNB021225,KRAS,KRAS抑制剂,元思生肽(原研),肿瘤,临床前,,Active,多肽,化药,环肽;难成药靶点,抑制剂,创新药,SYNB021225,,肿瘤领域,,DR078820,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['元思生肽'],1,['元思生肽(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,SYNB021225,SYNB021225
ShK-235,Kv1.3,Kv1.3抑制剂,Baylor College of Medicine(原研),类风湿性关节炎(差异化疾病),临床前,,Active,多肽,生物,环肽;差异化疾病,抑制剂,创新药,ShK-235;LrS235,,免疫领域;骨骼肌肉领域,,DR037473,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Baylor College of Medicine'],1,['Baylor College of Medicine(原研)'],免疫领域,类风湿性关节炎,"['免疫领域', '骨骼肌肉领域']",2,免疫领域,骨骼肌肉领域,,-1,-1,Immunology,Immunology,Musculoskeletal,,rheumatoid arthritis,ShK-235,ShK-235;LrS235
Syn3,BDNF,BDNF增强剂,Aingeal therapeutics(原研),快乐木偶综合症,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,增强剂,创新药,Syn3,,罕见疾病领域,,DR024934,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Aingeal therapeutics'],1,['Aingeal therapeutics(原研)'],,快乐木偶综合症,[],0,,,,-1,-1,,,,,happy puppet syndrome,Syn3,Syn3
Syn3,BDNF,BDNF增强剂,Aingeal therapeutics(原研),外伤性脑损伤,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,增强剂,创新药,Syn3,,神经领域,,DR024934,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Aingeal therapeutics'],1,['Aingeal therapeutics(原研)'],神经领域,外伤性脑损伤,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,traumatic brain injury,Syn3,Syn3
Syn3,BDNF,BDNF增强剂,Aingeal therapeutics(原研),难治性抑郁症,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,增强剂,创新药,Syn3,,精神领域,,DR024934,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Aingeal therapeutics'],1,['Aingeal therapeutics(原研)'],精神领域,难治性抑郁症,['精神领域'],1,精神领域,,,-1,-1,Psychiatry,Psychiatry,,,treatment-resistant depression,Syn3,Syn3
Synova macrocyclic peptide,not available,,AstraZeneca(Top20 MNC);元思生肽(原研),自身免疫性疾病,临床前,,Active,多肽,其他,环肽;中国无申报,其他,创新药,Synova macrocyclic peptide;Synova macrocyclic peptide (元思生肽);Synova macrocyclic peptide (Syneron Bio),,免疫领域,,DR076824,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,True,['AstraZeneca'],['元思生肽'],1,"['AstraZeneca(Top20 MNC)', '元思生肽(原研)']",免疫领域,自身免疫性疾病,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,autoimmune disease,Synova macrocyclic peptide (Syneron Bio),Synova macrocyclic peptide;Synova macrocyclic peptide (元思生肽);Synova macrocyclic peptide (Syneron Bio)
Synova macrocyclic peptide,not available,,AstraZeneca(Top20 MNC);元思生肽(原研),代谢疾病,临床前,,Active,多肽,其他,环肽;中国无申报,其他,创新药,Synova macrocyclic peptide;Synova macrocyclic peptide (元思生肽);Synova macrocyclic peptide (Syneron Bio),,内分泌及代谢领域,,DR076824,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,True,['AstraZeneca'],['元思生肽'],1,"['AstraZeneca(Top20 MNC)', '元思生肽(原研)']",内分泌及代谢领域,代谢疾病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Metabolic diseases,Synova macrocyclic peptide (Syneron Bio),Synova macrocyclic peptide;Synova macrocyclic peptide (元思生肽);Synova macrocyclic peptide (Syneron Bio)
T20K,IL-2,,Cyxone(原研),多发性硬化症相关视神经炎,临床前,,Active,多肽,化药,环肽,其他,创新药,T20K,,神经领域;罕见疾病领域,,DR044285,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Cyxone'],1,['Cyxone(原研)'],神经领域,多发性硬化症相关视神经炎,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,Multiple sclerosis-related optic neuritis,T20K,T20K
TB513,SIRPα,多肽偶联药物,Twinpig Biolab(原研),肿瘤,临床前,,Active,多肽;偶联药物,化药,环肽;肿瘤相关巨噬细胞;中国无申报;Potential First-in-Class;肿瘤免疫,多肽偶联药物,创新药,TB513,,肿瘤领域,,DR087533,否,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Twinpig Biolab'],1,['Twinpig Biolab(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,TB513,TB513
TB551,not available,多肽偶联药物,Twinpig Biolab(原研),胰腺癌,临床前,,Active,多肽;偶联药物,化药,环肽;中国无申报,多肽偶联药物,创新药,TB551;TB522,,肿瘤领域;罕见疾病领域,,DR045211,否,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Twinpig Biolab'],1,['Twinpig Biolab(原研)'],肿瘤领域,胰腺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,pancreatic cancer,TB551,TB551;TB522
TB712,CD18;STAT6,多肽偶联药物;反义疗法,Twinpig Biolab(原研),肿瘤,临床前,,Active,核酸;多肽;偶联药物,化药,环肽;JAK-STAT信号通路;小核酸;中国无申报;Potential First-in-Class,反义疗法;多肽偶联药物,创新药,TB712;TB711,,肿瘤领域,,DR084301,否,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Twinpig Biolab'],1,['Twinpig Biolab(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,TB712,TB712;TB711
TBR521,FAP,多肽偶联药物,Twinpig Biolab(原研),癌症,临床前,,Active,多肽;偶联药物,化药,环肽;中国无申报,多肽偶联药物,创新药,TBR521,,肿瘤领域,,DR087539,否,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Twinpig Biolab'],1,['Twinpig Biolab(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,TBR521,TBR521
TBR551,nectin-4,多肽偶联药物,Twinpig Biolab(原研),癌症,临床前,,Active,多肽;偶联药物,化药,环肽;中国无申报,多肽偶联药物,创新药,TBR551,,肿瘤领域,,DR087542,否,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Twinpig Biolab'],1,['Twinpig Biolab(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,TBR551,TBR551
TBR552,TROP2,多肽偶联药物,Twinpig Biolab(原研),癌症,临床前,,Active,多肽;偶联药物,化药,环肽;中国无申报;Potential First-in-Class,多肽偶联药物,创新药,TBR552,,肿瘤领域,,DR087544,否,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Twinpig Biolab'],1,['Twinpig Biolab(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,TBR552,TBR552
TBR553,ROR1,多肽偶联药物,Twinpig Biolab(原研),癌症,临床前,,Active,多肽;偶联药物,化药,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class;Wnt信号通路,多肽偶联药物,创新药,TBR553,,肿瘤领域,,DR087545,否,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Twinpig Biolab'],1,['Twinpig Biolab(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,TBR553,TBR553
TLR3 targeted Bicycle,TLR3,TLR3调节剂,Genentech(Roche)(Top20 MNC);Bicycle Therapeutics(原研),实体瘤,临床前,,Active,多肽,化药,环肽;Toll样受体信号通路;中国无申报;Potential First-in-Class;肿瘤免疫,调节剂,创新药,TLR3 targeted Bicycle;TLR3 targeted Bicycle (Bicycle Therapeutics),,肿瘤领域,,DR075803,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,True,['Genentech(Roche)'],['Bicycle Therapeutics'],1,"['Genentech(Roche)(Top20 MNC)', 'Bicycle Therapeutics(原研)']",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,solid tumors,TLR3 targeted Bicycle (Bicycle Therapeutics),TLR3 targeted Bicycle;TLR3 targeted Bicycle (Bicycle Therapeutics)
TNF-α-targeted cyclic peptides project,TNF-α,,GeneFrontier(原研),未知/待定,临床前,,Active,多肽,化药,环肽,其他,创新药,TNF-α-targeted cyclic peptides project;TNF-α-targeted cyclic peptides project (GeneFrontier),,其他领域,,DR088907,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['GeneFrontier'],1,['GeneFrontier(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,TNF-α-targeted cyclic peptides project (GeneFrontier),TNF-α-targeted cyclic peptides project;TNF-α-targeted cyclic peptides project (GeneFrontier)
TT-241X,not available,,Teitur Trophics(原研),神经痛,临床前,,Active,多肽,化药,环肽,其他,创新药,TT-241X,,麻醉镇痛领域,,DR011058,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Teitur Trophics'],1,['Teitur Trophics(原研)'],麻醉镇痛领域,神经痛,['麻醉镇痛领域'],1,麻醉镇痛领域,,,-1,-1,Anesthesia & Analgesia,Anesthesia & Analgesia,,,neuralgia,TT-241X,TT-241X
Tye-1002,SSTR2,多肽偶联药物,泰尔康生物(原研),小细胞肺癌,临床前,,Active,多肽;偶联药物,化药,环肽;差异化疾病,多肽偶联药物,创新药,Tye-1002,,肿瘤领域;罕见疾病领域,,DR034168,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['泰尔康生物'],1,['泰尔康生物(原研)'],肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,small cell lung cancer,Tye-1002,Tye-1002
Tye-1002,SSTR2,多肽偶联药物,泰尔康生物(原研),鼻咽癌(差异化疾病),临床前,,Active,多肽;偶联药物,化药,环肽;差异化疾病,多肽偶联药物,创新药,Tye-1002,,肿瘤领域;罕见疾病领域,,DR034168,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['泰尔康生物'],1,['泰尔康生物(原研)'],肿瘤领域,鼻咽癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,Nasopharyngeal cancer,Tye-1002,Tye-1002
Tye-1002,SSTR2,多肽偶联药物,泰尔康生物(原研),神经内分泌肿瘤,临床前,,Active,多肽;偶联药物,化药,环肽;差异化疾病,多肽偶联药物,创新药,Tye-1002,,肿瘤领域;罕见疾病领域,,DR034168,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['泰尔康生物'],1,['泰尔康生物(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,neuroendocrine tumors,Tye-1002,Tye-1002
Tye-2001,CaN;SSTR2;FKBP12,多肽偶联药物;CaN×FKBP12分子胶,泰尔康生物(原研),器官移植,临床前,,Active,多肽;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联药物;分子胶,创新药,Tye-2001;Tye2001,,其他领域,,DR059368,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['泰尔康生物'],1,['泰尔康生物(原研)'],其他领域,器官移植,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,organ transplant,Tye-2001,Tye-2001;Tye2001
ULT3,P. aeruginosa;S. aureus;E. coli;K. pneumoniae;A. baumannii,多肽类抗生素,Ultupharma(原研),细菌感染,临床前,,Active,多肽,生物,环肽;Potential First-in-Class,多肽类抗生素,创新药,ULT3,,感染领域,,DR008548,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Ultupharma'],1,['Ultupharma(原研)'],感染领域,细菌感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,bacterial infection,ULT3,ULT3
UNP-6457,MDM2;p53,MDM2×p53蛋白蛋白相互作用抑制剂,Unnatural Products(原研),未知/待定,临床前,,Active,多肽,化药,环肽;细胞凋亡;泛素-蛋白酶体系统;合成致死;难成药靶点;p53信号通路,蛋白蛋白相互作用抑制剂,创新药,UNP-6457,,其他领域,,DR061184,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Unnatural Products'],1,['Unnatural Products(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,UNP-6457,UNP-6457
US2025122242A1,Aβ,Aβ聚集抑制剂,WARF(原研),阿尔茨海默病,临床前,,Active,多肽,化药,环肽;Amyloid beta通路,聚集抑制剂,创新药,US2025122242A1,,神经领域,,DR084136,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['WARF'],1,['WARF(原研)'],神经领域,阿尔茨海默病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,Alzheimer's disease,US2025122242A1,US2025122242A1
US2025145665A1,TNF-α,TNF-α抑制剂,Bristol-Myers Squibb(Top20 MNC)(原研),自身免疫性疾病,临床前,,Active,多肽,化药,环肽,抑制剂,创新药,US2025145665A1,,免疫领域,,DR084139,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,['Bristol-Myers Squibb(Top20 MNC)(原研)'],免疫领域,自身免疫性疾病,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,autoimmune disease,US2025145665A1,US2025145665A1
US2025145665A1,TNF-α,TNF-α抑制剂,Bristol-Myers Squibb(Top20 MNC)(原研),炎症(未指明),临床前,,Active,多肽,化药,环肽,抑制剂,创新药,US2025145665A1,,免疫领域,,DR084139,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,['Bristol-Myers Squibb(Top20 MNC)(原研)'],免疫领域,炎症(未指明),['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,Inflammation (unspecified),US2025145665A1,US2025145665A1
VIAN-c4551,Ang2;VEGF,Ang2×VEGF抑制剂,ViAn Therapeutics(原研),湿性年龄相关性黄斑变性,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,VIAN-c4551,,眼科领域,,DR074000,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['ViAn Therapeutics'],1,['ViAn Therapeutics(原研)'],眼科领域,湿性年龄相关性黄斑变性,['眼科领域'],1,眼科领域,,,-1,-1,Ophthalmology,Ophthalmology,,,Wet age-related macular degeneration,VIAN-c4551,VIAN-c4551
VIAN-c4551,Ang2;VEGF,Ang2×VEGF抑制剂,ViAn Therapeutics(原研),糖尿病黄斑水肿,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,VIAN-c4551,,眼科领域,,DR074000,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['ViAn Therapeutics'],1,['ViAn Therapeutics(原研)'],眼科领域,糖尿病黄斑水肿,['眼科领域'],1,眼科领域,,,-1,-1,Ophthalmology,Ophthalmology,,,diabetic macular edema,VIAN-c4551,VIAN-c4551
VIAN-c4551,Ang2;VEGF,Ang2×VEGF抑制剂,ViAn Therapeutics(原研),糖尿病视网膜病变,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,VIAN-c4551,,眼科领域,,DR074000,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['ViAn Therapeutics'],1,['ViAn Therapeutics(原研)'],眼科领域,糖尿病视网膜病变,['眼科领域'],1,眼科领域,,,-1,-1,Ophthalmology,Ophthalmology,,,diabetic retinopathy,VIAN-c4551,VIAN-c4551
VRP-034,not available,多粘菌素类抗生素,Venus Remedies(原研),细菌感染,临床前,,Active,其他,化药,环肽;中国无申报,多粘菌素类抗生素,微创新,VRP-034;VRP-034 (Polymyxin B),,感染领域,,DR050842,否,印度,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Venus Remedies'],1,['Venus Remedies(原研)'],感染领域,细菌感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,bacterial infection,VRP-034,VRP-034;VRP-034 (Polymyxin B)
WN561,APLNR,APLNR激动剂,浙江大学医学院附属邵逸夫医院(原研),心血管疾病,临床前,,Active,多肽,化药,环肽;G蛋白偶联受体,激动剂,创新药,WN561,,心脑血管领域,,DR061928,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['浙江大学医学院附属邵逸夫医院'],1,['浙江大学医学院附属邵逸夫医院(原研)'],心脑血管领域,心血管疾病,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,cardiovascular disease,WN561,WN561
WO2021007436A1,Bcl-2;PD1;TNF-α,Bcl-2抑制剂;TNF-α抑制剂;PD1抑制剂,拓创生物(原研),癌症,临床前,,Active,多肽,化药,环肽;细胞凋亡;Potential First-in-Class;难成药靶点;肿瘤免疫,抑制剂,创新药,WO2021007436A1,,肿瘤领域,,DR075019,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['拓创生物'],1,['拓创生物(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2021007436A1,WO2021007436A1
WO2022034057A1,RARRES2,RARRES2类似物,Bayer(Top20 MNC)(原研),糖尿病,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,类似物,创新药,WO2022034057A1,,内分泌及代谢领域,,DR072334,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Bayer'],['Bayer'],1,['Bayer(Top20 MNC)(原研)'],内分泌及代谢领域,糖尿病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,diabetes,WO2022034057A1,WO2022034057A1
WO2022096394A1,MASP,MASP抑制剂,Bayer(Top20 MNC)(原研),心肌再灌注损伤,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,WO2022096394A1,,心脑血管领域,,DR072399,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Bayer'],['Bayer'],1,['Bayer(Top20 MNC)(原研)'],心脑血管领域,心肌再灌注损伤,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,myocardial reperfusion injury,WO2022096394A1,WO2022096394A1
WO2022096394A1,MASP,MASP抑制剂,Bayer(Top20 MNC)(原研),肾脏缺血再灌注损伤,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,WO2022096394A1,,泌尿生殖领域,,DR072399,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Bayer'],['Bayer'],1,['Bayer(Top20 MNC)(原研)'],泌尿生殖领域,肾脏缺血再灌注损伤,['泌尿生殖领域'],1,泌尿生殖领域,,,-1,-1,Genitourinary,Genitourinary,,,renal ischemia-reperfusion injury,WO2022096394A1,WO2022096394A1
WO2022115799A1,GC-C,anti-GC-C多肽偶联核素;225Ac标记的放射性药物,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),结直肠癌,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,WO2022115799A1,,肿瘤领域,,DR075156,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,结直肠癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,colorectal cancer,WO2022115799A1,WO2022115799A1
WO2022129254A1,amylin,amylin类似物,MedImmune(AstraZeneca)(Top20 MNC)(原研),糖尿病,临床前,,Active,多肽,化药,环肽,类似物,微创新,WO2022129254A1,,内分泌及代谢领域,,DR072408,是,美国,未知,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['MedImmune(AstraZeneca)'],['MedImmune(AstraZeneca)'],1,['MedImmune(AstraZeneca)(Top20 MNC)(原研)'],内分泌及代谢领域,糖尿病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,diabetes,WO2022129254A1,WO2022129254A1
WO2022129254A1,amylin,amylin类似物,MedImmune(AstraZeneca)(Top20 MNC)(原研),肥胖,临床前,,Active,多肽,化药,环肽,类似物,微创新,WO2022129254A1,,内分泌及代谢领域,,DR072408,是,美国,未知,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['MedImmune(AstraZeneca)'],['MedImmune(AstraZeneca)'],1,['MedImmune(AstraZeneca)(Top20 MNC)(原研)'],内分泌及代谢领域,肥胖,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,obesity,WO2022129254A1,WO2022129254A1
WO2022212947A1,KRAS G12D,KRAS G12D抑制剂,Indi Molecular(原研),癌症,临床前,,Active,多肽,化药,环肽;难成药靶点;Ras-Raf信号通路,抑制剂,创新药,WO2022212947A1,,肿瘤领域,,DR075973,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Indi Molecular'],1,['Indi Molecular(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2022212947A1,WO2022212947A1
WO2022223969A1,P-sel,P-sel抑制剂,Bicycle Therapeutics(原研),癌症,临床前,,Active,多肽,化药,环肽;差异化疾病;CLR信号通路,抑制剂,创新药,WO2022223969A1,,肿瘤领域,,DR081393,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2022223969A1,WO2022223969A1
WO2022223969A1,P-sel,P-sel抑制剂,Bicycle Therapeutics(原研),镰状细胞病,临床前,,Active,多肽,化药,环肽;差异化疾病;CLR信号通路,抑制剂,创新药,WO2022223969A1,,血液领域;罕见疾病领域,,DR081393,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],血液领域,镰状细胞病,['血液领域'],1,血液领域,,,-1,-1,Hematology,Hematology,,,sickle cell disease,WO2022223969A1,WO2022223969A1
WO2022223969A1,P-sel,P-sel抑制剂,Bicycle Therapeutics(原研),新型冠状病毒感染(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病;CLR信号通路,抑制剂,创新药,WO2022223969A1,,感染领域,,DR081393,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],感染领域,新型冠状病毒感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,novel coronavirus infection,WO2022223969A1,WO2022223969A1
WO2022253051A1,nectin-4,多肽偶联药物,药明康德(原研),肿瘤,临床前,,Active,多肽;偶联药物,化药,环肽,多肽偶联药物,创新药,WO2022253051A1,,肿瘤领域,,DR073933,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['药明康德'],1,['药明康德(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2022253051A1,WO2022253051A1
WO2023020485A1,EphA2,多肽偶联药物,药明康德(原研),实体瘤,临床前,,Active,多肽;偶联药物,化药,环肽;payload [海兔毒素衍生物：MMAE];受体酪氨酸激酶,多肽偶联药物,创新药,WO2023020485A1,,肿瘤领域,,DR077827,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['药明康德'],1,['药明康德(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,solid tumors,WO2023020485A1,WO2023020485A1
WO2023026994A1,dystrophin;TfR,多肽偶联药物,Takeda Pharmaceuticals(Top20 MNC)(原研),假肥大性肌营养不良,临床前,,Active,核酸;多肽;偶联药物,化药,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,创新药,WO2023026994A1,,骨骼肌肉领域;罕见疾病领域,,DR072159,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,True,['Takeda Pharmaceuticals'],['Takeda Pharmaceuticals'],1,['Takeda Pharmaceuticals(Top20 MNC)(原研)'],骨骼肌肉领域,假肥大性肌营养不良,['骨骼肌肉领域'],1,骨骼肌肉领域,,,-1,-1,Musculoskeletal,Musculoskeletal,,,Duchenne muscular dystrophy,WO2023026994A1,WO2023026994A1
WO2023048151A1,SARS-CoV-2 S protein,SARS-CoV-2 S protein抑制剂,Shionogi(原研);Hokkaido University(原研),新型冠状病毒感染,临床前,,Active,多肽,化药,环肽,抑制剂,创新药,WO2023048151A1,,感染领域,,DR078680,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['Shionogi', 'Hokkaido University']",2,"['Shionogi(原研)', 'Hokkaido University(原研)']",感染领域,新型冠状病毒感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,novel coronavirus infection,WO2023048151A1,WO2023048151A1
WO2023056368A1,DDX25,DDX25抑制剂,Department of Health and Human Services(原研),男性避孕,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,WO2023056368A1,,泌尿生殖领域,,DR075188,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Department of Health and Human Services'],1,['Department of Health and Human Services(原研)'],泌尿生殖领域,男性避孕,['泌尿生殖领域'],1,泌尿生殖领域,,,-1,-1,Genitourinary,Genitourinary,,,male contraception,WO2023056368A1,WO2023056368A1
WO2023061482A1,EphA2,多肽偶联药物,海思科(原研),肿瘤,临床前,,Active,多肽;偶联药物,化药,环肽;受体酪氨酸激酶,多肽偶联药物,创新药,WO2023061482A1,,肿瘤领域,,DR076750,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['海思科'],1,['海思科(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2023061482A1,WO2023061482A1
WO2023066314A1,nectin-4,多肽偶联药物,海思科(原研),肿瘤,临床前,,Active,多肽;偶联药物,化药,环肽,多肽偶联药物,创新药,WO2023066314A1,,肿瘤领域,,DR074311,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['海思科'],1,['海思科(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2023066314A1,WO2023066314A1
WO2023069332A1,eIF4E,eIF4E抑制剂,Merck & Co.(Top20 MNC)(原研),癌症,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,WO2023069332A1,,肿瘤领域,,DR072181,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2023069332A1,WO2023069332A1
WO2023084234A1,ACE2,ACE2结合剂,Bicycle Therapeutics(原研),新型冠状病毒感染,临床前,,Active,多肽,生物,环肽;肾素-血管紧张素-醛固酮系统,结合剂,创新药,WO2023084234A1,,感染领域,,DR073249,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],感染领域,新型冠状病毒感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,novel coronavirus infection,WO2023084234A1,WO2023084234A1
WO2023088236A1,MMP14,多肽偶联药物,海思科(原研),癌症,临床前,,Active,多肽;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联药物,创新药,WO2023088236A1,,肿瘤领域,,DR076760,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['海思科'],1,['海思科(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2023088236A1,WO2023088236A1
WO2023098072A1,nectin-4,177Lu标记的放射性药物;anti-nectin-4多肽偶联核素,北京大学第一医院(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,生物,环肽;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,WO2023098072A1,,肿瘤领域,,DR074317,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['北京大学第一医院'],1,['北京大学第一医院(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2023098072A1,WO2023098072A1
WO2023111350A2,CAIX,anti-CAIX多肽偶联核素;225Ac标记的放射性药物,3B Pharmaceuticals(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,WO2023111350A2,,肿瘤领域,,DR081398,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['3B Pharmaceuticals'],1,['3B Pharmaceuticals(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2023111350A2,WO2023111350A2
WO2023111350A2,CAIX,anti-CAIX多肽偶联核素;225Ac标记的放射性药物,3B Pharmaceuticals(原研),SPECT显像(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,WO2023111350A2,,诊断试剂领域,,DR081398,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['3B Pharmaceuticals'],1,['3B Pharmaceuticals(原研)'],诊断试剂领域,SPECT显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,SPECT imaging,WO2023111350A2,WO2023111350A2
WO2023121699A1,CTLA4,CTLA4抑制剂,KSURF(原研),癌症,临床前,,Active,多肽,生物,环肽;Treg细胞;Potential First-in-Class;肿瘤免疫,抑制剂,创新药,WO2023121699A1,,肿瘤领域,,DR073492,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['KSURF'],1,['KSURF(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2023121699A1,WO2023121699A1
WO2023136342A1,THBS1,THBS1抑制剂,Daiichi Sankyo(原研);PeptiDream(原研),外周动脉疾病,临床前,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,WO2023136342A1,,心脑血管领域,,DR081950,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['Daiichi Sankyo', 'PeptiDream']",2,"['Daiichi Sankyo(原研)', 'PeptiDream(原研)']",心脑血管领域,外周动脉疾病,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,peripheral arterial disease,WO2023136342A1,WO2023136342A1
WO2023136342A1,THBS1,THBS1抑制剂,Daiichi Sankyo(原研);PeptiDream(原研),严重肢体缺血(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,WO2023136342A1,,心脑血管领域,,DR081950,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['Daiichi Sankyo', 'PeptiDream']",2,"['Daiichi Sankyo(原研)', 'PeptiDream(原研)']",心脑血管领域,严重肢体缺血,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,critical limb ischemia,WO2023136342A1,WO2023136342A1
WO2023145860A1,c-Kit,c-Kit激动剂,Ajinomoto(原研),肿瘤,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,激动剂,创新药,WO2023145860A1,,肿瘤领域,,DR077477,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Ajinomoto'],1,['Ajinomoto(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2023145860A1,WO2023145860A1
WO2023165476A1,Sortilin,多肽偶联药物,智肽生物(原研),肿瘤,临床前,,Active,多肽;偶联药物,化药,环肽,多肽偶联药物,创新药,WO2023165476A1,,肿瘤领域,,DR081104,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['智肽生物'],1,['智肽生物(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2023165476A1,WO2023165476A1
WO2023169584A1,nectin-4,多肽偶联药物,智肽生物(原研),癌症,临床前,,Active,多肽;偶联药物,化药,环肽;payload [海兔毒素衍生物：MMAE],多肽偶联药物,创新药,WO2023169584A1,,肿瘤领域,,DR069124,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['智肽生物'],1,['智肽生物(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2023169584A1,WO2023169584A1
WO2023220634A2,EGFR,EGFR类似物,University of Pennsylvania(原研);Elicio Therapeutics(原研),癌症,临床前,,Active,多肽,化药,环肽;受体酪氨酸激酶;Potential First-in-Class,类似物,创新药,WO2023220634A2,,肿瘤领域,,DR077969,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['University of Pennsylvania', 'Elicio Therapeutics']",2,"['University of Pennsylvania(原研)', 'Elicio Therapeutics(原研)']",肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2023220634A2,WO2023220634A2
WO2023220836A1,SSTR2,125I标记的放射性示踪剂;anti-SSTR2多肽偶联核素,University of Alberta(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;中国无申报;Potential First-in-Class,多肽偶联核素;125I标记的放射性示踪剂,创新药,WO2023220836A1,,诊断试剂领域,,DR079687,是,加拿大,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['University of Alberta'],1,['University of Alberta(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,WO2023220836A1,WO2023220836A1
WO2023225661A1,PD1;PDL1,PD1×PDL1蛋白蛋白相互作用抑制剂,Bristol-Myers Squibb(Top20 MNC)(原研),癌症,临床前,,Active,多肽,化药,环肽;肿瘤免疫,蛋白蛋白相互作用抑制剂,创新药,WO2023225661A1,,肿瘤领域,,DR044937,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,['Bristol-Myers Squibb(Top20 MNC)(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2023225661A1,WO2023225661A1
WO2023228186A1,EGFR,EGFR结合剂,Ariel Precision Medicine(原研),癌症,临床前,,Active,多肽,化药,环肽;受体酪氨酸激酶;Potential First-in-Class,结合剂,创新药,WO2023228186A1,,肿瘤领域,,DR077977,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Ariel Precision Medicine'],1,['Ariel Precision Medicine(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2023228186A1,WO2023228186A1
WO2023244554A1,IL-1β,IL-1β抑制剂,Merck & Co.(Top20 MNC)(原研),动脉粥样硬化(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病;Potential First-in-Class,抑制剂,创新药,WO2023244554A1,,心脑血管领域,,DR045025,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],心脑血管领域,动脉粥样硬化,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,atherosclerosis,WO2023244554A1,WO2023244554A1
WO2023245016A1,IL-13,IL-13抑制剂,B.A.I. Biosciences(原研),皮肤病,临床前,,Active,多肽,化药,环肽;Th2通路;Potential First-in-Class,抑制剂,创新药,WO2023245016A1,,皮肤领域,,DR027504,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['B.A.I. Biosciences'],1,['B.A.I. Biosciences(原研)'],皮肤领域,皮肤病,['皮肤领域'],1,皮肤领域,,,-1,-1,Dermatology,Dermatology,,,skin disease,WO2023245016A1,WO2023245016A1
WO2024003313A1,IL-23R,IL-23R拮抗剂,Sanofi(Top20 MNC)(原研),炎症性肠病,临床前,,Active,多肽,化药,环肽;Th17通路,拮抗剂,创新药,WO2024003313A1,,免疫领域;消化领域,,DR027562,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Sanofi'],['Sanofi'],1,['Sanofi(Top20 MNC)(原研)'],免疫领域,炎症性肠病,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,-1,-1,Immunology,Immunology,Digestive System,,inflammatory bowel disease,WO2024003313A1,WO2024003313A1
WO2024010957A2,nectin-4,含铟放射性示踪剂;anti-nectin-4多肽偶联核素,Aktis Oncology(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,创新药,WO2024010957A2,,肿瘤领域,,DR081404,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Aktis Oncology'],1,['Aktis Oncology(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2024010957A2,WO2024010957A2
WO2024010957A2,nectin-4,含铟放射性示踪剂;anti-nectin-4多肽偶联核素,Aktis Oncology(原研),SPECT显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,创新药,WO2024010957A2,,诊断试剂领域,,DR081404,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Aktis Oncology'],1,['Aktis Oncology(原研)'],诊断试剂领域,SPECT显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,SPECT imaging,WO2024010957A2,WO2024010957A2
WO2024015958A1,IL-23R,IL-23R拮抗剂,Janssen Biotech(Johnson & Johnson)(Top20 MNC)(原研),自身免疫性疾病,临床前,,Active,多肽,化药,环肽;Th17通路,拮抗剂,创新药,WO2024015958A1,,免疫领域,,DR061912,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Janssen Biotech(Johnson & Johnson)'],['Janssen Biotech(Johnson & Johnson)'],1,['Janssen Biotech(Johnson & Johnson)(Top20 MNC)(原研)'],免疫领域,自身免疫性疾病,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,autoimmune disease,WO2024015958A1,WO2024015958A1
WO2024020159A1,KRAS G12D,KRAS G12D抑制剂,Merck & Co.(Top20 MNC)(原研),癌症,临床前,,Active,多肽,化药,环肽;难成药靶点;Ras-Raf信号通路,抑制剂,创新药,WO2024020159A1,,肿瘤领域,,DR061920,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2024020159A1,WO2024020159A1
WO2024043250A1,MDMX,MDMX抑制剂,Fujifilm(原研),癌症,临床前,,Active,多肽,化药,环肽;Potential First-in-Class;p53信号通路,抑制剂,创新药,WO2024043250A1,,肿瘤领域,,DR081963,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Fujifilm'],1,['Fujifilm(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2024043250A1,WO2024043250A1
WO2024052431A1,PSMA,anti-PSMA多肽偶联核素;含铟放射性示踪剂,3B Pharmaceuticals(原研),前列腺癌,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,创新药,WO2024052431A1,,肿瘤领域,,DR081408,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['3B Pharmaceuticals'],1,['3B Pharmaceuticals(原研)'],肿瘤领域,前列腺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,prostate cancer,WO2024052431A1,WO2024052431A1
WO2024052431A1,PSMA,anti-PSMA多肽偶联核素;含铟放射性示踪剂,3B Pharmaceuticals(原研),SPECT显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,创新药,WO2024052431A1,,诊断试剂领域,,DR081408,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['3B Pharmaceuticals'],1,['3B Pharmaceuticals(原研)'],诊断试剂领域,SPECT显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,SPECT imaging,WO2024052431A1,WO2024052431A1
WO2024083224A1,CCKBR;SSTR2,177Lu标记的放射性药物;anti-CCKBR×SSTR2多肽偶联核素,辐联科技(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,WO2024083224A1,,肿瘤领域,,DR081414,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['辐联科技'],1,['辐联科技(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2024083224A1,WO2024083224A1
WO2024094747A1,CNP,CNP类似物,Novo Nordisk(Top20 MNC)(原研),心力衰竭,临床前,,Active,多肽,化药,环肽,类似物,创新药,WO2024094747A1,,心脑血管领域,,DR067282,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Novo Nordisk'],['Novo Nordisk'],1,['Novo Nordisk(Top20 MNC)(原研)'],心脑血管领域,心力衰竭,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,heart failure,WO2024094747A1,WO2024094747A1
WO2024101386A1,KRAS,KRAS抑制剂,Chugai Pharmaceutical(Top20 MNC)(原研),癌症,临床前,,Active,多肽,化药,环肽;难成药靶点,抑制剂,创新药,WO2024101386A1,,肿瘤领域,,DR067444,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Chugai Pharmaceutical'],['Chugai Pharmaceutical'],1,['Chugai Pharmaceutical(Top20 MNC)(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2024101386A1,WO2024101386A1
WO2024114762A1,IL-23R,IL-23R抑制剂,翰森制药(原研),自身免疫性疾病,临床前,,Active,多肽,化药,环肽;Th17通路,抑制剂,创新药,WO2024114762A1,,免疫领域,,DR067818,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['翰森制药'],1,['翰森制药(原研)'],免疫领域,自身免疫性疾病,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,autoimmune disease,WO2024114762A1,WO2024114762A1
WO2024163691A1,TNFR1,TNFR1抑制剂,Merck & Co.(Top20 MNC)(原研),自身免疫性疾病,临床前,,Active,多肽,化药,环肽;细胞凋亡;差异化疾病,抑制剂,创新药,WO2024163691A1,,免疫领域,,DR069427,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],免疫领域,自身免疫性疾病,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,autoimmune disease,WO2024163691A1,WO2024163691A1
WO2024163691A1,TNFR1,TNFR1抑制剂,Merck & Co.(Top20 MNC)(原研),自身炎症性疾病(差异化疾病),临床前,,Active,多肽,化药,环肽;细胞凋亡;差异化疾病,抑制剂,创新药,WO2024163691A1,,罕见疾病领域;免疫领域,,DR069427,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,True,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],免疫领域,自身炎症性疾病,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,autoinflammatory disease,WO2024163691A1,WO2024163691A1
WO2024182044A1,Nrf2,Nrf2激活剂,Mayo Clinic(原研),炎症(未指明),临床前,,Active,多肽,化药,环肽;Keap1-Nrf2通路,激活剂,创新药,WO2024182044A1,,免疫领域,,DR069977,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Mayo Clinic'],1,['Mayo Clinic(原研)'],免疫领域,炎症(未指明),['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,Inflammation (unspecified),WO2024182044A1,WO2024182044A1
WO2024188291A1,HER2,anti-HER2多肽偶联核素;68Ga标记的PET药物,上海药物研究所(原研);Northeastern University(原研),卵巢癌(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;受体酪氨酸激酶;中国无申报,多肽偶联核素;68Ga标记的PET药物,创新药,WO2024188291A1,,肿瘤领域;罕见疾病领域,,DR070183,是,美国;中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,True,False,[],"['上海药物研究所', 'Northeastern University']",2,"['上海药物研究所(原研)', 'Northeastern University(原研)']",肿瘤领域,卵巢癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,ovarian cancer,WO2024188291A1,WO2024188291A1
WO2024188291A1,HER2,anti-HER2多肽偶联核素;68Ga标记的PET药物,上海药物研究所(原研);Northeastern University(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;诊断用放射性药物;受体酪氨酸激酶;中国无申报,多肽偶联核素;68Ga标记的PET药物,创新药,WO2024188291A1,,诊断试剂领域,,DR070183,是,美国;中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['上海药物研究所', 'Northeastern University']",2,"['上海药物研究所(原研)', 'Northeastern University(原研)']",诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,WO2024188291A1,WO2024188291A1
WO2024189611A1,calcitonin,calcitonin类似物,Yissum(原研),骨质疏松症,临床前,,Active,多肽,化药,环肽;中国无申报,类似物,创新药,WO2024189611A1,,骨骼肌肉领域;内分泌及代谢领域,,DR070268,是,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Yissum'],1,['Yissum(原研)'],骨骼肌肉领域,骨质疏松症,"['骨骼肌肉领域', '内分泌及代谢领域']",2,骨骼肌肉领域,内分泌及代谢领域,,-1,-1,Musculoskeletal,Musculoskeletal,Endocrinology & Metabolism,,osteoporosis,WO2024189611A1,WO2024189611A1
WO2024195709A1,FGFR,FGFR抑制剂,Fujifilm(原研),癌症,临床前,,Active,多肽,化药,环肽;受体酪氨酸激酶,抑制剂,创新药,WO2024195709A1,,肿瘤领域,,DR070420,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Fujifilm'],1,['Fujifilm(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2024195709A1,WO2024195709A1
WO2024199103A1,calcitonin,calcitonin类似物,奥达生物(原研),骨质疏松症,临床前,,Active,多肽,化药,环肽,类似物,创新药,WO2024199103A1,,骨骼肌肉领域;内分泌及代谢领域,,DR070368,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['奥达生物'],1,['奥达生物(原研)'],骨骼肌肉领域,骨质疏松症,"['骨骼肌肉领域', '内分泌及代谢领域']",2,骨骼肌肉领域,内分泌及代谢领域,,-1,-1,Musculoskeletal,Musculoskeletal,Endocrinology & Metabolism,,osteoporosis,WO2024199103A1,WO2024199103A1
WO2024199103A1,calcitonin,calcitonin类似物,奥达生物(原研),骨病,临床前,,Active,多肽,化药,环肽,类似物,创新药,WO2024199103A1,,骨骼肌肉领域,,DR070368,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['奥达生物'],1,['奥达生物(原研)'],骨骼肌肉领域,骨病,['骨骼肌肉领域'],1,骨骼肌肉领域,,,-1,-1,Musculoskeletal,Musculoskeletal,,,bone disease,WO2024199103A1,WO2024199103A1
WO2024227437A1,IL-23R,IL-23R抑制剂,海思科(原研),银屑病,临床前,,Active,多肽,化药,环肽;Th17通路,抑制剂,创新药,WO2024227437A1,,免疫领域;皮肤领域,,DR071166,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['海思科'],1,['海思科(原研)'],免疫领域,银屑病,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,-1,-1,Immunology,Immunology,Dermatology,,psoriasis,WO2024227437A1,WO2024227437A1
WO2024227437A1,IL-23R,IL-23R抑制剂,海思科(原研),炎症性肠病,临床前,,Active,多肽,化药,环肽;Th17通路,抑制剂,创新药,WO2024227437A1,,免疫领域;消化领域,,DR071166,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['海思科'],1,['海思科(原研)'],免疫领域,炎症性肠病,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,-1,-1,Immunology,Immunology,Digestive System,,inflammatory bowel disease,WO2024227437A1,WO2024227437A1
WO2024227437A1,IL-23R,IL-23R抑制剂,海思科(原研),克罗恩病,临床前,,Active,多肽,化药,环肽;Th17通路,抑制剂,创新药,WO2024227437A1,,消化领域;免疫领域,,DR071166,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['海思科'],1,['海思科(原研)'],消化领域,克罗恩病,"['消化领域', '免疫领域']",2,消化领域,免疫领域,,-1,-1,Digestive System,Digestive System,Immunology,,Crohn's disease,WO2024227437A1,WO2024227437A1
WO2024230246A1,FAP,anti-FAP多肽偶联核素,纽瑞特医疗(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联核素,创新药,WO2024230246A1,,肿瘤领域,,DR071565,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['纽瑞特医疗'],1,['纽瑞特医疗(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2024230246A1,WO2024230246A1
WO2024235273A1,CXCR4;FAP,anti-CXCR4×FAP多肽偶联核素,远大医药(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素,创新药,WO2024235273A1,,肿瘤领域,,DR071750,是,中国(港澳台),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['远大医药'],1,['远大医药(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2024235273A1,WO2024235273A1
WO2024238623A1,LRRK2,LRRK2变构抑制剂,University of Georgia(原研),阿尔茨海默病,临床前,,Active,多肽,化药,环肽;差异化疾病,变构抑制剂,创新药,WO2024238623A1,,神经领域,,DR071723,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['University of Georgia'],1,['University of Georgia(原研)'],神经领域,阿尔茨海默病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,Alzheimer's disease,WO2024238623A1,WO2024238623A1
WO2024238623A1,LRRK2,LRRK2变构抑制剂,University of Georgia(原研),帕金森病,临床前,,Active,多肽,化药,环肽;差异化疾病,变构抑制剂,创新药,WO2024238623A1,,神经领域,,DR071723,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['University of Georgia'],1,['University of Georgia(原研)'],神经领域,帕金森病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,Parkinson's disease,WO2024238623A1,WO2024238623A1
WO2024238623A1,LRRK2,LRRK2变构抑制剂,University of Georgia(原研),亨廷顿氏病(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病,变构抑制剂,创新药,WO2024238623A1,,神经领域;罕见疾病领域,,DR071723,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['University of Georgia'],1,['University of Georgia(原研)'],神经领域,亨廷顿氏病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,Huntington's disease,WO2024238623A1,WO2024238623A1
WO2024238623A1,LRRK2,LRRK2变构抑制剂,University of Georgia(原研),肌萎缩侧索硬化症(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病,变构抑制剂,创新药,WO2024238623A1,,神经领域;罕见疾病领域,,DR071723,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['University of Georgia'],1,['University of Georgia(原研)'],神经领域,肌萎缩侧索硬化症,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,amyotrophic lateral sclerosis,WO2024238623A1,WO2024238623A1
WO2024238623A1,LRRK2,LRRK2变构抑制剂,University of Georgia(原研),神经系统疾病,临床前,,Active,多肽,化药,环肽;差异化疾病,变构抑制剂,创新药,WO2024238623A1,,神经领域,,DR071723,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['University of Georgia'],1,['University of Georgia(原研)'],神经领域,神经系统疾病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,neurological disease,WO2024238623A1,WO2024238623A1
WO2024243509A1,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,UGARF(原研),神经退行性疾病,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,WO2024243509A1,,神经领域,,DR071797,是,,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['UGARF'],1,['UGARF(原研)'],神经领域,神经退行性疾病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,neurodegenerative diseases,WO2024243509A1,WO2024243509A1
WO2024243509A1,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,UGARF(原研),阿尔茨海默病,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,WO2024243509A1,,神经领域,,DR071797,是,,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['UGARF'],1,['UGARF(原研)'],神经领域,阿尔茨海默病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,Alzheimer's disease,WO2024243509A1,WO2024243509A1
WO2024243509A1,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,UGARF(原研),帕金森病,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,WO2024243509A1,,神经领域,,DR071797,是,,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['UGARF'],1,['UGARF(原研)'],神经领域,帕金森病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,Parkinson's disease,WO2024243509A1,WO2024243509A1
WO2024243509A1,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,UGARF(原研),亨廷顿氏病,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,WO2024243509A1,,神经领域;罕见疾病领域,,DR071797,是,,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['UGARF'],1,['UGARF(原研)'],神经领域,亨廷顿氏病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,Huntington's disease,WO2024243509A1,WO2024243509A1
WO2024243509A1,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,UGARF(原研),肌萎缩侧索硬化症,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,WO2024243509A1,,神经领域;罕见疾病领域,,DR071797,是,,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['UGARF'],1,['UGARF(原研)'],神经领域,肌萎缩侧索硬化症,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,amyotrophic lateral sclerosis,WO2024243509A1,WO2024243509A1
WO2024248042A1,MuSK,MuSK激动剂,National Hospital Organization(原研),重症肌无力,临床前,,Active,多肽,化药,环肽;受体酪氨酸激酶;Potential First-in-Class;Wnt信号通路,激动剂,创新药,WO2024248042A1,,罕见疾病领域;免疫领域,,DR071830,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['National Hospital Organization'],1,['National Hospital Organization(原研)'],免疫领域,重症肌无力,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,myasthenia gravis,WO2024248042A1,WO2024248042A1
WO2024259132A1,DLL3,anti-DLL3多肽偶联核素,Mariana Oncology(Novartis)(Top20 MNC)(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;Notch信号通路;Potential First-in-Class,多肽偶联核素,创新药,WO2024259132A1,,肿瘤领域,,DR072524,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2024259132A1,WO2024259132A1
WO2025007839A1,nectin-4,多肽偶联药物,韦恩生物(原研),肿瘤,临床前,,Active,多肽;偶联药物,化药,环肽,多肽偶联药物,创新药,WO2025007839A1,,肿瘤领域,,DR073180,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['韦恩生物'],1,['韦恩生物(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2025007839A1,WO2025007839A1
WO2025011611A1,FAP,anti-FAP多肽偶联核素,恒瑞医药(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联核素,创新药,WO2025011611A1,,肿瘤领域,,DR073838,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['恒瑞医药'],1,['恒瑞医药(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2025011611A1,WO2025011611A1
WO2025067477A1,A. baumannii,抗生素,人福医药(原研),鲍曼不动杆菌感染(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病;Potential First-in-Class,抗生素,创新药,WO2025067477A1,,感染领域,,DR077776,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['人福医药'],1,['人福医药(原研)'],感染领域,鲍曼不动杆菌感染,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,Acinetobacter baumannii infection,WO2025067477A1,WO2025067477A1
WO2025068348A1,PD1;CXCR4,CXCR4抑制剂;PD1抑制剂,University of Michigan(原研);Johns Hopkins University(原研);Cedars-Sinai(原研);Spexis(原研),癌症,临床前,,Active,多肽,化药,环肽;G蛋白偶联受体;中国无申报;Potential First-in-Class;肿瘤免疫,抑制剂,创新药,WO2025068348A1,,肿瘤领域,,DR077780,是,美国;欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,4,True,False,False,[],"['University of Michigan', 'Johns Hopkins University', 'Cedars-Sinai', 'Spexis']",4,"['University of Michigan(原研)', 'Johns Hopkins University(原研)', 'Cedars-Sinai(原研)', 'Spexis(原研)']",肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2025068348A1,WO2025068348A1
WO2025073871A1,TfR1,多肽偶联药物,Bicycle Therapeutics(原研),癌症,临床前,,Active,多肽;偶联药物,化药,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,创新药,WO2025073871A1,,肿瘤领域,,DR078215,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2025073871A1,WO2025073871A1
WO2025073871A1,TfR1,多肽偶联药物,Bicycle Therapeutics(原研),癫痫,临床前,,Active,多肽;偶联药物,化药,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,创新药,WO2025073871A1,,神经领域,,DR078215,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],神经领域,癫痫,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,epilepsy,WO2025073871A1,WO2025073871A1
WO2025073871A1,TfR1,多肽偶联药物,Bicycle Therapeutics(原研),眼科疾病,临床前,,Active,多肽;偶联药物,化药,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,创新药,WO2025073871A1,,眼科领域,,DR078215,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],眼科领域,眼科疾病,['眼科领域'],1,眼科领域,,,-1,-1,Ophthalmology,Ophthalmology,,,Eye diseases,WO2025073871A1,WO2025073871A1
WO2025073871A1,TfR1,多肽偶联药物,Bicycle Therapeutics(原研),神经系统疾病,临床前,,Active,多肽;偶联药物,化药,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,创新药,WO2025073871A1,,神经领域,,DR078215,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],神经领域,神经系统疾病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,neurological disease,WO2025073871A1,WO2025073871A1
WO2025077823A1,αvβ3,多肽偶联药物,海思科(原研),癌症,临床前,,Active,多肽;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联药物,创新药,WO2025077823A1,,肿瘤领域,,DR078571,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['海思科'],1,['海思科(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2025077823A1,WO2025077823A1
WO2025079064A1,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,Pepticom(原研),类风湿性关节炎,临床前,,Active,小分子,化药,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,WO2025079064A1,,免疫领域;骨骼肌肉领域,,DR078579,是,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Pepticom'],1,['Pepticom(原研)'],免疫领域,类风湿性关节炎,"['免疫领域', '骨骼肌肉领域']",2,免疫领域,骨骼肌肉领域,,-1,-1,Immunology,Immunology,Musculoskeletal,,rheumatoid arthritis,WO2025079064A1,WO2025079064A1
WO2025079064A1,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,Pepticom(原研),多发性硬化症,临床前,,Active,小分子,化药,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,WO2025079064A1,,神经领域;免疫领域;罕见疾病领域,,DR078579,是,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Pepticom'],1,['Pepticom(原研)'],神经领域,多发性硬化症,"['神经领域', '免疫领域']",2,神经领域,免疫领域,,-1,-1,Neurology,Neurology,Immunology,,multiple sclerosis,WO2025079064A1,WO2025079064A1
WO2025079064A1,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,Pepticom(原研),银屑病,临床前,,Active,小分子,化药,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,WO2025079064A1,,免疫领域;皮肤领域,,DR078579,是,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Pepticom'],1,['Pepticom(原研)'],免疫领域,银屑病,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,-1,-1,Immunology,Immunology,Dermatology,,psoriasis,WO2025079064A1,WO2025079064A1
WO2025079064A1,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,Pepticom(原研),斑块状银屑病,临床前,,Active,小分子,化药,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,WO2025079064A1,,免疫领域;皮肤领域,,DR078579,是,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Pepticom'],1,['Pepticom(原研)'],免疫领域,斑块状银屑病,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,-1,-1,Immunology,Immunology,Dermatology,,plaque psoriasis,WO2025079064A1,WO2025079064A1
WO2025079064A1,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,Pepticom(原研),系统性红斑狼疮,临床前,,Active,小分子,化药,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,WO2025079064A1,,免疫领域;皮肤领域,,DR078579,是,以色列,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Pepticom'],1,['Pepticom(原研)'],免疫领域,系统性红斑狼疮,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,-1,-1,Immunology,Immunology,Dermatology,,systemic lupus erythematosus,WO2025079064A1,WO2025079064A1
WO2025082283A1,FAP,FAP抑制剂,科伦博泰(原研),肿瘤,临床前,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,WO2025082283A1,,肿瘤领域,,DR078895,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['科伦博泰'],1,['科伦博泰(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2025082283A1,WO2025082283A1
WO2025082283A1,FAP,FAP抑制剂,科伦博泰(原研),诊断试剂(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病,抑制剂,创新药,WO2025082283A1,,诊断试剂领域,,DR078895,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['科伦博泰'],1,['科伦博泰(原研)'],诊断试剂领域,诊断试剂,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,diagnostic reagents,WO2025082283A1,WO2025082283A1
WO2025105948A1,PDL1,含锝放射性示踪剂;anti-PDL1多肽偶联核素,Instituto Nacional de Investigaciones Nucleares(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;中国无申报;Potential First-in-Class;肿瘤免疫,含锝放射性示踪剂;多肽偶联核素,创新药,WO2025105948A1,,肿瘤领域,,DR080180,是,墨西哥,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Instituto Nacional de Investigaciones Nucleares'],1,['Instituto Nacional de Investigaciones Nucleares(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2025105948A1,WO2025105948A1
WO2025105948A1,PDL1,含锝放射性示踪剂;anti-PDL1多肽偶联核素,Instituto Nacional de Investigaciones Nucleares(原研),SPECT显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;中国无申报;Potential First-in-Class;肿瘤免疫,含锝放射性示踪剂;多肽偶联核素,创新药,WO2025105948A1,,诊断试剂领域,,DR080180,是,墨西哥,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Instituto Nacional de Investigaciones Nucleares'],1,['Instituto Nacional de Investigaciones Nucleares(原研)'],诊断试剂领域,SPECT显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,SPECT imaging,WO2025105948A1,WO2025105948A1
WO2025106567A1,BNP,BNP类似物,Antlia Bioscience(原研),心力衰竭,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,类似物,创新药,WO2025106567A1,,心脑血管领域,,DR080184,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Antlia Bioscience'],1,['Antlia Bioscience(原研)'],心脑血管领域,心力衰竭,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,heart failure,WO2025106567A1,WO2025106567A1
WO2025106567A1,BNP,BNP类似物,Antlia Bioscience(原研),代谢疾病,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,类似物,创新药,WO2025106567A1,,内分泌及代谢领域,,DR080184,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Antlia Bioscience'],1,['Antlia Bioscience(原研)'],内分泌及代谢领域,代谢疾病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,Metabolic diseases,WO2025106567A1,WO2025106567A1
WO2025106567A1,BNP,BNP类似物,Antlia Bioscience(原研),肺病,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,类似物,创新药,WO2025106567A1,,呼吸领域,,DR080184,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Antlia Bioscience'],1,['Antlia Bioscience(原研)'],呼吸领域,肺病,['呼吸领域'],1,呼吸领域,,,-1,-1,Respiratory,Respiratory,,,pulmonary disease,WO2025106567A1,WO2025106567A1
WO2025112214A1,αvβ3,多肽偶联药物,碳云智能(原研),癌症,临床前,,Active,多肽;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联药物,创新药,WO2025112214A1,,肿瘤领域,,DR080677,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['碳云智能'],1,['碳云智能(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2025112214A1,WO2025112214A1
WO2025113628A1,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,辐联科技(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;177Lu标记的放射性药物,创新药,WO2025113628A1,,肿瘤领域,,DR080759,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['辐联科技'],1,['辐联科技(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2025113628A1,WO2025113628A1
WO2025113628A1,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,辐联科技(原研),PET显像(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病,多肽偶联核素;177Lu标记的放射性药物,创新药,WO2025113628A1,,诊断试剂领域,,DR080759,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['辐联科技'],1,['辐联科技(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,WO2025113628A1,WO2025113628A1
WO2025117586A1,DLL3,anti-DLL3多肽偶联核素;177Lu标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;Notch信号通路;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,WO2025117586A1,,肿瘤领域,,DR080706,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2025117586A1,WO2025117586A1
WO2025121943A1,CD51,多肽偶联药物,Soonchunhyang University(原研),结肠癌(差异化疾病),临床前,,Active,多肽;偶联药物,化药,环肽;差异化疾病;中国无申报;Potential First-in-Class,多肽偶联药物,创新药,WO2025121943A1,,肿瘤领域,,DR081040,是,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Soonchunhyang University'],1,['Soonchunhyang University(原研)'],肿瘤领域,结肠癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,colon cancer,WO2025121943A1,WO2025121943A1
WO2025122525A1,IgG,IgG降解剂,Biohaven Pharmaceuticals(Pfizer)(Top20 MNC)(原研),心力衰竭(差异化疾病),临床前,,Active,多肽;降解类药物,化药,环肽;差异化疾病,降解剂,创新药,WO2025122525A1,,心脑血管领域,,DR081010,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Biohaven Pharmaceuticals(Pfizer)'],['Biohaven Pharmaceuticals(Pfizer)'],1,['Biohaven Pharmaceuticals(Pfizer)(Top20 MNC)(原研)'],心脑血管领域,心力衰竭,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,heart failure,WO2025122525A1,WO2025122525A1
WO2025122525A1,IgG,IgG降解剂,Biohaven Pharmaceuticals(Pfizer)(Top20 MNC)(原研),扩张型心肌病(差异化疾病),临床前,,Active,多肽;降解类药物,化药,环肽;差异化疾病,降解剂,创新药,WO2025122525A1,,心脑血管领域;罕见疾病领域,,DR081010,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,True,['Biohaven Pharmaceuticals(Pfizer)'],['Biohaven Pharmaceuticals(Pfizer)'],1,['Biohaven Pharmaceuticals(Pfizer)(Top20 MNC)(原研)'],心脑血管领域,扩张型心肌病,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,dilated cardiomyopathy,WO2025122525A1,WO2025122525A1
WO2025137441A,SSTR2,64Cu标记的放射性示踪剂;anti-SSTR2多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,WO2025137441A,,肿瘤领域,,DR081688,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2025137441A,WO2025137441A
WO2025137441A1,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,创新药,WO2025137441A1,,肿瘤领域,,DR081687,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2025137441A1,WO2025137441A1
WO2025151982A1,PSMA;SSTR2,anti-PSMA×SSTR2多肽偶联核素;68Ga标记的PET药物,北京协和医院(原研);北京师范大学(原研),前列腺癌,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,WO2025151982A1,,肿瘤领域,,DR082544,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['北京协和医院', '北京师范大学']",2,"['北京协和医院(原研)', '北京师范大学(原研)']",肿瘤领域,前列腺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,prostate cancer,WO2025151982A1,WO2025151982A1
WO2025151982A1,PSMA;SSTR2,anti-PSMA×SSTR2多肽偶联核素;68Ga标记的PET药物,北京协和医院(原研);北京师范大学(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,WO2025151982A1,,诊断试剂领域,,DR082544,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['北京协和医院', '北京师范大学']",2,"['北京协和医院(原研)', '北京师范大学(原研)']",诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,WO2025151982A1,WO2025151982A1
WO2025153102A1,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,深景医药(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽,多肽偶联核素;177Lu标记的放射性药物,创新药,WO2025153102A1,,肿瘤领域,,DR082564,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['深景医药'],1,['深景医药(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2025153102A1,WO2025153102A1
WO2025160448A1,B7-H3,anti-B7-H3多肽偶联核素;225Ac标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,创新药,WO2025160448A1,,肿瘤领域,,DR082865,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2025160448A1,WO2025160448A1
WO2025191093A1,CRAF,CRAF抑制剂,University of Glasgow(原研),癌症,临床前,,Active,多肽,化药,环肽;差异化疾病;Potential First-in-Class;Ras-Raf信号通路,抑制剂,创新药,WO2025191093A1,,肿瘤领域,,DR085518,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['University of Glasgow'],1,['University of Glasgow(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2025191093A1,WO2025191093A1
WO2025191093A1,CRAF,CRAF抑制剂,University of Glasgow(原研),自身免疫性疾病(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病;Potential First-in-Class;Ras-Raf信号通路,抑制剂,创新药,WO2025191093A1,,免疫领域,,DR085518,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['University of Glasgow'],1,['University of Glasgow(原研)'],免疫领域,自身免疫性疾病,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,autoimmune disease,WO2025191093A1,WO2025191093A1
WO2025193569A1,LAG3;MHC-II,LAG3×MHC-II蛋白蛋白相互作用抑制剂,Bristol-Myers Squibb(Top20 MNC)(原研),癌症,临床前,,Active,多肽,化药,环肽;Potential First-in-Class;肿瘤免疫,蛋白蛋白相互作用抑制剂,创新药,WO2025193569A1,,肿瘤领域,,DR085669,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,['Bristol-Myers Squibb(Top20 MNC)(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2025193569A1,WO2025193569A1
WO2025199179A2,oxytocin,oxytocin类似物,Tonix Pharmaceuticals(原研),饮食障碍(差异化疾病),临床前,,Active,多肽,生物,环肽;差异化疾病,类似物,创新药,WO2025199179A2,,精神领域,,DR086088,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Tonix Pharmaceuticals'],1,['Tonix Pharmaceuticals(原研)'],精神领域,饮食障碍,['精神领域'],1,精神领域,,,-1,-1,Psychiatry,Psychiatry,,,eating disorder,WO2025199179A2,WO2025199179A2
WO2025199179A2,oxytocin,oxytocin类似物,Tonix Pharmaceuticals(原研),头痛(差异化疾病),临床前,,Active,多肽,生物,环肽;差异化疾病,类似物,创新药,WO2025199179A2,,麻醉镇痛领域,,DR086088,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Tonix Pharmaceuticals'],1,['Tonix Pharmaceuticals(原研)'],麻醉镇痛领域,头痛,['麻醉镇痛领域'],1,麻醉镇痛领域,,,-1,-1,Anesthesia & Analgesia,Anesthesia & Analgesia,,,Headache,WO2025199179A2,WO2025199179A2
WO2025214417A1,EGFR,EGFR抑制剂,元思生肽(原研),癌症,临床前,,Active,多肽,化药,环肽;受体酪氨酸激酶,抑制剂,创新药,WO2025214417A1,,肿瘤领域,,DR087082,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['元思生肽'],1,['元思生肽(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2025214417A1,WO2025214417A1
WO2025218677A1,αvβ6;αvβ3;FAP,anti-αvβ6×αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,范恩柯尔(原研),肿瘤,临床前,,Active,放射性药物;多肽;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,WO2025218677A1,,肿瘤领域,,DR087567,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['范恩柯尔'],1,['范恩柯尔(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2025218677A1,WO2025218677A1
WO2025218677A1,αvβ6;αvβ3;FAP,anti-αvβ6×αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,范恩柯尔(原研),PET显像,临床前,,Active,放射性药物;多肽;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,WO2025218677A1,,诊断试剂领域,,DR087567,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['范恩柯尔'],1,['范恩柯尔(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,WO2025218677A1,WO2025218677A1
WO2025218677A1-1,αvβ6;αvβ3;FAP,177Lu标记的放射性药物;anti-αvβ6×αvβ3×FAP多肽偶联核素,范恩柯尔(原研),肿瘤,临床前,,Active,放射性药物;多肽;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,创新药,WO2025218677A1-1,,肿瘤领域,,DR087569,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['范恩柯尔'],1,['范恩柯尔(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,WO2025218677A1-1,WO2025218677A1-1
WO2025224598A1,HER2,anti-HER2多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,创新药,WO2025224598A1,,肿瘤领域,,DR088078,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2025224598A1,WO2025224598A1
WO2025228156A1,URAT1,多肽偶联药物;siRNA疗法,炫景生物(原研),高尿酸血症,临床前,,Active,核酸;多肽;偶联药物,化药,环肽;小核酸;Potential First-in-Class;尿酸代谢通路,siRNA疗法;多肽偶联药物,创新药,WO2025228156A1,,内分泌及代谢领域,,DR088580,是,中国(内地),未知,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['炫景生物'],1,['炫景生物(原研)'],内分泌及代谢领域,高尿酸血症,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,hyperuricemia,WO2025228156A1,WO2025228156A1
WO2025232577A1,OXTR,OXTR拮抗剂,羚诺生物(原研),早产,临床前,,Active,多肽,化药,环肽;G蛋白偶联受体,拮抗剂,创新药,WO2025232577A1,,泌尿生殖领域,,DR089039,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['羚诺生物'],1,['羚诺生物(原研)'],泌尿生殖领域,早产,['泌尿生殖领域'],1,泌尿生殖领域,,,-1,-1,Genitourinary,Genitourinary,,,premature birth,WO2025232577A1,WO2025232577A1
WO2025236772A1,melanocortin receptor,melanocortin receptor激动剂,万邦德制药(原研),糖尿病(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class,激动剂,创新药,WO2025236772A1,,内分泌及代谢领域,,DR089479,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['万邦德制药'],1,['万邦德制药(原研)'],内分泌及代谢领域,糖尿病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,diabetes,WO2025236772A1,WO2025236772A1
WO2025236772A1,melanocortin receptor,melanocortin receptor激动剂,万邦德制药(原研),肥胖(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class,激动剂,创新药,WO2025236772A1,,内分泌及代谢领域,,DR089479,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['万邦德制药'],1,['万邦德制药(原研)'],内分泌及代谢领域,肥胖,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,obesity,WO2025236772A1,WO2025236772A1
WO2025236772A1,melanocortin receptor,melanocortin receptor激动剂,万邦德制药(原研),血脂异常(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class,激动剂,创新药,WO2025236772A1,,心脑血管领域,,DR089479,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['万邦德制药'],1,['万邦德制药(原研)'],心脑血管领域,血脂异常,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,,dyslipidemia,WO2025236772A1,WO2025236772A1
WO2025245483A1,MC4R,MC4R激动剂,Flagship Pioneering(原研),肥胖,临床前,,Active,多肽,化药,环肽;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,创新药,WO2025245483A1,,内分泌及代谢领域,,DR089783,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Flagship Pioneering'],1,['Flagship Pioneering(原研)'],内分泌及代谢领域,肥胖,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,obesity,WO2025245483A1,WO2025245483A1
WO2025246257A1,PPID;PPIA,PPIA抑制剂;PPID抑制剂,睿诺医疗科技(原研),癌症,临床前,,Active,多肽,生物,环肽;Potential First-in-Class,抑制剂,创新药,WO2025246257A1,,肿瘤领域,,DR090011,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['睿诺医疗科技'],1,['睿诺医疗科技(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,WO2025246257A1,WO2025246257A1
WO2025249754A1,IL-1β,IL-1β抑制剂,EyebioKorea(原研),炎症(未指明),临床前,,Active,小分子,化药,环肽;中国无申报;Potential First-in-Class,抑制剂,创新药,WO2025249754A1,,免疫领域,,DR090094,是,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['EyebioKorea'],1,['EyebioKorea(原研)'],免疫领域,炎症(未指明),['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,Inflammation (unspecified),WO2025249754A1,WO2025249754A1
WO2025255635A1,MC5R,MC5R激动剂,Monash University(原研),糖尿病,临床前,,Active,多肽,生物,环肽;G蛋白偶联受体;中国无申报,激动剂,创新药,WO2025255635A1,,内分泌及代谢领域,,DR090722,是,澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Monash University'],1,['Monash University(原研)'],内分泌及代谢领域,糖尿病,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,,diabetes,WO2025255635A1,WO2025255635A1
WP-101,not available,多肽类抗生素,WellPep(原研),尿路感染(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病;中国无申报,多肽类抗生素,创新药,WP-101,,感染领域;泌尿生殖领域,,DR084192,否,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['WellPep'],1,['WellPep(原研)'],感染领域,尿路感染,"['感染领域', '泌尿生殖领域']",2,感染领域,泌尿生殖领域,,-1,-1,Infectious Diseases,Infectious Diseases,Genitourinary,,urinary tract infection,WP-101,WP-101
WP-101,not available,多肽类抗生素,WellPep(原研),脓毒症,临床前,,Active,多肽,化药,环肽;差异化疾病;中国无申报,多肽类抗生素,创新药,WP-101,,感染领域,,DR084192,否,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['WellPep'],1,['WellPep(原研)'],感染领域,脓毒症,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,sepsis,WP-101,WP-101
WP-101,not available,多肽类抗生素,WellPep(原研),肺炎,临床前,,Active,多肽,化药,环肽;差异化疾病;中国无申报,多肽类抗生素,创新药,WP-101,,呼吸领域,,DR084192,否,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['WellPep'],1,['WellPep(原研)'],呼吸领域,肺炎,['呼吸领域'],1,呼吸领域,,,-1,-1,Respiratory,Respiratory,,,pneumonia,WP-101,WP-101
XTR024,SSTR,225Ac标记的放射性药物,先通医药(原研),小细胞肺癌,临床前,,Active,放射性药物;其他,其他,环肽;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物,创新药,XTR024,,肿瘤领域;罕见疾病领域,,DR080227,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['先通医药'],1,['先通医药(原研)'],肿瘤领域,小细胞肺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,small cell lung cancer,XTR024,XTR024
XTR024,SSTR,225Ac标记的放射性药物,先通医药(原研),神经内分泌肿瘤,临床前,,Active,放射性药物;其他,其他,环肽;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物,创新药,XTR024,,肿瘤领域;罕见疾病领域,,DR080227,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['先通医药'],1,['先通医药(原研)'],肿瘤领域,神经内分泌肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,neuroendocrine tumors,XTR024,XTR024
ZP10068,C3,C3抑制剂,Alexion Pharmaceuticals(AstraZeneca)(Top20 MNC);Zealand Pharma(原研),炎症(未指明),临床前,,Active,多肽,化药,环肽;中国无申报,抑制剂,创新药,ZP10068,,免疫领域,,DR025543,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,True,['Alexion Pharmaceuticals(AstraZeneca)'],['Zealand Pharma'],1,"['Alexion Pharmaceuticals(AstraZeneca)(Top20 MNC)', 'Zealand Pharma(原研)']",免疫领域,炎症(未指明),['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,Inflammation (unspecified),ZP10068,ZP10068
[111In]In-BCY18469,EphA2,含铟放射性示踪剂;anti-EphA2多肽偶联核素,Bicycle Therapeutics(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,含铟放射性示踪剂;多肽偶联核素,创新药,[111In]In-BCY18469,,肿瘤领域,,DR074871,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,[111In]In-BCY18469,[111In]In-BCY18469
[111In]In-BCY18469,EphA2,含铟放射性示踪剂;anti-EphA2多肽偶联核素,Bicycle Therapeutics(原研),SPECT显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,含铟放射性示踪剂;多肽偶联核素,创新药,[111In]In-BCY18469,,诊断试剂领域,,DR074871,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],诊断试剂领域,SPECT显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,SPECT imaging,[111In]In-BCY18469,[111In]In-BCY18469
[161Tb]Tb-DOTATATE,SSTR2,161Tb标记的放射性药物,Uppsala University(原研),神经母细胞瘤,临床前,,Active,多肽;放射性药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,161Tb标记的放射性药物,创新药,[161Tb]Tb-DOTATATE,,肿瘤领域;罕见疾病领域,,DR089674,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['Uppsala University'],1,['Uppsala University(原研)'],肿瘤领域,神经母细胞瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,Neuroblastoma,[161Tb]Tb-DOTATATE,[161Tb]Tb-DOTATATE
[161Tb]Tb-DPI-4452,CAIX,161Tb标记的放射性药物;anti-CAIX多肽偶联核素,Katholieke Universiteit Leuven(原研),胰腺导管癌,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;161Tb标记的放射性药物,创新药,[161Tb]Tb-DPI-4452,,肿瘤领域,,DR089695,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Katholieke Universiteit Leuven'],1,['Katholieke Universiteit Leuven(原研)'],肿瘤领域,胰腺导管癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,pancreatic ductal carcinoma,[161Tb]Tb-DPI-4452,[161Tb]Tb-DPI-4452
[177Lu]Lu-BCY18469,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,Bicycle Therapeutics(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,创新药,[177Lu]Lu-BCY18469,,肿瘤领域,,DR074872,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,[177Lu]Lu-BCY18469,[177Lu]Lu-BCY18469
[177Lu]Lu-RYZ-GPC3,GPC3,177Lu标记的放射性药物;anti-GPC3多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),神经内分泌前列腺癌(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class;Wnt信号通路,177Lu标记的放射性药物;多肽偶联核素,创新药,[177Lu]Lu-RYZ-GPC3,,肿瘤领域,,DR081253,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,神经内分泌前列腺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,neuroendocrine prostate cancer,[177Lu]Lu-RYZ-GPC3,[177Lu]Lu-RYZ-GPC3
[18F]AlF-NOTA-IMB,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,南京医科大学(原研),癌症,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;肿瘤免疫,多肽偶联核素;18F标记的PET药物,创新药,[18F]AlF-NOTA-IMB,,肿瘤领域,,DR081308,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['南京医科大学'],1,['南京医科大学(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,[18F]AlF-NOTA-IMB,[18F]AlF-NOTA-IMB
[18F]AlF-NOTA-IMB,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,南京医科大学(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;肿瘤免疫,多肽偶联核素;18F标记的PET药物,创新药,[18F]AlF-NOTA-IMB,,诊断试剂领域,,DR081308,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['南京医科大学'],1,['南京医科大学(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[18F]AlF-NOTA-IMB,[18F]AlF-NOTA-IMB
[18F]AlF-NOTA-IPB-GPC3P,GPC3,18F标记的PET药物;anti-GPC3多肽偶联核素,南方医科大学南方医院(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class;Wnt信号通路,多肽偶联核素;18F标记的PET药物,创新药,[18F]AlF-NOTA-IPB-GPC3P,,肿瘤领域,,DR081216,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['南方医科大学南方医院'],1,['南方医科大学南方医院(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,[18F]AlF-NOTA-IPB-GPC3P,[18F]AlF-NOTA-IPB-GPC3P
[18F]AlF-NOTA-IPB-GPC3P,GPC3,18F标记的PET药物;anti-GPC3多肽偶联核素,南方医科大学南方医院(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class;Wnt信号通路,多肽偶联核素;18F标记的PET药物,创新药,[18F]AlF-NOTA-IPB-GPC3P,,诊断试剂领域,,DR081216,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['南方医科大学南方医院'],1,['南方医科大学南方医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[18F]AlF-NOTA-IPB-GPC3P,[18F]AlF-NOTA-IPB-GPC3P
[225Ac]Ac-RYZ-GPC3,GPC3,225Ac标记的放射性药物;anti-GPC3多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),神经内分泌前列腺癌(差异化疾病),临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;差异化疾病;治疗用放射性药物;Wnt信号通路,225Ac标记的放射性药物;多肽偶联核素,创新药,[225Ac]Ac-RYZ-GPC3,,肿瘤领域,,DR081255,否,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,True,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,神经内分泌前列腺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,neuroendocrine prostate cancer,[225Ac]Ac-RYZ-GPC3,[225Ac]Ac-RYZ-GPC3
[64Cu]Cu-NECT-224,nectin-4,64Cu标记的放射性示踪剂;anti-nectin-4多肽偶联核素,Helmholtz-Zentrum Dresden-Rossendorf(原研),尿路上皮癌,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,创新药,[64Cu]Cu-NECT-224;[64Cu]Cu-TKR2-24,,肿瘤领域,,DR086897,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Helmholtz-Zentrum Dresden-Rossendorf'],1,['Helmholtz-Zentrum Dresden-Rossendorf(原研)'],肿瘤领域,尿路上皮癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,urothelial carcinoma,[64Cu]Cu-NECT-224,[64Cu]Cu-NECT-224;[64Cu]Cu-TKR2-24
[64Cu]Cu-NECT-224,nectin-4,64Cu标记的放射性示踪剂;anti-nectin-4多肽偶联核素,Helmholtz-Zentrum Dresden-Rossendorf(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,创新药,[64Cu]Cu-NECT-224;[64Cu]Cu-TKR2-24,,诊断试剂领域,,DR086897,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Helmholtz-Zentrum Dresden-Rossendorf'],1,['Helmholtz-Zentrum Dresden-Rossendorf(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[64Cu]Cu-NECT-224,[64Cu]Cu-NECT-224;[64Cu]Cu-TKR2-24
[64Cu]Cu-NODAGA-BL34,CXCR4,64Cu标记的放射性示踪剂;anti-CXCR4多肽偶联核素,University of British Columbia(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,[64Cu]Cu-NODAGA-BL34,,肿瘤领域,,DR089511,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['University of British Columbia'],1,['University of British Columbia(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,[64Cu]Cu-NODAGA-BL34,[64Cu]Cu-NODAGA-BL34
[64Cu]Cu-NODAGA-BL34,CXCR4,64Cu标记的放射性示踪剂;anti-CXCR4多肽偶联核素,University of British Columbia(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,创新药,[64Cu]Cu-NODAGA-BL34,,诊断试剂领域,,DR089511,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['University of British Columbia'],1,['University of British Columbia(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[64Cu]Cu-NODAGA-BL34,[64Cu]Cu-NODAGA-BL34
[67Cu]Cu-NODAGA-BL34,CXCR4,67Cu标记的放射性药物;anti-CXCR4多肽偶联核素,University of British Columbia(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,67Cu标记的放射性药物;多肽偶联核素,创新药,[67Cu]Cu-NODAGA-BL34,,肿瘤领域,,DR089512,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['University of British Columbia'],1,['University of British Columbia(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,[67Cu]Cu-NODAGA-BL34,[67Cu]Cu-NODAGA-BL34
[67Cu]Cu-SAR-bisRGD,αvβ3,anti-αvβ3多肽偶联核素;67Cu标记的放射性药物,Memorial Sloan Kettering Cancer Center (MSKCC)(原研);Clarity Pharmaceuticals(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素;67Cu标记的放射性药物,创新药,[67Cu]Cu-SAR-bisRGD,,肿瘤领域,,DR081266,否,美国;澳大利亚,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['Memorial Sloan Kettering Cancer Center (MSKCC)', 'Clarity Pharmaceuticals']",2,"['Memorial Sloan Kettering Cancer Center (MSKCC)(原研)', 'Clarity Pharmaceuticals(原研)']",肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,[67Cu]Cu-SAR-bisRGD,[67Cu]Cu-SAR-bisRGD
[68Ga]Ga-B6FA-01,αvβ6;FAP,68Ga标记的PET药物,武汉大学中南医院(原研),肿瘤,临床前,,Active,小分子;放射性药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物,创新药,[68Ga]Ga-B6FA-01,,肿瘤领域,,DR089673,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['武汉大学中南医院'],1,['武汉大学中南医院(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,[68Ga]Ga-B6FA-01,[68Ga]Ga-B6FA-01
[68Ga]Ga-B6FA-01,αvβ6;FAP,68Ga标记的PET药物,武汉大学中南医院(原研),PET显像,临床前,,Active,小分子;放射性药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物,创新药,[68Ga]Ga-B6FA-01,,诊断试剂领域,,DR089673,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['武汉大学中南医院'],1,['武汉大学中南医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[68Ga]Ga-B6FA-01,[68Ga]Ga-B6FA-01
[68Ga]Ga-BCY18469,EphA2,anti-EphA2多肽偶联核素;68Ga标记的PET药物,Bicycle Therapeutics(原研),肿瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]Ga-BCY18469,,肿瘤领域,,DR074873,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,[68Ga]Ga-BCY18469,[68Ga]Ga-BCY18469
[68Ga]Ga-BCY18469,EphA2,anti-EphA2多肽偶联核素;68Ga标记的PET药物,Bicycle Therapeutics(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]Ga-BCY18469,,诊断试剂领域,,DR074873,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[68Ga]Ga-BCY18469,[68Ga]Ga-BCY18469
[68Ga]Ga-DOTA-Ahx-VGB3,VEGFR1;VEGFR2,anti-VEGFR1×VEGFR2多肽偶联核素;68Ga标记的PET药物,Tehran University of Medical Sciences(原研),乳腺癌,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;受体酪氨酸激酶;中国无申报;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]Ga-DOTA-Ahx-VGB3,,肿瘤领域,,DR081199,否,伊朗,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Tehran University of Medical Sciences'],1,['Tehran University of Medical Sciences(原研)'],肿瘤领域,乳腺癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,breast cancer,[68Ga]Ga-DOTA-Ahx-VGB3,[68Ga]Ga-DOTA-Ahx-VGB3
[68Ga]Ga-DOTA-Ahx-VGB3,VEGFR1;VEGFR2,anti-VEGFR1×VEGFR2多肽偶联核素;68Ga标记的PET药物,Tehran University of Medical Sciences(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;受体酪氨酸激酶;中国无申报;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]Ga-DOTA-Ahx-VGB3,,诊断试剂领域,,DR081199,否,伊朗,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Tehran University of Medical Sciences'],1,['Tehran University of Medical Sciences(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[68Ga]Ga-DOTA-Ahx-VGB3,[68Ga]Ga-DOTA-Ahx-VGB3
[68Ga]Ga-DOTA-BP1,BCMA,anti-BCMA多肽偶联核素;68Ga标记的PET药物,北京大学第一医院(原研),多发性骨髓瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]Ga-DOTA-BP1,,肿瘤领域;血液领域;罕见疾病领域,,DR081101,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,临床前,,,,pre-clinical,临床前,,pre-clinical,1,True,True,False,[],['北京大学第一医院'],1,['北京大学第一医院(原研)'],肿瘤领域,多发性骨髓瘤,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,-1,-1,Oncology,Oncology,Hematology,,multiple myeloma,[68Ga]Ga-DOTA-BP1,[68Ga]Ga-DOTA-BP1
[68Ga]Ga-DOTA-BP1,BCMA,anti-BCMA多肽偶联核素;68Ga标记的PET药物,北京大学第一医院(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,创新药,[68Ga]Ga-DOTA-BP1,,诊断试剂领域,,DR081101,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,临床前,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['北京大学第一医院'],1,['北京大学第一医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[68Ga]Ga-DOTA-BP1,[68Ga]Ga-DOTA-BP1
[68Ga]Ga-ES-02,HER2,anti-HER2多肽偶联核素;68Ga标记的PET药物,山东大学齐鲁医院(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;受体酪氨酸激酶,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]Ga-ES-02,,诊断试剂领域,,DR081177,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['山东大学齐鲁医院'],1,['山东大学齐鲁医院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[68Ga]Ga-ES-02,[68Ga]Ga-ES-02
[68Ga]Ga-ES-02,HER2,anti-HER2多肽偶联核素;68Ga标记的PET药物,山东大学齐鲁医院(原研),结直肠癌,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物;受体酪氨酸激酶,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]Ga-ES-02,,肿瘤领域,,DR081177,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['山东大学齐鲁医院'],1,['山东大学齐鲁医院(原研)'],肿瘤领域,结直肠癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,colorectal cancer,[68Ga]Ga-ES-02,[68Ga]Ga-ES-02
[68Ga]Ga-RCC78,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,同济医学院(原研),肾细胞癌,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]Ga-RCC78;[68Ga] Ga-RCC78,,肿瘤领域,,DR089497,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['同济医学院'],1,['同济医学院(原研)'],肿瘤领域,肾细胞癌,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,renal cell carcinoma,[68Ga]Ga-RCC78,[68Ga]Ga-RCC78;[68Ga] Ga-RCC78
[68Ga]Ga-RCC78,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,同济医学院(原研),PET显像,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,创新药,[68Ga]Ga-RCC78;[68Ga] Ga-RCC78,,诊断试剂领域,,DR089497,否,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['同济医学院'],1,['同济医学院(原研)'],诊断试剂领域,PET显像,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,,PET imaging,[68Ga]Ga-RCC78,[68Ga]Ga-RCC78;[68Ga] Ga-RCC78
[αTH]EMP-100,c-Met,anti-c-Met多肽偶联核素;含钍放射性药物,Edinburgh Molecular Imaging(原研),实体瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,含钍放射性药物;多肽偶联核素,创新药,[αTH]EMP-100,,肿瘤领域,,DR021193,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Edinburgh Molecular Imaging'],1,['Edinburgh Molecular Imaging(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,solid tumors,[αTH]EMP-100,[αTH]EMP-100
[βTH]EMP-100,c-Met,anti-c-Met多肽偶联核素;含钍放射性药物,Edinburgh Molecular Imaging(原研),实体瘤,临床前,,Active,多肽;放射性药物;偶联药物,化药,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,含钍放射性药物;多肽偶联核素,创新药,[βTH]EMP-100;[βTH]EMP-100 ,,肿瘤领域,,DR021191,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Edinburgh Molecular Imaging'],1,['Edinburgh Molecular Imaging(原研)'],肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,solid tumors,[βTH]EMP-100,[βTH]EMP-100;[βTH]EMP-100 
alzheimer disease treatment,Aβ,,Interprotein(原研),阿尔茨海默病,临床前,,Active,多肽,化药,环肽;Amyloid beta通路,其他,创新药,alzheimer disease treatment;alzheimer disease treatment (Interprotein),,神经领域,,DR050453,是,日本,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Interprotein'],1,['Interprotein(原研)'],神经领域,阿尔茨海默病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,Alzheimer's disease,alzheimer disease treatment (Interprotein),alzheimer disease treatment;alzheimer disease treatment (Interprotein)
anti-TBC peptide,M.tb,,Hamlet Pharma(原研),肺结核,临床前,,Active,多肽,化药,环肽,其他,创新药,anti-TBC peptide;anti-TBC peptide (tuberculosis plectasin),,感染领域,,DR075136,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Hamlet Pharma'],1,['Hamlet Pharma(原研)'],感染领域,肺结核,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,,tuberculosis,anti-TBC peptide (tuberculosis plectasin),anti-TBC peptide;anti-TBC peptide (tuberculosis plectasin)
bleeding disorders program,not available,,Hemab(原研);Gubra(原研),出血,临床前,,Active,多肽,其他,环肽,其他,创新药,bleeding disorders program;bleeding disorders program (Gubra),,其他领域,,DR074440,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['Hemab', 'Gubra']",2,"['Hemab(原研)', 'Gubra(原研)']",其他领域,出血,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,Bleeding,bleeding disorders program (Gubra),bleeding disorders program;bleeding disorders program (Gubra)
certepetide-drug conjugate,CD51,多肽偶联药物,Catalent(Novo Nordisk)(Top20 MNC)(原研);Lisata Therapeutics(无权益),实体瘤,临床前,,Active,多肽;偶联药物,化药,环肽;Potential First-in-Class,多肽偶联药物,创新药,certepetide-drug conjugate;certepetide-drug conjugate (Catalent),,肿瘤领域,,DR084115,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,True,['Catalent(Novo Nordisk)'],['Catalent(Novo Nordisk)'],1,"['Catalent(Novo Nordisk)(Top20 MNC)(原研)', 'Lisata Therapeutics(无权益)']",肿瘤领域,实体瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,solid tumors,certepetide-drug conjugate (Catalent),certepetide-drug conjugate;certepetide-drug conjugate (Catalent)
compsorbin,CFH,CFH抑制剂,Amyndas Pharmaceuticals(原研),自身免疫性疾病,临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,compsorbin;AMY-301,,免疫领域,,DR063167,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Amyndas Pharmaceuticals'],1,['Amyndas Pharmaceuticals(原研)'],免疫领域,自身免疫性疾病,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,autoimmune disease,compsorbin,compsorbin;AMY-301
compsorbin,CFH,CFH抑制剂,Amyndas Pharmaceuticals(原研),炎症(未指明),临床前,,Active,多肽,化药,环肽;Potential First-in-Class,抑制剂,创新药,compsorbin;AMY-301,,免疫领域,,DR063167,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Amyndas Pharmaceuticals'],1,['Amyndas Pharmaceuticals(原研)'],免疫领域,炎症(未指明),['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,Inflammation (unspecified),compsorbin,compsorbin;AMY-301
cyclic peptide PSD-95 Inhibitors,PSD95,PSD95抑制剂,Avilex Pharma(原研),未知/待定,临床前,,Active,多肽,化药,环肽,抑制剂,创新药,cyclic peptide PSD-95 Inhibitors;cyclic peptide PSD-95 Inhibitors (Avilex Pharm),,其他领域,,DR025013,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Avilex Pharma'],1,['Avilex Pharma(原研)'],其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,cyclic peptide PSD-95 Inhibitors (Avilex Pharm),cyclic peptide PSD-95 Inhibitors;cyclic peptide PSD-95 Inhibitors (Avilex Pharm)
cyclic peptide project 40,not available,,诺诚健华(原研),自身免疫性疾病,临床前,,Active,多肽,化药,环肽,其他,创新药,cyclic peptide project 40;cyclic peptide project 40 (诺诚健华);cyclic peptide project 40 (InnoCare Pharma),,免疫领域,,DR077456,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['诺诚健华'],1,['诺诚健华(原研)'],免疫领域,自身免疫性疾病,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,autoimmune disease,cyclic peptide project 40 (InnoCare Pharma),cyclic peptide project 40;cyclic peptide project 40 (诺诚健华);cyclic peptide project 40 (InnoCare Pharma)
cyclo-CRLLIF,HIF-1α;HIF-2α;ARNT,HIF-2α×ARNT蛋白蛋白相互作用抑制剂;HIF-1α×ARNT蛋白蛋白相互作用抑制剂,University of Southampton(原研),癌症,临床前,,Active,多肽,化药,环肽;HIF信号通路;Potential First-in-Class,蛋白蛋白相互作用抑制剂,创新药,cyclo-CRLLIF,,肿瘤领域,,DR087634,否,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['University of Southampton'],1,['University of Southampton(原研)'],肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,cyclo-CRLLIF,cyclo-CRLLIF
integrin α4β7 program,α4β7,α4β7拮抗剂,Quantum Intelligence(原研),炎症性肠病,临床前,,Active,多肽,化药,环肽;中国无申报,拮抗剂,创新药,integrin α4β7 program;integrin α4β7 program (Quantum Intelligence),,免疫领域;消化领域,,DR069280,是,韩国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Quantum Intelligence'],1,['Quantum Intelligence(原研)'],免疫领域,炎症性肠病,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,-1,-1,Immunology,Immunology,Digestive System,,inflammatory bowel disease,integrin α4β7 program (Quantum Intelligence),integrin α4β7 program;integrin α4β7 program (Quantum Intelligence)
macrocyclic peptide 5L1,Mcl-1,Mcl-1抑制剂;Mcl-1分子胶,山东大学(原研);智峪生科,癌症,临床前,,Active,多肽,化药,环肽;细胞凋亡;非降解型分子胶;Potential First-in-Class,抑制剂;分子胶,创新药,macrocyclic peptide 5L1;macrocyclic peptide 5L1 (山东大学);macrocyclic peptide 5L1 (Shandong University),,肿瘤领域,,DR077255,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],['山东大学'],1,"['山东大学(原研)', '智峪生科']",肿瘤领域,癌症,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,cancer,macrocyclic peptide 5L1 (Shandong University),macrocyclic peptide 5L1;macrocyclic peptide 5L1 (山东大学);macrocyclic peptide 5L1 (Shandong University)
macrocyclic peptide antagonist of IL-11,IL-11,IL-11拮抗剂,徐州医科大学(原研),肾纤维化(差异化疾病),临床前,,Active,多肽,化药,环肽;差异化疾病;Potential First-in-Class,拮抗剂,创新药,macrocyclic peptide antagonist of IL-11;macrocyclic peptide antagonist of IL-11 (Xuzhou Medical University),,泌尿生殖领域,,DR084897,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['徐州医科大学'],1,['徐州医科大学(原研)'],泌尿生殖领域,肾纤维化,['泌尿生殖领域'],1,泌尿生殖领域,,,-1,-1,Genitourinary,Genitourinary,,,renal fibrosis,macrocyclic peptide antagonist of IL-11 (Xuzhou Medical University),macrocyclic peptide antagonist of IL-11;macrocyclic peptide antagonist of IL-11 (Xuzhou Medical University)
macrocyclic peptide therapeutics,not available,,Pfizer(Top20 MNC);Circle Pharma(原研),未知/待定,临床前,,Active,多肽,化药,环肽,其他,创新药,macrocyclic peptide therapeutics;macrocyclic peptide therapeutics (Pfizer),,其他领域,,DR078876,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,True,['Pfizer'],['Circle Pharma'],1,"['Pfizer(Top20 MNC)', 'Circle Pharma(原研)']",其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,macrocyclic peptide therapeutics (Pfizer),macrocyclic peptide therapeutics;macrocyclic peptide therapeutics (Pfizer)
neurodegenerative disease program,not available,,Histide(原研),神经退行性疾病,临床前,,Active,多肽,生物,环肽,其他,创新药,neurodegenerative disease program;neurodegenerative disease program (Histide),,神经领域,,DR046820,是,欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Histide'],1,['Histide(原研)'],神经领域,神经退行性疾病,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,,neurodegenerative diseases,neurodegenerative disease program (Histide),neurodegenerative disease program;neurodegenerative disease program (Histide)
non-addictive analgesic peptide,not available,,PreveCeutical Medical(原研),疼痛,临床前,,Active,多肽,化药,环肽;中国无申报,其他,创新药,non-addictive analgesic peptide;non-addictive analgesic peptide (PreveCeutical),,麻醉镇痛领域,,DR014390,是,加拿大,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['PreveCeutical Medical'],1,['PreveCeutical Medical(原研)'],麻醉镇痛领域,疼痛,['麻醉镇痛领域'],1,麻醉镇痛领域,,,-1,-1,Anesthesia & Analgesia,Anesthesia & Analgesia,,,pain,non-addictive analgesic peptide (PreveCeutical),non-addictive analgesic peptide;non-addictive analgesic peptide (PreveCeutical)
oral macrocyclic peptide drugs,not available,,Argenx(原研);Unnatural Products(原研),未知/待定,临床前,,Active,多肽,化药,环肽;中国无申报,其他,创新药,oral macrocyclic peptide drugs;oral macrocyclic peptide drugs (Unnatural Products),,其他领域,,DR087728,是,美国;欧洲,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['Argenx', 'Unnatural Products']",2,"['Argenx(原研)', 'Unnatural Products(原研)']",其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,oral macrocyclic peptide drugs (Unnatural Products),oral macrocyclic peptide drugs;oral macrocyclic peptide drugs (Unnatural Products)
oral macrocyclic peptides,not available,,Biogen(原研);Dayra Therapeutics(原研),免疫相关疾病,临床前,,Active,多肽,化药,环肽,其他,创新药,oral macrocyclic peptides;oral macrocyclic peptides (Dayra Therapeutics),,免疫领域,,DR089273,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],"['Biogen', 'Dayra Therapeutics']",2,"['Biogen(原研)', 'Dayra Therapeutics(原研)']",免疫领域,免疫相关疾病,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,,immune related diseases,oral macrocyclic peptides (Dayra Therapeutics),oral macrocyclic peptides;oral macrocyclic peptides (Dayra Therapeutics)
αvβ6 inhibitor,αvβ6,αvβ6抑制剂,Lassogen(原研),肿瘤,临床前,,Active,多肽,生物,环肽;Potential First-in-Class,抑制剂,创新药,αvβ6 inhibitor;αvβ6 inhibitor (Lassogen),,肿瘤领域,,DR005870,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Lassogen'],1,['Lassogen(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,αvβ6 inhibitor (Lassogen),αvβ6 inhibitor;αvβ6 inhibitor (Lassogen)
αvβ8 inhibitor,αvβ8,αvβ8抑制剂,Lassogen(原研),肿瘤,临床前,,Active,多肽,生物,环肽,抑制剂,创新药,αvβ8 inhibitor;αvβ8 inhibitor (Lassogen),,肿瘤领域,,DR053232,是,美国,全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他,,,,,pre-clinical,临床前,,pre-clinical,1,True,False,False,[],['Lassogen'],1,['Lassogen(原研)'],肿瘤领域,肿瘤,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,,tumor,αvβ8 inhibitor (Lassogen),αvβ8 inhibitor;αvβ8 inhibitor (Lassogen)
多肽偶联核素创新药物,not available,多肽偶联药物,安吉生物(原研);纽瑞特医疗,未知/待定,临床前,,Active,多肽;偶联药物,化药,环肽,多肽偶联药物,创新药,多肽偶联核素创新药物;多肽偶联核素创新药物 (安吉生物);peptide-conjugated nuclide innovations (Anji Biotechnology),,其他领域,,DR044216,是,中国(内地),全球;中国(内地);中国(港澳台);美国;欧洲;日本;其他;未知,,,,,pre-clinical,临床前,,pre-clinical,2,True,False,False,[],['安吉生物'],1,"['安吉生物(原研)', '纽瑞特医疗']",其他领域,未知/待定,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,,unknown/pending,peptide-conjugated nuclide innovations (Anji Biotechnology),多肽偶联核素创新药物;多肽偶联核素创新药物 (安吉生物);peptide-conjugated nuclide innovations (Anji Biotechnology)
